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Prion diseases are rare, invariably fatal, neurodegenerative diseases, occurring in
sporadic, genetic and iatrogenic forms in animals and humans, for which there is no
aeceptahlc diagnostic test in life and no effective treatment. In humans the commonest
prion disease is Creutzfeldt-Jakob Disease (CJD). Systematic prospective public
health surveillance (PHS) ofCJD was initiated in the UK in 1990 in response to the
detection of a novel prion disease in cattle, bovine spongiform encephalopathy (BSE).
The aim of PHS was to detect any change in the elinico-pathological phenotypc of
CJD that could be attributable to human exposure to BSE. In this thesis I present a
series of studies that evaluate various aspects of the PHS ofCJD in the UK, 1990 -
2006.
From 1990 to 2006, 2154 suspect CJD cases were referred to the National CJD
Surveillance Unit (NCJDSU); 57% had a clinical or neuropathological diagnosis of
CJD. Sporadic CJD (sCJD) accounted for the majority of cases. Age adjusted sCJD
incidence increased over time in association with an increasing use ofCSF 14-3-3
protein for case classification. Genetic prion disease accounted for 9.4% of all cases;
54 iatrogenic CJD cases mediated by recognised routes of transmission were
identified. Variant CJD (vCJD), a novel human prion disease, was characterised by
the NCJDSU in 1996; by 2006 there had been 165 incident cases in the UK. The
primary vCJD epidemic peaked in the UK in 2000 (27 incident cases) and has been in
decline since. Secondary transmission of vCJD through the transfusion of labile blood
components has been identified, occurring during an asymptomatic phase of illness.
The prevalence of asymptomatic vCJD infection in the population is not known. In
characterising vCJD and contributing to establishing an aetiological link with BSE,
the NCJDSU met a primary aim of PHS. In an evaluation the NCJDSU was found to
be flexible, acceptable, sensitive, timely and representative. Falling post mortem rates
and an increasing reliance on clinical diagnostic criteria, with evidence of sub-optimal
and differential use of investigations to support a diagnosis of sCJD and vCJD are of
concern, as is the rising positive predictive value of the system in the face of falling
referral rates. NCJDSU operational criteria for the assessment of EEGs for case
classification in sCJD were prospectively validated. The sensitivity of EEG was low
and specificity high; EEG remains a valuable non-invasive investigation in sCJD if
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used in conjunction with other diagnostic tools. With the establishment of systematic
prospective PHS the reliance on death certificates to ascertain suspect cases has
diminished. The sensitivity and specificity of a death certificate diagnosis of prion
disease in the UK are high. Death certificate data provide valid estimates of prion
disease mortality in the UK.
Uncertainty around the epidemiology and pathogenesis of vCJD and the emergence of
novel atypical prion diseases in animals which pose an as yet unknown threat to
human health, provide the imperative to continue systematic prospective PHS ofprion
disease in humans in the UK for the foreseeable future. The NCJDSU is well placed
to achieve this.
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Chapter 1. Background to this thesis
Introduction
Prion diseases are a group of rare, invariably fatal, neurodegenerative diseases
affecting animals and humans (Table 1). Aetiologically sporadic, genetic and
iatrogenic forms of these diseases exist. Prion diseases are also known as
Transmissible Spongiform Encephalopathies (TSEs) because of their transmission
potential and associated ncuropathological features. However not all prion disease arc
transmissible.(l) Therefore throughout this thesis I will refer to prion diseases rather
than TSEs. In humans, the commonest form of prion disease is Creutzfcldt-Jakob
Disease (CJD). Systematic prospective CJD surveillance was initiated in the UK in
1990 following the characterization of bovine spongiform encephalopathy (BSE), a
novel prion disease in cattle, to which the UK population was widely and
involuntarily exposed. The potential threat to human health posed by BSE was, at that
time, unknown. In this thesis I report the findings of a number of studies that evaluate
various aspects of the surveillance of CJD in the UK from 1990 through 2006.
This thesis is organised into six chapters. In this chapter I provide an overview of the
current scientific knowledge in relation to prion diseases, explaining the rationale for
the surveillance ofprion diseases in humans, based on a literature search strategy. In
the second chapter 1 describe the epidemiology ofCJD according to disease subtype
in the UK from 1990 through 2006 using data collected by the National CJD
Surveillance Unit (NCJDSU). In chapter three, I present the findings of the first ever
evaluation of the NCJDSU. A study to prospectively validate the NCJDSU
operational criteria for the assessment of electroencephalography (EEG) in case
classification of sporadic CJD (sCJD) is described in chapter four. Chapter five is
devoted to an examination of the role of death certificates in the surveillance of prion
diseases in the UK. Finally, in chapter six 1 present a general discussion of the
findings from these studies, placing them in the context of forthcoming challenges to
continued systematic prospective prion disease surveillance in the UK. Each chapter
is organized in a standard format: a brief introduction, an outline the of aims and
objectives of the chapter, a description ofmethods used, presentation of results, a
bullet point summary of the key findings from the chapter followed by a discussion
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and conclusions. Tables and figures are adjacent to the corresponding text. References
are listed in a single reference list which precedes the appendices to this thesis.
Tabic 1 Prion diseases in animals and humans
Animal Prion Diseases
Bovine Spongiform Encephalopathy (BSE)
Chronic Wasting Disease (CWD)
Exotic ungulate spongiform encephalopathy
Feline spongiform encephalopathy (FSE)
Scrapie
Transmissible mink encephalopathy (TME)
Zoo primate spongiform encephalopathy
Human Prion Diseases
Crcutzfeldt-Jakob Disease (CJD)




Sporadic Fatal Insomnia (SFI)
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Literature review
This literature review comprises of five sections. The first describes the methodology
of the literature review. The second provides an overview of prion diseases and their
molecular basis. A brief account of prion diseases in animals, focusing on the key
issues in relation to human health, follows. In the fourth section prion diseases in
humans will be described. In the final section public heath surveillance (PI IS) will be
defined and the rationale for prion disease surveillance in humans will be explored.
Search strategy
Keyword search syntax was developed in MEDLINE using the following terms:
'((Creutzfeldt Ja?ob) AND ('Disease' or 'Syndrome')) or 'CJD' or 'Prion Disease' or
'TSE' or 'Transmissible spongiform encephalopath$'. The strategy was translated,
database specific subject headings added, and syntax run in the following electronic
databases accessed via the OVID interface: MEDLINE, MEDLINE In- Process &
Other Non-Indcxcd Citations, Cochrane Central Register of Controlled Trials,
Cochrane Database of Systematic Reviews, Database ofAbstracts ofReviews of
Effects, EMBASE and PsycINFO. Articles were limited to those published in the
English language; no other limits were set.
The grey literature was examined to identify further, potentially relevant resources.
The following search terms were used: 'CJD' or 'TSE' or 'Prion Disease'.
Specific resources accessed included: TRIP, IS1 Web of Knowledge, National
Research Register, Medical Research Council (MRC) Research Register, ReFeR (UK
Department of Health Research Findings Electronic Register), Index of Conference
Proceedings (accessed via the British Library's Public Catalogue), Dissertation
Abstracts, ClinicalTrials.gov, and Intute. A number of additional resources were
accessed as outlined in Appendix 1.
Reference lists of selected articles were reviewed and citation checks carried out to
identify further potentially relevant studies. All retrieved citations were downloaded
using bibliographic software into a database for management (Reference Manager
11). This search was regularly updated throughout the preparation of this thesis to
identify critical gaps in the literature and inform the direction of this research. The
28
final search was carried out on 1st November 2010. In excess of 6,500 documents
were retrieved. I screened the titles and abstracts of all documents to determine their
relevance in relation to the scope of the literature review. The full text of all
potentially relevant material was reviewed.
Prion diseases and their molecular basis
From the mid-1950s prion diseases were considered 'slow virus diseases' due to their
long incubation periods and presumed viral aetiology. In the late 1960s the 'protein-
only' hypothesis was proposed.(2;3) This signalled a paradigmatic shift in biological
theory. The hypothesis suggested that the infectious agent was a sclf-rcplicating
protein rather than a virus. This was supported by a number of observations, largely
based on research conducted using the scrapie agent in sheep or animal models. The
transmissible nature of scrapie had been demonstrated by Cuille and Chelle in
1936.(4) Yet despite extensive research, a virus had not been isolated. The scrapie
agent was resistant to ultraviolet and ionizing radiation that would modify any nucleic
acid found in viruscs.(5) Paradoxically it was sensitive to treatments that denatured
proteins such as sodium hydrochloride and proteases.(6) In 1982 Stanley Prusincr and
colleagues isolated an infectious fraction from a scrapie infected animal model.(6)
The term 'Prion', derived from proteinaceous and infectious, was used to describe this
agent. Although initially received with scepticism, Prusiner's theory gained
popularity. Jn recognition of his work he was awarded the 1997 Nobel Prize in
Physiology or Medicine.(7)
The current definition of a Prion is a
"Proteinatious infectious particle that lacks nucleic acid."(7)
According to the 'protein-only' hypothesis the prion protein can exist in a non¬
pathogenic conformation known as PrPc (Figure la) and a pathogenic conformation
known as PrPSc (Figure lb). Of note, PrPSc, the pathogenic conformation of PrPc, may
also be referred to as PrPTSE. PrPSc is partially resistant to breakdown by proteases
and the resistant fragment is designated PrPrcs. The abnormal disease-related prion
protein is typically detected as PrPrcs; PrPres and PrPSc are ofien used interchangeably
in the prion disease literature, despite their different specific references. These
29
technical issues are not directly relevant to this thesis and will not be explored further.
PrPSc will be used throughout this thesis to denote disease-related prion protein.
Figure 1 Illustration of the proposed non-pathogenic and pathogenic
conformations of prion protein in humans (8)
(A) Non-pathogenic PrPc containing mostly a-helical structure (red ribbons). (B) Pathogenic PrP^ containing most fi-plcatcd
sheets (green arrows) with a small portion of ot-helices (spiral shaped red ribbons).
PrPc is a naturally occurring cellular glycoprotein with a predominantly a-helical
structure weighing approximately 35 kD. It is covalently linked to cellular membranes
via a glycosylphosphatidylinositol anchor. PrPc is encoded by a single copy gene,
named PRNP, which is located on the short arm of chromosome 20 (Figure 2).(7) The
entire protein coding region is contained within one exon. PrPc is expressed in most
cells, but found in high concentrations in neurones. The precise biological function of
PrPc is not known although there is growing evidence to suggest a neuro-protective
role.(9;10) Transgenic mice without PRNP are resistant to prion diseases, implying
that PrPc is essential for prion disease developmental 1) However such mice appear to
have normal life expectancy shedding little light on the normal function of PrPc. PrPSc
is thought to bind to the host PrPc inducing self-replicating conformational change,
from a predominantly a-helical structure into a structure consisting of predominantly
U-pleated sheets.(12) The process by which this occurs is not fully understood. In
sporadic and genetic prion disease transformational change is thought to occur
spontaneously; in acquired prion disease, in response to exposure to an exogenous
agent. As a result of conformational change the biochemical properties of PrPc differ
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from PrPSc.(13) Although the change in prion protein conformation is a central
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Figure 2 Human prion gene variation showing positions of pathogenic
polymorphisms and pathogenic mutations (14)
Prion strains and prion protein typing
The demonstration that distinct clinico-pathological prion disease phenotypes can
occur in one species, with distinct and stable experimental transmission properties,
has led to the concept that multiple prion strains exist. These disease strains are most
convincingly distinguished by their biological properties in living organisms (in terms
of incubation periods and neuropathological profdes). In laboratory studies strains can
be maintained through successive passages both within (for example from mouse to
mouse model) and between (for example from sheep to mouse model) species, but
transmission experiments are not the most convenient or rapid way of determining
strain variation. Unfortunately, in the absence of a final characterisation of the prion,
the molecular underpinning of agent strain variation is not yet understood and there is,
therefore, no direct method of agent strain identification. It is hypothesised that the
strain-specific characteristics of prion diseases are determined by the structural
conformation of PrPSc. Different protein structures can be studied by differential
responses to proteases and differential glycosylation patterns and this 'prion protein
typing' has provided a molecular basis to characterise strain behaviour. Western blot
has been used to describe different prion protein types according to the size of the
proteolytic fragment (ranging from 19 to 21 kDa) and the degree of glycosylation that
occurs following proteinase K digestion (the ratio of di, mono and unglycosylatcd
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PrpSc) pnon protein types have been used as a means of identifying and
differentiating different prion diseases (for example sCJD and vCJD) and arc regarded
by many as being surrogate markers for agent strain. The complexities of prion
protein typing and its true relationship to agent strain are beyond the scope of this
thesis and will not be discussed further.
The species barrier
The species barrier refers to a difficulty in transmitting an infectious disease between
species. In prion disease, this can be illustrated using the example of scrapie, BSE and
vCJD. Humans have been exposed to scrapie in sheep for several centuries. There is
no evidence of transmission of scrapie from sheep to humans. However there is
compelling evidence of transmission of BSE from cattle to humans, the same prion
strain having been identified in BSE and vCJD.(l 5; 16) To date all
neuropathologically confirmed cases of vCJD in humans have occurred in individuals
with a common polymorphic residue at Codon 129 (AG-methionine to GTG-valine,
Ml29V) of PRNP, implying that the primary structure of PrPc may be important in
determining prion perpetuation. The species barrier has been used to explain the
relative rarity of vCJD despite the widespread exposure of the UK population to
BSE.(17) The species barrier may not however be absolute so as to prevent disease
transmission. There is evidence to suggest that in prion disease, rather than preventing
transmission, the species barrier may significantly lengthen the mean incubation
period; if sufficiently lengthened disease may not become clinically apparent prior to
the death of the infected host.(18;19) In prion disease, after two or three subsequent
passages of the infectious agent within species, adaptation can occur and the
incubation period may regress back to the previous mean. Prion strain is important in
determining effective transmission between species leading some commentators to
suggest that the term species barrier should be replaced with "transmission
barrier".(17) A number of other factors are known to influence effective transmission
including the distribution of tissue infectivity, the route of transmission and the
infective dose.
Prion diseases in animals
Prion diseases are known to affect a number ofmammals (Table 2).(20) To facilitate
in vivo modelling prion diseases have also been transmitted to primates (non-human)
and transgenically modified rodents, the latter in an attempt to overcome the species
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or transmission barrier. In the section that follows I will briefly describe prion
diseases in animals. This section will focus specifically on issues that are directly
relevant to human health. Therefore a more detailed account of BSE, the only
zoonotic animal prion disease will be provided, with an outline of the control
measures initiated in the UK following the characterisation of BSE. In common, there
arc no definitive ante-mortem diagnostic tests for prion diseases in animals or
humans. These diseases arc universally fatal; no effective treatments are available.
Table 2 Prion diseases in animals
Year Animal Disease
1732 Sheep and goats Scrapie
1947 Mink (fanned) Transmissible mink encephalopathy (TME)
1967 Deer and Elk (farmed and wild) Chronic Wasting Disease (CWD)
1986 Cattle Bovine Spongiform Encephalopathy (BSE)
1986 Ungulates (nyala, gemsock, eland, large Exotic ungulate spongiform encephalopathy*
kudu, Arabian orxy, bison, ankolc cow)
1990 Domestic cats and captive felidae Feline spongiform encephalopathy (ESE)*
(puma, cheetah, ocelot, tiger and lion)
1996 Captive non-human primates Zoo primate spongiform encephalopathy*
(rhesus monkeys and lemurs)
*prion strain indistinguishable from BSE
An overview of prion diseases in animals
Scrapie, the archetypal prion disease, has been reported in the UK since the 18th
Century.(21) Much of the research that has informed our current understanding of
prion diseases is based on studies of scrapie. Naturally occurring scrapie has been
reported throughout Europe and North America. Despite extensive epidemiological
investigation, the aetiology and mechanisms of transmission of scrapie are not fully
understood. There is a similar paucity of data describing the aetiology and routes of
transmission ofCWD, a disease of wild and farmed deer and elk, largely confined to
North America. Epidemiological studies of TME, which occurs in isolated epidemics
among farmed mink again largely confined to the USA, suggest a food borne
exposure, although transmission studies to support this are lacking. The animal prion
diseases that have emerged in a range of species since 1990 arc thought to be BSE
related; in some the prion strain has been shown to be indistinguishable from
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BSE.(22) BSE is the only animal prion disease that is known to pose a threat to
human health.
BSE
In this section I will briefly describe the BSE epidemic and outline a chronology (to
2006) of events in relation to the control measures directly relevant to human health
that were instigated in the UK following the detection of BSE. The clinical features of
BSE are not directly relevant to this thesis and will not be described.
The epidemiology ofBSE in the UK
BSE was described in the UK in 1986, although modelling suggests that the first cases
occurred, undetected, in the South of England between 1977 and 1983.(23-25). The
epidemic rapidly evolved reaching a peak of 36,680 cases per annum in 1992,
equivalent to a rate of 6,636 cases per million bovines aged over 24 months (Figure
3).(26;27) The annual number of cases has consistently fallen since. As of 2009,
approximately 184,600 cases of BSE had been confirmed in cattle in the UK.(27)
Mathematical modelling suggests that between 1 and 3 million cattle may have been
















Figure 3 Time course of the BSE epidemic in the UK, 1986-2000, with dates of
major precautionary interventions, adapted from Brown et al (29)
The mammalian ban on meat and bone meal in March 1996 extended a 1994 ban for farmed food animal species to include all
mammalian species. SBO specified bovine offal (brain, spinal cord, thymus, tonsil, spleen, and intestines from cattle >6














From 1989 onward BSF cases were reported in most European countries; countries
outside Europe such as Japan and Canada were also affected.(27) Small epidemics or
isolated cases have been reported in 24 countries. BSE may have been spread through
the movement of infected animals between European states which would, in part,
explain the scarcity of BSE in non-European countries. The Falkland Islands, Oman
and the USA have reported isolated BSE cases in imported animals only. The export
of BSE contaminated meat and bone meal (MBM) from the UK to be used in cattle
feed may have introduced BSE to indigenous cattle. In countries where BSE has been
reported in indigenous cattle, epidemics have differentially matured according to the
timing of specific control measures (Figure 4).(30) For example the number of cases
peaked in Switzerland in 1995, Portugal in 1999, France, Ireland, Germany and
Belgium in 2001 and Spain in 2003. Outside the UK, the incidence of BSE has been
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Figure 4 Number of BSE cases in selected European countries by year of onset,
adapted from Smith and Bradley. (30)
The origin ofBSE
The origin of BSE is unknown. Initially it was suggested that BSE was caused by
direct transmission of scrapie, or a scrapie-like agent, from sheep to cattle.(31;32)
This hypothesis was founded on a number of observations. Scrapie had been endemic
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in the UK for several centuries. The UK had a high ratio of sheep to cattle. The
neuropathological appearance of BSE was similar to that of scrapie. The practice of
feeding meat and bone meal (MBM) including material from fallen sheep to calves as
a protein supplement was common in the UK and could have facilitated oral
inoculation of the disease. Critics note that the prion strain in BSE is distinct from all
known strains of scrapie and that epidemiological or experimental evidence to support
the direct transmission of scrapie from sheep to cattle is lacking.
Some commentators believe BSE originated in cattle. Until recently there was no
compelling evidence to support this, although in the absence of disease surveillance
sporadic BSE might not have been detected if occurring infrequently. In 2004 atypical
forms ofBSE were identified through active disease surveillance, which involves the
testing of asymptomatic animals for disease. It has been hypothesised that
sporadically occurring atypical BSE in cattle may be the origin of classical BSE.
Other commentators believe that BSE arose as a result of a spontaneous mutation of
PRNP. Indeed there is recent evidence to suggest that BSE is hcritable.(33)
Alternative theories regarding the origin of BSE are not currently supported by
scientific rescarch.(25) In 2004 SEAC, the Spongiform Encephalopathy Advisory
Committee in the UK, stated it
"unlikely that the origins ofBSE would ever be determined conclusively."(34)
The origin ofthe BSE epidemic
Experimental and epidemiological research supports the theory that the BSE epidemic
was propagated through the use ofMBM in cattle feed. MBM is a high protein
supplement that has been fed to cattle, sheep, pigs and chickens in the UK and used in
agriculture as a plant fertilizer for several decades. MBM is produced by rendering
waste products from several animal species including cattle and sheep. The rendering
process separates protein from fat (tallow). The protein component is ground to
produce MBM. Tallow is used in certain foods consumed by humans (for example
gelatine) and animals (for example pet food). It is also used in pharmaceutical and
cosmetic products. Changes in rendering processes in the UK in the decade prior to
the emergence of BSE, largely driven by economic factors, resulted in the use of
lower temperatures and less solvent.(31) Consequently the BSE agent, once
introduced into the rendering process, would not have been inactivated and would
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have entered the animal food chain though MBM. Whilst similar changes in the
rendering process took place in Europe, albeit to a lesser extent, the UK was the first
country to feed MBM to young calves; young calves appear to be more susceptible to
BSE.(35) This theory is supported by the observation that an excess number of BSE
cases were observed in dairy cattle relative to beef cattle. Dairy cattle in the UK were
rapidly, 1 to 2 weeks following birth, weaned onto a diet ofmilk substitutes and
MBM. Experimental studies have shown that less than lgram of infected cow brain
ingested orally is sufficient to transmit BSE to cattle; Vi gram to transmit the disease
to sheep or goats.(25) Several cycles of BSE may have occurred before the disease
was formally recognised. During this time infected cattle may have entered the human
food chain or been recycled and re-entered the animal food chain as MBM, the latter
amplifying BSE infectivity in MBM. It should be noted that other factors such as
maternal transmission may have contributed to the epidemic, but at a much lower
level insufficient to maintain the epidemic.
BSE control measure in the UK
An excellent and contemporary chronology of events in relation to BSE has been
produced by The Department for the Environment Food and Rural Affairs.(36)
Readers wishing a comprehensive review are directed to this publication. The salient
events in relation to human health are summarized in the section that follows.
In 1987 the first case report of BSE appeared in the peer reviewed press. In June 1988
an expert group, the Southwood Working Party, met on the advice of the Chief
Medical Officer (CMO). Their remit was to investigate BSE and examine the possible
threat to human health posed by this novel prion disease. Shortly thereafter BSE
became a notifiable disease. Rapid epidemiological studies implicated MBM in the
propagation of BSE. A ban on incorporating ruminant proteins in ruminant feed was
announced - the 'ruminant feed ban'. In August of 1988 the Southwood Working
Party advised that animals showing signs of BSE should be slaughtered and destroyed
(compulsory slaughter). Compensation was paid to farmers at a rate of 50% for
confirmed BSE cases and 100% for slaughtered cattle that did not have BSE. This
differential compensation scheme may have led to under-reporting of suspect cases
and the further entry of infected cattle into the human food chain. In recognition of
this full compensation was paid for all suspect cases slaughtered as of February 1990.
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A further measure recommended by the Southwood Working Group was the
destruction ofmilk from infected cattle. In December 1988 BSE was designated a
zoonosis. The Southwood Report was published in February 1989. The Government
accepted all of the Groups' recommendations.
Whilst the Southwood Working Group initially reported that BSE was unlikely to
present a significant threat to humans, they recommended an expert committee be
formed to advise on research in relation to BSE. The Tyrcll Committee was formed in
February 1989. In June 1989 the Specified Bovine Offal Ban (SBO) was introduced
which banned the use of those categories of offal from cattle that were most likely to
be infectious from use in human food based largely on existing knowledge of the
pathogenesis and infectivity of scrapie. In 1990 the EU restricted the export of cattle
from the UK to member stales to cattle under six months old and banned the export of
SBO containing material. Nevertheless UK companies continued to export SBO
containing materials to outside the EU area. SEAC was formed in April 1900 to
provide independent scientific advice on prion diseases in animals and humans. A
National CJD Surveillance Unit (NCJDSU) was established the same year with the
aim of detecting any change in the clinico-pathological phenotype ofCJD in humans
that might be attributable to exposure to BSE.
Two important events occurred in 1990. Firstly, it was demonstrated that BSE could
be experimentally transmitted within (cattle to cattle transmission) and between
species (to pigs via infra-cerebral inoculation and to mice via the oral route).
Secondly, Feline Spongiform Encephalopathy (FSE), a novel prion disease affecting a
domestic cat in the UK was described, with a prion strain indistinguishable from BSE.
Following these events, the SBO ban was extended to all animal feed, including bird
and pet food. Despite these control measures, infected cattle continued to be bom
after the ban in the UK in large numbers, suggesting on-going exposure. Cross-
contamination of feed (a restriction on the use ofMBM in feed for pigs and poultry
was not recommended until March 1996) is thought to have sustained the epidemic
and undermined the control measures that had been put in place. In 1992 the use of
head meat after the skull had been opened was prohibited to prevent possible
contamination from bovine brain; head meat being a common constituent of
processed meat products such as pics and sausages. In 1995, The Ministry for
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Agriculture, Farming and Food reported that some abattoirs were ignoring the SBO
ban. Additional concerns were raised about the possible inclusion ofmaterial from the
spinal cord in mechanically recovered meat (MRM). In 1995, a ban on the extraction
ofMRM from the spinal cord of cattle, prohibiting the use ofMRM in food for
human consumption, was introduced.
In March 1996 a clinico-pathologically distinct form ofCJD, vCJD, was
described.(37) Shortly thereafter SEAC announced a probable link between BSB and
vCJD and the EU banned the export of British beef. More stringent control measures
were instigated including a ban on the incorporation of all mammalian protein into
animal feed introduced in August 1996 (introduced in EU states in 2001) - 'the
Reinforced Feed Ban'. A small number of cases in animals born after this reinforced
ban were described. Whilst some may be attributable to maternal transmission, the
possibility of residual contamination of feed, or an alternate route of transmission
unrelated to feeding, remained. The SBO ban was superseded by the 'Specified Risk
Materials' ban which more specifically identified tissues ofhigh infectivity that
should be removed from healthy animals slaughtered for human consumption, based
on experimental evidence. This included a stipulation that the whole head of cattle
over 6 months of age should be treated as tissue of high infectivity. Shortly thereafter
the heads of sheep and goats were removed from the food chain as a precautionary
measure. In April 1996 the over 30 month rule was instated banning cattle over 30
months of age from the food chain (classical BSE is typically clinically apparent in
cattle aged between 4 and 5 years old). These cattle were selectively culled and their
carcasses incinerated. The over 30 month rule was superseded in 2005 by cohort and
offspring culls in the UK in line with activities in the EU.
The transmission ofBSE
In experimental studies BSE has been successfully transmitted to humanized
transgenic mice and primates who develop clinical signs and symptoms consistent
with vCJD. As previously noted the prion strain in BSE in cattle and vCJD in humans
are similar indicating a likely causal association. The prion strain in FSE is
indistinguishable from BSE; experimental studies have confirmed transmission of
BSE to cats via the oral route. Neither pigs, nor chickens (both exposed to MBM
feed) are susceptible to BSE via the oral route. However sheep orally inoculated with
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BSE develop a scrapie-like illness. There are no recorded instances of BSE in sheep
outside experimental studies. This would however present a realistic threat to human.
Atypical prion diseases: scrapie and BSE
Atypical cases of scrapie and BSE have been ascertained through active surveillance,
a process of seeking out cases which may involve testing asymptomatic animals.
These cases are clinically and pathologically distinct from classical scrapie and BSE.
The epidemiology of these diseases has not been fully characterised due to the small
number of cases detected to date, most of which have been detected in asymptomatic
healthy animals slaughtered for human consumption, or fallen stock with few clinical
signs. Molecular and transmission studies suggest that the prion strain in atypical
disease is distinct from that in classical disease. The origin of atypical scrapie and
BSE are unknown. Cases appear to be sporadic. It is not clear whether these are
entirely novel prion diseases or previously unrecognised diseases which are now
being detected through active surveillance. Interestingly in transmission studies an
evolution toward the classical BSE strain occurs when transgenic mice are inoculated
with atypical BSE. This has led some commentators to suggest that atypical BSE may
have been the origin of the BSE epidemic.(38;39) It should be considered that if
sporadically occurring atypical BSE was the origin of the BSE epidemic, eradication
of BSE may not be possible although existing control measures should prevent a
further epidemic in cattle. Of concern, the molecular subtype of atypical BSE has
been shown to be similar to molecular subtypes described in sCJD in humans.(40;41)
To date there have been no published accounts of the transmissibility of atypical BSE
by oral inoculation. A comprehensive assessment of the risk to human health from
these atypical prion diseases is not available, however in 1997 SEAC considered that
in light of existing control measures for classical BSE,
"the risk ofspread to other cattle, sheep and goats is likely to he very low,
assuming as with classical BSE, environmental transmission is
negligible the risk to human health is likely to he very low to
negligible."(42)
The surveillance of prion diseases in animals
The principal aims of prion disease surveillance in animals are to monitor trends in
the occurrence of disease and evaluate the effectiveness of control measures. The
public health imperative for this relates to the threat to human health posed by BSE
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and the as yet un-quantified threat to human health posed by atypical prion diseases in
cattle, sheep and goats. As previously noted BSE-rclatcd prion diseases have been
identified in a number of species. There is a theoretical risk of transmission of BSE to
small ruminants. To date this has not been described outside laboratory studies.
However in laboratory studies the pathogenesis of BSE in sheep differs from that in
cattle such that it has been suggested that the current approaches to testing animals
slaughtered for human consumption in the UK might not identify sheep
asymptomatically infected with BSE.(43) If BSE were to emerge in sheep, this would
pose a threat to human health. It should also be considered that novel animal prion
disease may be identified through disease surveillance.
Disease surveillance may be passive or active. Passive surveillance involves the
reporting of suspect (by definition symptomatic) cases to the authorities. Active
surveillance involves seeking out cases. Passive surveillance of BSE was carried out
from the point of recognition of the first case in 1986. This involved a process of
farmers and/or veterinarians reporting suspect BSE cases to the authorities. In 1988
BSE was made a notifiable disease meaning that there was a legal requirement for
owners to notify the authorities of a. suspect case. In 1994 the laboratory diagnosis of
prion disease in an animal of any species became notifiable. In 2001 under EU
legislation it became a legal requirement to inform the authorities ofsuspect prion
disease in any species of animal. Scrapie has been notifiable in the UK since 1993.
Active surveillance of BSE has been carried out in the UK since 1999 (2001 in the
EU). In the UK active surveillance currently involves the testing of all fallen stock
and cattle slaughtered for emergency (sick cattle) or entry into the food chain aged
over 48 months, for BSE. Rapid post mortem diagnostic tests have allowed testing for
BSE in animals fit for human consumption prior to entry into the human food chain.
Active surveillance of scrapie has been carried out in the UK since 2002. Surveillance
activities include annual sheep abattoir and fallen stock surveys; the former may
identify asymptomatic disease and the latter symptomatic disease.
The rapid fall in the number of BSE cases 3-4 years after the institution of control
measures in the UK (Figure 3) and the evolving epidemics elsewhere (Figure 4) lend
epidemiological evidence to support the hypothesis that MBM was the vector for the
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BSE epidemic. Control measures are however expensive to maintain. As the BSE
epidemic draws to a close there will be increasing pressure to relax or remove these
measures. On-going disease surveillance in animals will be crucial in monitoring the
impact that such changes might have on trends in disease occurrence.
Prion diseases in humans
Despite the rarity of prion diseases in humans a number of issues have led to intense
public, political and scientific interest in this area: (1) the lack of a practical and
acceptable ante-mortem diagnostic test (2) lengthy incubation periods during which
an individual may be infectious but asymptomatic (3) the transmissibility of the
disease from human to human and animal to human during an asymptomatic stage (4)
the resistance ofprion proteins to decontamination (5) the lack of an effective
treatment in the context of an invariably fatal illness. This section is organised into
five major sub-headings. The first three will, in turn, examine sporadic, acquired and
genetic prion diseases in humans (Table 3). The fourth, briefly reviewing therapeutic
approaches to human prion diseases, applies to all human prion diseases irrespective
of aetiology. A final sub-heading will review measures to reduce human to human
transmission ofprion diseases in the UK.







Variant Creutzfeldt-Jakob Disease (vCJD)
Iatrogenic Creutzfeldt-Jakob Disease (iCJD)
Genetic
Genetic Creutzfeldt-Jakob Disease (gCJD)
Fatal familial Insomnia (FFI)
Gcrstmann-Straussler-Schcinker Disease (GSS)
Diagnostic criteria for the classification of human prion diseases arc outlined in
Appendix 2 and will be referred to throughout this thesis.
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Sporadic prion diseases
This section will focus on sCJD which accounts for up to 85% of all human prion
diseases. Two further forms of sporadic prion disease in humans are recognised.
These will be briefly described at the end of this section.
Creutzfeldt-Jakoh Disease (CJD)
The term Creutzfeldt-Jakob Disease was first introduced in 1922 to describe five
cases published in two separate case reports by German ncuroscientists, IIG
Creutzfeldt and AM Jakob. Of the original cases described by Creutzfcldt and Jakob a
retrospective analysis has shown that only two of five would have met the current
diagnostic criteria for sCJD.
Epidemiology
Worldwide the incidence of sCJD is reported to vary from 0.44 to 1.61 per million
persons per year.(44) Due to the rapid clinical course and universal fatality of sCJD,
mortality rates arc commonly used as a proxy measure for incidence. Most countries
with mature surveillance systems report an increase in sCJD mortality over time.(44-
47) This has largely been attributed to improved case ascertainment mediated through
formalized disease surveillance, improved access to and use of diagnostic
technologies and an increased awareness of prion diseases among the public and
health care professionals.(44;45;48) As a notable exception, sCJD mortality rates in
the USA have remained stable over time despite an increase in surveillance
activity.(49) This raises the possibility, however remote, that the increase in mortality
in other countries is attributable to increasing exposure to an unknown exogenous risk
factor.
Studies from Europe, North America, Japan and Australia have consistently reported
sCJD mortality peaking in individuals aged 60 - 79 years, and falling
thcreaf!er.(47;48;50-53) In 2005, Ladogana el al reported an age-specific sCJD
mortality rate of less than 1 per million persons per year in those aged under 50 years,
rising to 6-7 per million persons per year in the age group 70-79 years and falling to
2-5 permillion persons per year in those aged 80 years and over, using pooled data
from 11 international collaborators from the EUROCJD group.(44) Commentators
have suggested that this finding may be explained by under-ascertainment of sCJD
cases in the very eldcrly.(48) This hypothesis is supported by a recent increases in
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age-specific mortality rates observed in association with increased surveillance
activity.(52;54;55)
sCJD is reported to affect men and women in proportions consistent with the age and
sex structure of the population under study. A recent study by Holman and co-workers
reported no apparent sex difference in sCJD mortality rates in those aged under 60
years of age, but a slightly higher sCJD mortality rate in men relative to women aged
over 60 years of age (49); a finding that has been duplicated elsewhcre.(44) No
socioeconomic gradient in sCJD has been demonstrated. However studies from the
USA consistently report an excess of cases among white relative to black
populations.(49) This may be due to ascertainment bias. Racial differences in access
to health care have been documented. However racial differences in disease
occurrence may also reflect genetic susceptibility/resistance factors. For example,
Plaitakis et al reported an excess of cases of sCJD in Crete where the incidence rate
was five times higher than expected.(56) The authors demonstrated a higher than
expected proportion of the local population had a susceptible PRNP Codon 129
genotype (methionine homozygote).
Spatio-temporal clusters of sCJD have been described. In some cases investigation
has revealed that the disease has a genetic rather than sporadic aetiology such as in
Slovakia,(57) Chile,(58) Israel,(59) France,(60) Italy(61) and Japan.(62) In others,
exhaustive investigation has failed to reveal an explanation for the higher than
expected number of cases. Such clusters have been reported in France,(63;64)
England,(65;66), Japan,(67) the USA (68) and Australia.(69;70) In the absence of an
alternative explanation it has been proposed that enhanced surveillance in
geographically defined areas may have led to apparent clustering.(70;71)
Risk factors
The cause of sCJD is not known. Putative risk factors have been investigated through
case control studies conducted in America, Japan and Europe. Given the temporal and
spatial distribution of cases some commentators have suggested that an environmental
exposure is unlikely.(72) Studies to date have largely focused on risk factors that
might indicate possible case to case transmission or zoonotic spread from animal to
human. Case control studies examining putative risk factors for sCJD are summarised
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in Table 4. Due to the rarity of sCJD, the multiplicity of putative risk factors and the
potential latency period between exposure and disease development, case control
studies are an appropriate epidemiological tool for exploring aetiology. However,
there are a number of limitations to this study design that should be considered in
interpreting these results. The most significant limitation is that case control studies
arc prone to bias, a systematic error in the design, analysis or reporting of a study that
leads to incorrect conclusions being drawn. This may be information bias (systematic
difference in the way that information on exposure and/or outcome is assessed
between cases and controls) or selection bias (controls are not representative of cases
with respect to all factors except outcome). Case control studies are always
retrospective, both exposure and outcome have occurred at the time of data collection,
therefore conclusions regarding temporality between an exposure and outcome cannot
be drawn. Finally sCJD is a rare condition. Most studies have had small sample sizes
and therefore limited statistical power. Consequently studies demonstrating an
association between an exposure and sCJD often have wide confidence intervals
reflecting uncertainty as to the true measure of association and can be difficult to
interpret. A number of approaches have been taken to attempt to increase sample sizes
and statistical power. Several studies recruited more than one control per case. It can
be difficult recruiting additional controls particularly in studies employing a matched
design whereby cases and controls arc matched on key variables such as age, sex or
residency. Alternative approaches include collaborative studies (73-75) and the
pooling and re-analysis of data from published studics.(76) Due to the rarity of sCJD
and the diverse geographical spread of cases, even in a comparatively small
geographically area such as the UK, national case control studies are extremely time
consuming and expensive to carry out; standardising methodologies across countries
is extremely challenging.
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As can be seen in Table 4, very few putative risk factors arc consistently associated
with sCJD. Seven studies found an association between surgical intervention and
sCJD, although the timing (from within 5 years of symptom onset to lifetime surgical
history) and type ofprocedure ('any', head, neck, face, ophthalmological,
orthopaedic, gynaecological, peripheral vascular, gastrointestinal) varied
significantly.(73;78;79;82;84;87;88) These findings may in part be explained by bias
(control selection and assessment of exposure). Two studies have however reported a
dose-response effect which would provide additional evidence to support an
association.(82;87) Whilst unrecognised contamination occurring during surgical
procedures may represent a route of transmission of sCJD, due to the inherent
limitations of these studies firm conclusions cannot be drawn. Indeed a recent re-
analysis of data from six case-control studies reporting the relationship between
sCJD and surgery stated that
"variation in the type ofcontrol subjects used and in exposure assessment in
case-control studies may partially explain conflicting data regarding the
association between surgery and G/D."(90)
Medical risk factors of trauma or physical injury were identified in two studies
(78;79) although the sample sizes in these studies were small and confidence
intervals wide. A subsequent pooled analysis of American, Japanese and UK studies
found no association.(76) Positive family history of dementia in a first degree
relative was reported more common in sCJD cases than controls in three
studies.(74;80;89) Some of these studies have included genetic prion disease cases
and the possibility of differing Codon 129 genotype distributions between cases and
controls was not adequately explored.(74) More recently a comprehensive German
study confirmed that sCJD cases were more likely than controls to report a family
history of dementia; this could not be explained by the inclusion of genetic prion
disease cases or the distribution ofPRNP Codon 129 gcnotyping.(89) An excess of
ApoE4 allele carriers was reported in sCJD cases with a family history of dementia,
although the association between ApoE4 and sCJD is the subject of intense debate. It
is noteworthy that family history of dementia was self-reported and may be subject to
reporting bias as the relatives of individuals with sCJD may be more likely to recall
and report a positive family history than healthy control subjects. There are isolated
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reports of sCJD occurring in spousal couples,(91) siblings and co-workers,(92) but
little evidence of case to ease transmission through social contact.
Given interest in a possible actiological association between animal prion diseases
and sCJD, several studies have examined diet, exposure to animal products and
occupation. Isolated associations with exposure to leather products, living or working
on a farm or market garden, working in an animal laboratory or as a butcher and use
of hoof and horn fertilizer have not been reproduced.(81) The study by Cocco et al
using death certificate data to ascertain both cases and controls identified nine
occupations in seven industries associated with sCJD in addition to working as a
butcher and working in the office of a physician.(81) In the absence of a biologically
plausible hypothesis for the relationship between these occupations and sCJD and a
lack of supporting epidemiological evidence these associations are likely to be
spurious associations that have arisen due to multiple comparisons. Many studies
report inverse relationships between sCJD and various exposures. For example Zerr
et al reported a reduced likelihood of sCJD cases reporting any surgery when
compared to controls (odds ratio (OR) 0.68 (95%CI 0.48 - 0.98).(75) This is unlikely
to represent a protective effect. The authors re-analysed their data according to
control selection and found that hospital control reported exposure to medical and
surgical interventions more frequently than non-hospital (population) controls
thereby biasing their results toward the null.
Clinical features
Non-specific prodromal symptoms, such as weight loss, lethargy, disordered sleep,
headache, depression or anxietymay be reported at onset. It is not clear whether
these initial symptoms relate specifically to sCJD or arc reported as a result of recall
or reporting bias.(80) In most cases a rapidly progressive global dementia follows,
although the clinical presentation may vary. Other recognised clinical presentations
include a pure cerebellar onset (the Brownell-Oppenheimer variant) and cortical
blindness (the Heidenhain variant). As the clinical picture progresses signs and
symptoms reflect global neurological involvement. Dementia is present during the
course of the clinical illness in 97% of cases, cerebellar signs in 87% and myoclonus
in 81%.(93) Extra-pyramidal and pyramidal features are reported to occur in 74%
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and 55% of cases respectively. Visual symptoms ranging from blurred vision, visual
hallucinations and visual field defects to cortical blindness are reported in over half
(58%) of all cases. Pain is rarely reported. Seizures occur in around 12% of cases,
typically in the later stages of illness. Akinetic mutism dominates the terminal phase
of illness. Most patients succumb to aspiration or dependant pneumonia a median of
5 months (mean 7.3 months) after symptom onsct.(94) A survival advantage has
been reported in association with a number of sociodemographic characteristics
(female, young age at onset) and diagnostic features (PRNP Codon 129
heterozygosity, CSF 14-3-3 positivity and Prion Protein Type 2).(94)
Diagnostic criteria
Diagnostic criteria for sCJD were first proposed by Masters et al in 1979.(95) These
included clinical features (progressive dementia and at least two ofmyoclonus,
visual or cerebellar disturbance, pyramidal or extra-pyramidal dysfunction, or
akinetic mutism) and typical electroencephalography (EEG) findings. In 2000 a
cerebrospinal fluid (CSF) biomarker of neuronal injury, CSF 14-3-3 protein, was
added to the clinical criteria.(96;97) The case definition of sCJD applied by the
WHO for surveillance purposes at the time of data collection for this thesis is
outlined in Appendix 2.(98) These criteria have a sensitivity and specificity of 92%
and 71% respectively.(99) Recently, acknowledging the role of magnetic resonance
imaging (MRI) in the diagnosis of sCJD, a change to the diagnostic criteria has been
proposed.(99) The data collected in this thesis pre-date these developments therefore
the published criteria referred to in Appendix 2 will be applied throughout this thesis.
Differential diagnoses
The differential diagnosis of sCJD is wide, encompassing a range of neurological and
psychiatric conditions (Tabic 5). The most common differential diagnosis is
Alzheimer's Disease following a rapid course.(l;100;101) In younger patients
enccphalitic processes are more commonly found. A less frequently, but potentially
treatable differential diagnosis, is Hashimoto's encephalitis.
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Table 5 Clinical differential diagnosis of sCJD, adapted from Zerr et al (93)
Frequent Rare
Alzheimer's Disease Parkinson's Disease
Lewy Body Dementia Psychiatric disease
Inflammatory diseases of the (INS Multi-system atrophy
Vascular / hypoxic encephalopathy Frontotemporal Dementia




Intracerebral tumour or metastasis
Wcrnicke-Korsakow syndrome
Hydrocephalus
Investigations that support a diagnosis of sCJD
In the section that follows I will focus on investigations of proven value in sCJD.
These include EEG, MRI, CSF 14-3-3 protein, PRNP Codon 129 genotyping, full
sequencing of PRNP for mutations and neuropathological studies (ante-mortem brain
biopsy and autopsy). Routine haematological and biochemical biomarkers are
typically normal in all forms ofprion disease.
Electroencephalogram (EEG)
The EEG was first recognised as being of diagnostic value in sCJD in 1954 (102) and
incorporated into diagnostic criteria in 1979.(95) The characteristic features
associated with sCJD on EEG are periodic sharp wave complexes (PWSC) (Figure
5). PSWC arc usually generalized although lateralizcd or focal complexes are
recognised. Lateralized complexes often evolve into typical bilateral PSWC. Criteria
for the quantitative assessment of EEG in suspect sCJD were proposed by Steinhoff
and Knight and adopted by the WHO for surveillance purposes (Table 6).(98) These
criteria have not been prospectively validated in large scale studies and for several
reasons the use of these criteria in the UK and elsewhere has been limited. For
example in the UK there is significant variation in access to and use of digital
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recording for EEGs. As a result the assessment of EEG for disease surveillance
purposes remains largely subjective (personal communication R. Knight).
ECG 100 0 20 Hz
Figure 5 EEG recording showing a 'typical' EEG with generalised PSWC in a
case of sCJD (14)
Table 6 Criteria for the quantitative assessment of EEG in suspect sCJD (98)
Strict periodic activity
Variability of inter-complex intervals is <500 ms
Continuous periodic activity for at least one 10-second period
Bi or tri-phasic morphology of periodic complexes
Duration ofmajority of complexes ranges from 100 to 600 ms
Periodic complexes can be generalized or latcralized but not regional or asynchronous
The EEG often evolves over the course of the clinical illness in sCJD.(103) In the
early stages the EEG may show non-specific background slowing or FIRDA-likc
activity (Frontal Intermittent Rhythmic Delta Activity). Subsequent EEGs may show
PSWC. In the advanced stages of disease PSWC reduce and may disappear. The
timing of this investigation is therefore crucial. An EEG too early or too late in the
course of the clinical illness may not detect typical findings; serial EEGs maximise
the diagnostic yield. Approximately two thirds of sCJD cases develop a typical EEG
at some point in the course of their clinical illness. In a series of 150 confirmed sCJD
eases, Steinhofif et al reported that 64% developed a typical EEG, first recorded a
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mean of 3.7 months (SD 3.1) after onset and recorded 2.3 months (SD 3.4) before
death.(104)
The sensitivity, specificity and positive predictive value (PPV) of a typical EEG in
sCJD are 58% - 66%, 74% - 91% and 93% - 95% rcspcctively.(96;97; 104; 105)
Much of the data on the diagnostic value of EEG in sCJD has been published by the
German CJD Surveillance Unit. This group recently reported a fall in the sensitivity
ofEEG from 66% (1996 - 2000) to 32% (2001 - 2003).(106) The authors attributed
this to the increasing use of CSF 14-3-3 protein which has led to suspect sCJD cases
being referred to the surveillance unit at an earlier stage, prior to the onset of PSCW
on EEG. Similar findings have been reported elsewhere in Europe.(107)
Collins et al, in a study of 2083 neuropathologically confirmed sCJD cases,
demonstrated that the sensitivity of EEG varied according to molecular subtype.(97)
In addition, the likelihood of a typical EEG increased with age and decreased with
disease duration (disease duration <6 months more likely to have a typical EEG than
duration > 6 months). The authors also showed that a typical EEG was more likely in
the last, compared to the first, third of illness.
The EUROCJD group reported temporal trends in the use of investigations to support
a diagnosis of definite or probable human prion diseases across 11 countries from
1993 through 20002.(107) EEG was more commonly undertaken than MRI or CSF
14-3-3 protein examination; up to 80% of definite or probable prion disease cases
underwent EEG examination at some point in the courses of their clinical illness.
However the trend was toward a fall in the number of cases undergoing EEG
examination over time, mirrored by a rise in CSF 14-3-3 protein examinations. As a
result, the annual proportion of patients meeting the WHO diagnostic criteria as a
probable case of sCJD based on EEG and clinical features alone fell from 95% in
1993 to 3% in 2002.
PSWC arc not pathognomonic of sCJD and have been demonstrated in patients with
alternate diagnoses as outlined in Table 7.
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Table 7 Differential diagnosis of PSWC-like pattern on KEG
Ncurodcgencrative Alzheimer's Disease, Lewy Body Dementia
Vascular Dementia, Acute Cerebral Thrombosis or Kmboli,
Cerebral Neoplasm
Encephalitis especially Herpes Simplex Encephalitis,
Subacute Sclerosing Panencephalitis
Multiple Cerebral Abscesses, AIDS Dementia
Hepatic encephalopathy, MELAS, hyperammonaemia, hypoxia,
hyperparathyroidism, hypo and hypernatraemia, hypoglycaemia
Baclofen, mianserin, metrizamidc, lithium toxicity,









One small study from the German CJD Surveillance Unit examined inter-observer
variation in the reporting of EEGs using the objective criteria described in Table 6 to
assess EEGs.(105) Two reviewers blindly assessed 68 EEGs from 29 suspect sCJD
cases (15 sCJD cases and 14 non-cases diagnosed using the WHO clinical criteria
that include assessment ofEEG; of note the diagnosis was not neuropathologically
confirmed in any of the non-cases). The authors report a kappa statistic of 0.95,
indicating almost perfect agreement between reviewers, a sensitivity of 67% and
specificity of 86%. In a follow up study Steinhoff and colleagues presented a
comprehensive review of EEG data collected by the same unit from 1996 through
2000.(104) All EEGs in this study were objectively scored using the same criteria by
a single reviewer. Sensitivity, specificity, positive and negative predictive values of
64%, 91%, 95% and 49% (without associated 95% confidence intervals) were
reported. Intra-observer variation was not assessed in this series. Indeed, there arc no
published reports of intra-observer variation in the assessment ofEEG, despite
seminal studies, such as that by Stcinhoff el al, utilizing a single reviewer to assess
all EEGs.(104) A validation study of objective or subjective criteria for the
evaluation of EEG for case classification in sCJD should include an assessment of
both intra and inter-observer variation. This is a critical gap in the literature.
Given potential variation in subjective EEG reporting and the importance of EEG in
the diagnostic criteria for sCJD, it is essential that as many EEGs as possible are
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reviewed by PUS systems. Large studies reporting surveillanec data, such as that by
Collins et at, do not report the proportion of EEGs that were examined by a member
of the surveillance team.(97) Nor do they provide information on the number of
suspect eases referred to the P1IS system that underwent EEG examination. Yet,
these data arc required to determine the completeness of case ascertainment by PHS
systems.
Cerebrospinal fluid (CSF)
As with EEG, lumbar puncture examination to obtain cerebrospinal fluid (CSF) is an
extremely common investigation undertaken in the investigation of subacute
encephalopathy. In the appropriate clinical context, the detection ofCSF 14-3-3
protein, a physiological cellular protein released in large quantities following
neuronal injury, is a useful diagnostic test for sCJD (Figure 6). The detection ofCSF
14-3-3 protein by immunoblot was incorporated into the WHO diagnostic criteria for
sCJD in 2000. By 2000 the proportion of definite or probable sCJD cases undergoing
CSF 14-3-3 protein testing was comparable to the proportion undergoing EEG (over
90%).(107)
The reported sensitivity and specificity ofCSF 14-3-3 protein are between 43 - 100%
and 84 - 100% respectively.(96;97; 108-117) The sensitivity and specificity are
known to vary according to a number of factors. Cases with younger age at onset and
longer illness duration (>6 months) arc more likely to have a negative
examination.(97;109;l 10; 118) Molecular subtype is an important determinant of
positivity; CSF 14-3-3 protein has a higher sensitivity in MM1, MV1, VV1 and VV2
molecular subtypes than in the MM2 or MV2 subtypcs.(97;109;l 10; 116-118) Unlike
EEG examination the timing of this investigation in relation to the clinical course of
the disease does not influence the probability of a positive result.(97;l 18)
55
123456789
Figure 6 Western Blot of CSF 14-3-3 protein (14)
Lanes 1, 2, 3 are positive for CSF 14-3-3; Lanes 4, 5, 6 are weakly positive for CSF 14-3-3; Lanes 7, 8 and 9 are negative for
CSF 14-3-3 Lanes 1 and 2 are from two patients with sCJD; Lanes 3 and 4 are from patients who have hat! a stroke; Lanes 5, 6,
7, 8 and 9 contain CSF samples from patients who do not have CJD. In the UK weakly positive CSF 14-3-3 results are not
considered to be supportive of a diagnosis of sCJD.
Various studies have reported sensitivities using different methods of detecting CSF
14-3-3 protein. The most widely applied method is Western Blot (Figure 6), which
requires a qualitative assessment of the result by an experienced biomedical scientist
and produces sensitivities and specificities ranging from 84 - 100% and 60 -
100%.(96;97; 109-115) Other quantitative methods including ELISA (Hnzyme-linked
immunosorbent assay), capture essay and sICMA (sandwich
immunochemiluminometric assay) have slightly lower sensitivities and specificities.
(116)
A positive CSF 14-3-3 protein test result has been reported in a number of
conditions, although most are distinguishable clinically from sCJD (Table 8).
Other brain specific proteins have been explored as diagnostic tools in sCJD, cither
alone or in combination with CSF 14-3-3 protein, although as yet none have been
incorporated into the diagnostic criteria. Tau, phosphorylated Tau and NSE (neuronal
specific enolase) are markers of neuronal damage whilst S-lOOb is a marker of
astrocytic gliosis. The most promising in sCJD is Tau which reportedly has a
sensitivity and specificity approaching that ofCSF 14-3-3 protein.(113; 119; 120)
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Table 8 Differential diagnosis of a positive CSF 14-3-3 protein examination
Neurodegenerative Alzheimer's Disease, Lewy Body Dementia, Erontotemporal Dementia,
Corticobasilar Degeneration
Vascular Dementia, Acute stroke including subarachnoid haemorrhage
Carcinomatous Meningitis from small-cell lung cancer,
Paraneoplastic Encephalopathy, Glioblastoma
Viral encephalitis especially Herpes Simplex Encephalitis,
Subacute Sclerosing Panencephalitis
Multiple Cerebral Abscesses, AIDS Dementia
Hepatic encephalopathy, hyperammonaemia, hypoxia,













Other CSF abnormalities have been described in sCJD. In a Huropean collaborative
study of 450 neuropathologically confirmed sCJD cases. Green and co-workers
describe an elevated total protein concentration of greater than 0.6 g/L as the most
common abnormality of the CSF, affecting around 10% of sCJD cases.(121) The
total protein concentration was greater than Ig/L in approximately 1%. The
prevalence of oligocolonal bands in the CSF was 4.4%, which is less than the
reported prevalence in the general population. A white cell count of greater than 5
cells/pl was extremely uncommon. The authors concluded that significantly elevated
white cell counts and total protein concentrations would suggest a diagnosis other
than sCJD.
Whilst an extremely valuable investigation, CSF 14-3-3 protein requires a lumbar
puncture which is an invasive test. In addition to being expensive, CSF 14-3-3
protein assays require experienced and highly skilled biomedical scientists to
perform analyses and interpret results. This investigation may therefore not be
widely available in some countries. In the UK for example CSF 14-3-3 protein
testing is available through the NCJDSU, not local or regional laboratories. Requests
for this investigation are received from across the UK and the service is provided
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free at the point of access. Centralisation of the service ensures quality control and
location of the service within the PUS unit ensures rapid recognition of suspect cases
of sCJD. The UK CSF 14-3-3 protein service also acts as a WHO reference centre
and processes samples from countries which do not readily have access to this
resource.
Magnetic Resonance Imaging (MRI)
Until recently the principal value of neuroimaging in sCJD was to exclude a
potentially treatable differential diagnosis. Most suspect sCJD cases undergo a
computed tomography (CT) scan of the brain. CT is usually normal, although in the
late stages of disease (6 months or more after symptom onset) cerebral atrophy is
seen in up to 20% of cases.(122) Decreased metabolism and changes in cortical
blood flow have been reported in small case series using positron emission
tomography (PET) and single photon emission computed tomography (SPECT)
respectively. These findings have not been validated in large scale prospective
studies and the diagnostic utility of such imaging modalities is unclear. There is
however significant interest in the use of SPECT scanning in certain molecular
subtypes of sCJD in which MRI is of limited value, for example the MM2
subtypc.(123)
MRI is the ncuroimaging modality of choice in CJD, irrespective of aetiological
subtype. A number ofMRI sequences are of value in sCJD. Initially T2-weighted
and proton density (PD) weighted images were favourcd.(124;125) These have
largely been superseded by the more sensitive sequences of fluid attenuated inversion
recovery (FLAIR) and diffusion weighted imaging (DWI).(99;106;126;127) DWI is
considered the most sensitive of these sequences, followed by FLAIR and T2
weighted imaging. (127; 128)
Characteristic findings on MRI include bilateral hyper-intense signal in the putamen
and caudate (although asymmetrical involvement of the corpus striatum can occur)
and so called 'cortical ribboning' denoting high signal in the cerebral cortex (Figure
7). (99;124;126;129) Occasionally features suggestive of the 'pulvinar sign,' hyper-
intensity of the pulvinar nucleus relative to the anterior putamen, have been reported.
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A recent study by Zerr et al reported the greatest diagnostic accuracy ofMRI (in the
appropriate clinical context) when high signal was detected in both the caudate
nucleus and putamen, or in two of the following cortical regions: parietal, temporal
or occipital.(99) Over 80% of definite or probable sCJD cases had evidence of these
changes on FLAIR or DW1 imaging in this European collaborative study. In an
earlier study Huropcan collaboration examining 1063 ncuropathologically confirmed
sCJD cases, just over a third had evidence of basal ganglia high signal on MRI
scanning; this study did not however consider cortical high signal, only basal ganglia
changes.(97) In a small cases series (n=26) Shiga and co-workers reported cortical
high signal only in 42% of definite or probable sCJD cases, basal ganglia high signal
only in 13% and high signal in both in 46%.(126)
Figure 7 MRI showing cortical (left) and basal ganglia (right) high signal on
DWI sequences in sCJD (14)
The use ofMRI has increased over time reflecting increasing availability of this
investigation and a growing recognition of its diagnostic value in suspect sCJD. The
proportion of definite or probable sCJD cases undergoing MRI examination
increased from approximately 15% in 1993 to around 70% in 2002 in the multi¬
centre EUROCJD collaborative study by Pedro-Cucsta et ul.( 107)
MRI changes have been observed as early as 3 weeks following symptom onset and
prior to the detection of LEG abnormalities.(126;130) Unlike CSF 14-3-3 protein and
59
EEG, MRI findings arc not associated with age at onset or disease duration.(97) MRI
appears to be of value in rarermolecular subtypes of sCJD. Meissner et al evaluated
MRI scans from 211 pathologically confirmed sCJD cases from 12 countries,
correlating MRI findings to molecular subtypes.(127) Basal ganglia high sign was
most commonly reported in the MM1, MV2 and VV2 subtypes, cortical ribboning in
the MM2, MV1 and VV1 subtypes and thalamic high signal in the MV2 and W2
subtypes.
It is difficult to determine the sensitivity and specificity ofMRI in sCJD for a
number of reasons. The diagnostic technology has evolved rapidly and as previously
noted the sensitivity and specificity of this investigation varies according to the MRI
sequences used; in many studies these were not optimized. Moreover, the diagnostic
value of cortical high signal has only recently been recognised. Early studies reported
basal ganglia high signal only.(97;l 06) The most recent study to report the sensitivity
and specificity ofMRI defined a positive scan as one showing high signal in the
caudate nucleus and putamen or high signal in two of three cortical regions (parietal,
occipital or temporal) on DWI or FLAIR sequences.(99) The authors reported a
sensitivity and specificity of 83%. In this study the addition of these MRI criteria to
the current WHO diagnostic criteria improved the overall sensitivity of the diagnostic
criteria from 92% to 98% without compromising specificity (71 % both current and
proposed criteria). The additional cases detected through MRI scanning were of the
rare molecular subtypes, such as W1 and MV2, in which EEG and CSF 14-3-3
protein are of limited diagnostic value. Based on this evidence the authors have
called for MRI criteria to be added to the currentWHO diagnostic criteria for sCJD.
At the time ofwriting this had not yet occurred although appeared imminent.
Basal ganglia high signal has been reported in a number of conditions, most ofwhich
are clinically distinguishable from sCJD (Table 9).
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Tabic 9 Differential diagnosis of basal ganglia high signal on MRI
Neurodegenerati ve Alzheimer's Disease, Lewy Body Dementia, Frontotemporal Dementia,
Mitochondrial disease (Leigh's Disease), Huntington's Disease
Vascular Dementia
Carcinomatous Meningitis from small-cell lung cancer,
Paraneoplastic Encephalopathy, Glioblastoma
Lymphocytic encephalitis, Progressive multifocal
lcucoenccphalopathy, viral encephalitis
Subacute Sclerosing Panencephalitis, AIDS Dementia, Multiple Sclerosis
Hepatic encephalopathy, hypoxia, hypoglycaemia, Wilson's
Disease












MRI findings can be difficult to interpret. Basal ganglia changes are often missed,
especially in elderly populations. Schroter et al reported that characteristic changes
in the basal ganglia are missed in up to 80% of images if these are not specifically
sought by a neuroradiologist.(124) This is consistent with earlier findings from
Zeidler et al in the UK.(131) Two large studies have reported intra and inter-observer
variation in the examination ofMRI imaging in suspect sCJD cases. Tschampa et al
examined 442 MRI scans from 193 consecutive suspect sCJD cases referred to the
German Surveillance Unit between 2001 and 2003.(106) Three reviewers
independently assessed the scans. The overall kappa statistic for inter-observer
agreement was 0.53 indicating moderate agreement; when only scans considered
diagnostic were considered this rose to 0.66 indicating substantial agreement. Almost
two thirds of definite or probable sCJD cases had evidence of basal ganglia high
signal on MRI in this series and the sensitivity, specificity and positive predictive
values of these MRI findings varied from 60 - 71%, 82 - 90% and 94 - 96%
respectively between the three reviewers. Intra-observer agreement was not reported
in this study but was examined in a recent study by Zerr et al who examined 436
MR! scans from suspect sCJD cases referred to 12 European surveillance centres
between 1998 and 2007.(99) Five neuroradiologists blindly reviewed one scan per
patient. A kappa statistic of 0.64, indicating substantial agreement was reported for
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intra-obscrvcr variance; whilst kappa statistics varying from 0.45 (moderate
agreement) to 0.64 (substantial agreement) were reported for inter-observer variance.
Genetic analysis
The phenotype of genetic disease maybe clinically indistinguishable sCJD. The
principal indication to test for a mutation ofPRNP in suspect sCJD is to exclude
genetic disease. The EUROCJD consortium report that genetic analysis was
performed on approximately 64% of all definite or probable cases of human prion
disease referred to national disease surveillance units; mutations were detected in
8.5%.(107) These figures have been relatively stable across time (1993-2002).
The PRNP polymorphic residue at Codon 129 determines susceptibility to
sCJD.(l 32) In European populations the Codon 129 allelic distribution is as follows:
methionine homozygote 37%, methionine hcterozygotc 51% and valine homozygote
12%.( 133) However in European studies over 70% of sCJD cases are methionine
homozygote.(134) Codon 129 genotype influences age at onset, disease duration and
clinical phenotype. Across Europe an estimated 70% of all definite or probable
human prion disease cases ascertained by national surveillance units participating in
the EUROCJD consortium underwent genotype analysis; this figure is invariant over
time (1993-2002).(107)
Neuropathology
Neuropathological examination is required to reach a definite diagnosis in all prion
diseases. Neuropathological material can be obtained ante-mortem through brain
biopsy or at post mortem following death.
Brain biopsy
Brain biopsy is an invasive investigation that involves removal of a small area from
the non-dominant frontal cerebral cortex under general anaesthesia. Associated with
serious complications and non-diagnostic in over 40% of cases, brain biopsy is
reserved for suspect cases in which a treatable differential diagnosis is considered
likely.( 135) Heinemann el al reported the neuropathological findings in all suspect
CJD cases referred to the German Surveillance Unit (1993-2005) that underwent
brain biopsy (n=26).(135) Biopsy was non-diagnostic in 42% (n=l 1). In a further
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42% (n~l 1) sCJD was confirmed, although almost half (n=5) of these individuals
met the WHO diagnostic criteria as a probable case of sCJD prior to biopsy. A
potentially treatable diagnosis was identified in just 3 (12%) suspect cases
(vasculitis, chronic encephalitis and progressive encephomyelitis with rigidity and
myoclonus) although none of these patients improved clinically following treatment.
Between 10-20% of dementias are considered 'revcrsiblc.'(136) However one study
has shown that less than half of all 'reversible' dementias improve with treatment
and only around 10% fully reverse with treatment^ 136) Beyond clinical
considerations, there are further issues in relation to the need for appropriate facilities
and the destruction or decontamination of surgical instruments following brain
biopsy that may determine the availability of this investigation.
Post mortem examination
In the absence of a non-invasive ante-mortem diagnostic test post mortem
examination following death is extremely important in suspect CJD. In the UK an
estimated 70% of suspect CJD cases undergo post mortem examination,(72) however
post mortem rates are falling.(l 37) Views toward this practice may have changed
over time meaning that relatives are less likely to consent to, and clinicians may be
more reluctant to request, post mortem examination. There have been several highly
publicised issues relating to informed consent and organ retention in the UK in recent
years which may have negatively influenced public opinion.
Pedro-Cuesta et al reported significant international variation in rates of post mortem
in countries participating the EUROCJD project (1993-2002).(107) For example
Slovakia reported autopsy rates of 100% whilst Spain, Germany and Italy reported
rates of less than 60% (definite or probable sCJD cases). In the UK the rate
fluctuated at around 80%. It is noteworthy however that this study did not report
autopsy rates in all suspect cases referred to surveillance systems over time. Only
around half of all suspect cases referred to surveillance systems meet the WHO
diagnostic criteria for definite or probable disease.(138) In Japan, the rate ofpost
mortem examination among all suspect prion disease cases referred to their
surveillance system is quoted as approximately 25%.(139) In Germany 38% of all
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suspect sCJD eases (n=358) referred to the surveillance system over a three year
period (1993-1996) underwent autopsy; 49% of cases that met the W110 diagnostic
criteria as a probable case of sCJD in life, 39% who met the criteria as a possible
case in life and just 18% that did not meet the diagnostic critcria.(lOO) As previously
noted practical issues relating to the examination of ncuropathological material in
suspect CJD may limit the use ofpost mortem examination, for example access to
appropriate facilities and infection control issues.(140)
Neuropathological features
Macroscopic changes in sCJD are confined to the central nervous system. On gross
examination cerebral or cerebellar atrophy may be observed. Microscopically, a
classical triad of features are found: spongiform degeneration, astrocytosis and
neuronal loss (Figure 10). Spongiform change may be localized or widespread.
Amyloid plaques composed of PrP may be detected in up to 10% of cases. Definitive
diagnosis requires immunocyochcmical detection of PrPSc (Figure 8).
•. mm,
Figure 8 Microscopic and immunocytochemical features of sCJD (14)
The MM1 subtype of sCJD is characterised by microvacuolar spongiform change in the cerebral cortex, composed of small
relatively uniform rounded vacuoles in the neuropil. Haematoxylin and eosin (H&E) stain (left); Severe neuronal loss and
gliosis in the MM2 (thalamic) subtype of sCJD is a typical neuropathological finding, most evident in the medial and anterior
thalamic nuclei. There is relatively little spongiform change present in the affected areas. H&E stain (centre).
Immunocytochcmistry for prion protein in the MM2 (cortical) subtype of sCJD shows widespread perivacuolar accumulation.
A fine background granular/synaptic pattern of abnormal prion protein accumulation is also evident (right).
Molecular subtyping
Molecular subtype, the Codon 129 genotype in association with PrPSt prion protein
typing, influences the clinico-pathological phenotype in sCJD.(141) In sCJD two
major PrPSc prion protein types have been described: Type 1 (21 kDa non-
glycosylated PrPSc) and Type 2 (19 kDa non-glycosylated PrPSc).(142) PRNP Codon
129 genotype and PrPSc prion protein type have been combined to produce a
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molecular classification for sCJD that includes 6 major subgroups: MM1, MM2,
MV1, MV2, VV1 and VV2 which explain much of the phcnotypic variability in
sCJD.(133;143;144) The clinical and ncuropathological features described in Parchi
et aVs classification are outlined in Table 10.(133) As can be seen from Table 10
several disease subgroups correlate directly with well-defined clinical presentations
of sCJD such as that MM1 and VV2 subgroup. Other subgroups, such as the MM2
and VV2, correlate with what would be considered 'atypical' presentations of sCJD,
rare presentations, early age at onset and/ or long illness durations. The MM1 and
MV1 molecular subtypes have been grouped together in this classification because
phenotypically they are indistinguishable.
Two alternate classifications exist. Hill et al describe three prion protein types in
sCJD: Type 1, 2 and 3 (a fourth is described found uniquely in vCJD).(145) In the
Hill classification Type 1 PrPSc is approximately 0.5 kDa higher than Type 1 in
Parchi and all cases are methionine homozygote. Broadly speaking Hill Type 1 and 2
appear to correlate with Parchi Type 1, and Hill Type 3 (and 4) with Parchi Type 2.
Zanusso et al's classification is similar however these authors identified two groups
ofMM1 cases distinguishable based on the pH sensitivity of PrPSc; clinically the pi I
sensitive group have a shorter disease duration than the pH insensitive group.(146)
Whilst heterogeneity in clinical phenotype in the MM 1 subgroup is recognised,
differences in PrPSc pH sensitivity have not been consistently reproduced.(143) In
summary, both Hill and Zanusso are similar to Parchi except the former argue for a
further sub-grouping of MM1 cases based on PrPSc and clinical phenotype, although
this view is not supported by the current literature.(143)
A more pressing issue undermining the Parchi classification is the co-existence of
two PrPSc types. In 12 - 44% of sCJD cases Type 1 and Type 2 PrPSc are found
concurrently.(147) Some commentators suggest that these estimates may be
significantly lower than the true figures;(148) others argue that methodological
issues such as examining a small number of cases and bias in case selection,
examining a limited number of samples from each case and the areas of the brain that
have been sampled (focal areas ofmixed protein type have been described) and the
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use of novel tcehnologics that do not produce consistent results, may have led to an
overestimation of the co-existence of Type 1 and Type 2 PrPSc.(147) In the largest
study to date, examining samples from 200 consecutive cases, Parchi et al estimated
that PrPSc Types 1 and 2 coexist in approximately 35% of sCJD cases.(147) In this
study mixed protein types occurred more frequently in the MM genotype than the
MV or VV genotypes. In such cases the MM1 clinical phenotypc predominated,
although exceptions were noted. These results are not consistent with smaller studies
that have variably reported the coexistence of PrPSc Types 1 and 2 occurring most
frequently in MM or MV,(149) MV (150) and MV or VV genotypes (151), with
associated variation in the predominant clinical phenotype. Some of the variation
between studies may be explained by the methodological limitations previously
highlighted and a systematic approach is required to ensure comparability of studies.
An updated nomenclature proposed by Parchi et al based on their recent study has
been reproduced in Table 11 .(147)
Collins et al reported diagnostic sensitivities across molecular subtypes in analysis of
743 definite sCJD cases.(97) The distribution ofmolecular subtypes was as follows:
MM1 60%, MM2 4%, MM 1/2 4%, MV1 5%, MV2 10%, MV1/2 1.%, VV1 2%,
W2 14% and W1/2 1% (1/2 indicating mixed protein types). MM1 patients were
older than other subtypes at disease onset and had the shortest median illness
duration whilst cases with MM2 or MV2 subtype had the longest median illness
duration. Cases with an MM 1 molecular subtype were more likely to have a typical
EEG than others. CSF 14-3-3 protein positivity was most likely in the MM1 and
VV2 subgroups whilst the W2 subgroup was most likely to have MRI consistent
with sCJD. Unfortunately the study lacked statistical power to adequately address
clinical phenotype in mixed protein cases.
Increasingly complex molecular classifications have been developed. Their relation
to the clinical and neuropathological phenotype is unclear. This area is becoming
increasingly uncertain.
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Table 11 Nomenclature and classification of sCJD subtypes, adapted from
Parchi et al (147)










MM/MV1+2C 26 As in MM/MV1 but with clusters of
large vacuoles associated to perivacuolar and
coarse PrP deposition mainly in cerebral cortex
or thalamus.
2 As in MM/MV2C but with synaptic-
typc PrP staining in the molecular layer
of the cerebellum.
3 Virtually indistinguishable from VV2.
1 Virtually indistinguishable from MV2K.
3 As in MV2K but with clusters of large
vacuoles associated to perivacuolar and
coarse PrP deposition mainly in cerebral
cortex.
<1 As in MV2T but with clusters of large
vacuoles associated to pcrivacuolar and
coarse PrP deposition mainly in cerebral
cortex.
It is largely based oil Codon 129 PRNP genotype, which can be either methionine (M) or valine (V) and the PrPSc type (1 or 2
according to Parchi ct al(l 33)). Since both MM2 and MV2 groups are associated to 2 distinct phenotypes, these arc further
defined with a third parameter (capital letter) referring to distinctive histopathological features: K kuru type amyloid plaques, C
predominant cortical pathology with confluent vacuoles and perivacuolar PrP staining, T prominent thalamic pathology with




Two further sporadic prion diseases have been described in humans.
At the time ofwriting nine pathologically confirmed cases of Sporadic Fatal
Insomnia had been reported in the literature.(152) The clinical phenotype in
Sporadic Fatal Insomnia differs from Fatal Familial Insomnia (FF1), a genetic prion
disease, in age of symptom onset and disease duration only.
Protease-sensitive prionopathy (PSPr) was characterised by Gambetti et al in
2008.(153) This novel prion disease has a non-specific phenotype and the
investigations typically of value in other forms of human prion disease, such as EEG,
MRI and CSF 14-3-3 protein, are of limited utility. In the Gambetti series 3% (11) of
all sCJD eases referred to the National Prion Disease Pathology Surveillance Center
in Ohio (USA) between 2002 and 2006 were identified as being PSPr eases. Further
cases have been identified following publication of this series, including two cases in
the UK and one in the Netherlands.(154;155) These data underscore the importance
of clinical and pathological disease surveillance and the need for high levels of case
confirmation in suspect sCJD cases and atypical dementias.
Acquired prion diseases
Acquired prion diseases have arisen as a result of the transmission of infection from
human to human (iCJD and Kuru) and from animal to human (vCJD).
Iatrogenic CJD (iCJD)
Over 400 cases of iCJD, attributable to the transmission of sCJD via health care
associated interventions, have been reported worldwide.(156) The global distribution
of iCJD is shown in Table 12.(156) The first case of iCJD was reported in 1974 in
the recipient of a corneal transplant in the USA. sCJD was confirmed following
autopsy in both recipient and donor. Two further cases were reported several years
later in individuals that had undergone elcctrocorticography for intractable epilepsy
also in the USA. The electrodes used in both procedures had previously been
implanted in a patient that died of pathologically confirmed sCJD. The electrodes
had been disinfected and sterilized between uses. These same electrodes were
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inserted into the frontal lobes of a primate who later developed clinieal and
ncuropathologieal features of sCJD thus eonfirming the route of transmission.
Further iatrogenic transmissions of sCJD via neurosurgical instrumentation have
been reported in the UK and France. There have been no new reports of transmission
via depth electrode or through the use of contamination of neurosurgical
instrumentation for three dccadcs.(156)
Table 12 Global distribution of iCJD adapted from Brown et al (156)
Surgical procedures Pituitary Hormone Therapy
Dura Surgical EFG Corneal Growth Gonadotropin
mater instruments needle transplant hormone Hormone
Argentina 1


















UK 7 3 51 1
USA 3 1 26
Total 196 4 2 2 194 5
Additional possible single cases after corneal transplant or keratoplasty (not included in the table) occurred in Japan, the UK, and the USA. f
Brazil and New Zealand human growth hormone (hGH) was prepared in the USA; Qatar hGH was prepared in France. Additional possible single
cases due to hGH (not included in the table) occurred in The Netherlands, Scandinavia, and New Zealand.
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Cadaveric-derived dura mater grafts
Cadaveric-derived dura mater grafts account for almost half of all cases of iCJD,
with half of these reported in Japan.(156) The first case of iCJD related to the use of
a cadaveric-derived dura mater graft was reported in 1987. Most cases have been
associated with the use of the Lyodura graft produced prior to 1987 by one
manufacturer; a small number of cases have been reported in the recipients of
Tutoplast grafts produced in Germany. Grafts were produced by pooling dura from
different donors; tissue had not been treated according to current recommendations
regarding decontamination. Synthetic dura mater grafts are now available
commercially.
Cadaveric-derived pituitary hormones
The first case of cadaveric-derived human growth hormone (hGH), used to treat
children with growth hormone deficiency since the late 1950s, was reported in 1985.
Further cases followed, predominantly in France, the UK and USA; in all cases
exposures were pre-1985. Isolated cases of iCJD related to the use of cadaveric-
derived pituitary gonadotrophin (hGnH) have been reported in Australia. Pituitary
hormone was produced in batches with each containing up to 2000 pituitary glands.
In all cases of iCJD associated with the injection (intramuscular or subcutaneous) of
cadaveric-derived pituitary hormones the decontamination procedures adopted were
not stringent enough to meet current recommendations. In the UK and the USA the
young age at treatment onset and prolonged duration of treatment appear to be risk
factors for developing iCJD among recipients.(156) In France all exposures occurred
during a two year window (1983-1985) suggesting significant contamination of
product during this period.
Clinicalfeatures
Table 13 outlines the clinical features of iCJD.(156) Reports suggest that
investigations including EEG, CSF 14-3-3 protein and MRI are consistent with
sCJD.(156) An excess ofPRNP Codon 129 methionine homozygote cases arc
reported relative to the population distribution of this genotype, suggesting a genetic
susceptibility. The polymorphism at PRNP Codon 129 appears to have little
influence over the clinical phenotype, the exception being in the French hGH cases
in whom a shortened incubation period is associated with PRNP Codon 129
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heterozygosity^ 157) The route of exposure does appear to influence clinical
phenotype. Cerebellar signs are prominent in peripheral routes of exposure.
Ncuropathologically cases are generally indistinguishable from sCJD with some
variability in the distribution of spongiform change, neuronal loss and astrocytosis.
In hGH cases cerebellar disease is prominent with pronounced cerebellar atrophy and
PrP positive amyloid plaque formation. Plaques arc also seen in the spinal cord.
Table 13 Clinical and pathological features of iCJD, adapted from Brown et al
(156)
Mode of infection Agent entry Mean incubation Clinical presentation
into brain period (range)
Corneal transplant Optic nerve 18 — 320 months Dementia/cerebellar
Stereotactic EEG Intracerebral 16 — 20 months Dementia/cerebellar
Neurosurgery Intracerebral 12 — 28 months Visual/dementia/cerebellar
Dura mater graft Cerebral surface 16 - 23 years Cerebellar (visual/dementia)
Growth hormone Haematogcnous (?) 4-36 years Cerebellar
Gonadotrophin Haematogcnous (?) 12 — 16 years Cerebellar
Kuru
The first accounts of kuru were published in 1957 by Gajdusek and Zigas.(l 58)
Within a decade the epidemiology of the disease had been characterised. Kuru is a
subacute neurodegenerative disease occurring in a geographically defined area in the
Eastern Central Highlands of Papua New Guinea.(l 59) It has been suggested that the
origin of kuru may have been a single human case of sCJD.(l 60) The epidemic was
propagated by mortuary rituals in which women and children ate the brains and
internal organs of deceased relatives. The proscription of ritual cannibalism in the
mid-1950s interrupted transmission and curtailed the epidemic. No cases of kuru
have been documented in individuals born after 1959. Together with age at onset,
these data can be used to estimate the incubation period of kuru. The shortest
incubation period is estimated to be 5 years, the longest 56 years, with a mean of 12
years.(17;161) The clinical phenotype of kuru is uniform. The disease presents with a
pure cerebellar syndrome. Cognitive impairment is late and mild. Death typically
occurs 12 months (range 6 to 36 months) following onset.(162) The PRNP Codon
129 genotype is known to influence both susceptibility and incubation period in
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kuru.( 161; 163; 164) Methionine homozygosity at Codon 129 is associated with
shorter incubation periods and a rapid demise; heterozygosity is associated
remarkably long incubation periods. Female survivors of the kuru epidemic are
mostly heterozygotcs suggesting that heterozygosity conferred some degree of
protection.(165) Recently a study by Mead et al detected a novel polymorphism at
Codon 127 (G127V) in a large number of susceptible PRNP Codon 129 methionine
homozygote women who lived in the region during the kuru endemic.(166) This
polymorphism is believed to confer resistance to kuru. The polymorphism was not
found in kuru cases and has not been detected in other populations. The authors
concluded that this is evidence of
"a complex selection event in the Forepopulation at PRNP during the kuru
epidemic (166)
The significance of kuru
For a period kuru was considered ofhistorical interest only. Following the
emergence of vCJD there was renewed interest in kuru. Kuru is the only known
epidemic of human prion disease, sustained through human to human transmission of
an exogenous infectious agent via a peripheral route (oral inoculation).(167)
Infection resulted in a surprisingly consistent clinical phenotype. Although
incubation periods varied markedly these were typically long (up to and beyond 50
years). More recently evidence of genetic selection in the closed population exposed
to kuru has emerged. Detailed study of the clinical phenotype, incubation periods,
routes of transmission and factors determining genetic susceptibility/resistance have
provided valuable insights that have informed policy and practice in relation to both
human and animal prion diseases.
Variant CJD (vCJD)
In 1995 the NCJDSU identified a number ofCJD cases in young individuals (aged at
death <30 years old) presenting with an unusual clinico-pathological phenotype. By
April 1996 the first ten cases of 'new variant' or simply 'variant' CJD as it would be
known were characterised in an article published in the Lancet medical journal, and
an aetiological link to BSE in cattle, proposed.(37)
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Epidemiology
In the UK the primary vCJD epidemic peaked in 2000 (27 incident cases and 28
deaths) and has been in decline since (Figure 9).(46) As of the 1st November 2010,
221 definite or probable cases of vCJD had been reported worldwide; 174 in the UK
(Table 14).(46) Outside the UK the greatest number of cases have been in France,
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Figure 9 Annual number of vCJD deaths worldwide, 1995 to 2010 (46)
Accurate as of 1st November 2010
A number of other countries have experience isolated cases of vCJD (Table 14). In
many, the affected individuals spent time in the UK during the BSE epidemic or
were reportedly exposed to UK derived beef products from this era.(168)
Comparative studies of vCJI) cases from the UK and France suggest that a common
agent is responsible for cases in both locations; phenotypically cases are
indistinguishable with the exception of age at onset (French cases were on average 8
years older at symptom onset than UK cases).(169)
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Tabic 14 Total number of incident vCJD cases worldwide, 1995 - 2010 (46)
Country Number of incident Number of incident eases
eases (alive) due to secondary transmission










Saudi Arabia 1 0
Accurate as of 1sl November 2010
Three vCJD eases in the UK have been attributed to secondary transmission via the
transfusion of labile blood components (red blood cells, fresh frozen plasma and
platelets, plasma derivatives such as Factor VIII, immunoglobulin or albumin).(154)
For disease surveillance purposes these cases are considered vCJD cases not iCJD
cases. They will therefore be addressed in this section of the thesis. There are no
reported episodes of secondary transmission of vCJD outside the UK.
Mathematical modelling techniques have been used to predict the size of the vCJD
epidemic. Initial estimates were wide, ranging from 70 to 136,000 deaths in the UK
attributable to vCJD, reflecting uncertainty around the epidemiology and
transmission potential of the disease.(170;171) The most recently published model
(2010) considers known susceptibility/resistance factors and known primary and
secondary routes of vCJD transmission. This model has estimated that an additional
390 (95% credibility interval 84 - 3000) incident vCJD cases will emerge in the UK
between 2010 and 2079.(172) The authors concluded stating
"even in the absence ofany further control measures, we do notfind self-
sustaining epidemics."(.172)
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A slight male preponderance of vCJD cases has been noted.(154) The median age at
symptom onset is 26 years (range 12-74 years); this has not changed significantly
over timc.(154) The reason for an excess incidence in younger age groups is not
clear. It has been argued that differential dietary exposure alone is not sufficient to
explain this finding.(173) An examination of vCJD deaths in the UK according to
birth cohort revealed significantly different epidemic curves in those born in or
before the 1970s compared to those born in the 1980s.(154) There were no deaths
prior to 1999 in the latter cohort. This may indicate a greater susceptibility in the
very young following exposure or reflect age dependant differences in incubation
periods.(173) There have been no cases of vCJD born after 1989 (the year of the
SBO ban).
An excess of vCJD cases in the 'North' of the UK relative to the 'South' has been
rcportcd.(154) As of 2008, the rate of vCJD (according to place of residence as of
January 1991) was 4.42 per million population in the North, compared to 2.92 in the
South. The North was defined as Scotland, North of England, Yorkshire and
Humberside and the North West of England whilst the South was defined as Wales,
West and East Midlands, East Anglia, the South West and South East of England.
Extensive examination of the geographical distribution of cases in the UK has
revealed a single cluster of 5 cases in the Leicestershire area, attributed to local
butchery practices.(174)
Risk factors
There is compelling evidence from experimental transmission studies to support an
actiological link between BSE in cattle and vCJD in humans.(15;85;175;176) The
only large case control study to examine risk factors in vCJD was published by the
NCJDSU in 2006.(85) Examining 136 definite or probable vCJD cases and 922
general population controls, the study found an increased likelihood of reporting
consumption of beef and beef products (likely to contain mechanically recovered
meat) and chicken in vCJD cases compared to controls (> once per week vs. < once
per week). No other robust evidence ofmedical, surgical (including dental),
occupational, animal exposure or dietary risk factors were identified. The limitations
of case control studies have been noted. Other risk factors for vCJD appear to be
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young age and PRNP Codon 129 genotype (all definite or probable vCJD cases to
date have been methionine homozygote at PRNP Codon 129). It is unclear whether
PRNP Codon 129 genotype is genuinely risk factor, or whether vCJD in non-
methionine homozygotcs has yet to emerge due to an extended incubation period. A
recent case report in the Lancet identified a possible case of vCJD in a Codon 129
hetcrozygotc who died without post mortem.(177) Whilst the polymorphism at
Codon 129 is considered the most important genetic risk factors for vCJD other
candidate loci have recently been identified that may confer susceptibility/resistance
and warrant further investigation.(178)
Secondary transmission via blood transfusion
To date there have been no conclusive reports of vCJD secondary transmission via
health care associated procedures other than the transfusion of labile blood
components. Three cases of vCJD attributable to the transfusion of labile blood
components have been identified through the Transfusion Medicine Epidemiological
Review study (TMER) in the UK.(179) All three individuals received non-leucocyte
deplete red blood cells from asymptomatic individuals who developed vCJD between
17 months and 42 months after donating blood. The recipients developed symptoms
of vCJD 6 Zz years to 8 years, 4 months post transfusion. Transfusion related vCJD
cases have been phenotypically indistinguishable from other cases of vCJD.
To date the TMER study has identified 66 recipients of vCJD implicated labile blood
components from 18 donors.(180) A retrospective case note review examined the
medical case notes of 33 deceased recipients and found no evidence that any further
recipients expressed clinical signs or symptoms suggestive of vCJD during lifc.(181)
Only four of these recipients survived greater than 5 years post-transfusion. Tissue
was not available to examine for evidence of asymptomatic infection in any of the
deceased recipients however evidence from the kuru epidemic suggests that the
minimum incubation period is likely to be 4 Zz years.
Abnormal PrPSc has been detected in the lymphoreticular system (LRS) of two
further recipients of vCJD implicated labile blood components in the UK. Both were
neurologically normal at the time of death; both were methionine heterozygote at the
PRNP Codon 129. These cases have been termed 'asymptomatic vCJD infections.'
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The first ease, identified through the TMER study and reported in 2004, died of
unrelated causes 5 years after receiving a vCJD implicated transfusion.(19)
Neuropathological examination at autopsy was normal however PrPSc was detected
in the spleen and a cervical lymph node. PrP'Sc has been detected on a single
specimen taken from the spleen at autopsy of a second individual, a haemophiliac
who had received pooled plasma products, red blood cells and underwent numerous
invasive medical procedures including endoscopy.(182) This case was ascertained
through a collaborative prospective surveillance study between the UK Haemophilia
Centre Doctor's Organisation (UKHCDO) and NCJDSU. There are a large number
of uncertainties around the pathogenesis of vCJD and the significance of
asymptomatic vCJD infection. These issues will be discussed in greater detail later.
Clinical features
Behavioural change (withdrawal, apathy, aggression), psychiatric symptoms (ranging
from emotional lability to psychosis) and/or painful sensory symptoms predominate
at onset.(l 83-185) Many patients are referred to a psychiatrist rather than neurologist
for initial investigation. Neurological signs are not present until a median of 6.25
months after symptom onset. Neurological signs include global cognitive
impairment, ataxia and movement disorder (myoclonus or choreoathetosis). In the
terminal stages the clinical picture is similar to sCJD; patients are usually akinetic
and mute, some develop cortical blindness. Death occurs a median of 14 months
(range 9 - 35) following symptom onset. The median age at death is 29 years (range
19-41).
Diagnostic criteria
The clinical picture in vCJD has been remarkably consistent. This facilitated the
rapid development of clinico-pathological diagnostic criteria, despite the novelty and
rarity of the condition. WHO diagnostic criteria were introduced in 1998 based on
characterization of the initial cases. These were amended in 2002 to include tonsil
biopsy and later a footnote added in relation to EEG findings (Appendix 2).(98) In
the most comprehensive and contemporary series to date, Heath et al (2010)
described the sensitivity and specificity of diagnostic criteria for vCJD in 106
neuropathologically confirmed cases ascertained by the NCJDSU from 1995 through
2004 and 45 pathologically confirmed non-cases.( 186) The study reported the
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sensitivity, specificity, positive and negative predictive values of the diagnostic
criteria (met the diagnostic criteria as a probable ease during life) to be 83% (75 -
90), 100% (92 - 100), 100% (96 - 100) and 71% (59 - 82) respectively. Twelve
pathologically confirmed cases of vCJD did not fulfil the diagnostic criteria on the
basis of insufficient clinical features.
Differential diagnoses
The study by Heath et al reported the final outcome of 99 suspect vCJD cases that
met the WHO diagnostic criteria as a possible vCJD case at some point in the course
of their clinical illness. The majority (n=83) were classified as definite or probable
vCJD cases, three remained possible vCJD cases and a further eight were classified
as sCJD cases. In three cases an alternate ncuropathological diagnosis was reached
(Alzheimer's Disease, viral encephalitis and subacute sclerosing panencephalitis). In
one case a clinical diagnosis of Wilsons disease was reached and in the final case a
formal clinical diagnosis was not reached but the patient spontaneously improved.
Investigations that support a diagnosis of vCJD
Routine haematological and biochemical investigations arc typically normal in
vCJD. Transient abnormalities of liver function tests are reported in up to half of all
cases although this may not be disease specific. EEG is less useful in suspect vCJD
than in suspect sCJD. The EEG is often normal in early disease, progressing to show
non-specific abnormalities during the late stages of illness. In isolated cases PSWC
have been described on EEG in the terminal stages.(98) CSF examination is typically
normal.(121) The sensitivity of CSF biomarkers in vCJD is low; CSF 14-3-3 protein
has a sensitivity of 40% (95%CI 30 - 50), Tau 24% (16 - 35), slOOb 62% (51 - 72)
and NSE 24% (10 -45).(109) Phosphorylated Tau has shown some promise in
discriminating between vCJD and other forms of dementia, including sCJD, but not
sufficient to warrant inclusion in the diagnostic criteria.(187)
The section that follows will focus on diagnostic investigations ofproven value in
vCJD, which arc those investigations included in the WHO diagnostic criteria. It is
noteworthy that vCJD is a relatively new entity and therefore there are fewer studies
in this area than for sCJD which has been extensively studied.
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MRI
The neuroimaging modality of choice in vCJD is MRI scanning. Neuroimaging using
CT scanning is typically normal or occasionally shows generalised atrophy. Other
imaging modalities such as SPECT scanning show non-specific changes.
Two case reports of hyper-intensity in the pulvinar nucleus of the thalamus were
published in 1996.(188; 189) The following year Zeidler et al noted high signal in the
posterior thalamus in two of the first 14 cases of vCJD reported in the UK (on T2 and
PD weighted MRI sequences).(183) The MRI findings correlated with pathological
changes found in the thalamus. In an update of this study published in 2000, Will et
al describe bilateral high signal in the posterior thalamus in 77% of definite or
probable vCJD in the UK (n=35).(184) More recently Heath et al report
characteristic findings in 91% of vCJD cases in the UK (106 confirmed cases from
1995-2004).(186) The so called 'pulvinar sign' has been incorporated into the WHO
diagnostic criteria.(98) This describes
"a characteristics distribution ofsymmetrical hyper-intensity of the pulvinar
nucleus (posterior nucleus) of the thalamus (relative to the grey matter ofthe
anteriorputamen and normal cerebral cortex)" (Figure 10).(98)
Figure 10 The Pulvinar sign on MRI in vCJD (FLAIR sequence) (14)
In a case-control study examining 36 pathologically confirmed vCJD cases and 57
controls the sensitivity and specificity of these radiological changes were 78% (60 -
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90) and 100% (94 - 100) respectively (intra-observer reliability extremely high;
kappa statistic >0- 8).( 190) This study examined T2 and PD weighted images. A
subsequent study examining 86 pathologically confirmed vCJD cases also found that
the sensitivity and specificity of the pulvinar sign in vCJD was extremely high.( 191)
The most sensitivity sequences were FLALR followed by PD and T2 weight images.
Very few DWI images were available for review although the value of this sequence
has since been recognised. Other radiological features less commonly seen on MRI
in vCJD include high signal in the dorsomedial thalamic nuclei ("hockey stick" sign),
periaqueductal grey matter, caudate head and deep white matter.(191) Cerebral
atrophy is rarely seen.
The differential diagnoses of thalamic high signal on MRI scanning are outlined in
Table 15.(98) Of note two reports of the classical pulvinar sign in sCJD have been
published.(192;193) Other reports in vCJD indicate that the pulvinar sign may
disappear with disease progression.(191) Given the novelty and rarity of vCJD
extensive studies reporting the timing ofMRI changes in relation to disease course
have not been published.
Table 15 Differential diagnosis of thalamic high signal on MRI scanning (98)
Pulvinar and dorsomedial nuclei high signal Thalamic high signal excludingpulvinar
sCJD Carbon monoxide poisoning
Benign intracranial hypertension Japanese Nipositu encephalitis
Cat-scratch disease Wernicke encephalitis
Alpers syndrome Bithalamic glioma
Post-infectious encephalitis Thalamic infarction
Genetic analysis
The principal use of genetic analysis in vCJD is to exclude genetic disease. To date
all definite or probable vCJD cases have been PRNP Codon 129 methionine
homozygotes.
Tonsil biopsy
Despite uncertainty regarding the pathogenesis of vCJD, early recognition of the
presence of PrPSc in the tonsils of patients with vCJD, but not other forms of prion
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disease, both ante- and post mortem led to the inclusion of this investigation in the
diagnostic criteria.(194) The initial case series was based on tonsil samples from nine
vCJD cases, all of which tested positive; there were no positive results in the control
or 'other' CJD groups.(194) These data suggest a high sensitivity and specificity but
the numbers arc very small. A positive tonsil biopsy elevates the diagnostic
classification from possible to probable, however examination of ncuropathological
material is still required to reach a definitive diagnosis. In the study by Heath et al
just 15 of the 106 neuropathologically confirmed cases of vCJD underwent tonsil
biopsy.(186) Tonsil biopsy was positive in all but one case. The procedure requires
general anaesthetic and is associated with risks including haemorrhage and sepsis.
Moreover a negative result docs not definitively exclude vCJD and does not assist in
excluding alternate diagnoses such as sCJD.(195)
Neuropathology
Brain biopsy can be used to reach a definitive diagnosis in life and exclude
potentially treatable differential diagnoses but is not, as previously discussed,
without risk. More commonly pathological material is obtained at post mortem.
Issues relating to both post mortem examination and brain biopsy have been
discussed previously and will not be revisited here.
Ncuropathological features
vCJD is neuropathologically distinct from other forms of human prion disease.(37)
In all forms of human prion disease spongiform change, neuronal loss and
astrocytosis are present. In vCJD these changes arc most marked in the basal ganglia
and thalamus. Similarly, neuronal loss and astrocytosis arc most prominent in the
posterior thalamus, correlating with MRI findings. The most defining feature
however is the presence of 'florid plaques' in the cerebral and cerebellar cortical grey
matter. These are "abundant kuru-typc fibrillary PrP plaques often surrounded by a
halo of spongiform change."(98) In addition to florid plaques, small plaques are seen
clustered within the cerebral and cerebellar cortex, unrelated to spongiform change.
Ofnote other tissues, the dorsal root and trigeminal ganglia, the retina, optic nerves
and substantia gelatinosa of the spinal cord also stain positive for abnormal prior
protein. The pathological features of vCJD arc shown in Figure 11. Beyond the
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central nervous system, abnormal prion protein is also detectable in LRS tissue
including the appendix, tonsils, spleen and lymph nodes.
Figure 11 Pathological features in vCJD (14)
The characteristic pathological feature in vCJD is the florid plaque (centre) composed of large radiating fibrils of amyloid with
a dense core and paler periphery, surrounded by a halo of spongiform change. Multiple smaller plaques are present
elsewhere in this image and there is severe neuronal loss with accompanying astrocytosis. H&E stain.
Molecular subtyping
A single prion strain has been described in vCJD which shares features in common
with the strain characteristics found in BSE. vCJD is characterised by a Type 2B
prion protein with a predominantly diglycosylated band.
Genetic prion diseases
Genetic prion diseases account for between 10-15% of all human prion
diseases.(196) Genetic prion disease is caused by disease specific mutations in
PRNP, inherited in an autosomal dominant pattern. Mutations can be point or
insertion. In the absence of ncuropathological material, the diagnosis of a genetic
prion disease requires the presence of a PRNP disease causing mutation or a positive
family history in an individual with appropriate clinical features (Appendix 2). The
criteria thus recognise the ever increasing number of PRNP mutations that have been
characterised and that up to half of all cases of genetic prion disease report no
significant family history.(98;196) The penetrance of some mutations is variable;
individuals with the mutation do not necessarily develop the disease, or development
of the disease may be, for example, age dependent.(196) There is no evidence of
genetic anticipation.
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Genetic disease is broadly considered in three phenotypes: genetic CJD (gCJD),
Gerstmann-Strausslcr-Schcinkcr Disease (GSS) and Fatal Familial Insomnia (FFI).
In practice these groupings include diverse clinic-pathological phenotypes. The
haplotypc, the pathogenic mutation in association with a polymorphic residue
(usually at Codon 129 but other polymorphism have been described including Codon
171 (N/S), 219 (E/K), the deletion of one 24-bp octapeptide repeat and 12 other
silent polymorphisms) determines the clinical phenotype. Perhaps the most
significant aspect of genetic prion disease is that it can be clinically and
pathologically indistinguishable from sCJD. Detailed accounts of the clinical
phenotypes associated with specific haplotypcs can be found in a number of
manuscripls.(98; 152; 197-200) I would direct an interested reader to these resources.
The geographical distribution of genetic prion diseases is significantly different from
other human prion diseases. Overall the incidence of genetic prion disease was
reported to be 0.17 per million population in countries in the EUROCJD consortium
from 1999 through 2002 with two thirds of cases accounted for by genetic CJD.(196)
Clusters of gCJD cases associated with a specific mutation have been reported in
Israel, Chile, Italy and Slovakia.(196) In the example of Slovakia 70% of all human
prion diseases were actiologically genetic (largely attributable to a single mutation,
the E200K mutation) and the annual mortality rate from genetic prion disease was
1.1 per million population^ 196) This compares to 6.6% and 0.2 permillion
population in the UK. Some mutations are reported exclusively in geographically
defined populations and are exceptionally rare, affecting one kindred or a single
individual.
Treatment of human prion disease
Whilst a number of agents have been studied, to date no treatments of proven value
have been identified in human prion disease. A 2008 systematic review identified 34
primary research studies examining 15 drugs.(201) Just one randomised control
study was identified. This suggested a slowing of cognitive decline associated with
the use of flupirtinc. The remaining studies were ease scries; 20 studies examined
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one patient, three studies reported on more than ten patients. The latter studies
examined the use of quinaerine, mcpacrine and pentosan polysulphatc with mixed
results. Primary research studies were limited by poor study design and inadequate
reporting. Research in this area is further hindered by the heterogeneity of the
populations studied, including genetic prion diseases, vCJD and sCJI) eases, and the
diversity of the clinical phenotype within each group.
Measures to reduce the risk of secondary transmission of prion disease
This section will review the control measures that have been put in place to reduce
the risk of human to human transmission ofprion disease in the UK. Control
measures to reduce the risk of animal to human transmission in the UK were
explored in the section on prion diseases in animals and will not be revisited here. A
number of issues are important with respect to prion diseases that must be considered
when discussing control measures to reduce the risk of iatrogenic transmission: (1)
long incubation periods during which an individual may be asymptomatically
infected and infectious (2) lack of a valid diagnostic test to detect asymptomatic
infection (3) resistance of prion protein to routine decontamination procedures. In the
section that follows I will review some of the key issues and uncertainties relating to
asymptomatic vCJD infection, before examining specific control measures relating to
human prion diseases in the UK.
Asymptomatic vCJD infection
Abnormal PrPSc has been detected in the LRS of neurological Iy normal individuals
that received vCJD implicated labile blood components. These individuals are
considered to have 'asymptomatic vCJD infection'. However the pathogenesis of
vCJD is poorly understood. It is not known for example whether all asymptomatic
but infected individuals are infectious, whether all infected individuals will develop
disease or, whether a sub-group will remain asymptomatic but infectious carriers or
whether a further sub-group will clear the disease without ever developing
symptoms. A number of synonyms have been used to describe these states including
prc-clinical, sub-clinical and pre-symptomatic disease. For consistency throughout
this thesis 1 will use the term asymptomatic infection to refer to these synonyms. The
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prevalence of asymptomatic infection and potential for asymptomatic but infected
individuals to transmit vCJD are important parameters for public health planning,
including the establishment and maintenance of control measures.
Prevalence studies
A number of studies have been undertaken to inform the public health response to
the possibility of a health care associated secondary epidemic of vCJD. The aim of
these studies has been to estimate the prevalence of asymptomatic infection in the
population. Of note, in these studies the detection of PrPSc is considered evidence of
asymptomatic infection without implying infectiousness.
Hilton et al retrospectively examined 11,247 appendix and 1,427 tonsil samples from
histopathology departments across the UK.(202) Samples, from the 1961 - 1985
birth cohort, were anonymised prior to testing. In addition, appendix samples from
vCJD patients, either at autopsy or surgery prior to symptom onset, were examined.
PrPSc was detected in three appendix samples, two ofwhich were from asymptomatic
individuals that subsequently developed vCJD giving a prevalence of 292 per million
population (95% CI 60 - 853). This study retrospectively examined paraffin
embedded tissue samples. In such studies frozen tissue is unavailable thereby
limiting the study to histological examination (immunohistochemistry) and
precluding biochemical testing (immunoblotting).
Erosh et al, prospectively examined 2000 consecutive tonsillectomy specimens using
immunohistochemistry and immunoblotting.(203) No samples tested positive. Given
the rarity of vCJD this study is likely to be underpowered due to the small sample
size, an issue compounded by the fact that almost half of the study population were
in a birth cohort unlikely to have had substantial dietary exposure to BSE
contaminated food products.
More recently Clewley and colleagues examined 63,007 tonsil pairs electively
removed and stored in the National anonymous tissue archive for Scotland and
England between 2004 and 2008.(204) Using both biochemical and histological
diagnostic technologies there were no positive results in the study. The overall
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prevalence of disease related prion protein was 0 per million population (0 - 59); in
the 1961 - 1985 birth cohort the prevalence was 0 permillion population (0 - 289).
The authors offered three possible explanations for the discrepancy between this and
the previous study by Ililton el al: the sensitivity of the tests (in the absence of a
definitive diagnostic test to confirm infectivity), the representativeness of the sample
and the natural history of prion protein infectivity.
The pathogenesis of vCJD is not fully understood. It is not clear at what stage in the
disease process PrPSc might be detected and in which tissues. The LRS has been
chosen for these studies as PrPSc has been detected in appendix and tonsil tissue in
both in vCJD cases and asymptomatic individuals that received vCJD implicated
transfusions of labile blood components. Whilst PrPSc has been detected by both
immunoblotting and immunohistochemistry in the tonsil tissue of vCJD cases it has
never been detected in an asymptomatic individual. Animal studies would however
suggest that PrPSc docs accumulate in this tissue and can be detected prior to
symptom onsct.(205;206) The sensitivity and specificity of any test will be
influenced by the distribution ofprion infectivity in tissue during incubation and the
timing of testing. The significance of a positive result is also unclear. In animal
studies PrPSc has been cleared following inoculation.(207) It is not clear therefore
whether the detection of PrPSc in tissue removed from an individual will mean that
the individual in question will develop vCJD, and if so when. Thus far studies in this
area have used unlinked anonymised samples. There are complex ethical issues to be
considered in carrying out linked or named studies in the face of such uncertainties
and in the context of an untreatable and invariably fatal disease.
Asymptomatic vCJD infection in non-methionine homozygote Codon 129
genotypes
One further issue worthy of discussion is the detection of PrPSc in asymptomatic
individuals with a non-mcthionine homozygotc Codon 129 genotype both in the
anonymiscd studies described above and through disease surveillance (TMER and
UKHCDO) in the UK. This finding implies that non-mcthionine homozygotes arc
susceptible to vCJD. This is congruent with animal studies that have shown a species
barrier in transmission of BSE to human transgenic mice, but efficient transmission
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of vCJD between human transgenic mice.(208) A gradient of cffieiency according to
PRNP Codon 129 genotype (MM to MV to VV) was reported although crucially all
genotypes were susceptible. PRNP Codon 129 genotype determined clinico-
pathologieal phenotype. Codon 129 methionine hcterozygotes or valine homozygotes
were likely to remain in an infectious asymptomatic stage extending beyond their
natural life span. These data support the hypothesis that a significant but as yet un¬
qualified population of asymptomatic but infectious individuals may exist;
individuals that may donate blood or other tissues and undergo invasive medical
procedures. If novel routes of vCJD transmission emerge, the possibility of a self-
sustaining secondary epidemic of vCJD will become increasingly real.
Control measures in the UK
The transmission of sCJD, vCJD and genetic prion disease will be addressed here. In
this section I will refer to an "at increased risk" ofCJD group. This is a group of
asymptomatic individuals who have been informed that they are "at increased risk"
of developing CJD as a result of their medical or family history (Table 16).(209)
They are considered at risk for public health purposes. They have been informed of
their status and advised not to donate blood or organs and in turn, to inform health
care providers prior to any medical intervention such that appropriate precautions can
be taken to minimise the potential for further transmission, in the event that they
have asymptomatic infection. There arc over 6,500 individuals in this group, the
majority ofwhom are patients with bleeding disorders that received UK sourced
plasma products between 1980 and 2001.
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Table 16 Individuals "at increased risk" of developing CJD in the UK (209)
1. Individuals with a pathogenic mutation of the PRNP gene
2. Individuals with a blood relative with a pathogenic mutation of the PRNP gene
3. Individuals with > 2 hlood relatives affected by human prion disease
4. Recipients of human derived hormone products
5. Individuals that underwent intradural neurosurgical or spinal procedures pre-1992
6. Individuals identified by the CJD Incidents Panel as having undergone surgery with instruments
previously used on someone who has gone on to develop CJD or become "at increased risk" or
developing CJD
7. Individuals who have received an organ or tissue from a donor infected with CJD or "at increased
risk" of CJD
8. Individuals who have been identified prior to high risk surgery as having received blood or blood
components from > 80 donors since January 1980
9. Individuals who have received blood from someone who has developed variant CJD
10. Individuals who have donated blood to someone who subsequently developed variant CJD
11. Individuals who have received blood from someone who has given blood to a patient that
subsequently developed variant CJD
12. Individuals treated with certain implicated UK sourccd plasma products between 1980 and 2001
A number of factors are considered in determining the risk of human to human
iatrogenic transmission, including the distribution of PrPSc in tissue and bodily fluids,
the route of transmission, the dose of infectivity and the agent. As previously noted,
the detection of PrPSc does not necessarily infer infectivity, nor does its absence
exclude it. In general high levels of PrPSc are assumed to represent a greater risk of
infection. These data have been used to inform an assessment of the relative risk
associated with various procedures. Tissues are classified as high, medium or low
risk. Central nervous system tissues are considered high risk in all prion diseases.
Ophthalmological procedures on the anterior segment of the eye (cornea, iris, ciliary
body and lens) are considered medium risk and procedures in the posterior segment
of the eye (retina, retinal pigment epithelium, choroid, subretinal fluid and optic
never) high risk. PrPSc is found in higher levels in vCJD in the peripheral nervous
system, LRS and alimentary tract than in other prion diseases; these tissues are
considered a medium risk in vCJD.(210)
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Cadaveric-dcrivcd human dura mater grafts and pituitary hormones
The use of cadaveric-derived human pituitary hormone was banned in the UK in
1985; the use of cadaveric-derived human dura mater grafts in 1992. Incident cases
of iCJD via these routes of transmission continue to be reported due to prolonged
incubation periods; some are retrospectively identified through case reviews applying
emergent diagnostic technologies. It would be anticipated that these forms of
iatrogenic disease will rapidly disappear given interruption to the route of
transmission, in much the same way as has been observed with the kuru epidemic.
Organ donation
There no recorded episodes of iCJD attributed to the transplantation of body organs.
Organ donation is prohibited in individuals dying of dementia or suspect prion
disease. Individuals designated "at increased risk" of CJD are requested not to donate
organs or other bodily fluids.
Surgical procedures
Where possible single use instruments are recommended for invasive medical
procedures involving tissues of high to medium infectivity in suspect prion disease
cases or individuals "at increased risk" ofCJD.(209) Where this is not possible,
instruments may be quarantined and re-used exclusively on the index case.
Alternatively instruments are destroyed. No special precautions are required for low
infectivity tissues or bodily fluid.
A number of general preventative measures have been implemented. There has been
significant investment to improve decontamination facilities although the cost
effectiveness of this is unknown.(211) Efforts have been made to track all surgical
instruments and avoid migration of instruments between surgical sets, a measure that
is cost effective.(211) In 2001 all re-usable tonsillectomy surgical instruments were
withdrawn and single use instruments recommended for all patients undergoing this
procedure. However reports rapidly emerged of increasing surgical complications
related to these single use instruments, in particular haemorrhage due to ineffective
diathermy, and this decision was swiftly reversed. In 2006 (updated 2008) the
National Institute for Health and Clinical Excellence in the UK issued further
guidance on reducing the risk of iCJD transmission via invasive medical
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procedures.(211) This recommended that all accessories for ncuroendoscopies should
be single use, but that there was no evidence of cost effectiveness for single use
instruments for other procedures including neurosurgery, ophthalmological surgery,
tonsillectomy and endoscopy. The guidance further stipulated that single use
instruments should only be used where they were of a comparable quality to rc-
uscable instruments.
In instances of possible iatrogenic exposure through health care associated
procedures, cases are reviewed by the CJD Incidents Panel (CJD IP) who investigate
and advise on further action.
Dentistry
Uncertainties remain regarding the risks associated with dental procedures,
particularly endodontic treatment which involves contact with dental pulp.(212) A
survey of decontamination procedures in dental surgeries in Scotland identified
serious short comings in the practice of cleaning and decontaminating dental
cquipmcnt.(213) Whilst studies in humans have not detected infcctivity in the oral
cavity, in animal models vCJD infectivity has been detected in the oral cavity in both
the symptomatic and asymptomatic stages of disease.(214) In light of these data
single use instrument were recommended for use in endodontic procedures (files and
reamers) in 2007.(215) Further advice issued in 2009 stated
"Other instruments or device types for which a reliable cleaning regime is
not available should also be consideredfor replacement by single-use types
or the single use ofreprocessible types."(216)
Blood transfusion and donation
There is no compelling evidence to suggest that sCJD or genetic prion diseases arc
readily transmissible from human to human through the transfusion of labile blood
components. By contrast, evidence from basic science and epidemiological studies
suggest that vCJD is transmissible through the transfusion of labile blood
components. In the absence of a blood test to detect infectivity in humans much of
the evidence from this area is based on animal models of infectivity. It is not clear
how reflective these studies are of the pathogenesis of vCJD in humans. Animal
models suggest that infectivity in the blood is low relative to levels in the brain,
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during the incubation period and following symptom onset.(217) Infectivity in blood
is distributed evenly between plasma and leukoeytes, with very low or absent levels
in red blood cells or platelets.(218) Steps taken in the UK to reduce the risk of
secondary transmission via blood products include leukodepletion which is thought
to reduce the risk by up to 40% (Table 17). (219;220) Prion reduction filters have
been developed to reduce infectivity in labile blood components. These have shown
promise in animal studies but their utility in humans is unknown.(221)
Table 17 Measures taken to reduce the risk of secondary transmission of vCJD
through the transfusion of blood and blood products in the UK(219;220)
Year Measure
Recall and discard labile blood components and plasma derivatives from donors who
1997
subsequently developed vCJD
Importation of plasma destined for fractionation from non-UK sources (fully
1998
implemented October 1999)
1998 Lcukoreduction of labile blood products (fully implemented Autumn 1999)
Importation of fresh frozen plasma (FFP) for recipients born after January 1st 1996 (fully
implemented 2004)
Permanent exclusion of whole blood donors who received a transfusion of blood
components after January 1st 1980 in the UK
2004
Permanent exclusion of blood donors who have received a transfusion of blood
component or plasma derivative from the UK after January 1st 1980
Importation of FFP for recipients aged < 16 years old
Permanent exclusion of donors who received a transfusion of blood components or
plasma derivatives anywhere in the world after January 1sl 1980
2005 Permanent exclusion and notification of donors whose donations have been transfused to
recipients who later developed variant CJD
Progressive replacement of platelet pools with apheresis (single-donor) platelets.
Apheresis platelets recommended for children <16 years old
note these measures cover the period examined in the studies in this thesis ] 990 - 2006
Screeningfor PrPSc
Considerable effort has gone into the development of a blood test to detect PrPSc in
humans. Such a test could be used to screen all blood and organ donations for
example. A number of issues would need to be considered prior to the introduction of
a universal screening programme. There are major deficiencies in our understanding
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of how PrPSc, if detected, relates to infectivity and the likelihood of developing
clinical disease. A simple, safe, validate and acceptable screening test is required.
The test would need to have a high sensitivity (ability to detect true positives) and
specificity (ability to detect true negatives). Establishing these qualities in the
absence of a gold standard test to detect PrPSc is challenging. Whilst sensitivity and
specificity arc properties of a test, the PPV, that is the likelihood that an individual
with a positive test result will have the disease, is determined by the prevalence of
disease in the population being screened. The population prevalence of asymptomatic
PrPSc infection is unknown, but thought to be low. Applying a screening test in this
context is likely to result in a large number of false positive results. In most
screening programmes an individual with a positive result from screening would be
offered a diagnostic test. However a simple, safe, validated and acceptable diagnostic
test in this context does not exist and given the uncertainties surrounding the natural
history of asymptomatic PrPSc infection the interpretation of a diagnostic test would
be problematic. There arc wider issues relating to whether it is necessary to inform
screened individuals of abnormal results given the natural history of asymptomatic
infection is poorly understood and in the absence of an effective treatment. The
likely consequence of screening in this context will be the identification of an
increasing number of individuals designated 'at increased risk' ofCJD with all the
inherent implications for these individuals, their families and the health care service.
In short, the costs (financial, physical or psychological) of screening to the
individual, health service and society, should not outweigh the public health benefits.
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Public Health Surveillance
In this section I will define public health surveillance (PIIS), briefly outline the
rationale for, and challenges in, PHS in relation to human prion diseases and describe
the evolution of PHS system for human prion diseases in the UK and beyond.
Public Health Surveillance
Public Health Surveillance (PHS) has been defined as
"the on-going, systematic collection, analysis, and interpretation ofdata
(e.g., regarding agent/hazard, riskfactor, exposure, health event) essential to
the planning, implementation, and evaluation ofpublic health practice,
closely integrated with the timely dissemination of these data to those
responsible forprevention and control."(222)
A number of factors are considered when determining whether a condition merits
PHS. These include the frequency of the disease (incidence or prevalence), the
severity (case-fatality), the preventability, the transmissibility or potential for an
outbreak to occur, the costs associated with the condition and the level ofpublic
interest and media attention.
The rationale for PHS of human prion diseases
The term 'prospective' will be used to refer to real-time surveillance. Intermittent
CJD surveillance studies were conducted both prospectively and retrospectively in
England and Wales from 1970 and retrospectively in Scotland and Northern Ireland
from 1980. In the UK continuous systematic prospective PHS ofCJD was instigated
in 1990 as recommended by both the Southwood Working Party and the Tyrell
Committee. The primary aim of systematic prospective CJD surveillance in the UK
was to detect any changes in the clinico-pathological phenotype ofCJD that might be
attributable to exposure to BSE. It should be noted that the term CJD has historically
been used as an umbrella term to describe a range ofphenotypically and
aetiologically diverse prion diseases, including for example sCJD and GSS. The term
'prion disease' is now more frequently used in this context to reflect our advancing
knowledge of this heterogeneous group of diseases.
In 1996 the NCJDSU characterised a clinico-pathologically distinct form of CJD,
vCJD, which would later be aetiologically linked to BSE in cattle. A WHO
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consultation the same year examined the public health issues relating to human and
animal prion diseases.(223) At this time just ten cases of vCJD had been
characterised and cases were confined to the UK. Whilst the most likely explanation
for the emergence of vCJD was exposure of the UK population to BSE, scientific
evidence to support this hypothesis was lacking. The epidemiology and natural
history of vCJD were yet to be determined, the size and distribution of the primary
vCJD epidemic un-quantified and the potential for a secondary epidemic unknown.
An opportunity to address many of these uncertainties through PHS existed. Global
surveillance of all forms of CJD was recommended based on a number ofprinciples.
An aetiological link with BSE in cattle seemed likely. Indigenous and imported BSE
had been reported outside the UK indicating that a wider population may have been
exposed to BSE and potentially at risk of developing vCJD. Knowledge about the
clinical phenotype of vCJD was based on the experience ofjust ten cases. The
possibility of a clinical phenotype indistinguishable from sCJD remained. Many
developed countries had mature PHS systems for CJD in place and this experience
was considered crucial in detecting a novel disease phenotype.
The social andpolitical climate in the UK
The demonstration of a novel and universally fatal disease in humans attributed to
BSE (a disease attributed to intensive farming practices), to which the UK population
had been widely and involuntary exposed for a decade, in the face of repeated
reassurances from the scientific and political communities, generated considerable
controversy. Public anger and mistrust were tangible and fuelled by a sensationalist
media who dubbed vCJD "human mad cow disease". An urgent need for the
development of national and international public health policy supported by robust
scientific evidence and facilitating effective communication of the risk to restore
public confidence, was recognised.
The relationship between PHS in animal and human prion diseases
Whilst I have focused here on PHS of human prion diseases, the aetiological link
between vCJD and BSE in cattle underlines the importance of concurrent PHS for
animal prion diseases. The need for PHS of animal prion diseases is of increasing
importance for two reasons. Firstly, there have been calls for the relaxation of the
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control measures instigated during the BSE epidemic. On-going surveillance is
essential to ensure that BSE docs not re-emergc if control measures arc removed or
relaxed. Secondly, atypical forms of prion disease in animals arc being described
with increasing frequency. The risk that these atypical diseases may present to
human health has not yet been quantified. Issues relating to the surveillance of prion
diseases in animals have been reviewed and will not be examined further.
Methods of PHS
PHS can be passive or active. In passive surveillance cases are ascertained by direct
referral (without prompting) or through other mechanisms without prior solicitation
from the PHS system. For example a clinician aware of the PHS system might refer a
suspect case without prompting, or vital statistics such as death certificates might be
used to monitor trends in mortality. This approach has a number of advantages. It is
(relatively) inexpensive, can be useful if covering a large geographical area with a
disparate population and if consistent methods are applied over time can provide
valuable information to assess temporal trends in disease occurrence. There arc
however a number of caveats that should be considered. This approach often relies
on routinely collected data which may have extremely limited clinical information
and a low sensitivity for detecting cases. Depending on the objectives of the PHS
system such data may not be fit for purpose. The representativeness of the data
should also be considered. For example voluntary notification of suspect cases by
clinicians or other health care professionals may result in an excess of notifications
from those with a specialist interest in the area and a dearth of referrals from others.
This bias can lead to under-ascertainment or simulate clustering of cases.(70)
In active surveillance cases are actively sought by the PHS system. For example, by
contacting health care professionals and reminding them to notify the PHS system of
suspect cases, or conducting special surveys in targeted populations. These
approaches are likely to produce more detailed information, be more sensitive
methods of ascertaining cases, and subject to less bias. However as would be
anticipated active surveillance is more expensive, and both labour and time intensive.
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In practice PHS systems often use both active and passive surveillance. For example,
cases may be ascertained through unsolicited direct referral from any health care
professional but the PHS may regularly contact a targeted group of health care
professionals reminding them to refer suspect cases. Periodic enhanced active
surveillance in specific high risk groups might be carried out in time limited and
externally funded studies based on research priorities. The approach adopted will
depend upon the objectives of the PHS system and the resources available.
Strategies in the PHS of prion diseases
Three commonly used strategies to ascertain suspect cases include direct referral,
specialist surveys and the use of routine data.(98) Each will be addressed in turn and
the relative merits of each approach evaluated. The approach ultimately adopted by
the surveillance system will depend upon a number of factors including the
epidemiology of the disease, existing infrastructure and reporting mechanisms, the
population under study (including the size and geographical distribution), the aims of
objectives of the PHS system and the resources available. In practice most countries
employ multiple and overlapping method of case ascertainment in the surveillance of
CJD.
Direct referral
The PHS system receives direct referrals of confirmed or suspect cases from health
care professionals and/or members of the public. This may be an entirely passive
process in which unsolicited referrals are received. Alternatively the PHS system
may issue frequent reminders to specific professional groups such as neurologists,
neuropathologists and neurophysiologists, encouraging referral of all suspect cases.
The professional groups targeted are typically those that have an increased likelihood
of encountering cases based on the clinical illncss.(72;98) Perhaps unsurprisingly
reports received by this group are considered one of the most sensitive and specific
strategies of case finding. Reports received from other health care professionals or
the public are considered less sensitive.(72;98) Whilst assumptions have been made
regarding the sensitivity and specificity of referrals made to PHS systems,
contemporary data to support these assumptions are lacking. Prion diseases arc rare
with a diverse clinic-pathological phenotype. The assessment of clinical features and
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investigations that support a diagnosis of prion disease requires skill and expertise. In
this context the willingness of the PUS system to advise on the investigation and
management of a suspect case may encourage direct referral of suspect cases.
The WHO recommend that the number of referrals received by a prion disease PHS
system should exceed the number of confirmed cases by a factor of 2 or more to
increase the likelihood of ascertaining cases.(98) If the surveillance system is not
meeting this target, enhanced contact with rcferrers may be necessary. Many prion
disease PHS systems have broad referral criteria reflecting the lack of a single,
acceptable diagnostic test for prion disease in life in the context of a diverse disease
phenotype, and a core objective of detecting novel prion disease. For this reason
many systems also endeavour to clinically review suspect cases and/or any
associated investigations. The ability of a PHS system to review a high proportion of
non-cases will be determined in part by the resource available to operate the system.
It should be considered that the number of direct referrals to a PHS system and hence
the ratio of cases to non-cases referred to and reviewed by the system may be
vulnerable to changes in awareness about prion diseases among the public and health
care professionals in addition to the prevailing political agenda. For example in the
UK following the characterisation of vCJD and intense media coverage a significant
increase in the number of direct referrals received by the NCJDSU occurred which
resulted in a change in the ratio of cases to non-cases being referred.
Many surveillance systems are centralised due to the rarity of prion diseases and the
expertise required in the assessment and interpretation of surveillance data.
Increasingly diagnostic services such as neuropathology or CSF 14-3-3 protein
testing are offered by PHS systems. These services are valuable in ascertaining
suspect cases not referred to the PHS system dircctly.(224)
Specialist Surveys
This approach involves enhanced active surveillance in sub-groups that arc
considered to be at greater risk of human prion disease than the general population.
An obvious example would be enhanced surveillance in the family members of an
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individual known to have a pathogenic PRNP mutation or individuals known to have
received cadaveric-derived hGII during a specified time period.
In the UK a number of special surveys have been carried out. The Health Protection
Agency (HPA) in the UK maintains a database of all individuals who have been
informed that they arc "at increased risk" ofCJD for public health purposes; a
second database containing information on individuals considered to be at low or
uncertain risk of iCJD is also maintained. This latter group have not been informed
of their status. This database facilitates rapid identification and comprehensive long-
term follow up of individuals potentially exposed to CJD through medical
interventions. A complementary prospective cohort study, The National Prion
Monitoring Cohort, co-ordinated by the National Prion Clinic (NPC) is currently
recruiting patients diagnosed with, or at high risk of, all forms of human prion
disease. In addition to contributing to surveillance activities, research of this nature
offers an invaluable opportunity to document the natural history of human prion
disease and explore diagnostic and therapeutic opportunities. However such studies
are expensive, require high levels of participation and low rates of attrition to ensure
adequate statistical power to provide meaningful results.
Three further UK based studies arc worthy of mention. The TMER study is a
collaborative study between the UK Blood Transfusion Services (UKBTS) and the
NCJDSU.(179) The UKBTS are notified of definite or probable sCJD, vCJD and
genetic prion disease cases ascertained by the NCJDSU. The UKBTS determine
whether the case has received a blood transfusion or is a blood donor. If the case has
been a recipient, the donor is in turn traced; if the case has been a donor, the recipient
is in turn traced. The aim of this study is to identity episodes of transfusion
transmitted infection. Through this study four episodes of transfusion transmitted
vCJD have been identified (one asymptomatic); no episodes of transfusion
transmitted sCJD or genetic prion disease have been identified.
Active surveillance among individuals with congenital or acquired haemophilia who
received UK sourccd plasma products between 1980 and 2001, was initiated in 2001
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in a collaborative study between the UKHCDO and the NCJDSU.(182) This study
involves the prospective and retrospective examination of tissue removed from the
LRS or central nervous system during surgical procedures in life or at autopsy
following death in patients with haemophilia in the UK. Informed consent is required
for tissue to be examined, cither provided by the patient, or their next of kin if the
patient is deceased. The success of the study will be determined, in part, by
participation rates. To date, tissue from 17 neurologically normal haemophiliac
patients has been examined. PrPSc has been detected in the spleen of one deceased
patient.
Finally, the Progressive Intellectual and Neurological Deterioration (PIND) study
uses an existing surveillance network among highly motivated paediatricians to
identify vCJD in children.(225) This strategy is effective for a number of reasons.
The existing paediatric surveillance system has extremely high participation rates.
Referrals to the surveillance system arc made prospectively, while patients are alive,
therefore the identification of a potential case facilitates rapid public health action if
required. Operationally clinical information on all PIND cases is reviewed by a panel
of expert paediatric neurologists in an attempt to reach a diagnosis. This step is
extremely important because the rate of post mortem among children with PIND is
surprisingly low. Finally, the clinical phenotype of vCJD in children is not well
described. To date six vCJD cases in children have been ascertained through this
study.
This is not an exhaustive account of enhanced surveillance efforts, rather an outline
highlighting some of the strategics adopted to improve surveillance in specific sub-
populations in the UK. Integral to the success of these strategies is the co-operation
of a diverse range of agencies external to the PHS system and of course the
remarkable willingness of patients and their significant others to participate in
surveillance.
Routinely collected data
Readily available and low cost, routinely collected and collated morbidity
(hospitalisation) and mortality (death certificates) data can be used in PHS. Death
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certification by a clinician is a statutory requirement therefore coverage is universal.
These data are used for official purposes and are generally current. The rapid clinical
course in sCJD and universal fatality of the condition means that mortality data arc a
reasonable proxy measure for incidence; this is not necessarily so for other prion
diseases. Suspect cases must be deceased before they will be identified therefore
prompt public health action is not facilitated by this method of case finding. In
addition only individuals recorded by the certifying doctor as having died ofCJD or
as having a co-morbid diagnosis ofCJD that contributed to but did not directly cause
death will be identified. Some studies utilising death certificates examine only the
underlying cause of death, that is the condition that led directly to death.(47;51)
Others consider multiple causes of death, including the underlying cause of death and
any co-morbid conditions that may have contributed but not led directly to death.(50)
The information recorded on death certificates is routinely coded using the
International Classification of Diseases (ICD) 9 (pre-1996) and 10 (post-1996). The
accuracy of death certificates in identifying prion disease cases therefore depends
upon the accuracy of both the diagnosis (as made by the certifying clinician) and the
accuracy of ICD coding. The USA consider the periodic analysis of death certificates
to be the most "systematic and cost effective" method of disease surveillance in
CJD.(50) A number of studies examining temporal trends in CJD mortality using
routinely collected death certificate data have been published.(47;49;51 ;226;227)
Advocates of the use of death certificates in surveillance usually quote a 1995
manuscript by Davanipour et al which examined 69 neuropathologically confirmed
sCJD cases reporting that 80% were identified by death certificate review; a false
positive rate of 8.3% was noted. The authors concluded that the examination of death
certificates was a reliable and sensitive method of case finding compared to
alternative strategies (direct referral from neuropathologists and review of hospital
records). Other studies have produced less convincing evidence of the utility of death
certificates. In Italy, Conti et al compared data from the National CJD Surveillance
Service to official death records. The authors reported misclassification ofCJD status
by death certificates in up to 50% of cases from 1996 to 1999. In the UK, Will et al
found that just two thirds of cases certified as dying from sCJD met the WHO
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diagnostic criteria as a definite, probable or possible cases of sCJD in the 1980s and
early 1990s; use of death certificates as the sole method of ease ascertainment would
have resulted in 22 - 28% of definite or probable sCJD eases being missed.(72)
In the UK, review of death certificates is used as a "safety net" to maximise case
ascertainment and as a method of follow up of non-cases referred to the
NCJDSU.(72) To date no studies examining the changing sensitivity of death
certificates over time, or the impact of age on the sensitivity of death certificates in
the surveillance of prion disease have been published. It might be expected for
example that the sensitivity of death certificates would be greater in younger patients
who may have been more thoroughly investigated and have undergone post mortem
examination, than in older patients. It is questionable whether a system reliant solely
on examination of vital statistics would have detected vCJD and very unlikely that
such a system would have been able to rapidly characterise the condition to facilitate
prompt public health action.
In the UK, virtually all elective and emergency health care is provided free at point
of access by the National Health Service (NHS). Data arc routinely collected on all
episodes of hospital care in the UK. Given the clinical course of illness associated
with prion disease, the majority of suspect cases will, at some stage in their clinical
illness, be hospitalised and may therefore be detected in an examination of
hospitalisation records. Elsewhere organisational and structural differences in access
to and use of health care services may profoundly influence case finding using
hospitalisation data. Cultural differences in health seeking behaviour may exist
between or within counties resulting in certain groups, for example
socioeconomically deprived or ethnic minority groups, being less likely to engage
with medical services. This should be considered in the interpretation of
hospitalisation data.
There arc a number of other weaknesses of hospitalisation data. As for death
certificate data, hospitalisation data usually record a variable number of discharge
diagnoses for each episode of hospital care. These discharge diagnoses are then ICD
103
coded. As for death certificate data, the accuracy of these data is determined by the
accuracy of both the diagnoses and the ICD coding. To the best ofmy knowledge,
there arc no published data specifically addressing the accuracy, sensitivity,
specificity and completeness of hospitalisation data in the surveillance of prion
disease.
The use of routinely collected data is advantageous because it is readily available,
inexpensive and often contemporary. It is important to consider whether the data
available are fit for purpose and whether the limitations of the data (accuracy,
sensitivity, specificity, coverage, potential biases) are acceptable.
Compulsory reporting of prion disease
In some countries, for example Australia, Austria, Ireland, France, Germany and
Sweden, prion diseases arc notifiable, there is a statutory requirement for clinicians
to report prion disease cases to the PHS system. In other countries, such as the UK,
there is no legal obligation for health care professionals to report cases; the reporting
of cases to the PI IS system relies upon the co-operation of health care professionals
and the public. Compulsory reporting of prion diseases may be adopted as a means of
maximising case ascertainment, monitoring trends in disease and facilitating prompt
public health action. A key issue that must be considered is the definition of a 'case'.
For example in Australia notification is required if there is a strong clinical suspicion
ofCJD whilst in Austria there is a compulsory requirement to inform the PHS
system of ncuropathologically confirmed cases only. An unintended effect of the
former approach to compulsory reporting might be that clinicians defer notification
of suspect cases to the PHS system until case confirmation is available. Indeed
following the introduction of compulsory notification in Slovakia, referrals to the
surveillance system fell.(24) The decision by authorities in the UK not to make CJD
a notifiable disease on the grounds that this might reduce the number of suspect cases
referred to the PHS system, particularly atypical cases that did not fulfil the
diagnostic criteria, was vindicated by the BSK cnquiry.(24)
A final point to consider is that of compulsory autopsy. In Austria for example
neuropathological examination of all suspect prion disease cases is mandatory.
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Whilst such an approach results in high levels of case confirmation it may not be
culturally acceptable. In the UK there is no legal requirement for a suspect prion
disease case to undergo autopsy examination on expiration, unless instructed to do so
by a coroner or in Scotland a procurator fiscal.
The challenges of PHS of human prion diseases
The detection of human prion diseases through PHS is difficult for a number of
reasons. Human prion diseases are exceptionally rare. In surveillance systems
employing direct referral, case ascertainment requires a high level of co-operation
from health care professionals, patients and their significant others. The clinical and
neuropathological phenotype of human prion disease is diverse therefore prion
disease may not be considered as a differential diagnosis in life. This is compounded
by a lack of a simple and acceptable ante-mortem diagnostic test. Diagnosis in life
requires the application of diagnostic criteria based on clinical features and
supportive investigations (Appendix 2). Specialist expertise is required in assessing
clinical features and conducting and interpreting investigations. An excellent
example of this is the EEG in sCJD. Whilst objective criteria have been adopted by
the WHO for the assessment of EEG for case classification in sCJD, these have not
been prospectively validated and due to practical issues around the application of
these criteria the assessment of EEG in many European countries including the UK
remains largely subjective. The interpretation of EEG in the hands of a general
neurophysiologist may be very different lfom the interpretation of the same EEG in
the hands of an expert in the field of prion disease. To ensure adequate clinical and
diagnostic expertise centralization of PHS is often necessary. This is expensive and
may be logistically difficult if the PHS system covers a large geographical area.
Central to PHS is the requirement for a case definition of the event under study. A
primary aim of the NCJDSU was the detection of a change in the clinico-
pathological phenotype ofCJD that might be attributable to BSE; vCJD was detected
without a case definition.(37) The first case definition of vCJD was based upon the
characterization of first ten cases ascertained by the NCJDSU.(223) Indeed it is only
in the last year, 15 years after the first case, than the diagnostic criteria of vCJD have
been validatcd.(186) In sCJD diagnostic technologies have evolved rapidly,
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including CSF 14-3-3 protein, MRI, genetic analysis and molecular subtyping,
necessitating regular review and updating of diagnostic criteria. The completeness of
case ascertainment will, to an extent, be influenced by the quality of diagnoses in
suspect CJD cases referred to the PUS system which in turn is dependent upon the
introduction and application of these diagnostic technologies in clinical practice. The
PHS system must be responsive to rapid transfer of scientific research into clinical
practice.
Neuropathological examination following death of a suspect case referred to the PHS
system is essential to achieve high levels of case ascertainment and a pre-requisite
for identifying novel disease phenotypes which may not meet pre-defined diagnostic
criteria for known disease phenotypes. In some countries the post mortem rate among
hospitalised patients is extremely high. In the UK rates ofpost mortem, as previously
noted have fallen in recent years, which may threaten the activities of the PHS
system.
As demonstrated in the preceding pages, much of the progress that has been made in
understanding human prion diseases has come directly from the study of animal
prion diseases or indirectly from the use of animal models to study human disease.
An effective PHS system will work collegiately with basic scientists in veterinary
and human medicine, clinicians, electrophysiologists, neuroradiologists,
neuropathologists, epidemiologists and public health specialists to translate scientific
research into clinical practice and in turn disease surveillance. Data derived from the
PHS system will be used to develop and evaluate national and international policy.
Finally, in some countries, such as the UK, the PHS system interfaces directly with
the general public, patients and their significant others, advising on treatment and
care in suspect cases and communicating risk in lay terms.
One final challenge of PHS ofprion diseases is the interpretation of surveillance
data. Year to year fluctuations in the incidence of disease are extremely difficult to
interpret due to the rarity of the disease. Temporal data must be interpreted with
caution and consideration given to other factors (clinical practice, diagnostic
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advances, public awareness, media attention, political will) that may have
contributed, directly or indirectly, to any observed change. Direct comparison of
national with internationally collected surveillance data can assist greatly in
interpreting temporal trends in disease occurrence, but only if these data are equally
robustly collected and valid.
International PHS systems in human prion diseases
National CJD PHS systems and disease registers had been operating throughout
Europe since the 1970s.(54) In the early 1990s in response to the BSE epidemic
several European countries including France (1992), Italy, Germany and the
Netherlands (all 1993) established systematic prospective CJD surveillance systems.
A number of international collaborative surveillance and research projects have been
undertaken. These will be described in the section that follows.
EUROCJD
In 1993 an international research and surveillance project, EUROCJD, including
seven collaborators (Austria, France, Germany, Italy, the Netherlands, Slovakia,
Spain and the UK) received EU funding.(54) The aim of the study was to produce
comparable international data describing the epidemiology ofCJD in Europe. In
1996 the network expanded to include Switzerland and non-European collaborators
in Australia and Canada. The same year a survey of the surveillance methodologies
used in EU member states identified significant variation in the application of
diagnostic criteria and reporting between countries, thereby threatening the
comparability and hence utility of surveillance data.(228) The study suggested that
harmonisation of PHS methodologies would facilitate collective and comparative
examination of international data. The first steps recommended were the application
of common diagnostic criteria, the creation of a minimum dataset for reporting and
the use of internationally agreed surveillance methods. Common diagnostic criteria
were adopted, a minimum datasct defined and strategics for conducting disease
surveillance described in the 2003 'WHO Manual on the Surveillance ofHuman
TSE'.(98) The EUROCJD network has continued to expand, now including 34
countries worldwide each providing data from their national surveillance systems
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(Figure 12). In turn the aims of the group have evolved to foeus on the detection and
characterization of vCJD and other forms of novel prion disease in humans.
Figure 12 European CJD Surveillance 1993 - 2009, adapted from Will (229)
NEUROCJD
In 1998 a further surveillance network, NEUROCJD, was formed. Members included
Belgium, Denmark, Finland, Greece, Iceland, the Republic oflreland, Israel,
Norway, Portugal, Sweden and the UK. The principal aim of this group was
harmonization of PHS methodologies. With the exception of the UK all member
states had a population of less than 12 million people. Some of the difficulties in
carrying out surveillance of a rare disease in a large country with a geographically
dispersed population have been discussed. There are also significant challenges faced
by smaller countries. In a country such as Iceland for example with a population of a
little over 300,000 it may be several years before a single case of sCJD (incidence
approximately 1 permillion population) is detected by the PHS system. Yet
significant financial resource and expertise is required to operate a PFIS system, the
sustainability of which is questionable. The NEUROCJD network offered the
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possibility for small countries to collaborate to share diagnostic and public health
expertise and set research priorities. As for the EUROCJD network, members of this
consortium retained autonomy over the operating characteristics of their PHS
systems but common standards were adopted for the application of diagnostic
criteria, diagnostic methodologies and reporting of surveillance data. Of note, the
NHUROCJD network is no longer in operation.
SEEC-CJD
In 2001 a further collaborative surveillance network was established covering central
and eastern European countries and China, with similar aims to the EUROCJD
project.
Operational characteristics ofinternational PHS systems
Beyond brief accounts of national PUS systems included in the methods sections of
published studies that report the epidemiology of prion disease in specific
populations, data describing and comparing the operating characteristics of prion
disease PUS systems are surprisingly sparse. I am aware of two studies, both
unpublished, describing the operating characteristics of selected members of the
EUROCJD and NEUROCJD groups.(230;231) Data from these studies is
reproduced in Table 18. The primary data collected by these studies was different
therefore a comprehensive picture of the operational characteristics of international
prion disease PHS systems is not available. However, a number of general
observations can be made. Firstly, with one exception all PHS systems were centrally
operated. In common, most countries utilized more than one approach,
epidemiological, neuropathological and/or neurological, to surveillance. In almost
three quarters of countries there was a statutory obligation to report prion disease
cases to the PHS system. Analysis from the NEUROCJD network suggests that,
contrary to previous evidence, no significant change in reporting of cases occurred in
countries in which prion diseases became notifiable during the period covered by the
study.(230) In general the criteria for referral to the PHS systems were poorly
described; for many referral of 'all suspect cases' were the only stated criteria. As
previously noted there are difficulties in setting strict criteria for referral to a prion
disease PHS system given the diverse clinico-pathological phenotype and the aim of
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many PIIS systems to detect novel or atypical prion diseases. The application of
diagnostic criteria at referral might result in such cases being missed. However broad
criteria might result in a high proportion of suspect cases being referred which do not
have prion disease with the PIIS system being unable to respond. There was
significant variation in the strategics adopted to ascertain cases between systems,
although most employed multiple approaches to case ascertainment including direct
referral, review of routine data and/or laboratory reports. Finally only half of all PHS
systems reviewed suspect cases in life. Whilst reviewing suspect cases in life is
considered by many to be the most sensitive approach to surveillance, the cost and
logistical difficulties associated with this may be prohibitive. Lack of clinical review
of suspect cases might be expected to affect levels of case ascertainment given that
the diagnostic criteria, in the absence of neuropathological confirmation, require
assessment of the presence of core clinical features in addition to supportive
investigations. However mortality rates for sCJD are remarkably consistent between
countries over time, ranging from 0.53 - 1.7 per million population. Moreover
countries in which suspect cases are not reviewed by a neurologist have ascertained
incident vCJD cases.(46) To fully interpret these data rates of post mortem
examination among suspect cases referred to the PHS systems would be required.
Unfortunately these data were not available for all countries. Within the NEUROCJD
consortium post mortem rates ranged from 40% to 100%. Where post mortem rates
are high this may result in an apparent excess of cases simply because the diagnosis
is confirmed in individuals that do not meet the diagnostic criteria.(54) In countries
where post mortem rates are low obtaining clinical data on as many suspect cases as
possible is extremely important.
These data confirm significant international variation in operating characteristics of
prion disease PHS systems. However, irrespective of the methodological approach to
surveillance adopted, mortality rates from surveillance data appear broadly
consistent. The application of common diagnostic techniques, diagnostic criteria and
standardised reporting have ensured that the data reported arc fit for purpose.(46)
On-going monitoring to ensure that this continues to be the case as PHS systems
expand and mature, and new PHS systems emerge, is crucial. Timely and robust
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international comparative data arc vital in the interpretation of changes in disease
occurrence or elinico-pathologieal phenotype that may occur nationally.
Evaluation of PHS systems
A vital, yet often overlooked, step in PHS is evaluation. Evaluation can be used to
determine whether the PHS system is fit for purpose and meeting its stated
objectives. Periodic evaluation of PHS systems is recommended to ensure that
surveillance is both efficient and effective.(222) Detailed guidelines on the
evaluation of PHS systems have been produced by the Centre of Disease Prevention
and Control (CDC).(222) These guidelines outline the attributes of the PHS system,
including simplicity, flexibility, data quality, acceptability, sensitivity, predictive
value positive, representativeness, timeliness, and stability, that should be considered
in evaluation. It is remarkable that despite the considerable investment in global
prion disease PUS, the significant changes that have occurred over the two decades
in which systematic prospective prion disease PHS has been in place and the political
and public health imperative of ensuring that surveillance is robustly conducted,
published examples of evaluations of prion disease PHS systems are vanishingly
rare.
Two evaluations of the EUROCJD network (one unpublished) have been
produced.(231 ;232) An evaluation of the EUROCJD network was carried out by the
European Centre for Disease Prevention and Control (ECDC) in 2007.(232) The only
published account of this evaluation is a summary report which fails to describe the
evaluation methodology or provide a detailed account of the results of the evaluation.
The summary report concluded by recommending improved reporting of
epidemiological data collected through surveillance, improved database management
with the developing of standard operating procedures (SOPs) to support this,
improved communication with national epidemiologists, and collaboration with non-
EU surveillance systems. An earlier, unpublished, evaluation of the EUROCJD
network by Pcdro-Cucsta et al (2003) applied the 1998 CDC methodology for the
evaluation of PUS systems. The challenges of examining system attributes such as
sensitivity and PPV in the absence of a gold standard ante-mortem test and variable
post mortem rates were highlighted. The authors found significant variation in rates
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of referral of suspect prion disease cases to PHS systems among the young (< 50
years old), with greater referral rates in countries that had previously reported a high
incidence of specific prion disease (for example genetic prion disease). International
variation in the quality of diagnosis based on the use of diagnostic technologies
(including post mortem, CSF 14-3-3 protein and genetic analysis) in sCJD cases that
met the diagnostic criteria, and delays in reporting, were also noted.
Two further evaluations of national surveillance systems have been carried out.
Robotin et al evaluated the Australian Surveillance System in 2002 applying the
CDC criteria.(233) Recommendations to improve the sensitivity and timeliness of the
PHS system were made. It was not possible to fully assess certain aspects of the
surveillance system as vCJD has never been detected in Australia. More recently in
2008 the Canadians undertook an evaluation of their National Prion Disease Program
(1998 — 2008); PHS is one of three core activities of this program.(234) This external
evaluation used both quantitative and qualitative approaches to examine the
relevance, success, design and delivery of the Prion Disease Program. The study did
not examine the system attributes described by the CDC therefore direct comparison
with the Australian study is not possible. The evaluation noted that whilst the PHS
system appeared be delivering well with a high level of satisfaction among the health
care professionals that used the system a number of areas could be improved. These
included the development of SOPs to ensure consistency in operating procedures
when staff changed, entry of epidemiological data onto a database to facilitate
analysis and dissemination of findings beyond reporting of the minimum monitoring
dataset, and improved engagement with more remote areas within Canada. One
further issue not raised in this evaluation but of importance should be highlighted. It
has been said that
"the strength ofan evaluation depends on the ability of the evaluator to
assess these characteristics [the attributes ofthe surveillance system] with
respect to the system's objectives. "(235)
The formal objectives of the Canadian surveillance system were not clearly defined
when this evaluation took place. Indeed the authors of the evaluation reported that a
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"visionfor the CJDSS /CJD Surveillance system] appears to be developing
and that "there is limited awareness of theformal mission and objectives by
PDP[Prion Disease Program/ managers and staff!"(234)
These evaluations are unlikely to be applicable to the UK. The P11S systems differ
from that in UK with respect to their methodologies and objectives. The system
attributes that arc crucial to the success of each of these national or indeed
international collaborative PHS systems, will differ from those in the UK. The CDC
note that an evaluation must
"consider those attributes that are ofthe highest priorityfor a given system
and its objectives. "(222)
The Australian evaluation for example was unable to adequately assess the flexibility
of the surveillance system in response to vCJD because they had not detected a vCJI)
case. This is significantly different from the UK which has experienced the greatest
number of vCJD cases worldwide.
The need for an evaluation of the NCJDSU
Systematic prospective CJD surveillance has been carried out in the UK since 1990.
During this time a novel human prion disease attributed to BSE in cattle has been
characterised and previously unrecognised routes of human to human transmission of
prion disease identified. Significant advances in diagnostic technology have led to
the revision of the diagnostic criteria applied by the NCJDSU in case classification.
Operationally the NCJDSU has responded to these changing demands. There has
never been an evaluation of the CJD surveillance system in the UK. There is an
urgent need for such a study.
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Summary
• Prion diseases are rare, invariably fatal neurodegenerative diseases affecting
animals and humans for which there is no effective treatment and no acceptable
or practical ante-mortem diagnostic test.
• Aetiologically sporadic, genetic and acquired forms of disease exist.
• The infectious agent is thought to be a pathogenic isoform (PrPSc) of a normal
cellular protein (PrPc), the precise biological function of which is unknown.
• The binding of PrPSc to PrPc results in self-replicating conformational change.
• Multiple prion strains are thought to exist, determined by their structural
conformations and glycosylation patterns, and distinguished by their biological
properties, including incubation periods and neuropathological profiles.
• The true nature of prions and the neuropathogenesis of prion disease are not well
understood.
• BSE in cattle is the only animal prion disease known to be zoonotic.
• The origin of BSE is unknown; the epidemic in the UK was propagated through
intensive farming practices. Control measures interrupted the epidemic, but not
before the widespread exposure of the UK population to BSE.
• In humans the commonest form of prion disease is CJD.
• Systematic prospective PHS ofCJD was initiated in the UK to identify any
change in the clinico-pathological phenotype ofCJD attributable to BSE.
• In 1996 the NCJDSU in the UK characterised vCJD, a novel human prion disease
aetiologically linked by epidemiological and transmission studies to BSE.
• The vCJD primary epidemic has been smaller than many feared and in decline in
the UK since 2000. However with the potential for exceptionally long incubation
periods (> 50 years) this may continue at a low level for many years to come.
• There has been clear evidence of genetically determined susceptibility/resistance
and/or genetically determined incubation periods in vCJD.
• Secondary transmission of vCJD through the transfusion of labile blood
components, a novel route of transmission, has been identified with transmission
occurring during an asymptomatic stage. To date no further routes of
transmission have been identified as yet.
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Given the widespread exposure of the UK population to BSE there is potential
for a self-sustaining secondary vCJD epidemic if a large population of
asymptomatic but infectious individuals exist.
Population prevalence estimates of asymptomatic vCJD infection in the UK have
ranged from 0 to 853 per million population, although the studies that produced
these estimates have significant methodological limitations.
The natural history and pathogenesis of vCJD is poorly understood. The
significance of detecting abnormal prion protein in these studies is unknown.
Despite scientific uncertainty public health measures have been instigated to
minimise the risk of human to human transmission of vCJD.
The success of control measures in preventing human to human and animal to
human transmission ofprion disease can only be determined by on-going
monitoring of epidemiological trends in disease through PHS.
Robust comparative data arc vital to interpret national PHS data.
The surveillance of all forms ofCJD has led the recognition of an increasingly
diverse clinico-pathological phenotype of sCJD and genetic prion disease;
genetic prion disease may be clinically indistinguishable from sCJD.
Emergent diagnostic technologies have been incorporated into increasingly
sensitive and specific clinical diagnostic criteria, although an acceptable and
practical ante-mortem diagnostic test remains elusive.
The relationship between molecular genetics and clinico-pathological phenotype
is becoming increasingly complex and uncertain in sCJD.
Despite intensive epidemiological study the underlying aetiology of sCJD
remains unknown; determining the risk of secondary transmission is challenging
although novel routes of transmission have not emerged in three decades.
Through active surveillance atypical animal prion diseases have been described.
The threat they pose to human health is as yet unknown however, recent evidence
suggests a possible link between atypical prion disease and some sCJD subtypes.
There is a clear rationale for the on-going systematic prospective PHS of prion
diseases in the UK.
Periodic evaluation of the PHS system is crucial to ensure that the system meets
its objectives. This forms the basis of this thesis.
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Aims and objectives of this thesis
In this thesis I will evaluate various aspects of the surveillance of human prion
diseases in the UK from 1990 through 2006. Consideration was given to this overall
aim and the critical gaps in the evidence base identified from the literature review.
This aim was in turn translated into the following objectives:
1. To describe the epidemiology of prion disease in the UK according to disease
subtype using surveillance data collected by the NCJDSU, from 1990 through
2006
2. To evaluate the NCJDSU using CDC guidelines for evaluating PHS systems as a
standard for assessing the performance of the system (1990 - 2006)
3. To prospectively validate the operational criteria for the assessment of EEG in
the surveillance of suspect sCJD in the UK (2005 - 2006)




A number of definitions will be applied throughout this thesis.
• 'Suspect case' will denote an individual referred to the NCJDSU as a suspect
prion disease case. This does not make any inference about case classification.
• Unless stated otherwise, the term 'case' will refer to a definite or probable prion
disease case as defined in the WHO diagnostic criteria (Appendix 2).
• Unless stated otherwise, the term 'non-case' will refer to a suspect case that does
not fulfil the WHO diagnostic criteria as a possible (or greater) case.
• Unless otherwise stated case classification refers to case classification at the time
of data censoring.
• Where reference has been made to a specific aetiological subtype of prion disease
this will be defined, for example sCJD will be used to describe sporadic CJD.
The term 'prion disease' will be used to denote all forms of human prion disease.
• The following abbreviations will be used throughout: sCJD to denote sporadic
CJD, vCJD to denote variant CJD and iCJD to denote iatrogenic CJD and gCJD
to denote genetic CJD.
• Where the term 'CJD' appears without identification of an aetiological subtype
this will also denote all forms of human prion disease.
• The term genetic prion disease will encompass all forms of genetic prion disease
including GSS, FFI and genetic CJD.
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Chapter 2. The epidemiology of prion disease in the
UK, 1990-2006
Introduction
In chapter 1, I outlined the epidemiology and diagnostic features of prion disease
according to actiological subtype using a literature search strategy. There have been
numerous developments in the 16 years since systematic prospective PHS ofCJD
was initiated in the UK. These include, but arc not limited to, the identification of a
novel human prion disease, the identification of novel routes of disease transmission,
the characterisation of an increasingly diverse clinico-pathological phenotype of
known prion disease, emergent diagnostic technologies and the incorporation on
these technologies into clinical diagnostic criteria. In this chapter I will use data
collected by the NCJDSU from 1990 through 2006 to describe the epidemiology and
diagnostic features of prion disease in the UK according to disease subtype. These
data will provide essential context for the forthcoming chapters evaluating various
aspects of disease surveillance in the UK.
Aim
The aim of this chapter was to describe the epidemiology and diagnostic features of




All suspect prion disease cases referred to the NCJDSU between 1st May 1990 and
31st December 2006 were followed for a minimum of two years until 31st December
2008. An electronic search of the NCJDSU minimum monitoring dataset was carried
out to identify all prion disease 'cases,' at the time of data censoring (as previously
defined). The paper-based NCJDSU case record of each case was examined by hand
and the following information extracted: sex, date of birth, date of death, date of
symptom onset, clinical presentation, case classification, disease subtype (sporadic
variant, iatrogenic or genetic), date of referral to NCJDSU and referral source. The
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number, result and date of EEG, MRI and CSF 14-3-3 protein examinations were
eollccted. In addition, details of genetic analyses, brain biopsy and post mortem
examination were collected. In genetic prion disease cases, a recorded family history
ofprion disease in a first degree relative was extracted from the cases note. For iCJD
cases, the route and date of exposure were recorded. Data extracted from case
records were anonymised and entered onto a password protected database maintained
on a desk top computer.
Definitions
Age, in years, was calculated at symptom onset, at referral to the NCJDSU and at
death. Unless otherwise stated, age was treated as a continuous variable. Clinical
presentation was determined by symptoms at onset and treated as a categorical
variable. For sCJD this was based on criteria developed by Knight and Will
(Appendix 3).(230) A 'typical clinical presentation' was considered as a clinical
presentation ofRPD, the Heidenhain variant or a cerebellar onset. An 'atypical
clinical presentation' was defined as any presentation other than RPD, the
Heidenhain variant or a cerebellar onset. For vCJD clinical presentation was
described in one of 3 categories: neurological, psychiatric or both (neurological and
psychiatric) characterizing the most prominent clinical features at onset (Appendix
4).(185) The source of referral was taken as the individual who initially contacted the
NCJDSU to discuss the case; this was treated as a categorical variable.
All EEGs and MRI scans undertaken during the course of the clinical illness were
requested for review by the NCJDSU. When available EEGs were reviewed by one
of two senior neurologists (RGW, RK). EEG's were classified using a five point
order categorical scale ranging from normal to 'typical'. According to the WHO
diagnostic criteria a 'typical' EEG can be used to change the classification of a
possible sCJD case to a probable sCJD case. In practice in the UK EEGs that are
considered highly suggestive but not entirely typical may also be used for case
classification based on the judgement of the reviewing clinicians. The operational
criteria employed in the UK for the assessment of EEG for case classification will be
discussed in greater detail in chapter 4.(98) For the purposes of this study an EEG
that was used for case classification will be referred to as a 'typical'. Where the EEG
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was unavailable for review by the NCJDSU, the EEG classification reported by the
local clinician was used. The time from symptom onset to first typical EEG was
calculated by subtracting the date of symptom onset from the date of first typical
EEG. This was measured in months.
All MRI scans, where available to the NCJDSU, were reviewed by one of two
designated neuroradiologists (DC, DS). Where unavailable, the local report was
used. In sCJD the MRI was considered positive if there was evidence of high signal
in the caudate nucleus and putamen or high signal in the striatum. In vCJD the MRI
was considered positive if the 'pulvinar sign' was present, defined as
"a characteristic distribution ofsymmetrical hyper-intensity of the pulvinar
nucleus (posterior nucleus) of the thalamus (relative to the grey matter ofthe
anterior putamen and normal cerebral cortex). "(98)
Negative scans did not meet these criteria. As noted in chapter 1 over time the
optimal sequences for detecting changes consistent with a diagnosis of sCJD and
vCJD on MRI scanning have been clarified, as have the specific features on MRI.
This study examined unselected surveillance data prior to and following these
developments. In this thesis I considered whether an MRI scan had been undertaken,
not the specific sequences used, and if so whether the features on MRI were
consistent with a diagnosis of sCJD or vCJD based on the above definitions. The
time from symptom onset to first positive MRI scan was calculated by subtracting
the date of symptom onset from the date of first positive MRI scan. This was
measured in months.
The National CSF 14-3-3 protein Reference Laboratory has been located in the
NCJDSU since 1997, although this investigation has been widely available in the UK
since 1996. The CSF 14-3-3 protein examination is either positive or negative. The
test can yield a 'weak positive' result. For the purposes of disease surveillance such
tests are considered negative results. A test may be requested but not processed. This
can arise because, for example, the sample is heavily blood stained or has been
inappropriately stored. Under these circumstances the test result may be invalid and
the laboratory will not process the sample. In such cases the test was recorded as not
being undertaken. The time from symptom onset to first positive CSF 14-3-3 protein
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examination was calculated by subtracting the date of symptom onset from the date
of first positive CSF 14-3-3 protein examination. This was measured in months.
The results of genetic analysis, PRNP Codon 129 genotyping and full sequencing of
PRNP for mutations, if performed, were recorded. Molecular subtyping according to
the Parchi classification where available was described.(147) The date and result of
tonsil and brain biopsies undertaken during life were recorded. The time from
symptom onset to positive biopsy was calculated by subtracting the date of symptom
onset from date of biopsy. This was measured in months. Post mortem examination
was recorded. Illness duration was measured by subtracting date of symptom onset
ffom the date of death. This was measured in months.
'Atypical sCJD cases' were defined as sCJD cases that were: aged under 50 years old
at symptom onset, had an illness duration of 1 year or more and/or had a clinical
presentation other than RPD, Hcidcnhain variant or cerebellar onset.
Statistical analyses
Data were cleaned and coded using the definitions outlined above. Cases were
examined according to disease subtype: sCJD, vCJD, iCJD and genetic prion disease.
For each disease subtype descriptive summary statistics were produced overall, and
by year of referral. Where data were normally distributed this was presented as mean
(standard deviation); skewed data were presented as median (inter-quartile range
unless otherwise stated). Univariate parametric tests of association between key
variables including age, sex, illness duration and year of referral were carried out (t
tests, Chi2 tests); where the assumptions of these tests were violated, non-parametric
equivalents were used (Fisher's exact test, Wilcoxon Ranksum test, Kruskal Wallis
2 • i i •
test). Chi tests for trend (or non-parametric equivalents where appropriate) were
used to compare proportions over time. The sensitivity of diagnostic investigations
(such as EEC, MRI and CSF 14-3-3 protein) was calculated as the proportion of
cases (according to disease subtype) that had a positive test result among those cases
(according to disease subtype) that underwent the investigation. The rate of post
mortem, presented as a percentage, was calculated as the number of cases
undergoing post mortem each year divided by the number of deaths that year.
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The NCJDSU has a limited remit in relation to the clinical surveillance of iCJD and
genetic prion disease, collecting a minimum reporting dataset on these cases only.
For these disease subtypes analyses were limited to basic descriptive statistics. The
NCJDSU is responsible for clinico-pathological surveillance of sCJD and vCJD
therefore more detailed analyses were carried out for these diseases.
Incidence and mortality rates
Annual age and sex-specific incidence and mortality rates of sCJD and vCJD were
calculated using denominator data from mid-year population estimates in the UK.
Incident cases were defined by year of referral to the NCJDSU; mortality by year of
death. Age standardised incidence and mortality rates of sCJD and vCJD were
calculated using data from the 2001 Census data and the direct method. A joinpoint
regression model was fitted to estimate the annual percentage change (APC) in age-
adjusted and agc-specific sCJD and vCJD incidence and mortality rates in men and
women, and to detect time points at which a significant change in the overall trend
occurred. To select the best-fitting model Baycsian Information Criterion (BIC) was
used. A maximum of three join points were allowed for each estimate. A
corresponding 95% confidence interval (CI) was calculated for each APC estimate.
Crude and adjusted case-fatality
Crude and adjusted case-fatality was calculated from the date of symptom onset. For
sCJD crude case-fatality at 6 months and 1 year was calculated as the proportion of
all cases that were dead at each time point; for vCJD case-fatality was calculated at 1
and 2 years reflecting the longer median survival in this disease. Median survival
was calculated using time from symptom onset to death. Log rank tests were used to
test for differences in survival experience by age group, sex, clinical presentation,
year of onset and molecular subtyping for sCJD and age group, sex, clinical
presentation and year of onset for vCJD. A Cox proportional hazards model, a
regression method for survival data, was used to analyse case-fatality. The Cox
model estimates hazard ratios and 95% confidence intervals. A hazard is the rate at
which an event occurs, in this case death. The hazard ratio is the hazard in one group
relative to the hazard in a comparison group, for example the hazard of death in the
youngest relative to the oldest age group, or the hazard of death in men relative to
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women. In modelling case-fatality adjustment was made for age group, sex, year of
onset and molecular subtype for sCJD. Molecular subtype was selected rather than
clinical presentation because the literature indicates that molecular subtype
determines clinical phenotypc.(147) For vCJD, analyses were adjusted for age group,
sex, year of onset and clinical presentation (among those tested to date all vCJD
cases have the same molecular subtype). Where a case was known to be alive,
survival time was censored at 31st December 2008 (minimum of 2 years follow up).
The proportional hazards assumption was tested using Schoenfeld residuals and was
met for each of the models at each time point.
Missing data
For all dates, where the month and year were available this was used and the mid¬
point of the month, the 15th, imputed. Where the day was missing but the start or end
of the month had been specified the 1st and 30th respectively were imputed. Where
the day and month was missing these data were excluded from analyses. In such
instances the number of observations that analyses arc based on is noted. In
calculating crude and adjusted case-fatality date of onset was missing for 14 cases
(all sCJD). These were excluded from further analyses. These cases did not differ
significantly with respect to age (P=0.297) or sex (P~0.702) from all other cases.
With the exception of regression analyses, all other analyses were carried out using
STATA Version 10 (Stata Corp. College Station, Texas, USA). Regression analyses
were carried out using Joinpoint Regression Program (Version 3.4.3). A level of
statistical significance of 0.05 was used throughout.
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Results
In total 1228 prion disease cases were ascertained by the NCJDSU between 1st May
1990 and 31st December 2006; 935 (76.1%) definite and 293 (23.9%) probable cases.
Overall, according to disease subtype, 893 (74.9%) were sCJD, 165 (13.5%) vCJD,
116 (9.4%) genetic prion disease and 54 (4.4%) iCJD cases. Over time there was a
significant change in the disease subtypes ascertained by the NCJDSU (P<0.001) as













a. 1990 1992 1994 1996 1998 2000 2002 2004 2006
Year
Figure 13 Distribution of disease subtypes of all prion disease cases ascertained
by the NCJDSU, 1990 - 2006
Sporadic CJD
From 1st May 1990 to 31st December 2006, there were 893 incident sCJD cases in
the UK, 689 (77.2%) definite and 204 (22.8%) probable sCJD cases (Table 19). In
total 432 (48.4%) cases were in men; 337 (49.1%) definite and 95 (46.6%) probable
cases. There was no significant difference in the proportion of definite or probable
cases according to sex (P= 0.346). However there was a significant reduction in the
proportion of all cases for which a ncuropathological diagnosis was available over
time, from 88.2% (15) in 1990 to 61.5% (40) in 2006 (P<0.001). The median age at
symptom onset was 67.1 years (IQR 60.6 - 74.2). This did not vary according to sex
(P=0.476) or case classification (P=0.223). The youngest sCJD case was 15.6 years
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old at symptom onset, the oldest 94.9 years. There was a significant increase in
median age at onset over time, from 60.9 years (59.2 - 67.8) in 1990 to 69.8 years
(61.0 - 77.2) in 2006 (P= 0.008). The median illness duration was 4.3 months (2.7 -
7.9). This did not vary according to sex (P=0.126) or over time (P=0.370). Cases
were most frequently referred by a neurologist (n=590, 66.1%), followed by a










Figure 14 Source of referrals of sCJD cases ascertained by the NCJDSU, 1990
2006
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Age and sex-specific incidence rates
Age-specific incidence rates of sCJD in men and women are shown in Figure 15. In
both men and women the incidence of sCJD in those aged under 50 years old was
low. Incidence rates rose thereafter to peak in men and women aged 70 - 79 years,
before falling in those over 80 years of age. In men there was no statistically
significant difference between incidence rates in those aged 60 - 69 years (rate 3.75
(95% CI 3.19 -4.32) per million), 70 - 79 years (rate 4.15 (3.43 -4.86) per million)
and 80 years and over (rate 2.74 (1.83 - 3.64) per million). In women incidence rates
in those aged 60 - 69 years (rate 3.26 (2.76 - 3.77) per million) were comparable to
incidence rates in those aged 70 - 79 years (rate 3.73 (3.14-4.32) per million).
However the decline in incidence rates in those aged 80 years and over was
significant (rate 1.57(1.10- 2.03) per million.) The 95% confidence intervals for
age-specific rates in men and women overlapped in each age group indicating that
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Figure 15 Age-specific sCJD incidence rates according to sex, 1990 - 2006
Temporal trends in age and sex-specific incidence rates
Over time the only statistically significant increase in the sCJD incidence rate was
observed in men aged 70 - 79 years old, in whom the annual percentage change
(APC) in incidence rate was 8.87% (4.54 - 13.38). In this group the incidence rate
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increased from 0.60 (0.00 - 1.78) permillion in 1990 to 7.75 (3.83 — 11.67) per
million in 2006. In women of the same age a non-significant increase in the
incidence rate from 0.83 (0.00 - 1.99) per million in 1990 to 4.23 (1.61 - 6.86) per
million in 2006 was observed. Similar non-statistically significant increases in sCJD
incidence were observed in men aged 60 - 69 years (from 1.11 (0.00 - 2.36) per
million to 4.52 (2.06 - 6.97) per million), men 80 years and over (from 0.00 per
million to 5.30 (0.65 - 9.95) per million), women aged 60 - 69 years (from 1.64
(0.20 - 3.07) per million to 2.95 (1.02 - 4.87) per million) and women aged 80 years
and over (from 0.00 per million to 2.85 (0.35 - 5.34) per million). There was no
significant increase, clinically or statistically, in the incidence of sCJD in men or
women under 60 years of age.
Age standardised incidence rates
Age standardised incidence rates of sCJD in men and women are shown in Figure 16
In men, the age standardised rate rose from 0.27 (0.07 - 0.47) per million in 1990 to
peak at 1.35 (0.93 - 1.77) per million in 2003 and has remained stable since. At the
end of the study period, 2006, the incidence rate permillion was 1.18 (0.79 - 1.56)
per million. In women the age standardised rate in 1990 was 0.33 (0.13 - 0.54) per
million. The rate peaked at 1.45 (1.02 - 1.88) per million in 2002. At the end of the
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Figure 16 Age standardised incidence rate of sCJD in men and women, 1990 -
2006
Temporal trends in age standardised incidence rates
There was a statistically significant increase in the age standardised incidence of
sCJD in men and a non-significant increase in women from 1990 through 2006. In
men, the APC in incidence was 5.20% (2.62 - 7.83). In women, this was estimated to
be 2.57% (-0.38-5.60).
Clinical presentation
The majority of sCJD cases, 61.6% (550), presented with a RPD, 11.5% (103) with a
cerebellar onset and 5.4% (48) with the Heidenhain variant (Figure 17). Almost a
fifth, 173, sCJD cases had an 'atypical clinical presentation', defined as a
presentation other than RPD, cerebellar onset or Heidenhain variant. There was no
significant difference in presentation according to sex (P= 0.653). Clinical
presentation was not specified for 19 (2.1%) sCJD cases. Over time there was no
significant change in the proportion of sCJD cases that had an atypical presentation

























Figure 17 Distribution of clinical presentations in sCJD cases, 1990 - 2006
Investigations to support a diagnosis of sCJD
In this section the use of EEG, MRI, CSF 14-3-3 protein, brain biopsy, PRNP Codon
129 genotyping, full sequencing for PRNP mutations and post mortem examination
in the investigation of sCJD cases will be described.
EEG
Overall 808 (90.5%) sCJD cases underwent at least one EEG examination during the
course of their clinical illness (Figure 18). There was no significant change in the
proportion of sCJD cases undergoing EEG examination over time (P= 0.779).
Overall the median number of EEGs undertaken was 1 (range 1 - 5). A non¬
significant fall in the median number ofEEGs from 2 (1 - 4) in 1990 to 1 (1-4) in
2006 was observed (P-D.088). Over a third, 302 (37.4%), of the sCJD cases that
underwent EEG examination had a typical EEG. There was significant year to year
variation in the proportion of patients with a typical EEG over the study period
(Figure 19). This ranged lfom a high of 59.4% (29) in 1994 to 23.0% (12) in 2001.
The overall trend however was toward a fall in the proportion of sCJD cases with a
typical EEG over time from 50.0% (8) in 1990 to 33.3% (19) in 2006 (P<0.001).
Overall, the median time from symptoms onset to typical EEG was 2.3 (1.3 - 3.5)
months (n=301). Over the study period the median time from symptom onset to
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Figure 19 Proportion of sCJD cases with a typical EEG among sCJD cases that
underwent at least one EEG examination, 1990 - 2006
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MRI
Overall 596 (66.7%) sCJD cases underwent at least one MRI examination (any
sequence) during the clinical course of their illness (Figure 20). The proportion of
sCJD cases undergoing at least one MRI examination increased significantly over
time, from 11.8% (2) in 1990 to 84.6% (55) in 2006 (P<0.001). Overall the median
number ofMRI undertaken in the investigation of sCJD cases was 1 (range 1 - 3);
this increased over time from 1 (range 1 - 1) in 1990 to 2 (range 1 - 3) in 2006
(PcO.OOl). Radiological changes consistent with sCJD were seen on MRI scans in
201 (33.8%) sCJD cases that underwent MRI examination (Figure 21). The
proportion of sCJD cases with a positive MRI scan increased significantly over time
from 0% (0) in 1990 to 45.5% (25) in 2006 (P<0.001). Overall, the median time from
symptoms onset to characteristic MRI scan was 3.8 (2.2 - 6.5) months (n=201). This
was invariant over time (P= 0.568).
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Figure 21 Proportion of sCJD cases with an MRI scan that had changes
consistent with sCJD among sCJD cases that underwent at least one MRI
examination, 1990 - 2006
CSF 14-3-3 protein (limited to 1996 onwards)
Almost two thirds of all sCJD patients, 431 (64.8%), underwent at least one CSF 14-
3-3 protein examination following the introduction of the investigation in the UK in
1996 (Figure 22). The proportion of sCJD cases undergoing CSF 14-3-3 protein
examination increased from 35.7% (15) in 1996 to 73.8% (48) in 2006 (P<0.001).
Overall the median number ofCSF 14-3-3 protein examinations was 1 (range 1 - 3).
This was invariant over time (P=0.564). CSF 14-3-3 protein was positive in 83.7%
(361) of all sCJD cases undergoing this investigation. There was year to year
variation in the proportion of sCJD cases with a positive CSF 14-3-3 protein
examination, from a high of 93.3% (14) in 1996 to a low of 68.4% (26) in 2000, but
no significant trend over time (P=0.237) (Figure 23). Overall, the median time from
symptoms onset to positive CSF 14-3-3 protein examination was 2.9 (1.9 - 5.3)
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Figure 22 Proportion of sCJD cases undergoing at least one CSF 14-3-3 protein
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Figure 23 Proportion of sCJD cases with a positive CSF 14-3-3 protein
examination among those undergoing CSF 14-3-3 protein examination, 1996
2006
Over time the relative importance of EEG and CSF 14-3-3 protein examination in
case classification has changed (Figure 24). The proportion of probable sCJD in
whom the diagnosis was based solely on EEG examination fell over the study period
following the introduction ofCSF 14-3-3 protein. Of note, whilst CSF 14-3-3 protein
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was not formally introduced into the WHO diagnostic criteria until 2000, this test
was widely available in the UK from 1996. Possible sCJD cases ascertained by the
NCJDSU from 1996 through 2000 that had a positive CSF 14-3-3 protein were
retrospectively classified as probable sCJD cases for disease surveillance purposes












Figure 24 Proportion of probable sCJD cases meeting the WHO diagnostic
criteria based on EEG, CSF 14-3-3 protein or both, 1996 - 2006
PRNP Codon 129 Genotyping
Genetic analysis for polymorphism at Codon 129 of PRNP was available for almost
two thirds, 580 (65.0%), of sCJD cases (Figure 25). There was no significant
difference in the proportion of sCJD cases undergoing PRNP Codon 129 genotyping
over the study period (P=0. 111). The distribution ofPRNP Codon 129 genotypes
among sCJD case ascertained over the study period is shown in Figure 26. The
majority of sCJD cases, 375 (64.7%), were methionine homozygous (MM), 103
(17.8%) valine homozygous (VV) and 102 (17.6%) heterozygous (MV). There was a
non-significant reduction in the proportion of sCJD cases with the MM genotype,
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Figure 25 Proportion of sCJD case for which P/f/VPCodon 129 genotyping was









Figure 26 Distribution ofPRNP Codon 129 genotypes, 1990 - 2006
Full sequencingfor mutations ofPRNP
Genetic prion disease may be clinically and neuropathologically indistinguishable
from sCJD and only an estimated 50% of genetic prion disease cases report a family
history of prion disease. Testing for mutations ofPRNP is important in ensuring that
genetic prion disease and sCJD cases are correctly classified. Half of all sCJD cases,
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451 (50.5%) underwent genetic testing to exclude a mutation ofPRNP. The
proportion of sCJD cases undergoing genetic testing to exclude a mutation ofPRNP
decreased overtime from 70.6% (12) in 1990 to 24.6% (16) in 2006 (P<0.001), as
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Figure 27 Proportion of sCJD cases undergoing genetic testing for a mutation of
PRNP, 1990 - 2006
Postmortem and brain biopsy
As of 31st December 2008, three neuropathologically confirmed sCJD cases referred
to the NCJDSU between 1st May 1990 and 31st December 2006 were still alive.
Overall 75.1% (668) of deceased sCJD cases underwent post mortem examination.
Over time there was a statistically significant reduction in the percentage of sCJD
cases undergoing post mortem examination, from 88.2% (15) in 1990 to 60.3% (38)
in 2006 (P<0.001) (Figure 28). Overall just 3.8% (34) of all sCJD cases underwent
brain biopsy in life. This was diagnostic in almost three quarters (n=25); the
remaining 9 sCJD cases in whom brain biopsy was non-diagnostic underwent post
mortem examination following death.
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Year of death
Figure 28 Rate of post mortem examination in sCJD cases according to year of
death, 1990-2006
PrPScprotein typing
PrPSc protein typing was carried out on 301 (43.7%) sCJD cases for which
neuropathological material was available following brain biopsy or post mortem
examination (Figure 29). Over time the proportion of sCJD cases for whom PrPSc
protein typing was available increased significantly (P<0.001).
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Year
Figure 29 Proportion of sCJD cases in whom PrPSc protein typing was available
among sCJD cases for which PrPSc protein typing was carried out, 1990 - 2006
140
The distribution of PrPSc protein type among sCJD eases for whom PrPSt protein type
analysis was available is shown in Figure 30. In total 189 (62.8%) sCJD cases were
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Figure 30 Distribution of PrPSc protein type in sCJD cases for whom prion
protein typing was available, 1990 - 2006
Molecular subtyping
Molecular subtyping was available for 299 sCJD cases in whom PrPSc protein type
and PRNP Codon 129 genotyping was known (Figure 31). The most common
molecular subtype was MM1, followed by MV2 and VV2. The characteristics of
sCJD cases according to molecular subtype are outlined in Table 20. The median
illness duration was shortest in sCJD cases with the MM! and VV1/2 subtype and
longest in those with the MM2 and MV1/2 subtype. EEG was most frequently
typical in the MM1 subtype and least frequently in theW subtypes. CSF 14-3-3
protein was most commonly positive in the MM 1 subtype, least frequently in the
MV2 and MM2 subtypes. MRI scanning was most commonly positive in theW
subtypes. Over time there was no significant change in the molecular subtype of
sCJD cases ascertained by the NCJDSU (P=0.991).
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Figure 31 Molecular subtyping of sCJD cases for whom PRNP Codon 129
genotyping and PrFSc protein typing was available, 1990 - 2006
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Sensitivity ofdiagnostic investigations in sCJD (limited to 1996 onward)
The sensitivity of EEG, MRI, CSF 14-3-3 protein and brain biopsy examinations in
sCJD cases that underwent these investigations is shown in Figure 32. Whilst MRI
was not at the time ofwriting included in the WHO diagnostic criteria for sCJD it
has been included here in recognition of its value in sCJD. CSF 14-3-3 protein
examination was the most sensitive of investigations over this period, being positive
in 83.9% (95% CI 80.0 - 87.2) of sCJD cases. The sensitivity of brain biopsy was
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Figure 32 Overall sensitivity of EEG, MRI, CSF 14-3-3 protein and brain biopsy
examinations in sCJD cases, 1996 - 2006
sCJD cases with negative EEG, MRI and CSF 14-3-3 protein examinations
From 1996 through 2006, 24 pathologically confirmed sCJD cases underwent at least
one EEG, at least one MRI and at least one CSF 14-3-3 protein examination, and all
three diagnostic investigations (EEG, MRI and CSF 14-3-3 protein) were negative.
This represents 4.9% of all pathologically confirmed sCJD and 3.6% of all sCJD
cases (definite or probable) ascertained over this ten year period. Men accounted for
13 (54.7%) of these sCJD cases. Compared to sCJD cases in whom one or more of
the aforementioned investigations was positive, sCJD cases in this group were
younger (median age 59.9 (52.1 - 67.4) years v.v. 67.4 (60.7 - 74.0) years, P< 0.001),
more likely to have an atypical clinical presentation (P<0.001), had a longer median
illness duration (16.6 (8.2 — 21.1) months vs. 4.2 (2.7 - 7.3) months, P< 0.001), were
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more likely to undergo brain biopsy during life (P=0.011) and post mortem
examination following death (P=0.004). However, there was no statistically
significant difference in PRNP Codon 129 genotype between the groups (P= 0.084).
Of these 24 sCJD, four (16.7%) underwent brain biopsy in life; this was diagnostic in
two (50%) cases.
Atypical sCJD Cases
'Atypical sCJD cases' were defined as sCJD cases aged under 50 years old at
symptom onset, that had an illness duration of 1 year ofmore and/or had a clinical
presentation other than RPD, Heidenhain variant or cerebellar onset; all other sCJD
cases were considered 'typical'. Over a quarter, 28.8% (256) sCJD cases were
considered atypical, of which 114 (45.5%) were male. Atypical sCJD cases included
173 sCJD cases with an atypical clinical presentation, 45 sCJD cases under 50 years
of age at symptom onset and 140 sCJD cases with an illness duration of over 1 year
(groups not mutually exclusive) (Figure 33). Figure 34 shows the proportion all sCJD
accounted for by atypical sCJD cases per year. There was no significant change in
the proportion of all sCJD cases accounted for by atypical sCJD cases over time
(P=0.118). The diagnosis of sCJD was pathologically confirmed in 223 (87.1%)
atypical sCJD cases. The sensitivity of EEG (25.9% vs. 41.8%, P<0.001) and CSF
14-3-3 protein (68.9% vs. 89.4%, P0.001) examination but not MRI scanning
(31.0% vs. 34.9%, P=0.324) was lower in atypical sCJD cases compared to typical
sCJD cases. Atypical sCJD cases were more likely than typical sCJD cases to
undergo brain biopsy during life (9.0% vs. 1.7%, P<0.001) and post mortem
examination following death (80.5% vs. 72.5%, P<0.001). Relative to typical sCJD
cases there was an excess ofPRNP Codon 129 heterozygotes (MV) among atypical
sCJD cases (P<0.001). Atypical sCJD cases were most frequently of the MM 1 (34)
molecular subtype, followed by MV1 (26), MV2 (19) and MM2 (16) molecular
subtypes. A greater than expected number of atypical sCJD cases had MM2, MV1,
MV2 and MV 1/2 mixed protein molecular subtypes (P<0.001).
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Figure 34 Proportion of all sCJD cases accounted for by 'atypical sCJD cases',
1990 - 2006
sCJD cases aged under 50years old at onset
In total 45 sCJD cases were aged under 50 years old at symptom onset, ofwhom 20
(44.4%) were male. Compared to sCJD cases aged 50 years and over at onset, sCJD
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cases aged under 50 years of age at onset were more likely to have an illness duration
of over 1 year (40.0% v.v. 14.4%, P<0.001) and more likely to have an atypical
clinical presentation at symptom onset (47.7% vs. 18.3%, P<0.001). The sensitivity
ofEEG (18.2% v.y. 38.5%, P=0.007) and CSF 14-3-3 protein (69.6% vs. 84.6%,
P=0.008) examination but not MRI scanning (35.9% vs. 33.6%, P=0.797) was lower
in sCJD cases aged under 50 years old at onset compared to sCJI) cases aged 50
years and over at onset. sCJD cases aged under 50 years old at onset were more
likely to undergo brain biopsy during life (13.3% vs. 3.3%, P<0.001) but not post
mortem after death (P=0.637) than sCJD cases aged 50 years and over at onset.
PRNP Codon 129 genotype distribution did not vary according to age at onset
(P=0.267). However a greater than expected number of sCJD cases aged under 50
years old at onset had the MM2 (5 / 26), MV1 (7 / 26) or VV1 (7 / 26) molecular
subtype (P0.001). A neuropathologically confirmed diagnosis was available in the
majority, 86.7% (39) of sCJD cases aged less than 50 years old at onset. The clinical
details of the six sCJD cases aged less than 50 years old at onset that did not have a
neuropathological diagnosis arc shown in Table 21. There is little evidence from the
clinical presentation or summary of diagnostic investigations to suggest that any of
these sCJD cases were in fact misclassificd vCJD cases.
Tabic 21 Clinical details of sCJD cases under 50 years of age at onset that did
not have a neuropathological diagnosis
Case Clinical EEG MRI CSF 14-3-3 Illness Duration
Presentation protein (months)
1 RPD Typical N/A N/A 4.3
2 RPD Typical Negative N/A 2.7
3 Cerebellar Typical Negative N/A 2.4
4 Stroke-like Not typical Positive Positive 5.5
5 Other focal Not typical Positive Positive 8.4
6 RPD Not typical Positive Positive 4.7




Crude case-fatality at 6 months and 1 year was 62.7% (560) and 84.3% (753)
respectively. Median survival overall was 4.3 (1QR 2.7 - 7.9) months; this was
invariant over time (P= 0.370). Median survival did not vary according to sex (P=
0.126). Median survival fell with increasing age, from 10.5 (4.6 - 20.9) months in
sCJD cases under 50 years of age to 3.0 (1.9 — 4.6) months to sCJD cases 80 years
and over (P<0.001). Figure 35 shows the survival time from symptom onset, by age
group. Median survival varied by clinical presentation (P<0.001). sCJD cases with
an atypical clinical presentation had a median illness duration of 9.2 (4.2 - 20.9)
months, compared to sCJD cases with a typical clinical presentation, 3.8 (2.6 - 6.6)
months (Figure 36). The shortest median survival was seen in sCJD cases with a
stroke-like onset, 2.4 (1.9 — 3.9) months; the longest for sCJD cases with a slowly
progressive dementia, 23.2 (16.3 - 30.0) months (Table 22). According to PRNP
Codon 129 genotyping the median survival was 3.3 (2.4 - 5.7) months for
methionine homozygotes, 9.3 (6.2 - 16.2) months for methionine hctcrozygotes and
6.2 (4.3 - 8.7) months for valine homozygotcs (P<0.001). As previously noted
illness duration varied according to molecular subtype.
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Illness Duration (months)
Figure 35 Kaplan Meier estimates of survival (months) in sCJD cases, 1990 -
2006, according to age group
Illness Duration (months)
Figure 36 Kaplan-Meier estimates of survival (months) in sCJD cases, 1990 -
2006, according to clinical presentation (typical or atypical)
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Table 22 Median Survival (months) in sCJD cases in the UK, 1990 - 2006,
according to clinical presentation
Clinical Presentation Number of sCJD cases Median Survival (months)
Rapidly Progressive Dementia 548 3.7(2.5-6.4)
llcidcnhain Variant 48 3.0(2.4-4.2)
Psychiatric Onset 42 7.1 (5.0-11.0)
Slowly Progressive Dementia 50 23.2(16.3-30.0)
Cerebellar Onset 103 5.2 (3.5-8.7)
Extra-pyramidal Onset 3 14.8(3.0-16.8)
Stroke-like Onset 20 2.4(1.7-3.4)
Sensory Onset 17 7.5 (4.8-12.4)
Other Focal Onset 39 6.7 (2.7-16.2)
Onset Missing 6 4.4 (2.3-9.8)
Adjusted case-fatality
Case-fatality was modelled adjusting for age group, sex, year of onset and molecular
subtype. The hazard of death six months after illness onset increased with age (Tabic
23). For example, at six months the hazard of death was seven times greater in sCJD
cases aged 80 years and over at onset relative to those aged less than 50 years old at
onset, Hazard Ratio (HR) 7.21 (2.69 - 19.31). The hazard of death did not vary
according to sex and did not improve over time (at either six month or 1 year end-
points). Following adjustment for age group, sex and year of onset the hazard was
lower in sCJD cases with the MM1 molecular subtype relative to all other molecular
subtypes, at both six month andl year end-points.
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Tabic 23 Hazard ratios for death (and 95% Confidence Intervals) at 6 months
and 1 year after symptom onset in sCJD cases from the UK (1990 - 2006),
adjusted for age group, sex, year of onset and molecular subtype
Hazard Ratios of death (95% CI)
6 months after onset 1 year after onset
<50 years 1.00 (Reference group) 1.00 (Reference group)
50 - 59 years 2.19(0.84-5.72) 1.93 (1.03 -3.58)
Age group 60 - 69 years 2.823(1.12-7.12) 2.57(1.41 -4.67)
70 - 79 years 4.19(1.66-10.60) 3.71 (2.02-6.81)
> 80 years 7.21 (2.69- 19.31) 6.06 (3.03- 12.10)
Sex Men v.v. Women 0.80 (0.60- 1.06) 0.85 (0.67 - 1.07)
MM1 1.00 (Reference group) 1.00 (Reference group)
MM2 0.10(0.02-0.42) 0.16(0.07-0.35)









MV 1/2 0.12(0.02-0.85) 0.10(0.02-0.40)
VV1 0.39(0.12-0.96) 0.51 (0.37-0.71)
VV2 0.34 (0.20-0.56) 0.47 (0.32 - 0.69)
W 1/2 0.83(0.34-2.03) 0.85(0.68- 1.07)
Year (onset) (per year) 0.98 (0.95-1.01) 1.00(0.97-1.03)
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sCJD mortality rates
Age and sex-specific mortality rates
Age-specific sCJD mortality rates in men and women are shown in Figures 37. As
would be anticipated given the high case-fatality and short illness duration, these
closely mirrored sCJD incidence rates. In both men and women sCJD mortality rates
in those aged under 50 years old were low, rising to peak in men and women aged 70
- 79 years, before falling in those over 80 years of age. In men there was no
statistically significant difference between sCJD mortality rates in those aged 60 - 69
years (rate 3.73 (3.17 - 4.29) per million), 70 - 79 years (rate 4.15 (3.43 - 4.86) per
million) and 80 years and over (rate 2.74 (1.83 - 3.64) per million). In women sCJD
mortality rates in those aged 60 - 69 years (rate 3.24 (2.74 — 3.74) per million) were
comparable to sCJD mortality rates in those aged 70 - 79 years (rate 3.68 (3.10 -
4.27) per million). However the declined in sCJD mortality rates in those aged 80
years and over was significant (rate 1.57 (1.10 — 2.03) per million.) The 95%
confidence intervals of age specific rates in men and women overlapped in each age
group indicating that overall there was no significant difference in age-specific sCJD
mortality rates according to sex.
Age group (years)
Figure 37 Age-specific sCJD mortality rates according to sex, 1990 - 2006
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Temporal trends in age and sex-specific mortality rates
Temporal trends in sCJD mortality rates elosely resembled temporal trends in sCJD
ineidenee rates. There was no clinically or statistically significant change in sCJD
mortality in men and women under 60 years of age. A clinically, but not statistically
significant increases in sCJD mortality rates in men aged 60 - 69 years and 80 years
and over and women over 60 years of age was observed. Finally a statistically
significant increase in Ihe sCJD mortality rate in men aged 70 - 79 years was
observed with an APC in the sCJD mortality rate of 9.47% (4.62 - 14.54).
Age standardisedmortality rates
Age standardised sCJD mortality rates in men and women are shown in Figure 38. In
men, the sCJD mortality rate was 0.27 (0.07 - 0.47) per million in 1990, rising to
peak at 1.36 (0.94 - 1.77) per million in 2003 and stabilising thereafter. At the end of
the study period, 2006, the sCJD mortality rate was 1.27 (0.87 - 1.67) per million. In
women, the sCJD mortality rate rose from 0.33 (0.13 - 0.54) per million in 1990 to
peak at 1.29 (0.88 - 1.69) per million in 2002 and stabilised thereafter. At the end of
the study period, 2006, the sCJD mortality rate was 0.90 (0.57 - 1.23) per million.
Year
Figure 38 Age standardised sCJD mortality rates in men and women, 1990 -
2006
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Temporal trends in age standardised mortality rates
Following adjustment for age there was a statistically significant increase in sCJD
mortality rates in both men and women across the study period. In men from 1990
through 2006 the APC in the sCJD mortality rate was 5.47% (2.45 - 8.58). In women
the APC in sCJD the mortality rate over the same period was 2.82% (0.21 - 5.50).
Variant CJD
From 1st May 1990 to 31st December 2006 there were 165 incident cases of vCJD in
the UK, 115 (70.0%) definite and 50 (30.0%) probable vCJD cases (Table 24). In
total, 92 (55.8%) vCJD cases were in men including 67 (58.3%) definite and 25
(50.0%) probable vCJD cases. There was no significant difference in the proportion
of definite or probable cases according to sex (P= 0.326). The median age at
symptom onset was 26.6 years (IQR 20.7 - 33.3). The youngest vCJD case was 12.6
years old at symptom onset; the oldest 74.4 years old. Age at symptom onset did not
vary according to sex (P=0.096) or change over time (P= 0.953). Of note all vCJD
cases ascertained by the NCJDSU over this period were born before 1989.
The majority of vCJD cases, 89.1% (143), were referred to the NCJDSU by a
neurologist. As of 31st December 2008, 3 probable vCJD cases referred to the
NCJDSU prior to 31st December 2006 were known to be alive; 2 men (aged 17.6 and
18.4 years at symptom onset) and one woman (aged 17.3 years at onset). These
individuals had illness durations of 74.5, 87.5 and 70.5 months respectively at the
time of data censoring.
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Age and sex-specific incidence rates
Age specific vCJD incidence rates in men and women are shown in Figure 39. In
men, the vCJD incidence rate increased from 0.17 (0.08 - 0.25) per million in those
aged 19 years and under, to peak at 0.95 (0.56 - 1.34) per million in those aged 25 -
29 years, before falling to 0.13 (0.07 - 0.18) per million in those aged 35 years and
over. The 95% confidence intervals for vCJD incidence rates in the age groups 20 -
24 years, 24 - 29 years and 30 — 34 years overlapped indicating that there was no
statistically significant difference in between groups. In women, the vCJD incidence
rate increased from 0.19 (0.09 - 0.27) permillion in those aged 19 years and younger
to peak at 0.86 (0.47 - 1.25) permillion in those aged 20 - 24 years before falling to
0.06 (0.03 - 0.09) per million in those aged 35 years and over. As for men, there was
no significant difference in the vCJD incidence rate in women aged 20 - 24 years, 25


















Figure 39 Age-specific vCJD incidence rates according to sex, T995 - 2006
- Men
-Women
( 1 1 1 1
19 20-24 24-29 30-34 >35
Age group (years)
156
Temporal trends in age-specific incidence rates
There was no statistically significant increase in vCJD incidence rates over time
according to age group in men or women. However, due to the small number of
incident vCJD cases in each age group and sex the analyses were underpowered. A
statistically non-significant but clinically relevant increase in vCJD incidence rates
was observed in men age 20 - 24 years in whom the vCJD incidence rate increased
from 0 per million in 1995 to peak at 2.85 (0.35 - 5.34) per million in 2000 before
falling to 0.63 (0.30 - 0.95) per million in 2006. A similar trend was observed in men
aged 25 - 29 years in whom the vCJD incidence rate increased from 0 per million in
1995 to 2.98 (0.60 - 5.36) per million in 2000 before falling to 0.95 (0.56 - 1.34). In
women a non-significant but clinically relevant increase in the vCJD incidence rate
from 0 permillion in 1995 to 2.25 (0.04 - 4.45) per million in 1997 in the age group
20 — 24 years was observed.
Age standardised incidence rates
Age standardised vCJD incidence rates in men and women are shown in Figure 40.
In men the age standardised vCJD incidence rate rose from 0.07 (0.03 - 0.17) per
million in 1995 to peak at 0.69 (0.39 - 1.00) per million in 2000, before falling to
0.11 (0.01 - 0.24) in 2006. In women, the vCJD incidence rate rose from 0.15 (0.03 -
0.27) per million in 1995 to 0.36 (0.13 — 0.54) in 2001 thereafter falling to 0.06 (0.00
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Figure 40 Age standardised vCJD incidence rate in men and women, 1995 -
Temporal trends in age standardised incidence rates
Following adjustment for age there was a statistically significant increase in the
vCJD incidence rate in men between 1995 and 2000. The APC in vCJD incidence
rate over this period was 42.60% (3.40 - 96.70). Between 2000 and 2006 the vCJD
incidence rate fell with an APC of-26.24% (-41.90 - -6.37). In women, there was no
statistically significant change in the vCJD incidence rate between 1995 and 2006
(APC-3.73 (-14.45-8.33)).
Clinical presentation
Over half of all vCJD cases, 86 (52.1%), presented with psychiatric symptoms at
onset, 52 (31.5%) with neurological symptoms (predominantly sensory disturbance),
and 27 (16.4%) with mixed psychiatric and neurological symptoms. Clinical
presentation varied by sex, with an excess ofmen presenting with psychiatric onset
relative to women (P= 0.034). There was no statistically significant difference in
clinical presentation with respect to age group (P=0.934) and no change in clinical




In this section the use of EEG, MRI, CSF 14-3-3 protein, tonsil biopsy, brain biopsy,
PRNP Codon 129 genotyping, full sequencing for PRNP mutations and post mortem
examination in the investigation of vCJD cases will be described.
EEG
All vCJD cases underwent at least one EEG examination during the course of their
clinical illness; 153 (92.7%) cases underwent multiple examinations (range 1 - 3).
The typical EEG described in sCJD (PSWC) was not found in any of the EEG
examinations undertaken.
MRI
The majority of vCJD cases, 163 (98.2%), underwent at least one MRJ examination
during the clinical course of their illness; 49 (29.7%) underwent multiple
examinations (range 1 - 3). Radiological changes consistent with vCJD were seen on
the MRI of 141 (85.5%) vCJD that underwent this investigation (any sequence).
Eighteen (11.0%) vCJD cases did not have signs consistent with vCJD on MRI
scanning. In two vCJD cases MRI scanning was reported as 'equivocal' and in a
further two vCJD cases the images were degraded due to movement artefact. Overall,
the median time from symptoms onset to characteristic MRI scan was 8.1 (5.9 -
10.5) months (n=140). This was invariant over time (P= 0.095).
CSF 14-3-3 protein (limited to 1996 onward)
The majority of vCJD cases, 126 (80.3%) underwent at least one CSF 14-3-3 protein
examination. There was no significant change over time in the proportion of vCJD
cases undergoing CSF 14-3-3 protein examination (P=0.115). CSF 14-3-3 protein
was positive in 53 (42.1%) vCJD cases. Overall, the median time from symptom
onset to positive CSF 14-3-3 protein examination was 8.6 (6.9 - 10.3) months. This
was invariant over time (P= 0.225).
Tonsil and brain biopsy
In total 35 (21.2%) vCJD cases underwent tonsil biopsy. Over time the there was a
significant increase in the proportion of vCJD cases undergoing tonsil biopsy
(P=0.023). vCJD cases that underwent tonsil biopsy did not differ significantly from
those who did not with respect to age (P=0.094), sex (P=0.561) or clinical
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presentation (P^0.340). Evidence of PrPSc was found in 33 (85.7%) vCJD cases that
underwent tonsil biopsy. In one vCJD case tonsil biopsy was 'equivocal' and in the
final vCJD case tonsil biopsy was negative for PrPSc. The median time from
symptom onset to positive tonsil biopsy was 10.7 (8.3 - 12.7) months. Interestingly,
of this group the majority, 29 (82.9%) had features on MR1 examination that
supported a diagnosis of vCJD prior to tonsil biopsy and hence were already
classified as a probable vCJD cases. Tonsil biopsy contributed to case classification
in just 6 (17.1%) of the vCJD cases that underwent this examination.
Ten (6.1%) vCJD cases underwent brain biopsy during life. These patients did not
differ significantly from others with respect to age (P=0.881), sex (P=l .000) or
clinical presentation (P=0.607). Interestingly, all but one of these vCJD cases had
MRI features consistent with a diagnosis of vCJD and met the WIIO diagnostic
criteria as a probable vCJD case prior to brain biopsy. Brain biopsy was diagnostic in
six of the ten vCJD cases; the remaining four cases all underwent post mortem
examination on expiration.
PRNP Codon 129 Genotyping
PRNP Codon 129 genotyping was available for 149 (90.3%), vCJD cases, with no
significant change over time in the proportion undergoing this investigation
(P=0.226). All vCJD cases undergoing this examination were methionine
homozygote at PRNP Codon 129.
PRNPmutation testing
Genetic testing to exclude a PRNP mutation was carried out on 128 (80.6%) vCJD
cases. There was no significant change in the proportion of vCJD cases undergoing
PRNP mutation testing over time (P=0.153).
Post mortem examination
As of 31st December 2008, three patients with probable vCJD referred to the
NCJDSU prior to 31st December 2006 were still alive. Of the 162 deceased vCJD
cases, 109 (67.3%) underwent post mortem examination. The rate of post mortem
examination in vCJD cases varied over time (P<0.001) (Figure 41). Initially the rate
was very high. A gradual decline in post mortem rates from 1999 (100%) through
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2002 (24%) occurred, during which the number of tonsil biopsies carried out was high. Post mortem rates have
fluctuated from 46% - 60% since 2002.
20
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Figure 41 Post mortem rate according to year of death in vCJD cases, 1995 - 2006
PrPScprotein typing
PrPSc protein typing was carried out on 75 (64.7%) vCJD cases for which pathological material was available
following tonsil biopsy, brain biopsy or post mortem examination. In all cases the PrPSc isotype was 2B.
Sensitivity ofdiagnostic investigations in vCJD
Figure 42 shows the proportion of all vCJD cases that underwent at least one MRI scan, tonsil biopsy or brain
biopsy and had a positive result from these investigations respectively, from 1996 and 2006. Tonsil biopsy was
the most sensitive of all investigations, with a sensitivity of 94.3% (86.6 - 1.00), followed by MRI scanning,














Figure 42 Sensitivity of diagnostic investigations in vCJD, 1996 - 2006
Definite vCJD cases with negative investigations
Between 1996 and 2006, nine definite cases of vCJD had a negative or non-
contributory MRI scan and did not undergo tonsil biopsy. Men accounted for 4
(44.4%) of these cases. There was no difference in age (P=0.384), sex (P=0.357) or
clinical presentation (P=0.649) between this group and all other vCJD cases. Just one
of nine these vCJD cases underwent brain biopsy in life. This was diagnostic.
Case-fatality
Crude case-fatality
Crude case-fatality at 1 and 2 years was 35.2% (58) and 86.7% (143) respectively.
Median survival overall was 13.8 (IQR 11.1 - 17.6) months. This was invariant over
time (P= 0.949). The median survival was greater in women, 15.7 (11.3 - 20.9)
months than in men, 13.2 (10.8 - 16.6) months (P= 0.026). Median survival varied by
age group as seen in Figure 43 (P<0.001). Cases in the youngest age group, aged 19
years and under had the longest median survival at 18.2 (13.6 - 32.6) months; cases
aged 25 - 29 years had the shortest median survival at 12.0 (10.0 - 16.5) months
(P<0.001). Median survival did not vary according to clinical presentation (P—0.211).
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Illness Duration (months)
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20-24 years ^ 35 years
25 - 29 years
Figure 43 Kaplan-Meier estimates of survival (months) in vCJD cases, 1995 -
2006, according to age group
Adjusted case-fatality
The hazard of death at 1 year increased with age (Table 25). Relative to cases aged
19 years and under at symptom onset, the hazard of death at 1 year was almost five
times higher in cases aged 25 - 29 years at symptom onset,, HR 4.57 (1.53 - 12.62).
The hazard of death increased with age in all groups, relative to the youngest age
group. Following adjustment for age group and year of symptom onset, the hazard of
death at 1 year did not vary according to sex or clinical presentation at onset. There
was no change in the hazard of death at 1 year over time, HR 1.02 (0.93 — 1.10).
Similar trends were observed for adjusted case-fatality at 2 years.
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Table 25 Hazard ratios for death (95% Confidence Interval) in vCJD cases at 1
and 2 years after symptom onset, adjusted for year of symptom onset, sex and
age group
Hazard Ratios (95% CI)
1 year 2 years
Year (onset) Per year 1.02 (0.93- 1.11) 1.06(1.00-1.12)
<19 years 1.00 (Reference) 1.00 (Reference)
20 - 24 years 2.17(0.65 -7.23) 2.00(1.10-3.62)
Age group 25 -29 years 4.57(1.53 - 12.62) 3.40(1.92 - 6.02)
30 - 34 years 3.96(1.34-12.11) 3.44(1.90-6.20)
> 35 years 4.04 (0.40- 1.22) 3.45 (1.92-6.17)
Sex Men vs. Women 0.70 (0.40- 1.22) 0.71 (0.50-1.01)
Clinical
Presentation






0.90 (0.55 - 1.48)
vCJD mortality rates
Age-specific mortality rates
As for sCJD, trends in mortality from vCJD closely mirrored trends in vCJD
incidence (Figure 44). The age-specific vCJD mortality rate increased from 0.14
(0.07 - 0.22) per million in men aged 19 years and under, to peak at 0.95 (0.56 -
1.34) per million in men aged 25 - 29 years, before falling to 0.12 (0.07 -0.17) per
million in men aged 35 years and over. In women, the age-specific vCJD mortality
rate increased from 0.16 (0.08 - 0.25) permillion in those aged 19 years and under,
to peak at 0.82 (0.44 - 1.19) permillion in those aged 20 - 24 years old, before
falling to 0.06 (0.03 - 0.09) permillion in those age 35 years and over.
Temporal trends in age-specific mortality rates
Over time there was no statistically significant increase in vCJD mortality rates in
cither sex or any age group. As for temporal trends in vCJD incidence rates this is
likely to be in part due to the small sample size leading to insufficient statistical
power to detect a change in the trend. In men a non-statistically significant but
clinically relevant increase in vCJD mortality rates was observed in those aged 25 -
29 years, in whom the incidence rate increased from 0 per million in 1990 to 2.48
(0.31 - 4.66) per million in 2000 before falling to 0.95 (0.56 - 1.34) permillion in
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2006. In women a similar trend was observed in vCJD cases aged 20 -24 years in
whom the mortality rate increased from 0 permillion to 2.89 (0.36 - 5.43) per














Figure 44 Age-specific vCJD mortality rates in men and women, 1995 - 2006
Age standardised mortality rates
Age standardised vCJD mortality rates in men and women are shown in Figure 45. In
men, the age standardised vCJD mortality rate rose from 0.07 (0.03 - 0.17) per
million in 1995 to peak at 0.52 (0.26 — 0.78) per million in 2000, before falling to
0.15 (0.00 - 0.29) in 2006. In women, the rate rose from 0.03 (0.00 - 0.08) per
million in 1995 to 0.46 (0.21 - 0.71) in 2000, before falling to 0.03 (0.00 - 0.09) per
million in 2006.
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Figure 45 Age standardised vCJD mortality rates in men and women, 1995 -
2006
Temporal trends in age standardised mortality rates
In men there was a statistically significant increase in vCJD mortality rates between
1995 and 2000, with an APC of 47.12% (13.87 - 90.09). From 2000 through 2006,
the vCJD mortality rate in men declined significantly such that the APC was -
21.34% (-33.47 - -7.00). In women there was no statistically significant change in the
vCJD mortality rate over the study period (APC 1990 - 2006: -2.55% (-15.56 -
12.45)).
vCJD cases attributed to the transfusion of labile blood components
Between 1st May 1990 and 31st December 2006, four vCJD cases (one
asymptomatic) transmitted through the transfusion of labile blood components, were
ascertained by the NCJDSU. All were the recipients of non-leukodcplcte red blood
cells that had been donated by individuals who subsequently developed vCJD. The
median time from blood donation to donor symptom onset was 18.3 (16.6 - 29.7)
months. For disease surveillance purposes, these cases are considered vCJD, rather
than iCJD cases. They have therefore been included in the figures already presented
under the section on vCJD. This group are however of special interest because they
have acquired vCJD through a previously unrecognised route of transmission.
Accordingly, the epidemiological characteristics of the group will be described in
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this section. Due to small numbers comparison with the entire cohort of vCJD cases
is not possible and this section will be limited to descriptive epidemiology only.
All three symptomatic vCJD cases were in men. The median age at symptom onset
was 68.8 (31.3 - 74.2) years. Clinical presentations varied: one case presented with
RPD, one with sensory features and the third with psychiatric symptoms. The median
incubation period from transfusion to symptom onset was 7.8 (6.5 - 8.3) years. All
three vCJD cases underwent EEC and MR1 examinations during the course of
clinical illness; none underwent CSF 14-3-3 protein examination. EEGs were
unremarkable in all three cases. The MRI scan was consistent with a diagnosis of
vCJD in one case only. These findings were first observed 4.7 months after symptom
onset, in the final phase (last quarter) of the clinical illness. The remaining two cases
also underwent MRI examination in the advanced stages of illness however imaging
was not consistent with vCJD in either case. The median duration of illness was 11.5
(10.3 - 13.3) months. All cases underwent post mortem examination; in addition one
case underwent tonsil biopsy in life from which PrPSc was detected. In all cases the
molecular subtype was MM 2B.
The asymptomatic case occurred in an individual that was methionine heterozygote
at PRNP Codon 129. PrPSc was detected in the spleen of this individual at post
mortem 5 years following transfusion of the implicated labile blood components.
This individual died from non-neurological cases and had no signs of symptoms
suggestive of vCJD in life.
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Iatrogenic CJD
In the UK, acquired CJD cases attributed to the use of cadavcric-dcrivcd human
pituitary hormones, cadaveric-derived dura mater grafts and the transfusion of labile
blood components have been ascertained by the NCJDSU. vCJD cases attributable to
the transfusion of labile blood components are considered vCJD cases for disease
surveillance purposes, not iCJD cases. These were addressed in the previous passage
and will not be revisited here. This section will focus on iCJD acquired via other
routes of exposure. The distribution of iatrogenic cases in the UK annually according
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Figure 46 iCJD cases in the UK according to year and route of exposure, 1990
2006
Cadaveric-derived human pituitary hormones recipients
In total, 49 cases of iCJD in the recipients of cadaveric-derived human pituitary-
derived hormone have been ascertained by the NCJDSU from 1st May 1990 through
31st December 2006; 41 definite and 8 probable cases. One iCJD case arose as a
result of administration of human gonadotrophin hormone (hGnJJ). The remainder as
a result of the administration of human growth hormone (hGH). The clinical
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phenotype in hGII and hGnll cases is similar. Therefore in the analyses that follow
these cases were grouped together and are referred to as hGH cases.
Men accounted for over half, 30 (61.2%) of all hGII-relatcd iCJD cases. The mean
age at symptom onset was 31.0 (SD 6.4) years. This did not vary by sex (P=0.862).
The majority of cases, 41 (83.7%) had a cerebellar onset; 7 (14.3%) presented with
psychiatric symptoms at onset. Median illness duration was 9.3 months (IQR 7.1 -
17.8). This did not vary by sex (P=0.231). Cases were administered hGH from 1968
through 1985, for a median of 6.0 (4.0 - 9.0) years. The mean age at first exposure
was 10.1 (SD 5.0) years and last exposure 16.3 (4.4) years. The mean incubation
period (from the midpoint of hGH administration) was 16.9 (4.3) years (range 10 —
27 years). The minimum and maximum mean incubation periods were 13.9 (4.3)
years with a range of 5 - 17 years, and 19.3 (5.7) years with a range of 7 — 23 years,
respectively. As of 31st December 2008, 48 cases were known to be deceased.
During the course of the clinical illness 35 hGH-related iCJD cases were known to
have undergone EEG examination; none showed changes that would be considered
typical of sCJD (PSWC) (Table 26). Of the 34 hGH-rclatcd iCJD cases known to
have undergone MRI examination, 8 (23.5%) had features were consistent with
sCJD. Characteristic MRI findings were reported a median of 9.5 (7.5 - 13.5) months
after symptom onset. CSE 14-3-3 protein was positive in over half, 13 (56.5%) of the
hGH-related iCJD cases known to have been tested. CSF 14-3-3 protein was first
positive a median of 5.0 (2.7 - 6.2) months after symptom onset.





Sensitivity of test, %
(95%CI)
EEG 35/36 0/35 0
MRI 34 / 38 8/34 23.5% (9.3-37.8)
CSF 14-3-3 protein 23/49 13/23 56.5% (36.3 - 76.8)
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Codon 129 genotyping was known in 63.4% (31) of hGH-rclatcd iCJD cases, of
whom 1 (3.2%) case was methionine homozygotes, 16 (51.6%) were heterozygotes
and 14 (45.2%) valine homozygotes. Median illness duration was significantly
longer in Codon 129 heterozygotes, 16.3 months (13.3 - 20.8), than valine
homozygotes, 6.3 months (5.3 - 7.9) (P<0.001). There was no significant difference
in mean incubation period according to Codon 129 genotype (P=0.310). Post mortem
examination was performed in 38 (80%) hGH-related iCJD cases; brain biopsy, in
life, in three.
Cadaveric-derived dura-mater graft recipients
Over the study period there were 5 cases of iCJD, 4 definite and one probable case,
in dura-matcr graft recipients. Two occurred in men. The median age at symptom
onset was 44.6 (33.6 - 46.7) years. Of the five cases, four presented with a cerebellar
syndrome, the fifth isolated sensory symptoms. All had received a Lyodura graft. In
four of the five, the date of grafting was known. This was between 1983 and 1987.
The median incubation period from dura-mater grafting to symptom onset was 7.5
(range 7.0 - 15.0) years. During the course of the clinical illness all cases underwent
serial EEG examinations. In three cases the EEG was considered typical for sCJD,
showing PSWC. The median time from symptom onset to typical EEG was 2.6 (1.4 -
3.8) months. Three cases underwent MRI scanning; one had radiological features
consistent with sCJD at 0.3 months after symptom onset. Only one case underwent
CSF 14-3-3 protein examination; this was negative. All five cases were deceased.
The median duration of illness was 6.2 (5.1 - 10.5) months. Post mortem
examination was carried out in four of the five cases. All cases (n=3) for whom prion




The NCJDSU was informed of 116 genetic prion disease cases from 1st May 1990 to
31st December 2006; 42 (36.2%) cases of Gerstmann-Strausslcr-Scheinkcr Disease
(GSS), 5 (4.3%) cases of fatal familial insomnia (FFI) and 69 (59.5%) cases of
genetic CJD (gCJD). Genetic prion disease accounted for 9.4% of all prion disease
cases in the UK over this period. The diagnosis was ncuropathologically confirmed
in 71 (61.2%) cases. As of 31st December 2008, 20 genetic prion disease cases
referred to the NCJDSU over the study period were known to be alive. Among the
deceased, the rate ofpost mortem examination was highest in FFI cases (100%); 25
(71.4%) GSS cases and 40 (58.0%) gCJD cases were known to have undergone post
mortem examination respectively. The characteristics of genetic prion disease cases
arc outlined in Table 27. A causative mutation was identified in 102 (87.9%) cases;
all FFI cases, 35 (83.3%) GSS cases and 62 (89.9%) gCJD cases. Over half, 67
(58.3%) of all genetic prion disease cases were known to have a family history of
prion disease; 2 (40.0%) FFI cases, 24 (57.1%) ofGSS cases and 41 (59.4%) gCJD
cases.
GSS
There was a preponderance ofwomen with GSS (female: male ratio of 2:1). Overall
the median age at symptom onset in GSS cases was 43.9 (37.5 — 55.2) years and
median illness duration 39.0 (29.0 — 72.6). In the UK the most common mutation in
GSS cases was the P102L mutation, accounting for 61.9% of all GSS cases. There
was no statistically significant difference in median age at onset (P^0.1750) or
median illness duration (P=0.1936) by causative mutation in GSS patients.
FFI
All FFI cases were caused by the D178N mutation. In FFI cases the median age at
symptom onset was 49.3 (39.0 - 60.7) years and median illness duration 12.1 (9.2 -
20.8) months.
Genetic CJD
Octapeptide repeat insertion mutations accounted for 43 (62.3%) of all gCJD cases.
Overall median age at symptom onset was 43.9 (37.5 - 55.2) years, with median
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illness duration of 20.9 (5.9 - 93.0). With an increasing number of repeats, the age at
symptom onset fell (P=0.0012). E200K mutations accounted for 19 (27.5%) of all
gCJD cases. The median age at symptoms onset in cases was an E200K mutation
was 60.1 (51.6 - 66.0) years with median illness duration of 4.4 (2.5 - 8.6) months.
In total 16 (84.2%) gCJD cases with an E200K mutation were initially referred to the
NCJDSU as a case of suspect sCJD and 14 (73.7%) were visited by a NCJDSU
neurologist in life.
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Summary of key findings
• 72.7% of all prion disease cases ascertained in the UK from 1990 through 2006
were sCJD, 13.5% vCJD, 9.4% genetic prion disease and 4.4% iCJD.
• sCJD incidence and mortality peaked in men and women aged 70 - 79 years.
• Age standardised sCJD mortality rates increased over time in men and women.
• A trend toward increasing sCJD mortality was observed in men and women aged
over 60 years old; this was significant in men aged 70 - 79 years old only.
• Overall median survival in sCJD was 4.3 months (invariant over time).
• Rates of case confirmation fell over time (sCJD and vCJD).
• EEC was commonly used in the assessment of sCJD cases although the
sensitivity of this investigation was low and had fallen over time.
• Over time CSF 14-3-3 protein examination was increasingly used to support a
diagnosis of sCJD in sCJD cases.
• Overall, fewer than half of all sCJD cases underwent genetic testing to exclude a
PRNP mutations; in 2006 just one if every four sCJD cases.
• From 1990 through 2006, 165 vCJD cases were ascertained in the UK including
4 vCJD cases attributed to the transfusion of labile blood components.
• The primary vCJD epidemic peaked in 2000 (2001) in men (women) and has
been in decline since.
• Median age at symptom onset in vCJD was 26.6 years (invariant over time).
• Median survival in vCJD cases was 13.8 months (invariant over time). Relative
to older age groups, survival was greatest in those aged < 19 years old.
• All vCJD cases tested were PRNP Codon 129 methionine homozygote.
• From 1990 through 2006, 54 iCJD cases were ascertained in the UK; 48 hGH-
related, 1 hGnH-rclated and 5 in cadaveric-derived dura mater grafts recipients.
• Fewer than expected hGH-relatcd iCJD cases were PRNP Codon 129 MM.
• 60% of genetic prion disease was accounted for by gCJD, 36% GSS and 4% FFI.
• A causative mutation was identified in over 90% of genetic prion disease cases.
• A quarter of all gCJD cases were attributable to the E200K mutation.
• In 40% of genetic prion disease cases no significant family history was reported.
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Discussion
In this chapter I described the epidemiology ofCJD in the UK according to disease
subtype using data collected over 16 years ofprospective surveillance in a country of
almost 62 million people. This study examined 1,228 prion disease cases, including
935 (76.1%) with a ncuropathologically confirmed diagnosis. A discussion of the key
findings from this chapter follows.
sCJD
Trends in incidence and mortality rates
One of the most striking findings from this study is the consistent increase in age
standardised sCJD mortality rates in men and women in the UK from 1990 through
2006. Due to the rarity of the sCJD minor statistical fluctuations in disease
occurrence can cause an apparent excess of cases. This underscores the need for
national longitudinal monitoring of temporal trends in disease occurrence using
systematically collected data and the importance of having robust international data
for comparison. Several countries with established systematic prospective disease
surveillance systems, including Germany,(48) France,(236) Italy,(52)
Switzerland,(237) Japan,(47) Canada(44) and Australia(44;238) have reported
similar findings. In most countries a sustained increase in sCJD incidence/mortality
has been attributed to improved case ascertainment as a result of systematic
prospective surveillance and increasing awareness ofall forms ofCJD.(44;45;48)
Diagnostic advances such as CSF 14-3-3 protein examination may also have
contributed to these trends.(48;96;239) In the UK, CSF 14-3-3 protein is the most
sensitive investigation used to support a diagnosis of sCJD and an increasing
proportion ofprobable sCJD cases are meeting the clinical diagnostic criteria based
on this investigation. Molecular subtyping has provided significant insights into the
diverse clinico-pathological phenotype of sCJD which may have resulted in
ascertainment of rare subtypes.(240) In Switzerland for example a two fold increase
in the incidence of sCJD between 2000 and 2001 was attributed to an increase in case
ascertainment of the rare MV2 subtype; an increase in sCJD incidence was
accompanied by a significant change in the age and sex distribution of cases.(237) In
the UK there has been a non-significant increase in sCJD cases with an MV orW
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genotype over time. This may then be evidence of improved ascertainment of rarer
sCJD subtypes by the NCJDSU. However there has been no significant change in the
proportion of 'atypical cases' over the study period as would be expected if this
increased had been significant. These data suggest that whilst increasing
ascertainment of rarer subtypes may have contributed to the overall trends in
incidence/mortality, they are unable to fully explain them.
An examination of age-specific trends in sCJD incidence/mortality provides some
additional insight to these data. In keeping with the published literature
incidence/mortality rates were low in those under 50 years of age, increasing to peak
in those aged 70 - 79 years of age, before falling in those aged 80 years and
over.(44;47;48;50-52;238) This trend was seen in both men and women. A decline in
sCJD incidence/mortality in those aged 80 years and over of age is incongrucnt with
other neurodegenerative diseases but well described in sCJD. If sCJD is a truly
sporadic disease then a continuous increase in the number of cases with increasing
age would be expected.(241) Most commentators attribute an age-related fall in
sCJD incidence/mortality to systematic under-ascertainment of cases in the very
elderly. In the present study there was no significant difference in
incidence/mortality rates for sCJD in men aged 60 - 69 years, 70 - 79 years or 80
years and over. In women there was a significant decline in incidence/mortality in
the very elderly (80 years and over) compared to those aged 70 - 79 years. Indicating
that in the UK there may be evidence of differential under ascertainment in sCJD
cases according to sex. Over time there were clinically but not statistically significant
increases in sCJD incidence/mortality in men and women over 60 years of age. The
only statistically significant increase in sCJD incidence/ mortality occurred in men
aged 70 - 79 years of age. These data suggest that in the UK the increase in sCJD
incidence/mortality has occurred as a result of increased ascertainment of sCJD cases
in men and women over 60 years of age with the greatest increase over time in men
age 70 - 79 years. It remains possible that increasing incidence/mortality rates are
attributable to increasing exposure to an unknown exogenous risk factor for sCJD.
However exhaustive case-control studies have not provided compelling evidence of a
putative risk factor for sCJD and the demonstration of this phenomenon in different
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population over time using surveillance data collected by different methodologies
make this possibility remote.
Is it possible that the apparent increase in incidence of, and mortality from, sCJD in
the UK is actually due to misclassification of vCJD cases? This seems unlikely for a
number of reasons. Firstly, the increase in incidence of, and mortality from, sCJD has
not solely been confined to the UK, but observed in countries which have not
reported BSE, such as Australia.(44;238) Secondly, in the UK and elsewhere the
clinical phenotype of vCJD has been remarkably consistent and efficiently detected
through routine surveillance. Thirdly, an examination of age-specific rates reveals
that the sCJD incidence and mortality rates in men and women under 60 years of age
are low and have not increased over time as would have been expected if these cases
were due to vCJD; just 5% (45) of sCJD cases were aged less than 50 years old at
symptom onset. In keeping with the published literature sCJD cases under 50 years
of age were less likely to have a classical sCJD clinical course and supportive
investigations including PSWC on EEG and a positive CSF 14-3-3 protein
examination, than sCJD cases aged 50 years and over at symptom onset.
Reassuringly, the diagnosis was neuropathologically confirmed in the majority, 87%,
of sCJD under 50 years of age at onset; of the 6 for which a neuropathological
diagnosis was unavailable, none had clinical features or investigations that would
support a differential diagnosis of vCJD. Fourthly, as previously noted there has been
no significant change over time in the proportion of'atypical' sCJD cases which
would be expected if these cases were vCJD. Finally, there has been a non¬
significant decrease in the proportion of sCJD cases with a methionine homozygote
genotype over time; were these cases attributable to vCJD a rise in the proportion of
cases with the methionine homozygote genotype would be expected.
Diagnostic investigations in sCJD
Falling rates ofcase confirmation
Definitive diagnosis ofCJD requires examination ofneuropathological material
obtained from brain biopsy in life or autopsy following death. Overall a
ncuropathological diagnosis was available 77.2% (689) sCJD cases; 664 from
autopsy examination following death and an additional 25 from brain biopsy in life.
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Brain biopsy in life is rare and was undertaken in just 3.8% (34) of all sCJD cases,
although in this population the sensitivity was high; brain biopsy was diagnostic in
73.5% (25) of cases. The remaining 9 cases with non-diagnostic brain biopsies all
underwent post mortem examination following death. Post mortem rates in sCJD
cases in the UK fell over time. A number of factors may have contributed to this
including the willingness of clinicians to request an autopsy, the willingness of
relatives to consent to an autopsy and the availability of appropriate facilities to carry
out the examination^ 137) An increasingly diverse clinical spectrum of sCJD has
been recognised and the value of investigations such as EEG, MRI and CSF 14-3-3
protein in specific molecular subtypes of sCJD, clarified.(97) The inclusion of CSF
14-3-3 protein examination in the WHO diagnostic criteria has increased the
sensitivity of a clinical diagnosis of sCJD to over 90%; MRI scanning has also made
a significant contribution, particularly in atypical cases, although not yet
incorporated into the diagnostic critcria.(99) From a disease surveillance perspective
it is essential to ensure that a high proportion of suspect sCJD cases undergo post
mortem examination following death. This maximises case ascertainment and
provides valuable information on differential diagnoses and the diagnostic value of
investigations, such as CSF 14-3-3 protein and MRI scanning, to inform clinical
practice and research in this area. However the relatives of a sCJD cases may be
reticent to consent to post mortem examination, and clinicians to ask for this, if it has
been possible to reach a clinical diagnosis in life with a high degree of certainty.
Thus an unintended consequence of the increasingly sensitive diagnostic criteria for
sCJD may have been a fall in case confirmation rates.
EEG
The value of EEG in sCJD has been recognised for a number of decades and this
investigation is generally available in local and certainly regional centres throughout
the UK. In the UK the EEG remains the supportive diagnostic investigation most
commonly utilised in sCJD cases; consistently over 90% of sCJD cases underwent at
least one EEG during the course of their clinical illness. This is in contrast to
international trends which show a reduction in the use of EEG in sCJD cases over
timc.(l 07) However the median number of EEGs undertaken per case in the UK has
fallen over time. A corresponding reduction in the sensitivity of EEG, from 50% in
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1990 to 33.3% in 2006 was observed. The timing of EEG examination in sCJD is
important. EEG findings often evolve such that serial examinations may be required
before PSWC are detected. It is likely that the fall in the number of EEGs carried out
per case has contributed to the falling sensitivity of EEG in the UK over time. The
introduction ofCSF 14-3-3 protein as a viable diagnostic alternative to serial EEG
examinations may have contributed to this. In Germany, Tschampa et al described
the sensitivity and specificity of EEG in sCJD (definite or probable sCJD cases) as
32% and 94% respectively using data collected by the German Surveillance Unit
between 2001 and 2003.(106) The estimated sensitivity in the study by Tschampa et
al was comparable to that in the present study. Tschampa et al attributed the falling
sensitivity of EEG over time in Germany (previous reports placed the sensitivity of
EEG at 64% from 1996 through 2000 (104)) to suspect sCJD cases being referred to
the surveillance unit earlier in the disease process, prior to the development of PSWC
on EEG. They hypothesised that this has arisen as a result of the increasing use of
CSF 14-3-3 protein examination to support a diagnosis of sCJD, although evidence
to support this hypothesis was not provided. If this were the case in the UK it might
be expected that the median time from symptom onset to first positive CSF 14-3-3
protein examination would have fallen over time. However this has not happened
despite the increasing use ofCSF 14-3-3 protein examination in the investigation of
sCJD cases. Data from the UK suggest that CSF 14-3-3 protein and for that matter
MR1 scanning are being used in addition to EEG examination in the investigation of
sCJD cases, with the latter investigations are being pursued in preference to serial
EEGs. Overall, the median time from symptom onset to first typical EEG was shorter
than the median time from symptom onset to first positive CSF 14-3-3 examination
or first positive MRI scan.
CSF 14-3-3 protein
In this study CSF 14-3-3 protein was the most sensitive supportive diagnostic
investigation in sCJD cases. The use ofCSF 14-3-3 protein in the investigation of
sCJD cases has increased significantly over time. Increasingly CSF 14-3-3 protein is
contributing to the diagnosis ofprobable sCJD cases. Nevertheless, CSF 14-3-3
protein is less frequently undertaken in the investigation of sCJD cases in the UK
when compared to other countries.(107) This may be a reflection on clinical practice
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in the UK. CSF 14-3-3 protein requires lumbar puncture examination. Lumbar
puncture examination is commonly undertaken in the investigation of subacute
encephalopathy. However CSF 14-3-3 protein examination may not be considered at
the time of lumbar puncture examination (this test in not available locally in the UK,
only nationally) and the CSF sample obtained may not be appropriate for CSF 14-3-3
protein examination at a later date. If a diagnosis of sCJD has been made based on
clinical features and a supportive EEG it may be clinically inappropriate to repeat a
lumbar puncture examination solely for CSF 14-3-3 protein examination. Moreover
in a moribund patient in whom consent has already been granted for post mortem
examination on expiration and a treatable differential diagnosis has been excluded,
lumbar puncture examination may be considered cruel and unnecessary.
MRI scanning
The value ofMRI in sCJD has been reinforced recently and there have been renewed
calls for the inclusion ofMRI in clinical diagnostic criteria for sCJD.(99) Consistent
with other European countries, MRI is increasingly being used in the UK in the
investigation of sCJD.(107) MRI scanning is increasingly available in local centres
although anecdotally this may be less available in the UK than elsewhere (personal
communication R. Knight). The sensitivity ofMRI in the present study (33.8%
overall) was lower than published reports, the most recent ofwhich by Zerr el al
described the sensitivity ofMRI using pooled data from definite or probable sCJD
cases ascertained by the EUROCJD consortium as 83%. It should be noted however
that the data in the present study span 16 years of prospective surveillance over
which time the features on MRI scanning that are considered consistent with a
diagnosis of sCJD have been defined and the optimal imaging sequences identified.
The study by Zerr et al was limited to an examination ofDWI or FLAIR imaging
sequences only. The surveillance data analysed in the present study reflect routine
clinical practice and arc therefore unselected images many ofwhich were not taken
using the recently agreed optimal imaging sequences. This is likely to explain the
lower sensitivity that I report. It is not clear whether an examination of only DWI
and FLAIR images using contemporary data from the surveillance system in the UK
would produce comparable results as the study by Zcrr et al. Finally, MRI is known
to be of particular value in the rarer subtypes of sCJD, especially the MV1, MV2 and
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VV1 subtypes. The distribution of Codon 129 genotypes and molecular subtypes in
the present study is comparable to that in the study be Zerr and colleagues, therefore
the lower sensitivity that we report is unlikely to be attributable to the population
under study.
Full sequencingfor PRNPmutations
Worryingly, only half of all sCJD cases underwent testing to exclude a mutation of
PRNP. This proportion fell significantly over time such that in 2006 just one in four
sCJD cases underwent full sequencing of PRNP. Genetic prion disease may present
in a clinical syndrome that is indistinguishable from sCJD (for example E200K
mutation) and a significant proportion of genetic prion disease cases do not report a
family history of prion disease. It is possible that genetic prion disease cases have
been misclassified as sCJD. The proportion of all prion disease cases accounted for
by genetic disease was almost 10%, fluctuating from 5% to 13% annually. Despite
only a quarter of sCJD cases undergoing PRNP mutation testing in 2006, almost 13%
of all prion disease cases ascertained by the NCJDSU in 2006 were aetiologically
genetic. It is unlikely then that a significant degree ofmisclassification of cases has
occurred. In the UK most prion disease cases arc incapacitated at the time of
diagnosis and consent to undertake genetic testing is provided by the next of kin,
who is often a first degree relative. The diagnosis of genetic prion disease has
significant implications for a patients relatives' — the penetrance of some mutations is
variable, some individuals that have the mutation will not develop the disease but for
those that do there is currently no disease modifying therapy available for this
universally fatal condition. This may, in part, explain low levels of genetic testing.
Molecular subtyping
Molecular subtyping was available for a third of all sCJD cases. This figure is
consistent with estimates lfom the EUROCJD network.(97) Type 1 and 2 PrPSc was
found to co-exist in 6.5% of all cases which is considerably lower than the literature
suggests with estimates varying from 12% to 44%. There are methodological
limitations of the studies in this area. Many have examined small samples with
significant bias in case selection and methodological variation in the diagnostic
technologies used and approach to sampling of tissue. The present study utilises data
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collected in routine surveillance. Neuropathological tissue was reviewed by the
NCJDSU pathologist (JI) in the majority, 297, of the cases for which molecular
subtyping was available. However, retrieval of brain tissue is carried out in centres
across the UK and whilst guidance on tissue sampling is available this may not be
followed. This is likely to have contributed to the low estimate ofmixed protein
subtypes in the UK. Indeed Collins et al, examining data collected by the EUROCJD
consortium in routine surveillance from 1992 to 2002, also found type 1 and type 2
PrPSc co-existed in just 6% of the 743 sCJD cases they studied.(97) The distribution
of molecular subtypes I found was in keeping with that reported by Collins et al.(97)
The most common subtype was MM1 followed by MV2 andW2. The clinical
phenotype was also in keeping with this study. For example, MV1 cases were the
oldest at disease onset and MM2 and VV1 the youngest whilst illness duration was
shortest in the MM1 subtype and longest in the MM2, MV2 and MV 1/2 subtypes.
MM! cases were the most likely to have a typical EEG, VV2 cases a positive MRI
scan and the sensitivity ofCSF 14-3-3 protein was over 90% in the MM1, MM 1/2,
MV1, W2 and VV 1/2 subtypes. Over time there has been no significant change in
the distribution of molecular subtypes in cases ascertained by the NCJDSU.
Survival in sCJD cases
Illness duration is commonly used as an indicator of clinical phenotypc in sCJD. It
was considered important in this study to determine whether median survival had
changed over the study period and to examine the predictors of survival in this
population. Overall median survival from sCJD was 4.3 months. Increased survival
from sCJD has been reported in those with young age at onset, women, Codon 129
methionine heterozygotes, cases with a positive CSF 14-3-3 protein and Type 2
PrPSc.(94) Following adjustment for age group, sex, year of symptom onset and
molecular subtype, there was an excess risk of death at 6 months and 1 year in
individuals aged 70 - 79 years and 80 years and over, compared to those aged under
50 years at symptom onset. This age related effect has been documented previously
and may relate to co-morbidity contributing to death.(94) There was no effect of sex
on survival at either 6 months or 1 year. Previous studies in this area have produced
conflicting accounts of the effect of sex on survival.(94) Following adjustment for
age group, the hazard of death at 6 months remained highest in the MM1 and VV1/2
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subtypes and at 1 year the MMl, VV2 and VV1/2 subtypes. There has been no
significant change in the distribution ofmolecular subtypes of sCJD cases in the UK
and no significant therapeutic advances over the study period. It is perhaps
unsurprising then that there has been no significant increase in median survival in
sCJD cases over time in the UK.
vCJD
vCJD was characterised in the UK in 1996.(37) Systematic prospective surveillance
provided longitudinal data characterising the clinico-geno-pathological profile of all
prion diseases in the UK from 1990. These data were essential in confirming that
vCJD was indeed a novel prion disease with a distinct clinico-pathological
phenotype. International surveillance data were equally important in determining that
this phenomenon was unique (initially at least) to the UK. A case definition and
diagnostic criteria based on these early cases was rapidly developed and
subsequently adopted by the WHO for disease surveillance purposes.(242) Despite
intensive systematic prospective surveillance efforts worldwide vCJD has been
identified in only 11 countries outside the UK; 80% of all cases worldwide have
occurred in the UK.(46) Unsurprisingly given the rarity of the disease and the
concentration of cases in the UK, few data external to those collected by the
NCJDSU, are available for comparison. Indeed most published literature describing
the epidemiology of vCJD has been based upon cases ascertained by the NCJDSU.
The present study is therefore one of the most comprehensive accounts of the
epidemiology and diagnostic aspects of vCJD available.
The significance of age at onset
In contrast to sCJD (67.1 years (60.6 - 74.2)), the median age at symptom onset in
vCJD cases was 26.6 years (20.7 - 33.3). Interestingly, this has not changed over
time. All the vCJD cases ascertained by the NCJDSU were born prior to 1989, the
year that the SBO ban was introduced. This suggests that the SBO ban was effective
in preventing further exposure of the population to BSE. It would be anticipated that,
with time, the median age at symptom onset in vCJD cases would increase. The fact
that this has not occurred suggests that age related factors may influence the
incubation period of the disease; vCJD cases that were younger at the time of
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exposure experience longer incubation periods than vCJD cases that were older at the
time of exposure. The possibility of dietary exposure to BSE through MRM between
1989 and 1996 remains. Overall the incidence of vCJD was greatest in men aged 25
- 29 years and in women aged 20 — 24 years. Dietary exposure alone cannot explain
the age-related variation in vCJD incidence.(173) This observation suggests that
younger age groups arc more susceptible to BSE for a given level of exposure. The
mechanisms that might mediate this effect are as yet unknown. It has been suggested
that the development of Peyer's Patches in the gut, or a factor closely related to this,
is a major determinant of age-related susceptibility.(143;243)
Survival in vCJD cases
Median illness duration was significantly longer in vCJD (13.8(11.1-17.6) months)
than sCJD (4.3 (2.7 - 7.9) months). Crude median survival was significantly longer
in women than men in vCJD. However following adjustment for year of symptom
onset, clinical presentation and age group, this survival advantage was no longer
present. The hazard of death at one and two years was related to age such that
relative to those aged 19 years and under, older cases had a greater risk of death at
each time point. The reason for this is unclear. Individuals aged less than 35 years
old would not be expected to have significant co-morbidity that might contribute to
premature death. Differential recall of date of symptom onset according to age may
have contributed to this. Often symptoms are non-specific in early disease and the
majority of cases present with psychiatric symptoms. It is possible that the date of
onset is more accurately identified and recalled by the relatives of young cases who
may still be living at home with their parents and in full time education, compared to
those over 20 years of age who may be living independently and working. Age
related factors appear to influence susceptibility to vCJD and also incubation period,
therefore it is conceivable that age related factors might also influence illness
duration, although they do not appear to influence other aspects of the clinical
phenotype. In general, it is recognised that neurodegenerative brain disease in youth
is associated with longer illness duration. This observation may not therefore be
specific to vCJD.
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The primary vCJD epidemic
The primary epidemic of vCJD in the UK has been described in great detail. The
present data confirm published accounts.(37;183;184;186;244) The vCJD epidemic
peaked in 2000 in men, 2001 in women and has been in decline since. Significant
uncertainties around the parameters of the primary epidemic remain however. The
incubation period of vCJD is unknown. At the time ofwriting, incident cases
continue to emerge in the UK, albeit in small numbers. The incubation period can be
estimated to be up to and in all likelihood beyond, 22 years (from the SBO ban in
1989). Experience from Kuru suggests that incubation periods of up to and beyond
50 years are possible. All vCJD cases to date have been methionine homozygote at
Codon 129. The epidemiology of prion disease in humans suggests that other
genotypes will also be susceptible but that the clinical phenotype, including
incubation period, may vary. Combined, these data suggest that the primary epidemic
may continue, at a low level, for many years to come. Recent modelling work
predicted an additional 100 (11 - 220) incident vCJD cases from the primary
epidemical 72)
The clinico-pathological phenotype in non-methionine homozygotes
The clinical phenotype of vCJD has been remarkably consistent over time. The
majority of cases present with early psychiatric symptoms, many develop painful
sensory symptoms over the course of their illness, cerebellar signs and movement
disorders are prominent and cognitive decline is universal. The diagnostic criteria for
vCJD, developed following characterisation of the first 10 cases and amended in
2002 in recognition of the value of tonsil biopsy, were only formally evaluated and
validated in 2010.(186) Heath et al report the sensitivity, specificity and positive
predictive value of the diagnostic criteria for vCJD to be 83.0% (74.5 - 89.6), 100%
(92.1 - 100) and 100% (95.9 - 100) respectively.(186) The clinical phenotype of
vCJD presenting in genotypes other than methionine homozygote, is unknown. In
2008 a clinical diagnosis of 'possible' vCJD was reported in a methionine
heterozygote.(177) Investigations did not conclusively support a diagnosis of vCJD
although the clinical phenotype in this suspect case was indistinguishable from
vCJD. Post mortem examination was not undertaken following death therefore
diagnostic confirmation is unavailable in this case. It should be noted that between
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1996 and 2006, 5 suspect cases met the clinical criteria as a 'possible' ease of vCJD
that had alternate diagnoses - one Alzheimer's Disease, one Wilsons Disease, one
Viral Encephalitis, one subactc sclerosing panencephalitis and one case that
improved clinically although a clinical diagnosis was not reached.
Experience from other prion diseases suggest that the clinical phenotype of vCJD
may vary according to PRNP Codon 129 genotype. In turn, diagnostic sensitivities,
including the diagnostic criteria, may also vary according the PRNP Codon 129
genotype. It is not clear then whether vCJD cases in methionine heterozygotes or
valine homozygotes would be identified as suspect CJD cases and referred to the
NCJDSU. This highlights the importance of neuropathological examination in the
surveillance of all forms of CJD. Of the original cases described by Will et al in the
seminal case series, 30% were referred to the NCJDSU as a result of examination of
neuropathological material alone.(37) These cases would not otherwise have been
ascertained by the NCJDSU. In the UK post mortem rates in vCJD (and other prion
diseases) are falling which may have a significant impact on the ability of the PHS
system to detect vCJD in non-mcthionine homozygote genotypes. It should be
considered that the pathological phenotypc of vCJD in non-methionine homozygotc
genotypes may also differ from that in methionine homozygotes. In this context,
molecular subtyping using Western Blot examination and transmission studies,
linked to neuropathology will be central to surveillance activities.
The secondary vCJD epidemic
The identification of a novel human prion disease aetiologically linked to BSE in
cattle was a primary aim ofCJD surveillance in the UK and elsewhere. The
iatrogenic transmission of vCJD through the transfusion of labile blood components
has provided the imperative to continue PHS of CJD in the context of declining
primary epidemics of vCJD in humans and BSE in cattle. It is likely that there was
widespread exposure of the UK population to BSE. The prevalence of asymptomatic
vCJD infection in the population of the UK is unknown. However there is clearly
potential for transmission whilst in an asymptomatic phase of illness and non-
mcthionine homozygote genotypes appear susceptible. The detection of PrPSc in
peripheral tissues in vCJD raises the theoretical risk of transmission through surgery,
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principally ophthalmological, neurological, gastrointestinal and dental surgery.
Progress is being made toward the development of a blood test to detect PrPSc in
humans, although there are significant scientific and ethical issues that will need to
be addressed before this could be introduced as a screening tool at population level.
In the interim there is a clear rationale to continue public health surveillance of all
forms ofCJD.
iCJD
There have been over 400 cases of accidental transmission of sCJD through medical
or surgical interventions worldwide.(156) In the UK iCJD accounts for a little over
4% of all prion diseases in humans. Only France and Japan have reported a greater
number of iCJD cases.(156)
CJD attributable to cadaveric-derived human pituitary hormones
iCJD in the UK is largely attributable to the administration of cadaveric-derived
human pituitary hormones; the majority of cases as a result of the administration of
hGH and a single case as a result of the administration of hGnH. An estimated 95%
of all hGH-rclated iCJD cases worldwide have occurred in France, the UK and
USA.(156) Approximately 30,000 children worldwide have been treated with hGH.
In the UK an estimated 1 in every 100 recipients develops iCJD.(162) Cadaveric-
derived hGH was withdrawn in the UK in 1985 however incubation periods are
exceptionally long, known to range from 4 years to 36 years. The maximum
incubation period observed in the present study was 23 years. It would be anticipated
then that cadaveric-derived hGII related cases will continue to be reported in the UK
in the foreseeable future.
Consistent with published reports, the majority of the UK cases presented with a
progressive cerebellar syndrome at onset.(156) Gcnotyping was available in almost
two thirds of cadaveric-derived hGH iCJD cases. Assuming those a case for which
genotyping was unavailable were all methionine homozygotes, this genotype would
account for fewer than 40% of all cadaveric-derived hGH iCJD cases. This figure
remains lower that published accounts from the USA and France but is close to the
population distribution ofPRNP Codon 129 genotype in the UK. The NCJDSU
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collate a minimum datasct on cadavcric-dcrivcd hGH iCJD cases but is not directly
responsible for disease surveillance in this group. It is unlikely however that there
has been systematic under-ascertainment of cadaveric-derived hGH iCJD, or
differential ascertainment according to PRNP Codon 129 genotype. An accurate and
up to date register of cadaveric-derived hGH recipients in the UK exists. This group
arc reviewed by Professor Michael Preecc's team at the Institute of Child Health in
London. Communication between this team and the NCJDSU is excellent. The
clinical phenotype in cadaveric-derived hGH iCJD cases is fairly consistent,
irrespective ofPRNP Codon 129 genotype. It is unlikely that a classical clinical
picture in an individual known to be at risk would not be detected and reported to the
NCJDSU. The finding that the distribution of cadaveric-dcrivcd hGH iCJD cases in
the UK differs from the distribution of iCJD cases outside the UK is entirely novel
and warrants further investigation.
One case of iCJD attributable to cadaveric-derived hGnH was ascertained in this
study. This is exceptionally rare. Worldwide just 5 cases ofhGnH have been
reported.(156) The remaining 4 cases were reported in Australia with the last case
occurring over a decade ago. Use of cadaveric-derived hGnl I ceased in the UK in
1985. The maximum reported incubation period was 16 years, although this was
based on a small number of cases. It is unlikely then that further cases of cadaveric-
derived hGnH iCJD will emerge in the UK.
CJD attributable to cadaveric-derived dura mater grafting
A small number of iCJD cases attributable to cadaveric-derived dura mater grafting
have been observed in the UK in individuals that received Lyodura grafts between
1983 and 1987. In one case the date of grafting was not known. This individual died
in 2005. The minimum incubation period in this case is 22 years. The longest
recorded incubation period in iCJD via this route of exposure is 25 years.(245) The
clinical phenotype in iCJD cases attributable to cadaveric-derived dura mater




Overall genetic prion disease accounted for 9.4% of all prion disease cases
ascertained by the NCJDSU from 1990 through 2006. This figure is consistent with
pooled data from the EUROCJD consortium which estimated genetic prion disease to
account for 9.4% of all prion disease cases ascertained in 10 countries in Europe,
Australia and Canada from 1993 through 2002 (Slovakia excluded as over 70% of
CJD cases in Slovakia are attributable to genetic prion disease).(196)
The majority of genetic prion disease cases were accounted for by gCJD, 36% by
Gerstmann-Straussler-Scheinker Disease (GSS) and less than 5% by Fatal Familial
Insomnia (FFI). A causative mutation was identified in almost 90% of genetic prion
disease cases; the remainder were classified based on reported family history. In total
16 mutations of the PRNP gene, 10 point mutations and 6 octapeptide repeat
mutations were identified, of which two were novel point mutations that had not
previously been described (Y163STOP and D167G). Worldwide over 50 mutations
of the PRNP gene have been described although many are exceptionally rare and
limited to small geographical areas, a single family and in some cases a single
individual. (152)
Over half, 62% (43), of all gCJD cases were attributable to an insert mutation, the
commonest ofwhich was the 144bp insert mutation. The E200K mutation accounted
for the majority (over 80%) ofmissensc point mutations but only a quarter of gCJD
cases. This is contrary to published reports from other countries in which the E200K
mutation is consistently found to be the commonest mutation in gCJD.(152;196;246)
As previously noted the clinical phenotype in genetic prion disease may be
indistinguishable from sCJD. Therefore there may be under-ascertainment of gCJD
cases in the UK because PRNP mutation testing is not undertaken in all cases
referred to the NCJDSU. The clinical phenotype and causative mutations identified
in both GSS and FFI cases were consistent with published reports.(152)
Almost 40% of all genetic prion disease cases had no known family history of prion
disease. This is also in keeping with previous reports.(196) It is interesting to note
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that a family history of prion disease was more frequently reported in mutations
associated with a long clinical illness and least frequently reported in mutations
associated with a short clinical illness and a clinical phenotypc suggestive of sCJD,
such as the E200K and 96bp insert mutations. There arc a number of reasons that a
family history of prion disease may not be reported including a lack of knowledge of
family history and non-paternity. The penetrance of some mutations is incomplete,
and some mutations may arise spontaneously. The large proportion of genetic prion
disease cases that do not report a family history of prion disease highlights the
importance of undertaking PRNP mutation testing in suspect prion disease cases.
Strengths and limitations
This study examined longitudinal data prospectively and systematically collected
using standardised and reliable methods in the UK over a 16 year period. This is
therefore one of the most comprehensive accounts of the epidemiology ofprion
disease according to disease subtype, produced to date. There are a number of
limitations that should be considered. Minimal data were available on iCJD and
genetic prion disease cases limiting analyses. Analyses of all disease subtypes
included both definite and probable cases. Probable cases have met the diagnostic
criteria based on clinical features and supportive diagnostic criteria. The sensitivity
of the diagnostic criteria has increased over time but is not 100%. These data may
include a small number of individuals that met the diagnostic criteria but did not
have prion disease and exclude a small number of individuals that did not met the
diagnostic criteria but did have prion disease. Nevertheless, this approach is
internationally adopted and was therefore considered appropriate for this study.
Conclusions
The most significant finding over this period was the identification of a clinico-
pathologically distinct human prion disease, vCJD. The primary vCJD epidemic was
smaller than initially feared and has been in continued declined since 2000. There is
evidence of genetic susceptibility in vCJD, with all cases to date occurring in the
methionine homozygote genotype. Uncertainties exist as to the susceptibility and
incubation period in other genotypes and the associated phenotypic expression of
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disease in these groups. The transmission of vCJD via blood transfusion is a major
public health concern providing the imperative to continue prion disease surveillance
for the foreseeable future. The incidence of sCJD increased over the study period,
most likely attributable to improved case ascertainment through surveillance
activities linked to diagnostic advances. Declining autopsy rates, in both sCJD and
vCJD, and a significant fall in the proportion of sCJD cases undergoing PRNP
mutation testing over time, are of concern, with evidence of possible under-
ascertainment of genetic prion disease cases in the UK as a result of the latter. The
potential for distinct clinico-pathological forms of vCJD to emerge in individuals
with non-methionine genotypes, argues for continued clinico-geno-pathological
surveillance with broad referral criteria, high autopsy rates and examination of
atypical cases at the molecular level.
These data support on-going systematic prospective PHS of prion disease in the UK.
However they also provide evidence to suggest that the PHS system is under-
performing in areas. This warrants further investigation. In the chapter that follows 1
report the findings from the first ever evaluation of the NCJDSU.
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Chapter 3. An evaluation of the NCJDSU in the UK,
1990-2006
Introduction
In this chapter 1 report the findings of the first evaluation of the NCJDSU in the UK.
The importance ofperiodic evaluation of PHS systems and the paucity of published
studies evaluating prion disease PHS systems were outlined in Chapter 1; the need
for such a study in the UK was confirmed in the preceding chapter.
Aims and objectives
The aim of this chapter was to carry out the first evaluation of the NCJDSU in the
UK, applying an established framework for the evaluation of PHS systems. The
overall aim of the evaluation was to provide the first in-depth examination of the
operational characteristics, activities and outputs of the NCJDSU in relation to the
systems objectives.
Specific objectives of the evaluation related to the attributes of the PHS system that I
considered being the most important for the system to meet its objectives:
1. To assess the sensitivity of the PHS system.
2. To determine the ability of the NCJDSU to respond to changing demands over
time (flexibility).
3. To examine the quality of surveillance data produced by the NCJDSU (data
quality).
4. To explore the willingness of patients, relatives and health care providers to
participate in surveillance (acceptability).
5. To examine the timeliness of surveillance activities and outputs.




This evaluation applied guidelines published by the Centers for Disease Control and
Prevention (CDC), Atlanta and the World Health Organization (WHO).(222) This
approach first requires a detailed description of the public health importance of the
condition under surveillance. An outline of the PHS system, including the aims and
objectives of the system, the operational procedures, and resource, both financial and
personnel, required to operate the system, follows. Finally, specific attributes of the
PHS system are examined in detail including: simplicity, flexibility, data quality,
acceptability, sensitivity, positive predictive value, representativeness, timeliness,
stability and usefulness.
Data sources
Data collected by the NCJDSU were used to provide credible evidence against which
the attributes of the system could be assessed. All suspect cases of prion disease
referred to the NCJDSU between 1st May 1990 and 31st December 2006 followed for
a minimum of two years until 31st December 2008 at which point data were
censored. The following information was extracted from the NCJDSU's electronic
minimum monitoring: sex, date of birth, date of referral to NCJDSU, date of death,
case classification, disease subtype (sporadic, variant, iatrogenic, genetic), country
from which referral came. Two further cohorts were examined in greater detail.
'Selected years' cohort
This cohort consisted of all suspect prion disease cases referred to the NCJDSU at
three-yearly intervals (1991, 1994, 1997, 2000, 2003 and 2006). For this cohort the
NCJDSU paper-based case note was examined by hand and the following
information extracted: sex, date of birth, date of death, date of symptom onset,
clinical presentation, case classification, disease subtype, date of referral to
NCJDSU, referral source, date first sought medical attention, date first admitted to
hospital (if admitted), and date first reviewed by a neurologist (if reviewed). The
number, result and date ofEEGs, MRI scans and CSF 14-3-3 protein examinations
were collected. Details of genetic analyses, tonsil biopsy, brain biopsy and post
mortem examination were recorded. Whether the NCJDSU had centrally reviewed
available EEGs, MRI scans and pathological or neuropathological material was
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determined. In addition whether the NCJDSU had clinically examined the suspect
case, interviewed relatives of the suspect case and/or reviewed medical records from
primary and secondary care, was assessed. If a risk factor questionnaire had been
completed the number ofmissing or blank responses was assessed. The highest case
classification reached by a suspect case based on clinical and neuropathological
information was determined for all suspect cases; for those that met the diagnostic
criteria as a possible (or greater) case at any stage, details ofNCJDSU follow up and
the final clinical and/or pathological diagnosis where reached, were recorded.
Finally, a search of key variables from the NCJDSU electronic minimum monitoring
dataset was carried out to determine the degree ofmissing data for the entire cohort.
In a sub-group from this cohort, sCJD and vCJD cases for whom multi-source data
were complete, the accuracy of key variables from the minimum monitoring dataset
was checked against data available from the multiple sources. Data from this cohort
were used in most of the analyses that follow. The term 'selected years' will alert the
reader to the use of data from this cohort. Ofnote where analyses were limited to
suspect vCJD cases only, the selected years examined were 1997, 2000, 2003 and
2006.
Not referred in life cohort
This cohort consisted of all sCJD and vCJD cases ascertained by the NCJDSU
between 1st May 1990 and 31st December 2006 that were deceased at the time of
referral to the NCJDSU. For this cohort the NCJDSU paper-based case note was
examined by hand and in addition to the information described above, whether CJD
had been suspected in life (if so why), the date that referral to the NCJDSU was first
suggested (if known) and the highest classification reached in life based on clinical
not neuropathological information, was extracted. Data from this cohort were used to
examine the sensitivity of the PHS system.
Statistical analysis
All data were anonymised and entered onto three separate password protected
databases maintained on a desk top computer. Data were cleaned and coded using the
definitions applied in the previous chapter. In most cases multiple analyses using
different metrics were carried out to evaluate each system attribute. The metrics
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selected arc described in the results section. There follows a general description of
the statistical techniques applied to analyse these data. Where data were normally
distributed this was presented as mean (standard deviation); skewed data were
presented as median (inter-quartile range). Univariate parametric tests of association
between key variables (t tests, Chi tests); where the assumptions of these tests were
violated, non-parametric equivalents were used (Fisher's exact test, Wilcoxon
Ranksum test, Kruskal Wallis test). Chi tests for trend (or non-parametric
equivalents where appropriate) were used to compare proportions over time. Age
standardised rates of referral of suspect prion disease cases according to disease
subtype were calculated using denominator data from the 2001 Census data (direct
method). A joinpoint regression model was fitted to estimate the APC in age adjusted
referral rates overall and according to disease subtype and to detect time points at
which a significant change in the overall trend occurred. To select the best-fitting
model Bayesian Information Criterion (BIC) was used. A maximum of three join
points were allowed for each estimate. A corresponding 95% CI was calculated for
each APC estimate. To examine representativeness, age-specific rates of referral of
suspect sCJD and age-specific sCJD incidence rates for (definite or probable cases)
in men and women in Scotland, England, Wales and Northern Ireland were
calculated using mid-year population estimates for each year. Indirect
standardization was used to calculate a standardised referral ratio and standardised
incidence ratio for each country, relative to England.
All analyses were carried out using STATA Version 10 (Stata Corp. College Station,
Texas, USA). Regression analyses were carried out using Joinpoint Regression
Program (Version 3.4.3). A level of statistical significance of 0.05 was used
throughout. Note for analyses involving dates missing data were treated in the same
way as outlined in the previous chapter.
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Results
Description of the surveillance system
The rationale for prion disease PHS was outlined in chapter 1 and the epidemiology
of prion disease in the UK according to disease subtype, from 1990 through 2006,
described in chapter 2. 1 shall therefore move directly to a description of the PHS
system in the UK prior to an examination of specific attributes of the PHS system.
Systematic prospective surveillance ofCJD was initiated in the UK in May 1990 in
response to publication of the Report of the Working Party on Bovine Spongiform
Encephalopathy (Southwood Committee). The initial aim of the NCJDSU was to
identify a change in the clinic-pathological phenotype of CJD that could be
attributable to BSE; this was realized in 1996. In 2006, the objectives of the
NCJDSU were to
"monitor characteristics ofCJD, specifically sCJD and vCJD, to
identify trends in incidence rates and to study risk factorsfor the development
ofdisease. "(247)
Population under surveillance
The NCJDSU collect and report data on all suspect prion disease cases referred to
the NCJDSU that are resident in the UK at the time of symptom onset. The UK
includes four countries, Scotland, England, Northern Ireland and Wales covering an
area of approximately 242,514 square kilometres. England is the largest country
within the UK; approximately 83.8% of the population of the UK live in England,
8.4% in Scotland, 4.9% in Wales and 2.9% in Northern Ireland. In 1990 the
population in the UK was 57.2 million. This increased by 0.3% per annum to 60.6
million in 2006. Until mid-1999 this was driven by an increase in births and
reduction in deaths; post 1999 by immigration. Almost halfof the population, 49%,
arc men. In common with most industrialised countries the population is ageing.
Overall life expectancy increased from 73.4 years to 77.3 years in men, 78.9 years to
81.5 years in women, from 1990 through 2006. In the UK primary and secondary
health care is provided to all citizens, free at point of access, by the National Health
Service (NHS). Funding for public expenditure on health is provided by the UK
Treasury (revenue largely generated through taxation).
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Case definition
Suspect prion disease cases are classified according to internationally agreed criteria
(Appendix 2).(98) Over the period covered by this study these diagnostic criteria
were revised to reflect emergent disease (vCJD) and diagnostic advancement (CSF
14-3-3 protein, PRNP mutation testing and tonsil biopsy). Additional criteria are
used by the NCJDSU to further characterise suspect prion disease cases that do not
meet the diagnostic criteria, outlined in full below:
0.0 Unclassified: There is insufficient clinico-pathological information to classify
the suspect prion disease case.
1.0 Definite case as defined in the diagnostic criteria.
2.0 Probable case as defined in the diagnostic criteria.
3.0 Possible case as defined in the diagnostic criteria.
4.1 Diagnosis unclear: Suspect prion disease cases that do not meet the diagnostic
criteria as a definite, probable or possible case but for whom an alternate
diagnosis has not emerged. Prion disease remains a differential diagnosis.
4.2 Prion disease unlikely: Prion disease is considered unlikely because of
clinical features and/or results from investigations which do not support a
diagnosis of prion disease. This group includes individuals in whom an
alternate clinical diagnosis has been reached and those that have recovered
clinically without an alternate diagnosis being reached.
4.3 Definitely not CJD: an alternate neuropathological diagnosis is available.
As a minimum suspect prion disease cases are assigned a case classification:
• at the time of referral to the NCJDSU.
• following visit by a NCJDSU neurologist.
• when the NCJDSU review is complete (when it becomes apparent that no further
information regarding the suspect case will be forthcoming).
• on completion of the NCJDSU review a highest classification in life, based on
clinical not ncuropathological information is assigned
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Case classification may be revised at any stage following initial classification if
relevant information regarding the suspect case emerges.
Legal authority for collection of data
Prion diseases are not, nor have ever been, notifiable in the UK. There is no legal
requirement for patients, their relatives or health care professionals to participate in
disease surveillance.
Interface with other organisations
The NCJDSU is based in the Western General Hospital in Hdinburgh, Scotland and
affiliated with the University of Hdinburgh. The NCJDSU is a WHO Collaborative
Centre for Reference and Research on the Surveillance and Epidemiology ofHuman
Transmissible Spongiform Encephalopathies (Figure 47). The NCJDSU collects and
collates European CJD surveillance data for the European Centre for Disease Control
(ECDC), co-ordinating the EUROCJD network. The NCJDSU is also directly
involved in a number of other collaborative international networks including
NEUROCJD and NEUROPRION. Of note NEUROCJD no longer exists but was in
operation over the study period. Within the UK, the NCJDSU collaborates with the
Institute ofChild Health and the NPC (both located in London) in the surveillance of
iCJD and genetic prion diseases respectively. Other organisations such as the
General Registers Office (GRO) for England and Wales (and equivalent bodies in
Scotland and Northern Ireland), the British Paediatric Surveillance Unit and the
UKBTS work directly with the NCJDSU to provide information essential for disease
surveillance. Reporting pathways will be outlined in the sections that follow.
NCJDSU staff are directly involved in a number of Committees that inform public
health policy both nationally and internationally, for example SEAC in the UK and
internationally the European Medicines Agency.
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Figure 47 Diagram illustrating the organisations that the NCJDSU interfaces
with in the UK and internationally
Data sources
Multiple and overlapping sources of data are used to maximise ascertainment of
suspect cases. Suspect prion disease cases arc ascertained through passive
surveillance by direct notification from health care professionals, family members,
the general public or specialist interest groups, and the review of death certificates
coded under the specific rubric ofCJD which are forwarded to the NCJDSU by the
GRO for England and Wales (and equivalent bodies in Scotland and Northern
Ireland). Certain health care professionals, including neurologists, neuropathologists
and neurophysiologists receive a bi-annual reminder to refer any suspect prion
disease case to the NCJDSU. Additional cases may be ascertained via the National
CSF 14-3-3 protein service, neuropathology and molecular genetics laboratories,
which are based in the NCJDSU. Referrals to these services are unsolicited and can
be made without formal referral to the NCJDSU. For example, in 2006, the CSF 14-
3-3 protein service processed 245 samples from patients in the UK ofwhom just 58
(23.7%) were formally referred to the NCJDSU as a suspect prion disease case. The
annual numbers of referrals to the neuropathology and molecular genetics
laboratories more closely mirror formal referrals to the NCJDSU. Enhanced active
199
surveillance has been carried out by the NCJDSU in a number of on-going and time
limited, prospective and retrospective cohort studies, carried out in association with
partners. Several of these studies were described in detail in chapter 1, including the
PIND and the TMER studies.
Information collected
On notification of a suspect prion disease case, a designated neurologist from the
NCJDSU contacts the referring source by telephone to obtain relevant case-related
information including sociodemographic, clinical and diagnostic information, and
details of any known risk factors for iatrogenic disease. A unique identifier, the
NCJDSU number, is assigned to the suspect case and a paper-based case note
generated. Case classification, as previous described, is assigned to the suspect case.
A minimum dataset on all iCJD and genetic prion disease cases are held at the
NCJDSU for surveillance purposes. These cases are not routinely followed up by the
NCJDSU beyond this point. For suspect sCJD and vCJD cases verbal consent for the
NCJDSU to contact the suspect cases' rclative(s) to arrange a visit is obtained from
the refcrrer at the point of referral where appropriate. A NCJDSU neurologist visits
the patient and/or relatives, typically in hospital, hospice or at home. Where possible
the neurologist is accompanied by a research nurse. During this visit relative(s)
provide written informed consent for the NCJDSU to access the suspect cases'
medical records. The NCJDSU neurologist confirms the clinical history with the
relative(s). A detailed neurological examination of the suspect case is carried out.
The medical case notes and all available investigations (for example EEGs and MRI
scans) are reviewed by the NCJDSU neurologist. A proforma, the Patient Review
and Examination form, is completed in writing by the NCJDSU neurologist at the
time of this visit. The research nurse (or NCJDSU neurologist) completes a
structured risk factor questionnaire in writing, which includes residential,
occupational, dietary and medical histories with relative(s). During the visit the
NCJDSU neurologist will request that the refcrrer inform the local CCDC using a
standard reporting form, if the suspect case meets the diagnostic criteria as probable
or definite case of prion disease. Following the visit, the NCJDSU neurologist
requests copies of EEGs and MRI scans for central review at the NCJDSU. The
former are reviewed by one of two designated neurologists (RK, RGW), the latter by
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one of two designated neuroradiologists (DS, DC). Subsequent to the visit a letter is
written to the rcferrer briefly outlining the clinical impression of the NCJDSU
neurologist and stating the case classification based on the information available at
that time. The responsibility for on-going case management remains with the
referring clinical team, not the NCJDSU, although the NCJDSU will often advise on
further investigations and clinical management, including infection control issues.
Since 2000 a National Care Package has been available for CJD patients and their
families. The aim of this is to ensure that the care and social needs ofCJD patients
and their families are adequately met. This National Care Package is administered by
a National Care Co-ordinator based at the NCJDSU. Where the patient's family have
granted permission, the NCJDSU neurologist will inform the National Care Co¬
ordinator of the case.
Where the patient is deceased at the time of notification or dies prior to a NCJDSU
visit, the NCJDSU attempt to obtain as much clinical and diagnostic information as
possible. Suspect cases that were not referred to the NCJDSU in life are typically
referred by neuropathologists or ascertained by death certificate review. In the first
instance the clinician responsible for the suspect cases' care is contacted and clinical
and ncuropathological information regarding suspect case, if available, is requested.
For suspect cases ascertained through death certificate review in which there was no
clinical suspicion ofprion disease in life and no documentation supporting a
diagnosis of prion disease, the suspect case will be classified accordingly and the
NCJDSU record will be closed. Suspect cases that meet the diagnostic criteria as a
definite, probable or possible case of sCJD or vCJD, based on the information
available, are followed up. Permission is sought from the clinician that was
responsible for the patients care to contact the cases relative(s). If consent is
provided, a NCJDSU neurologist and research nurse visit the relative(s) to collect
information regarding the suspect cases' clinical illness and complete the risk factor
questionnaire. Where information is not available from the clinician responsible for
the suspect cases' care, despite repeated attempts to contact the clinician and/or local
health authority, the record will be closed.
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When a suspect case dies, medical records from primary and secondary care are
requested for review. These are reviewed by a NCJDSU neurologist and relevant
information extracted and entered onto a proforma (The Final Review Form). Data
from primary care are triangulated with data collected at the time of the NCJDSU
visit and hospital medical records to obtain a complete clinical history.
The death certificates of all suspect cases referred to the NCJDSU are requested from
the GRO (or equivalent bodies) so that the date and the underlying cause of death, as
recorded on the death certificate, can be ascertained. Where post mortem
examination has been carried out, the NCJDSU will endeavour to review any
available neuropathological material. If this is unavailable, a copy of the post mortem
report is requested.
NCJDSU case notes are periodically reviewed. The NCJDSU neurologist may
contact the referrer to request an update on the suspect cases condition following the
visit. Often an update on the clinical condition of a suspect case is received directly
from the cases relatives; this may be through on-going contact with the National Care
Co-ordinator. When no further information regarding the case is likely to become
available the review is closed.
Data storage and issues of privacy
The NCJDSU retain a paper-based case note for each formal referral. This contains a
hard copy of all proformas completed by NCJDSU staff, photocopies of suspect
cases medical records where these have been accessed, EEG tracings and MRI
images (where these have been provided), and all correspondence relating to the
case. Case notes are held in secure fire-proof filing cabinets in a locked room. A
minimal datasct on each suspect case referred to the NCJDSU is entered onto a
minimum monitoring database maintained using Visual FoxPro by the Study Co¬
ordinator's) Any errors in data entry are corrected on an informal basis when new
information becomes available or a change in cases classification occurs. Data from
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the risk factor questionnaire are double entered onto a separate database also
maintained using Visual FoxPro. A paper-based record of all miscellaneous contacts
with the NCJDSU (contacts with the NCJDSU that have not resulted in a formal
referral being made) is maintained for reference. Historically these were recorded on
an adhoc basis by a NCJDSU neurologist, and when passed to the Study Co¬
ordinator, stored in lever arch files. Latterly an effort has been made to
systematically record such contacts on an Excel spread sheet. Designated personnel
are responsible for maintenance of electronic data held by the NCJDSU, including
arrangements from back up. All data are held in accordance with the 1998 Data
Protection Act (UK). Multi-centre research ethics committee (M-REC) approval was
granted for data collected in relation to the case control study subsequent to passage
of the 1998 Data Protection Act.
Data analysis and reporting
Routinely published surveillance data are analysed by the Study Co-ordinator. A
designated statistician is employed by the NCJDSU and external statistical support is
provided by the London School ofHygiene and Tropical Medicine. Pathways for
data reporting have been established. Standardised reports are produced and
disseminated according to agreed protocols. Each month the Study Co-ordinator
updates the NCJDSU website with the number of suspect prion disease cases referred
to the NCJDSU and the annual number of deaths from definite or probable prion
disease according to aetiological subtype. Monthly figures are emailed by the
NCJDSU to the Department ofHealth (DH) and Scottish Centre for Infection and
Environmental Health (SCIEH). Each month the DH issues a press release and
updates their website with these data; SCIEH publish these figures in their weekly
report. A quarterly report summarising the number of definite or probable vCJD
cases to date according to vital status is published on the NCJDSU website. Tables of
definite or probable cases of vCJD by residence are sent quarterly by the NCJDSU to
each Regional Epidemiologist and UK Health Department to be cascaded to relevant
Districts. The NCJDSU provide data on the annual number of deaths and mortality
rate from sCJD, iCJD and genetic prion disease (definite or probable cases) and the
annual number of definite or probable vCJD cases according to year, to the
EUROCJD group for publication on the EUROCJD website.
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For each incident definite or probable vCJD case a number of agencies are informed.
The DI1 is informed by email of the gender, age, case classification and vital status.
In turn, the DH informs local government departments and the SKAC secretariat. The
IIPA are notified of the eases' NCJDSU number, gender, date of onset, date of
referral to the NCJDSU, date of birth, date of death and date that the case was first
classified as a definite or probable vCJD case. Finally, colleagues in the European
Union CJD Surveillance System, WHO Headquarters, CDC Atlanta, European
Commission, Alzheimer's Disease Society, Human BSE Foundation, BSE Enquiry
and other interested parties are sent the gender, age and case classification of the
incident case in addition to tables of the total number of definite or probable vCJD
cases according to vital status.
As part of the TMER study, the Medical Director of the relevant U1CBTS
(determined by residential history) is notified immediately of an incident vCJD case
(definite or probable). The Medical Director is provided with the case's name
(including maiden name), gender, date of birth, residential history, donation history
(dates and places of donation), case classification and country of residence at time of
referral to NCJDSU. In addition an anonymised copy, stripped ofpatient identifiable
data, is sent to the appropriate DH. The UKBTS are informed bi-annually of sCJD
and genetic prion disease cases (definite or probable) that were identified as blood
donors or were reported as being the recipient of labile blood components. The
case's name (including maiden name) and gender are provided. For blood donors, the
year of donation(s), home address at the time of donation(s) and location at which the
donation(s) were made are supplied. For the recipients ofblood product(s), the year
of the transfusion(s), home address at the time of transfusion(s), hospital where the
transfusion(s) occurred and the indication for the transfusion(s) are supplied.
Annually the NCJDSU produce a report which summarises the clinico-pathological
epidemiology ofhuman prion disease in the UK in the preceding year and outlines
surveillance activities. This report is published on the NCJDSU website. Surveillance
data arc also disseminated to the scientific community through publications in pecr-
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reviewed journals and presentations at scicntifie meetings, nationally and
internationally.
Resources required to operate the surveillance system annually
At inception the NCJDSU had an annual operational budget of £79,905 and
employed one neurologist and one Study Co-ordinator. By 2006, the NCJDSU
employed 34 staff (of whom 15 were primarily involved in clinical disease
surveillance) and had an annual operational budget of £1.8 million (Table 28). Core
funding is provided by DH (90%) and the Scottish Government Department of
Health (10%). Additional funding is provided through research grants won in open
competition; many of the staff employed by the NCJDSU are funded through such
grants, for example the European Study Co-ordinator.






1 Senior Clinical Scientist (CSF)
1 Senior Biomedical Scientist (CSF)
1 Molecular Geneticist
1 Laboratory technician (Genetics)
2 Clinical Research Fellows
2 Nurse Practitioners
1 Study Co-ordinator






1 Chief Biomedical Scientist (Ilistopathology)
3 Senior Biomedical Scientist (Ilistopathology)
1 Senior Research Fellow (Biochemistry)
3 Research Fellows (Biochemistry)
1 Laboratory technician (Biochemistry)




Annual Budget: £79,905 Annual Budget: £ 1,811,696
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Performance of the surveillance system
The CDC criteria highlight eight key areas in evaluation of a surveillance system.
Each will be addressed in turn. The metrics selected to examine one system attribute
may also be applicable to another. Where this is the case, rather than presenting
duplicate data, the reader has been signposted as appropriate.
Simplicity
"The simplicity ofa surveillance system refers to both its structure and ease
ofoperation. Surveillance systems should be as simple as possible while still
meeting their objectives. "(222)
From the point of referral to the NCJDSU, detailed clinical, diagnostic and
epidemiological data are collected from multiple data sources (Figure 48). The
assessment and interpretation of clinical and diagnostic information is required for
case classification; epidemiological data, including detailed sociodemographic,
family, medical, residential, occupational, travel, behavioural, lifestyle and dietary
histories data arc collected to investigate putative risk factors for prion disease and
explore possible routes of secondary transmission. Much of these data are collected
when the NCJDSU neurologist visits the suspect case. This visit typically lasts for 3
hours, although it can take much longer. Owing to the distance travelled to meet each
suspect case in person it is exceptionally rare for more than one visit to take place in
a day, indeed each visit, including travel time, can take upward of 12 hours.
Subsequent to the visit, time is spent entering electronic information on each suspect
case onto the minimum reporting datasct and the case control study database (risk
factor questionnaire). Data collected at interview are validated through the
examination of medical records from primary and secondary care. Available
diagnostic information including EEGs, MR1 scans and neuropathological material
are requested for review by designated staff at the NCJDSU. The UKBTS are
informed immediately of all definite or probable vCJD cases (bi-annually for sCJD
and genetic prion disease cases) to begin a process of tracing blood donations and
recipients. Individuals meeting the diagnostic criteria as a definite or probable case of
prion disease are able to access the National Care Package. Often the National Care
Co-ordinator will remain in direct contact with the case's relatives, facilitating follow
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up. The follow up of suspect cases that do not meet the diagnostic criteria is more
challenging. Typically this would occur through NCJDSU staff contacting the
rcfcrrcr at intervals to request an update on the patient's progress. In addition the
death certificates of all suspect cases referred to the NCJDSU arc routinely requested
and reviewed.
Whilst the NCJDSU provide data to a large number of agencies this process has been
streamlined through the use of standard reporting formats, electronic data transfer
and web publishing. A close working relationship with DH (and Scottish equivalent)
and HPA ensures rapid communication where issues of national public health
importance arise.
Interpretation: The surveillance system, whilst simple in design is operationally
complex.
Figure 48 The surveillance pathway in the UK
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Flexibility
"A flexible public health surveillance system can adapt to changing
information needs or operating conditions with little additional time,
personnel, or allocatedfunds. Flexible systems can accommodate, for
example, new health-related events, changes in case definitions or
technology, and variations in funding or reporting sources. "(222)
Over the study period the flexibility of the surveillance system has been challenged
by emergent disease (vCJD), the introduction of novel diagnostic technologies (MRI,
CSF 14-3-3 protein, PRNP Codon 129 genotyping and molecular subtyping) and
changing case definitions (the incorporation ofCSF 14-3-3 protein into diagnostic
criteria for sCJD). The flexibility of the surveillance system can be evaluated by
exploring how the system responded to these new demands.
The impact ofvCJD on referralpatterns and NCJDSU surveillance
activities
The impact of vCJD on the operational performance and public health function of the
surveillance system over this period can be explored by examining patterns of
referral of suspect prion disease cases to the NCJDSU. The annual number of
referrals received by the NCJDSU from 1990 through 2006 is shown in Figure 49.
Between 1990 and 2006 the NCJDSU received a total of 2,154 referrals, ofwhich
1,653 (76.7%) were suspect sCJD cases, 322 (15.0%) suspect vCJD cases, 121
(5.6%) suspect genetic prion disease cases and 58 (2.7%) suspect iCJD cases. The
annual number of referrals increased from 53 per year in 1990 to peak at 179 per
year in 2001 before falling to 109 per year in 2006. Over time there was a significant
change in the distribution of referrals received by the NCJDSU according to disease
subtype (P<0.001) (Figure 50). The annual number of suspect sCJD referrals
received by the NCJDSU increased from 50 in 1990 to peak at 133 in 2001 before
falling to 84 in 2006; for vCJD, from one in 1994 to a peak of 51 in 2000, before
falling to 10 in 2006. The number of suspect iCJD and genetic prion disease cases
referred was low, between zero and seven, and between zero and 13 referrals per
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Figure 50 Distribution of referral received by the NCJDSU according to disease
subtype, 1990 - 2006
Age standardised referral rates were examined to determine whether the observed
increase in the number of referrals received by the NCJDSU was simply as a result of
an increase in the size of the population under surveillance and population ageing
over time. The age standardised referral rate increased from 0.94 (0.69 - 1.19) per
million in 1990 to peak at 3.03 (2.58 - 3.47) per million in 2001, before falling to
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1.78 (1.44 - 2.11) per million in 2006 (Figure 51). The annual percentage change
(APC) in referral rate increased by 10.88% (7.33 - 14.55) from 1990 through 2000,
then decreased by -10.05% (-15.37 - -4.38) from 2000 through 2006.
Year
Figure 51 Age standardised rates of referral to the NCJDSU, 1990 - 2006
Age standardised referral rates according to disease subtype are shown in Figure 52.
The referral rate for suspect sCJD increased from 0.89 (0.65 - 1.14) permillion in
1990 to peak at 2.25 (1.87 - 2.63) permillion in 2001 before falling to 1.37 (1.08-
1.66) per million in 2006. From 1990 through 2001 there was a statistically
significant increase in the referral rate for suspect sCJD, with an APC of 6.55% (3.33
- 9.87). A significant reduction in APC of-10.24% (-18.19—1.52) from 2001
through 2006 followed. The referral rate for suspect vCJD, increased from 0.02 (0.00
- 0.07) per million in 1994, to peak at 1.08 (0.78 - 1.38) per million in 2000, before
falling to 0.20 (0.08 - 0.34) permillion in 2006. Regression modelling fitted three
joinpoints when modelling referral rates for vCJD over time. First, a non-significant
increase in APC of 266.31% (-74.91 - 5248.67) from 1994 through 1996. Then, a
non-significant increase in the APC of 10.09% (-17.98 - 47.76) from 1996 through
2000. Finally, a statistically significant decline in APC of -25.22% (-35.50 - -13.30)
from 2000 through 2006. The overall age standardised referral rate for suspect iCJD
was 0.06 (0.00 - 0.12) with no significant change over time (APC for 1990 through
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2006: 0.83% (-4.89 - 6.89)). There was a gradual increase in the referral rate for
suspect genetic prion disease over the study period from 0 per million in 1990 to 0.38
(0.16-0.59) permillion in 2006, equating to an APC of 4.62% (1.17-8.19).
Year
Figure 52 Age standardised referral rates according to disease subtype, 1990 -
2006
The response of the NCJDSU to an increase in the annual absolute number and rate
of referral was assessed by examining the proportion of referrals that were visited by
a NCJDSU neurologist across selected study years and the time from referral to
neurologist visit. Over these years 801 referrals were received by the NCJDSU; 613
suspect sCJD cases, 122 suspect vCJD cases, 18 suspect iCJD cases and 48 suspect
genetic prion disease cases. This section will focus on suspect sCJD and suspect
vCJD cases only as the NCJDSU surveillance remit in relation to iCJD and genetic
prion disease is limited.
A neurologist from the NCJDSU visited 379 (61.8%) suspect sCJD cases referred to
the NCJDSU over the selected time period; 85.8% of all definite or probable sCJD
cases, 52.8% of all possible sCJD cases and 29.7% of all non-sCJD cases (Table 29).
In 1997 fewer than expected definite or probable sCJD cases were visited by a
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neurologist from the NCJDSU (P<0.001), and in 1997 and 2000 fewer than expected
non-sCJD cases were visited by a neurologist from the NCJDSU (P<0.001).
Tabic 29 Number of suspect sCJD cases visited by a NCJDSU neurologist each
year according to case classification
Year of Number (%) of suspect sCJD referrals visited by NCJDSU neurologist
referral All suspect sCJD cases sCJI) cases Possible sCJD Not sCJD
1991 48 (67.6) 29 (85.3) 1 (25.0) 18(54.5)
1994 67 (63.2) 51 (92.7) 5 (45.5) 11 (28.2)
1997 59(51.8) 48 (76.2) 4 (42.9) 7(16.3)
2000 58 (48.7) 41 (83.7) 4 (50.0) 13 (21.7)
2003 82 (68.3) 71 (93.4) 1 (50.0) 10(25.0)
2006 65 (78.3) 51 (82.3) 4 (l(K).O) 10 (58.8)
Total 379 (61.8) 291 (85.8) 19(52.8) 69 (29.7)
CJD cases include classification 1.0 or 2.0; non-cases include classification 4.1, 4.2 and 4.3
The median number ofworking days from referral of a suspect sCJD case to visit by
a NCJDSU neurologist according to year of referral and vital status at the time of
visit is shown in Table 30. These data were not reliably recorded in 1991 - the date
of neurologist visit was frequently recorded as the date of referral - hence this year
has been excluded from analyses. Overall the median number ofworking days from
referral to visit by a NCJDSU neurologist was 5 (3 - 9) days for suspect sCJD cases
alive at the time of visit and 210 (110 - 286) days for suspect sCJD cases that were
deceased at the time of visit. There was a statistically significant yearly variation in
the median number ofworking days from referral to visit by a NCJDSU neurologist
for both those alive (P<0.001) and deceased (P--0.012) at the time of visit, although
the 95% confidence intervals for all years overlapped. The time from referral to visit
was significantly longer when the suspect case was deceased at the time of visit
compared to when the suspect case was alive at the time of visit. This is likely to
reflecting the time taken for the NCJDSU to collect detailed clinico-pathological
information on the suspect sCJD cases prior to visit to ensure that such individuals
met the diagnostic criteria. In addition, given there are no public health implications
of a diagnosis of sCJD it is often considered appropriate to delay approaching
grieving relatives to obtain consent for a visit.
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Table 30 Time from referral to visit by a NCJDSU neurologist, according to
year of referral and vital status at time of visit
Year of Median number ofworking days from referral of suspect sCJD case to visit (IQR)
referral
Number Alive at time of visit Number Deceased at time of visit
1994 49 4(3-7) 18 239 (135-286)
1997 42 6(3-11) 17 214(141 -286)
2000 43 7 (5 - 16) 15 142 (58-210)
2003 67 5(3-9) 15 264(213-270)
2006 57 4(3-5) 8 60 (8-131)
AH 257 5 (3 - 9) 88 210(110-286)
A neurologist from the NCJDSU visited 77 (63.1%) of all suspect vCJD cases
referred to the NCJDSU over selected years; 98.4% of all definite or probable vCJD
case, all possible vCJD cases and 21.8% of non-vCJD (Table 31). There was no
significant change over time in the proportion of suspect vCJD cases referred to the
NCJDSU that were visited by a NCJDSU neurologist (P=0.568). The median number
ofworking days from referral to the NCJDSU to visit by a NCJDSU neurologist was
7 (4 - 13) days in suspect vCJD cases alive at the time ofNCJDSU visit; this was
invariant over time (P=0.694). Just three suspect vCJD cases, all definite vCJD cases,
were deceased at the time of visit. For these cases the number ofworking days from
referral to visit was 4, 18 and 139 days, respectively. In the latter two cases referral
came from a neuropathologist and vCJD had not been suspected in life therefore
there was a delay in the neuropathologist informing the clinical team and in turn the
clinical team informing the relatives of the diagnosis before the NCJDSU could
attempt to obtain consent for a visit from the relatives.
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Tabic 31 Number of suspect vCJD referrals visited by a NCJDSU neurologist
each year according to case classification
Year of Number (%) of suspect vCJD referrals visited by NCJDSU neurologist
referral All suspect vCJD cases vCJD cases Possible vCJD Not vCJD
1994 0(0) 0 0 0(0)
1997 22 (64.7) 13 (100) 0 9 (42.9)
2000 32 (62.8) 28 (96.6) 1 (100) 3 (14.3)
2003 17 (65.4) 16(100) 0 1 (10.0)
2006 6 (60.0) 5(100) 0 1 (20.0)
Total 77 (63.1) 62 (98.4) 1 (100) 14(24.1)
CJD cases include classification 1.0 or 2.0; non-cases include classification 4.1, 4.2 and 4.3
New diagnostic technologies
A flexible system would demonstrate increasing use of emergent technologies to
support a diagnosis of prion disease in the suspect prion disease cases referred to the
NCJDSU. To explore this, the use of investigations to support a diagnosis of sCJD or
vCJD in suspect sCJD or vCJD cases referred to the NCJDSU over selected years
was examined.
Over time a statistically significant increase in the proportion of suspect sCJD cases
referred to the NCJDSU that underwent at least one EEG examination (P=0.015)
during the course of their clinical illness was observed (Figure 53). Similar trends
were seen in the use ofMR1 scanning (P<0.001) and CSF 14-3-3 protein
examination (P<0.001). In 1991 for example 83.1% of suspect sCJD cases referred to
the NCJDSU underwent one or more EEG examination, increasing to 91.6% in 2006.
Corresponding figures for MRI scanning were 7% in 1991 increasing to 85.5% in
2006 and for CSF 14-3-3 protein examination 34.9% in 1997 increasing to 88.7% in
2006. Less than half of all suspect sCJD cases underwent PRNP Codon 129
genotyping or full sequencing of PRNP to test for mutations. There was no
significant change in the proportion of suspect sCJD cases undergoing cither
investigation over time (P=0.302 and P=0.140 respectively). There was a significant
fall in the proportion of suspect sCJD cases undergoing post mortem examination on
expiration, from 62.7% in 1991 to 49.3% in 2006 (P=0.004). However among
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suspect sCJD cases for whom neuropathological material was available, either from
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Figure 53 Proportion of suspect sCJD cases referred to the NCJDSU over
selected years that underwent investigations that might support a diagnosis of
sCJD
There was no significant change over time in the proportion of suspect vCJD cases
undergoing MRI scanning (P-0.747) or CSF 14-3-3 protein examination (P=0.309)
during the course of their clinical illness (Figure 54). However, over 90% of suspect
vCJD cases underwent one or more MRI scan during the course of their clinical
illness, and it should be noted that CSF 14-3-3 protein is of limited value in the
investigation of suspect vCJD. Approximately half of all suspect vCJD cases referred
to the NCJDSU underwent PRNP Codon 129 genotyping and full sequencing for
PRNP mutations. This was invariant over time (P=0.802 and P=0.693 respectively).
There was a significant fall in the proportion of suspect vCJD cases undergoing post
mortem examination on expiration, from 81.8% in 1997 to 50.0% in 2006 (P=0.012).






































Figure 54 Proportion of suspect vCJD cases referred to the NCJDSU over
selected years that underwent investigations that might support a diagnosis of
vCJD
Changing diagnostic criteria
CSF 14-3-3 protein examination was incorporated into WFIO diagnostic criteria for
sCJD in 2000. Increasing use ofCSF 14-3-3 protein in the investigation of suspect
sCJD cases in the UK was described in the preceding section. An examination of the
number of probable sCJD cases that met the diagnostic criteria based on EEG and
clinical features or CSF 14-3-3 protein and clinical features gives some insight into
the application of these adapted criteria by the NCJDSU as a measure of the
flexibility of the system. Over 60% of all probable sCJD cases from 2000, 2003 and
2006 met the WIIO diagnostic criteria based on CSF 14-3-3 protein and clinical
features, compared to just approximately 15% based on EEG and clinical features
(Table 32). This indicates that CSF 14-3-3 protein has made a substantial
contribution to disease surveillance.
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Table 32 Suspect sCJD cases meeting WHO diagnostic criteria as a probable
case of sCJD based on EEG findings and clinical features or CSF 14-3-3 protein
and clinical features
Number (%) of probable sCJD cases
Year EEG findings and clinical features CSF 14-3-3 protein and clinical features
2000 1 (12.5) 5 (62.5)
2003 6(18.2) 19(57.6)
2006 3(11.1) 18(66.7)
Total 10 (14.7) 42 (61.8)
Over these years only two thirds of individual meeting the diagnostic criteria as a
definite, probable or possible sCJD cases underwent CSF 14-3-3 protein
examination; 95% underwent EEG examination. To determine the potential under-
asccrtainment of sCJD cases through the under-utilisation of CSF 14-3-3 protein
examination, the use of CSF 14-3-3 protein in the investigation of individuals
classified at data censoring as a possible sCJD case was examined (Table 33). The
maximum number of sCJD cases that may have been missed through under-
utilisation of CSF 14-3-3 protein examination over this period was 11.
Table 33 Assessment of the potential degree of under-ascertainment of sCJD
cases





CSF 14-3-3 protein, n (%)
Possible undcr-
ascertainment, n (%)
2000 8 8(100) 2 (25.0) 6 (75.0)
2003 2 2(100) 0(0) 2(100)
2006 4 4(100) 1 (25.0) 3 (75.0)
Total 14 14(100) 3 (21.4) 11 (78.6)
Interpretation: The flexibility of the surveillance system has been challenged in the
UK by emergent disease, new diagnostic technologies and changing diagnostic
criteria. Following the emergence of vCJD in the UK a significant increase in the
absolute number and age standardised rates of referral to the NCJDSU occurred,
peaking between 2000 and 2001. This was driven by an increase in referrals of
suspect sCJD and genetic prion disease in addition to suspect vCJD cases. The
NCJDSU was able to respond to this increasing demand, visiting a consistently high
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proportion of suspect vCJD cases in life. However, fewer than expected suspect
sCJD cases were visited in 1997 and 2000 and an increase in the median number of
working days from referral to visit was observed in these years. Given the limited
implications of a diagnosis of sCJD, it could be argued that the system responded
appropriately. Over time an increasing proportion of suspect sCJD cases underwent
EEG, MR1 scanning and CSF 14-3-3 protein examination during the course of their
clinical illness. However there was evidence of potential under-ascertainment of
sCJD cases attributable to the sub-optimal use of CFS 14-3-3 protein. Fewer than
halfof suspect sCJD cases underwent PRNP Codon 129 genotyping and full
sequencing ofPRNP for mutations, and post mortem rates in suspect sCJD and
suspect vCJD cases fell across the study period. The former is crucial in excluding
genetic prion disease which has a broad clinical phenotype and may be clinically
indistinguishable from sCJD, and the latter in case confirmation. Overall, these data
suggest that the NCJDSU is flexible and has responded appropriately to changing
demands. However the possible under-ascertainment of sCJD cases and limited use
of key diagnostic technologies is cause for concern. This latter issue will be
addressed in greater detail in the section that follows on data quality.
Data Quality
"Data quality reflects the completeness and validity of the data recorded in
thepublic health surveillance system ".(222)
The following metrics were considered:
1. The completeness of investigations to support a diagnosis of sCJD or vCJD in
suspect sCJD and vCJD cases referred to the NCJDSU
2. Review by the NCJDSU of EEG, MR1 and neuropalhological studies from
suspect sCJD cases and suspect vCJD cases referred to the NCJDSU
3. The extent to which multi-source clinical and diagnostic information on sCJD
and vCJD cases (definite or probable) has been reviewed by the NCJDSU
4. The degree ofmissing data from key variables in the minimum monitoring
dataset for all suspect prion disease cases referred to the NCJDSU
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5. The degree ofmissing data as measured by unknown or blank responses on the
risk factor questionnaire for any suspect sCJD case or suspect vCJD case for
whom the risk factor questionnaire was completed
6. The completeness of follow up of all suspect sCJD cases and suspect vCJD cases
that met the WHO diagnostic criteria at any stage in their clinical illness as a
possible sCJD or vCJD case.
The quality ofa diagnosis ofsCJD or vCJD
In the preceding section I described the changing use of investigations which support
a diagnosis of prion disease over selected years in suspect sCJD and suspect vCJD
cases. In Tables 34 and 35, the completeness of investigations that support a
diagnosis of sCJD or vCJD in suspect sCJD and suspect vCJD cases, according to
case classification at data censoring, over selected years are described. In suspect
sCJD cases there was evidence of differential use ofEEG, MRI, CSF 14-3-3 protein,
PRNP Codon 129 genotyping and PRNP mutation testing according to case
classification. sCJD cases (classification 1.0 or 2.0) were more likely than non-sCJD
cases (classification 4.1, 4.2 or 4.3) to undergo EEG examination (PO.OOl), MRI
scanning (P<0.001), PRNP Codon 129 genotyping (PO.OOl) and PRNP mutation
testing (PO.OOl) and possible sCJD cases (classification 3.0), were less likely that
other groups to undergo CSF 14-3-3 protein examination (P<0.001).
In suspect vCJD cases, there was no significant difference in the use ofMRI
scanning (P-0.328), CSF 14-3-3 protein (P-0.500) or tonsil biopsy (P=0.204)
according to case classification, although the number of suspect vCJD cases
(classification 1.0 or 2.0) undergoing tonsil biopsy was small. However non-cases
(classification 4.1, 4.2 or 4.3) were less likely that vCJD cases to undergo PRNP
Codon 129 genotyping (PO.OOl) or PRNP mutation testing (PO.OOl).
219





































































































































tDenominatordeceasedreferrals;"""LimitCJDca s( finiteprobable)wi htissu(neuro athologict i )
220
Review ofinvestigations that support a diagnosis ofsCJD and vCJD
It is crucial that the NCJDSU review investigations that support a diagnosis of sCJD
or vCJD in suspect cases. The National CSF 14-3-3 protein laboratory is based at the
NCJDSU. Quality assurance of this investigation can therefore be monitored. The
same cannot be said of EEGs, MRIs and pathological studies which arc carried out
and reported throughout the UK. The proportion of suspect sCJD cases for whom the
NCJDSU reviewed EEG, MR1 and neuropathological studies, and the proportion of
suspect vCJD cases for whom the NCJDSU reviewed EEG, MR1, neuropathological
and pathological (tonsil biopsy) studies, can be considered as a measure of data
quality. The denominator for these analyses is the number of suspect sCJD or vCJD
cases known to have undergone these investigations over selected years.
Suspect sCJD cases
In just over half of all suspect sCJD cases that underwent MRI scanning, images
were reviewed by the NCJDSU neuroradiologist (Table 36). There was an increase in
the proportion of suspect sCJD cases in which MRI imaging was reviewed over time
from 20.0% in 1991 to 71.8% in 2006 (PO.OOl). EEGs were reviewed by the
NCJDSU in 58.6% of all suspect sCJD cases that underwent EEG examination with
year to year variation in this proportion but no discernible temporal trend (P=0.243).
The NCJDSU reviewed neuropathological material obtained from brain biopsy in life
or post mortem following death in 48.0% and 75.1% respectively of suspect sCJD
cases for whom tissue was available with no significant change over time in either
(P=0.362 and P=0.112 respectively).
Suspect vCJD cases
The corresponding data for suspect vCJD cases are presented in Table 36. MRI
imaging was reviewed in a high proportion of suspect vCJD cases that underwent
this investigation; EEG in a smaller proportion possibly reflecting the limited value
of EEG in supporting a diagnosis of vCJD. Neuropathological tissue where available,
was reviewed for all brain biopsies undertaken and over 80% ofpost mortem
examinations. However tissue from tonsil biopsy was reviewed in only 58.3% of
suspect vCJD cases undergoing this investigation.
221














































































Multi-source informationfor sCJD and vCJD cases (definite orprobable)
Multi-source information is collected by the NCJDSU for each sCJD and vCJD case:
clinical examination of the case by a NCJDSU neurologist, interview with relatives,
review of hospital medical records and review ofmedical records from primary care.
Over selected years the completeness ofmulti-source information was assessed for
all sCJD and vCJD cases (Table 37). Overall, a neurologist from the NCJDSU
examined 90% of sCJD cases (alive at time of referral), with a decline in this
percentage in 1997 and 2000. Relatives of sCJD cases were interviewed in similar
proportions. Hospital records were reviewed in over 80% of sCJD cases, with a
decline in this percentage in 2006. An increase over time was noted in the percentage
ofmedical records from primary care that were reviewed for sCJD cases, although
overall medical records from primary care were reviewed in only 15.6% of all sCJD
cases. In all vCJD cases the NCJDSU neurologist examined the case and interviewed
the relatives. In the majority of vCJD cases hospital records were reviewed and
records from primary care accessed.
Tabic 37 Information available from various sources on sCJD cases and vCJD
cases (definite and probable) referred to the NCJDSU according to year of
referral
Year Clinical Exam * Interviewed Reviewed Hospital Reviewed primary
Relatives records Care recordsf
sCJD vCJD sCJD vCJD sCJD vCJD sCJD vCJD
1991 13(92.9) - 27(90.0) - 26(86.7) - 0 -
1994 30(96.8) - 43(89.6) - 44(91.2) - 2(4.2) -
1997 35(89.7) 12(100) 46(78.0) 12(100) 49(83.1) 11(91.7) 2(3.4) 9(75.0)
2000 30(83.3) 23(100) 33(80.5) 24(100) 35(85.4) 24(100) 9(22.0) 20(83.3)
2003 31(91.2) 6(100) 40(93.0) 7(100) 37(86.0) 7(100) 13(30.2) 7(100)
2006 24(92.3) 3(100) 29(82.9) 3(100) 24(68.6) 1(50.0) 9(27.3) 1(50.0)
Total 163(90.6) 44(100) 218(85.2) 46(100) 215(84.0) 43 (95.6) (15.6) 37(82.2)
'denominator alive at time of referral; tdenominator deceased patients
Information was available from all of the above sources for 107 (31.6%) sCJD cases
and 50 (81.0%) vCJD cases. Information was unavailable from any of the above
sources in 25 sCJD cases (of which 21 were neuropathologically confirmed sCJD
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cases); all 25 were deceased at the time of referral to the NCJDSU. In contrast,
information was available from at least one source in all vCJD cases.
Missing data — key variablesfrom minimum monitoring dataset
Case records of all suspect prion disease cases referred to the NCJDSU over selected
years were examined to determine whether key variables from the minimum
monitoring dataset identified by the WHO were missing (Table 38). As previously
noted, date of referral was often recorded as either date ofNCJDSU neurologist visit
or date of death in 1991. Whilst there were no missing data for this variable it was
not possible to validate this information. In suspect sCJD cases, where demise is
rapid, month and year of neurologist visit or death are a reasonable proxy for month
and year of referral; the same cannot be said for other disease subtypes, for example
suspect vCJD cases or suspect genetic prion disease, which are associated with
longer illness durations.
Tabic 38 Episodes ofmissing data from key variables in minimum monitoring
dataset (all suspect prion disease referrals received in selected years), according
to year
Number of episodes where data were missing (%)
Variable 1991 1994 1997 2000 2003 2006
Referral source 0 0 1 (0.6) 29 (16.3) 10(6.2) 6 (5.6)
Date of referral 0 0 0 0 0 0
Sex 0 0 0 0 0 0
Date of birth 1 (1.3) 2(1.8) 2(1.2) 1 (0.6) 0 0
Date of onset 12 (16.0) 16(13.7) 23(14.3) 15 (8.4) 9 (5.6) 6 (5.6)
Residence at onset 5 (6.7) 7 (6.0) 9(5.6) 7 (3.9) 4 (2.5) 2(1.9)
Date of death 0 0 0 0 0 0
*dates required MM/YY
Referral source was well recorded in the early years of surveillance but missing in
one in every six referrals received in 2000, and in over 5% of referrals received by
the NCJDSU in 2003 and 2006. Date of symptom onset was missing in almost one in
every six suspect prion disease cases referred to the NCJDSU in 1991, although there
was evidence that recording of this variable improved over time. Residence at onset
was missing in 6.7% of all suspect prion disease cases referred to the NJCDSU in
1991, falling to 1.9% in 2006. Of note over 70% of suspect prion disease cases
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referred to the NCJDSU for whom key variables from the minimum monitoring
dataset were missing were classified as non-cases (classification 4.1, 4.2 or 4.3). The
majority of these were suspect sCJD cases, reflecting the large proportion of suspect
sCJD referrals received by the NCJDSU relative to other disease subtypes.
As previously noted, multi-source data was available from clinical examination of
the case, interview with relatives, review of medical records in primary care and
review ofmedical records from secondary care in 107 sCJD and 50 vCJD cases. In
this group multi-source information was used to verify the data recorded for the key
variables of the minimum monitoring dataset described in Table 38 above. There
were no inaccuracies in data entry. In a minority of the case notes reviewed (<1%)
there was evidence that the Study Co-ordinator had triangulated data and corrected
inaccuracies in the recording of variables from the minimum monitoring datasct.
Blank responses in riskfactor questionnaire
Selected questions on the risk factor questionnaire (residential history, occupational
history, medical including surgical history, family history and a history of blood
donation / transfusion) were examined for suspect sCJD and vCJD cases for which
this had been completed. With the exception of an occasional isolated omission, data
recording was complete (98 - 100%).
The follow up ofsuspect sCJD and suspect vCJD cases
This section reviews the follow up of suspect sCJD and suspect vCJD cases referred
to the NCJDSU over selected years that met the WHO diagnostic criteria as a
possible, probable or definite case of sCJD or vCJD at any stage in the course of their
clinical illness.
Suspect sCJD cases
In total 418 suspect sCJD cases referred to the NCJDSU over selected years met the
diagnostic criteria as a possible (or greater) sCJD case at any stage in their clinical
illness. At the time of data censoring a neuropathological diagnosis had been reached
in 273 (65.3%), ofwhom 256 (93.8%) had sCJD. Pathologically confirmed non-
sCJD cases (n=l 7) were most commonly Alzheimer's Disease or Lcwy Body
Dementia (Table 39). At data censoring, 36 cases remain classified as possible
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sCJD; all were deceased with no prospect of further clinical information becoming
available. Five suspect sCJD cases were classified as 4.1, diagnosis unclear; no
further clinical information was available for these suspect cases despite repeated
documented attempts at follow up. A further 23 individuals were, at the time of data
censoring, classified as 4.2, indicating that sCJD was clinically unlikely. In this
group an alternate clinical diagnosis had been reached for 17 (Table 40), a further
two had improved clinically although a diagnosis had not been reached and in four
an alternate clinical diagnosis was unavailable although the referring clinician
confirmed that sCJD was no longer suspected.
Table 39 Cause of death as determined by a neuropathologist in suspect sCJD
cases that met the diagnostic criteria as a possible (or greater) sCJD case during
the course of their clinical illness but had an alternate neuropathologically
confirmed diagnosis
Cause of death Number
Alzheimer's Disease 6*







Multifocal calcifying leucoencephalopathy 1
*I)ual pathology in one patient
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Tabic 40 Alternate clinical diagnoses in individuals meeting the diagnostic
criteria as a possible (or greater) case of sCJD at any stage during their clinical
illness
Clinical Diagnosis Number
Encephalitis ? cause 3
Lewy Body Dementia 3
Iatrogenic effects of drugs 2
Steroid responsive encephalopathy 1





Normal Pressure Hydrocephalus 1
Paraneoplastic syndrome 1*
Seizures post head injury 1
*Brain not examined, primary lung tumour
A clinical or neuropathological diagnosis had not been reached at the time of data
censoring for 41 suspect sCJD cases that met the diagnostic criteria as a possible (or
greater) case of sCJD at any stage in their clinical illness, 36 individuals classified as
possible sCJD cases and five classified as 4.1, diagnosis unclear. Details of the
investigations undertaken to support a diagnosis of sCJD in this group during the
course of their clinical illness are shown in Table 41. EEG was commonly
undertaken but less than a third underwent CSF 14-3-3 protein examination whilst
over halfunderwent MR1 scanning. In four possible sCJD cases features on MRI
scanning supported a diagnosis of sCJD. Approximately a third of suspect sCJD
cases in this group underwent PRNP Codon 129 genotyping. The distribution of
Codon 129 genotypes was 42.9% (6) methionine homozygote, 28.6% (4) methionine
heterozygote and 28.6% (4) valine homozygote. Full sequencing for PRNP
mutations was not carried out in any suspect sCJD case in this group, and none had
undergone brain biopsy in life or autopsy following death.
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Tabic 41 Investigations undertaken in suspect sCJD eases that met the
diagnostic criteria as a possible (or greater) case of sCJD during the course of
their clinical illness in whom a clinical or neuropathological diagnosis had not
been reached at data censoring
Investigation Number (%)
EEG 40 (97.6)
CSF 14-3-3 protein* 8(32.0)
MRI 23 (56.1)
PRNP Codon 129 genotyping 14(34.2)
PRNP Mutation testing 0 (0)
Brain Biopsy 0 (0)
Post mortem 0 (0)
*denominator limited to 1997 onward
A neurologist from the NCJDSU visited 335 (80.1%) suspect sCJD cases and/or their
relatives that met the diagnostic criteria as a possible (or greater) sCJD case at any
stage in their clinical illness. The reason why a visit was not undertaken, where
known, is listed in Table 42.
Table 42 Reason why the NCJDSU did not visit suspect sCJD case that met the
diagnostic criteria as a possible (or greater) sCJD case at any stage in their
clinical illness
Reason for no visit from the NCJDSU Number (%)
No response by referring clinician to request for next of kin's details 19 (22.9)
No response from family to postal invitation to participate in surveillance 12 (14.5)
Family declined interview 3 (3.6)
Family not yet approached - awaiting further clinical / diagnostic information 3 (3.6)
Clinician advised against contacting family 2 (2.4)
Family felt 'too soon' for visit 2 (2.4)
Reason unknown 24 (28.9)
Of the 41 suspect sCJD cases in whom a clinical or ncuropathological diagnosis had
not been reached (36 possible and 5 diagnosis uncertain), 40 (97.6%) were known to
have died at data censoring; death certificates were available for review at the
NCJDSU for 39 (97.5%). Three quarters (26) of suspect cases classified as possible
CJD at data censoring had CJD recorded on their death certificate. In the remaining
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possible eases the underlying cause of death was recorded as dementia (5),
alzheimer's disease (1), stroke (1), brain tumour (1) and cause of death unknown (1).
Four of the five individuals classified as 4.1 (diagnosis uncertain) were known to
have died with the following recorded as the unerlying cause of death: dementia (1),
Alzheimer's disease (1), bronchopneumonia (1) and stroke (1). The vital status of the
fifth individual (referred in 2003 with a one year history of cerebellar symtpoms) was
unknown. In total then just 2 suspect sCJD cases that met the diagnostic criteria as a
possible sCJD case at any stage in their clinical illness were considered to have been
lost to follow up, that is a clinical or neuropathological diagnosis had not been
reached at data censoring and follow up information from primary care, secondary
care or a death certificate was unavailable.
Suspect vCJD cases
In total 69 suspect vCJD cases referred to the NCJDSU over this period met the
diagnostic criteria as a possible (or greater) vCJD case at any stage in their clinical
illness. A neuropathologically confirmed diagnosis was reached in 49 (71.1%). Of
these a diagnosis of vCJD was confirmed in 46 (93.9%). Three cases had an alternate
neuropathological diagnosis: one Alzheimer's disease, one Alzheimer's Disease and
amyloid angiography dual pathology and one subacute sclerosis panencephalitis. At
data censoring 17 suspect vCJD cases in this group were classified as probable vCJD
and one as a possible vCJD case. The latter individual died without post mortem
examination; tonsil biopsy was not performed ante-mortem and due to movement
artefact MRI scanning, although carried out, did not contribute to the diagnostic
process. Clinical diagnoses (viral encephalitis and a functional illness) had been
reached in the final two suspect vCJD cases in this group who were, at the time of
data censoring, classified as 4.2, vCJD clinically unlikely.
In all but two instances a neurologist from the NCJDSU had visited the suspect vCJD
cases in this group and/or their relatives to collect further information. In the latter
two suspect vCJD cases the family had refused a visit from the NCJDSU; these
suspect vCJD cases were classified, at the time of data censoring, as a probable vCJD
case and 4.2, vCJD clinically unlikely. The vital status, at data censoring, of all
suspect cases was known. Three individuals were known to be alive (two probable
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vCJD cases and one individual classified as 4.2 (vCJD clinically unlikely)). Death
certificates had been received by the NCJDSU for all but one deceased suspect case.
The latter individual, a neuropathologically confirmed vCJD case underwent brain
biopsy during life (tissue reviewed by the NCJDSU) and was known to have died
abroad.
Interpretation: These data confirm the findings from the preceding section that
examinations to support a diagnosis of sCJD and vCJD are being under-utilized in
the investigation of suspect sCJD and vCJD cases. This may compromise
surveillance efforts. The validation of clinical and diagnostic information has
generally improved over time, although there remains room for further improvement,
particularly in the review of medical cases records from primary and secondary care
and EEGs in the investigation of suspect sCJD cases. Overall data recording was
excellent and evidence of improvement over time. The follow up of suspect sCJD
and vCJD cases that met the diagnostic criteria as a possible sCJD or vCJD case at
any stage in the course of their clinical illness was also very good; less than 1% (2)
of suspect sCJD, and no suspect vCJD cases that met the diagnostic criteria as a
possible case at any stage in their clinical illness were lost to follow up.
Acceptability
"Acceptability reflects the willingness ofindividuals and organizations to
participate in the surveillance system. " (222)
Acceptability can be measured in a number ofways. Firstly rates and patterns of
referrals of suspect sCJD and vCJD cases can be considered. Secondly, the
willingness of suspect sCJD and vCJD cases and their relatives to participate in
surveillance can be examined. Thirdly, completion rates for questions in the risk
factor questionnaire can be assessed. These latter two metrics were addressed under
the subheading 'Data Quality' and will not be revisited here. Finally, the willingness
ofpublic health policy makers to use data from the NCJDSU to support and inform
decision making can be examined.
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Referral rates andpatterns
Referral rates to the NCJDSU from 1990 through 2006 were described under the
subheading 'Flexibility' and will not be recounted in detail here. A number of
additional points may be considered when examining referral rates and patterns.
Firstly, the proportion of suspect sCJD and vCJD eases referred to the NCJDSU in
whom a ncuropathologically confirmed diagnosis of sCJD and vCJD is reached.
These data are shown in Figure 55. The WHO recommends that the number of
suspect CJD cases referred to a surveillance system should exceed the number of
confirmed cases by a factor of two. As can be seen in Figure 56 there has been
variation over time in the proportion of suspect sCJD and vCJD cases referred to the
NCJDSU in whom a ncuropathological diagnosis of sCJD or vCJD was confirmed.
However this has always been maintained at a factor of two or more.
™ 0.2




Figure 55 Proportion of all suspect sCJD and vCJD cases referred to the
NCJDSU in whom a neuropathologically confirmed diagnosis of sCJD or vCJD
was reached according to year of referral, 1990 - 2006
The second issue that should be considered is the source of referral to the NCJDSU.
This metric was examined by analysing data from selected years of surveillance. A
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declining reliance on death certificate data in the ascertainment of suspect prion
disease cases could be considered a reflection of the acceptability of the surveillance
system to health care professionals and the public. For example, in 1991, 18.3% (13)
of all suspect sCJD cases referred to the NCJDSU were ascertained through death
certificates review alone; in 2006 this figure was zero. A number of professional
groups receive regular mailing asking them to refer suspect prion disease cases to the
NCJDSU. These include neuropathologists, neurophysiologists and neurologists.
Over selected study years 69.0% (49) of suspect sCJD cases and 71.1% (59) of
suspect vCJD cases referred to the NCJDSU were referred by these groups.
Unsolicited referrals are received from a number of other groups including general
physicians, psychiatrists, other health care professionals and even the relatives of
suspect cases. Over time the proportion of suspect sCJD referrals received by these
groups increased, from 12.7% (9) in 1991 to 21.7% (18) in 2006 (P=0.002). For
suspect vCJD cases from 23.1% (3) in 1997 to 50% (5) in 2006 (P=0.052).
It might be hypothesised that referrals from non-specialist groups are less desirable
that those from specialists groups, as they arc likely to have a lower sensitivity. As a
measure of sensitivity, the proportion of all referrals received by each referral source
that met the diagnostic criteria as a definite or probable case of sCJD and vCJD were
examined. Overall the sensitivity was 39.0% (35.0 -43.0) for suspect sCJD and
54.5% (45.2 - 63.7) for suspect vCJD (Table 43).
Tabic 43 Sensitivity of referral of suspect sCJD and vCJD cases from selected
years, according to referrals source
Sensitivity % (95% CI)
Suspect sCJD Suspect vCJD
Neurologist 28.0 (23.3-32.8) 56.2(45.9-66.5)
Neuropathologist 91.2 (83.9-98.6) 100
General Physician 50.8 (38.1 -63.6) 75.0 (32.6- 100)
Death Certificate 20.5 (7.8-33.1) -
Psychiatrist 25.0 (6.0-44.0) 14.3(0-40.2)
Neurophysiologist 50.0(15.3-84.6) -
Other 65.8(50.7-80.9) 50(19.0-81.0)
All 39.0 (35.0-43.0) 54.5 (45.2-63.7)
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Predictably the sensitivity was greatest when the referral came from a
neuropathologist for both suspect sCJD and suspect vCJD cases. Conversely, this
was lowest when suspect cases were ascertained through death certificate review or
referred by a psychiatrist. Interestingly the sensitivity was high when suspect cases
were referred by the 'other' group, which includes other health care professionals
and patients relatives. Sensitivity was greater for general physicians referring suspect
vCJD cases than neurologist, although not significantly so. For suspect sCJD cases
there was a significant difference. It should be considered however that whilst the
referral to the NCJDSU may have come from a general physician many suspect sCJD
and suspect vCJD cases are reviewed by a neurologist during the course of their
clinical illness. For example, 89.9% (549) of all suspect sCJD and 86.9% (106)
suspect vCJD cases referred to the NCJDSU were known to have been admitted to
hospital during the course of their clinical illness. Suspect sCJD cases were most
commonly admitted under a general physician, 33.1% (203), 24.5% (150) under the
carc of a neurologist and 13.5% (82) under the care of a geriatrician; suspect vCJD
cases under a neurologist 40.2% (49) ormental health specialist, 24.6% (30),
reflecting the prominent clinical features at onset. In total, 81.9% (502) of suspect
sCJD and 95.1% (116) of all suspect vCJD cases referred to the NCJDSU were
known to have been reviewed, as an in-patient or out-patient, by a neurologist.
A National Referral System was introduced by the ChiefMedical Officer (CMO) in
2004. This system required a National Reporting Form to be faxed by the notifying
clinician to NCJDSU, the NPC and the local CCDC. This system was intended to
replace the less formal notification system that had been in operation which allowed
referrers to contact the NCJDSU by telephone or in writing to informally discuss or
formally refer suspect CJD cases. In 2006 the National Reporting Form was
completed in just 14.8% (16) of all suspect prion disease cases referred to the
NCJDSU. The low level of participation in completing the National Reporting Form
indicates that this is not acceptable to referrers.
Use ofsurveillance data to inform public health policy
A final assessment of acceptability comes from the continued willingness of policy
makers to utilise data produced by the NCJDSU to support and inform public health
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decision making. For example, Prof. Will provided key testimony during the BSE
Inquiry, other senior NCJDSU staff frequently respond to parliamentary questions
regarding human prion disease and contribute to a number of committees providing
expert independent scientific advice to government or directly developing public
health policy, for example SEAC, the CJD IP and the ACDP.
Interpretation: High levels of participation of patients and relatives in disease
surveillance, and an increasing proportion of suspect cases referred to the NCJDSU
by a broadening range of referrers indicate that the system is acceptable. Limited use
of the National Reporting Form suggests that this mechanism for referral is not
acceptable and underscores the need for the NCJDSU to continue to accept referrals
by a number of mechanisms.
Sensitivity
"The sensitivity ofa surveillance system can he considered on two levels.
First, at the level ofcase reporting, the proportion ofcases ofa disease or
health conditions detected by the surveillance system can he evaluated.
Second, the system can be evaluatedfor its ability to detect epidemics. " (222)
In the absence of a measure of the true occurrence of CJD in the UK a number of
approaches can be adopted to assessing sensitivity. sCJD is not aetiologically linked
to an exogenous exposure and geographically there is little variation in disease
occurrence. The sensitivity of the NCJDSU could then be assessed by comparing the
incidence of sCJD in the UK to the incidence of sCJD elsewhere. Such comparisons
were drawn in chapter 1 and in the discussion of chapter 2 and will not be revisited
here, beyond noting that temporal trends in sCJD incidence and mortality in the UK
are comparable to temporal trends reported internationally. This is illustrated in
Figure 56 which shows sCJD mortality rates reported by selected EUROCJD
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Figure 56 sCJD mortality rates (per million population) reported in selected
EUROCJD countries, 1994 - 2006
Operationally, the NCJDSU aims to ascertain suspect cases sCJD and vCJD cases in
life to facilitate rapid public health action where required. One approach to assessing
sensitivity of the NCJDSU is to examine the proportion of all sCJD and vCJD cases
ascertained by the NCJDSU that were referred to the NCJDSU in life. This is a
measure of the sensitivity of the clinical surveillance system. In the section that
follows the cohort of definite or probable sCJD and vCJD cases ascertained by the
NCJDSU following death from 1990 through 2006 are described.
sCJD cases ascertained by the NCJDSUfollowing death
From 1990 through 2006, 188 sCJD cases (177 definite and 11 probable) were
referred to the NCJDSU following death, accounting for 21.1% of all sCJD cases
ascertained by the NCJDSU over this period. The overall sensitivity of ascertaining
sCJD cases in life was 78.5% (75.8 - 81.2), this increasing from 76.5% (62.2 - 90.7)
in 1990 to 87.7% (79.7 - 93.7) in 2006 (Figure 57).
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Figure 57 Annual number of sCJD cases ascertained by the NCJDSU according
to vital status at time of referral, 1990 - 2006
The majority, 112 (59.6%), of these sCJD eases were referred to the NCJDSU by a
neuropathologist (Figure 58). Of the six cases referred from 'other' sources, four
were from family members, one from a CCDC and one from a virologist.
□neurologist ° neuropathologist □ general physician
□death certificate ■ neurophysiology0 other
Figure 58 Referral source for sCJD cases referred to the NCJDSU after death,
1990-2006
sCJD case characteristics
In 22 sCJD cases no further information, beyond that provided in the time of referral,
was available despite repeated (unsuccessful) attempts to obtain further information
ffom primary and/or secondary care clinicians. This section will focus on the 166
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sCJD cases (155 definite and 11 probable) for whom information from one or more
sources (medical records from primary, medical records from secondary care or
interview with the patients' relatives) was available. The characteristics of this group
are described in Table 44. Of note, sCJD cases for whom further information from
one or more of the sources described above was available did not differ significantly
with respect to mean age (P=0.842) or sex (P=0.133) to those for whom no further
information was available.
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Tabic 44 Comparison of characteristics of sCJD eases referred to the NCJDSU
according to vital status at the time of referral, 1990 - 2006
Deceased at Referred in P
referral life value
Number of sCJD cases (definite or probable) 166 705
Men, n (%) 87 (52.4) 335 (47.5) 0.295
Mean age at death, Years (SD) 69.4 (9.7) 66.8 (9.7) 0.001
Clinicalpresentation, n (%) *
RPD 92 (55.4) 450 (63.9)
Heidenhain Variant 7 (4.2) 40 (5.7)
Psychiatric onset 14(8.4) 28 (4.0)
Slowly progressive dementia 12 (7.2) 36 (5.1)
Cerebellar onset 15(9.0) 84(11.9) 0.006
Extra-pyramidal onset 3(1.8) 0
Stroke-like onset 5 (3.0) 17 (2.4)
Sensory onset 7 (4.2) 12(1.7)
Other focal onset 9 (5.4) 31 (4.4)
Investigations that might support a diagnosis ofsCJD, n(%)
Underwent one or more EEC} examinations 120 (72.3) 685 (97.3) <0.001
EEG typical 34 (28.3) 265 (38.7) 0.098
Underwent one or more CSF 14-3-3 protein examinations 0 430(61.0)
Underwent one or more MR1 scans 69(41.6) 525 (74.6) <0.001
Features consistent with sCJD on MR1 15 (21.7) 186 (35.5) 0.154
Underwent PRNP Codon 129 genotyping 44 (26.5) 527 (74.8) <0.001
Methionine homozygote 21 (47.7) 347 (65.8)
Methionine heterozygote 9 (20.5) 92(17.5) 0.002
Valine homozygote 14(31.8) 88 (16.7)
Underwent PRNP Mutation testing 8 (4.8) 423 (60.1) <0.001
Underwent brain biopsy in life 2(1.2) 32 (4.6) <0.001
Brain biopsy diagnostic 1 (50.0) 24 (0.75) -
Underwent post mortem examination following death 154 (92.8) 491 (69.7) <0.001
Median illness duration, Months (IQR) 4.4 (2.5-8.8) 4.2 (2.7-7.7) 0.785
*Missing 2(1.2%) cases and 6(0.9%) cases
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Differential diagnoses considered in sCJD cases not referred to the NCJDSU in life
In three quarters of sCJD cases, 127 (76.5%), that were not referred to the NCJDSU
in life, the clinical team managing the patient had considered a diagnosis of sCJD
during the course of the clinical illness. sCJD was first considered as a differential
diagnosis a median of 89 (53 - 185) days after onset and 25 (13 - 54) days prior to
death in sCJD cases. Other differential diagnoses considered in life in this group arc
outlined in Table 45.
Table 45 Differential diagnoses considered by clinical team caring for sCJD





Lewy Body Dementia 7
Cerebrovascular Disease 6










Motor Neurone disease 2
Dementia ? Cause 2






The features, signs, symptoms and supportive investigations that led clinicians to
consider a diagnosis of sCJD arc outline in Table 46 below.
Table 46 Key clinical features and investigations that led clinicians to consider a
differential diagnosis of sCJD cases among sCJD cases not referred to the
NCJDSU in life
Features of illness that led sCJD to be considered Number
RPD 20
RPD + Cerebellar 22
RPD + Myoclonus 28
RPD + Visual 3
RPD + Myoclonus + Cerebellar 5
RPD + Myoclonus + Extra-pyramidal 1
Clinical signs /
RPD + Cerebellar + Visual 1
symptoms alone
Cerebellar 2




Dementia + Pyramidal + Extra-pyramidal 1
RPD + EEC 11
Clinical signs / RPD + Myoclonus + EEG 10
symptoms and RPD + Cerebellar + EEG 2
Supportive Cerebellar + EEG 1
Investigations Visual + EEG 1
RPD + MR1 1
Supportive EEG 11
Investigations alone MR1 2
Based on the clinical information available to the NCJDSU I determined the highest
case classification that each sCJD case would have reached in life (Figure 59). There
was insufficient clinical information to assign a case classification to one sCJD case
(classification 0.0). Just under a fifth, 31 (18.9%) of sCJD cases met the WHO
diagnostic criteria as a probable case of sCJD, 97 (58.4%) as a possible sCJD case
and 37 (22.3%) did not meet the WHO diagnostic criteria (case classification 4.1).
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A diagnosis ofCJD had been considered in 30 of the 31 sCJD cases that met the
WHO diagnostic criteria as a probable case of sCJD. In these patients sCJD was first
considered as a differential diagnosis a median of 58 (37 - 78) days after onset and
18(13- 48) days prior to death. In one case a recommendation to refer to the
NCJDSU was documented in the medical case notes 6 days prior to death. In four
further sCJD cases (three that met the WHO diagnostic criteria as a possible sCJD
case and one that did not meet the diagnostic criteria (case classification 4.1) in life),
a recommendation to refer the patient to the NCJDSU was documented in the
medical case notes prior to death. In these cases the median time from the
recommendation to refer to the NCJDSU being documented in the medical ease note
to death was 15 (8 - 18) days.
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Highest case classification in life
Figure 59 Highest case classification in life based on available clinical
information for sCJD cases deceased at the time of referral to the NCJDSU,
1990-2006
vCJD cases ascertained by the NCJDSUfollowing death
Over the entire study period four vCJD cases ascertained by the NCJDSU were
deceased at the time of referral; all were neuropathologically confirmed cases in men
aged 21.0 , 41.7, 69.9 and 74.9 years respectively. This group included one vCJD
case attributable to the transfusion of labile blood products. Two cases presented
with psychiatric onset and two rather unusually with RPD. In one case, a diagnosis of
sCJD had been considered based on RPD and cerebellar signs; this case had evidence
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of a 'pulvinar sign' on MRI but would not have met the W1IO diagnostic criteria as a
probable ease of vCJD because of insufficient clinical features. One vCJD case met
the WHO diagnostic criteria as a probable vCJD in life based on clinical features and
the presence of the pulvinar sign on MRI. vCJD had not been considered in life in
this individual who was one of the earliest vCJD cases (onset 1995) ascertained by
the NCJDSU. The overall sensitivity of the clinical surveillance system at detecting
cases in life was 97.6% (95.2 - 99.9) of vCJD cases.
The ability ofthe system to detect an epidemic
The sensitivity of the NCJDSU can also be assessed by examining the ability of the
system to detect an epidemic. vCJD was first described in cases ascertained by the
NCJDSU in 1996. Through the work of the NCJDSU the clinico-pathological
epidemiology of vCJD has been described and the primary and secondary epidemics
mapped. The clinical and epidemiological features of vCJD cases ascertained by the
NCJDSU from 1990 through 2006 were described in Chapter 2 and will not be
revised here. It is important to note that this metric captures the sensitivity of the
whole system, clinical and pathological.
Interpretation: sCJD incidence/mortality rates in the UK have followed temporal
trends which arc consistent with international data, suggesting that the system is
highly sensitive at detecting sCJI) cases. The number of sCJD cases ascertained in
life by the clinical surveillance system has increased over time. The clinical
surveillance system is highly sensitive at detecting vCJD cases. The sensitivity of the
NCJDSU was confirmed by its ability to detect and map both the primary and
secondary epidemics of vCJD in the UK. This is a measure of the sensitivity of both
the clinical and pathological aspects of the surveillance system.
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Positive predictive value
"Predictive value positive (PVP) is the proportion ofpersons identified as
having cases who actually do have the condition under surveillance. " (222)
Predictive value positive (PVP), more commonly referred to as the positive
predictive value (PPV), can be considered as the proportion of suspect prion disease
cases referred to the NCJDSU that actually had prion disease (definite or probable
cases). Applying this definition the overall PPV of the NCJDSU from 1990 through
2006 was 57.5% (55.4 - 59.6). Over time this increased significantly from 37.7%
(24.7 - 50.8) in 1990 to 76.1% (68.1 - 84.1) in 2006 (P<0.001). There was
significant variation in PPV according to aetiological subtype. Overall the PPV for
suspect sCJD cases was 54.5% (52.1 - 56.9). There was evidence of year to year
variation in the PPV between 1990 and 2001, following which the temporal trend
was toward an increase in PPV, from 45.0% (36.5 - 53.6) in 2001 to 76.2% (67.1 —
85.3) in 2006 (P<0.001). This increase in PPV was driven by an increase in the
proportion of all sCJD referrals meeting the diagnostic criteria as a probable sCJD
case, as illustrated in Figure 60, attributable to the contribution of CSF 14-3-3 protein
examination.
Overall, the PPV for suspect vCJD was 51.9% (46.4 - 57.3), with year to year
variation from, 29.0% (13.1 — 45.0) in 1996 to a high of 75.0% (56.0 - 94.0) in 2002
(P0.001), although this did not follow a temporal trend. This is remarkable
considering that vCJD was detected without a prior case definition. The overall PPV
for iCJD and genetic prion disease were high at 94.7% (88.9 - 100) and 95.9% (92.3
- 99.4) respectively and invariant over time (P=0.618 and P=0.239 respectively).
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Figure 60 Case classification (at data censoring) of suspect sCJD cases referred
to the NCJDSU according to year of referral, 1990 - 2006
Interpretation: The PPV of the NCJDSU was high and increased over time, overall
and for suspect sCJD.
Usefulness
"A public health surveillance system is useful if it contributes to the
prevention and control ofadverse health-related events, including an
improved understanding ofthepublic health implications ofsuch events. "
(222)
The NCJDSU's objectives in 2006 were to provide accurate longitudinal data on the
incidence and characteristics of all aetiological types of CJD and to study risk factors
for the development of disease. Over the study period the NCJDSU has achieved
many of its stated objectives. In chapter 2, using data from the NCJDSU, I described
long-term trends in the epidemiology of prion diseases in humans in the UK
according to disease subtype. During this period the NCJDSU identified and
characterised a novel human prion disease, vCJD, and provided data from
epidemiological and transmission studies in animals to support an aetiological link to
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BSE in cattle. These data were rapidly dissemination to the scientific community,
policy makers and public and, in turn, translated into public health practice and
national, indeed international, policy. The NCJDSU has been uniquely placed
through the on-going detection and characterisation of cases to develop and validate
new diagnostic technologies in relation to vCJD (and other prion diseases) leading to
the development and validation of diagnostic criteria for the purposes of disease
surveillance.(186) In 2003 the NCJDSU identified secondary transmission of vCJD
through a previously unrecognised route, the transfusion of labile blood components;
it continues to investigate other potential routes of transmission including dentistry,
surgery and maternal transmission through various studies including the on-going
case control study and the PIND study. To date symptomatic vCJD has been
identified in only PRNP Codon 129 methionine homozygotes. The identification of
vCJD in a non-methionine homozygote would have significant public health
implications. Experience from other human prion disease suggests that such
individuals will have long incubation periods, lengthening the primary epidemic.
However the major threat to public health is from potential secondary transmission
of vCJD arising from an un-quantified population of asymptomatic, but potentially
infectious individuals, who may be undergoing invasive medical procedures and
donating blood and/or tissue. The NCJDSU have been working closely with the
UKBTS to develop a blood test that can be used to identify abnormal prion protein.
If successful this could be applied to screening donations of blood and/or tissue
thereby limiting the potential for a secondary epidemic of vCJD.
Senior members of the NCJDSU are directly involved in influencing public health
practice and policy in relation to the prevention and control ofprion diseases in
humans through involvement in numerous committees including SEAC, the ACDP,
the CJD IP and the Advisory Committee on the Safety of Blood, Tissues and Organs
(SaBTO). In turn on-going disease surveillance is crucial to providing
epidemiological evidence to evaluate the success of control measures. Beyond a role
in monitoring disease trends, identifying transmission routes and advising on
prevention and control measures, the NCJDSU has had a role in therapeutic drug
trials for those affected by human prion diseases. In addition, the NCJDSU
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administer the National Care Package for CJD patients and their families and
therefore work closely with health care professionals, special interest groups, patients
and their families. A key role for the NCJDSU is to provide on-going advice and
support to these groups during the patient's clinical illness and beyond. Senior
member of the NCJDSU have held positions on the management committees of a
number of charitable support organisations including the Human BSH Foundation,
the UK CJD Support Network and other international support groups. In addition, the
NCJDSU also responds to enquiries from the general public and media. For example
between 2003 and 2006 the NCJDSU website received an average of 100,000 hits
per annum.
Scientific research and surveillance activities are closely linked and interdependent.
Fewer than half of the staff employed by the NCJDSU are primarily involved in
disease surveillance; the majority are primarily involved in scientific research. The
range of research is diverse, from transmission studies in animals in collaboration
with the Institute for Animal Health at Edinburgh University, to evaluation of
biomarkers for prion disease in humans with international collaborators (Anteprion
and Prionscreen), to an evaluation of the clinical diagnostic criteria for CJD in
association with international collaborators from the EUROCJD network. The
NCJDSU were founding members of the Scottish TSE Network and participate in a
range of other international surveillance and research networks including
NEUROPRION and NEUROCJD (the NCJDSU co-ordinated the latter which is no
longer in operation). Much of the research produced by the NCJDSU is externally
funded and disseminated through peer review; between 1990 and 2006 an average of
30 peer-reviewed manuscripts per annum were published by NCJDSU staff, in
addition to reports, book chapters conference presentations and abstracts, and other
non-peer reviewed publications.
Finally, the on-going willingness of the DH and the Scottish Executive Health
Department to provide core funding to the NCJDSU further underscores the
usefulness of the activities or the surveillance system and its output.
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Interpretation: The activities and output from the NCJDSU are useful, contributing
to providing support and care for patients and their families, advancing scientific
knowledge, sharing expertise of this rare disease, increasing surveillance activities
worldwide including the development of international surveillance networks, and the
development of public health policy in the UK and beyond.
Representativeness
"A surveillance system that is representative accurately describes the
occurrence ofa health event over time and its distribution byplace and
person." (222)
A measure of representativeness ideally requires information on the true occurrence
of disease in the population. This is not available. An assessment of
representativeness can however be made by examining the geographical distribution
of sCJD cases adjusted for the age and sex structure of the population. As previously
noted sCJD is not aetiologically linked to an exogenous exposure and the incidence
of sCJD shows very little variation according to geographical location. The age
adjusted incidence rate of sCJD (definite or probable cases) in men and women was
calculated for each country within the United Kingdom, England, Wales, Northern
Ireland and Scotland over the entire study period (1990 - 2006). A Standardised
Incidence Ratio (SIR) was calculated to compare the incidence of sCJD cases in each
country relative to the incidence in England, which was taken as the reference
population. Given the true occurrence of sCJD is not known these analyses were also
carried out for all suspect sCJD cases referred to the NCJDSU to assess whether
there was any significant difference in referral rates of suspect sCJD cases between
countries. These data are shown in Table 47.
In men and women the greatest absolute number of suspect sCJD referrals came from
England, however the rate of referral per million population was highest in Scotland
at 2.03 (1.58 -2.48) in men and 2.18 (1.75 - 2.62) in women. The SIR was
significantly higher in men (144.50 (114.21 - 180.36)) and women (131.11 (106.44 -
159.78)) in Scotland compared to the national average, but no different from the
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national average in Wales or Northern Ireland. Examining only sCJD eases
ascertained by the NCJDSU, incidence rates per million population varied very little
in men (0.80 - 0.90 per million population) according to country. In women the rate
was significantly lower in Northern Ireland (0.41 (0.08 - 0.74) permillion
population) compared to other countries. However when examining SIR in both men
and women, in all countries, these were not significantly different from 100. These
data indicate that whilst rates of referral of suspect sCJD were higher in Scotland,
there was no difference in the incidence of sCJI) according to country in the UK.


















































































"Timeliness reflects the speed or delay between steps in a surveillance
system. "(222)
Timeliness attempts to quantify the time that each step of surveillance takes. For
example, the time from symptom onset to a diagnosis of prion disease being
considered, the time from a diagnosis of prion disease being considered to the
suspect case being notified to the NCJDSU and the time from this notification to
public health action being initiated. For vCJD, where prevention and control
measures to minimise the risk of onward iatrogenic transmission are initiated
following the identification of a case by the surveillance system, timeliness is an
important system attribute. This is less important in sCJD. Nevertheless there is
merit in examining timeliness in relation to sCJD, as this is a process measure of the
performance of the surveillance system.
Typically an assessment of timeliness would quantify the time from symptom onset
to public health action. This is problematic. A number of intermediate steps exist
between these events, some ofwhich were outlined in the preceding paragraph, and
many ofwhich are outside the control of the NCJDSU. For example, it is the
responsibility of the referring clinical team, not the NCJDSU, to inform the local
CCDC who, in turn, collects and verifies information on the suspect cases past
medical history, including invasive medical procedures, blood, organ and other tissue
donation. Where an invasive medical procedure has been undertaken in an individual
symptomatic of prion disease or prior to a diagnosis of prion disease being made, the
local CCDC will send detailed information to the CJD IP who assess the potential for
onward transmission ofprion disease and determine what, if any, public health action
is required on a case by case basis. In practice public health action may be taken
prior to this occurring, for example surgical instruments may be removed from
circulation and quarantined until a decision from the CJD IP is available. Each of
these steps is beyond the control of the NCJDSU and data on the time interval
between steps is unavailable. In practice at the time of referral the NCJDSU collect
information on potential iatrogenic routes of transmission which facilitates prompt
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public health action if required. Through the National Reporting Form the local
CCDC should be informed at the same time as the NCJDSU of a suspect case and
initiate public health action. In reality the National Reporting Form is rarely
completed and the NCJDSU neurologist provides the referring clinical team with a
form to complete and forward to the local CCDC at the time of visit. It is the
responsibility of the NCJDSU to inform the UKBTS of definite or probable cases of
vCJD. This occurs as soon as an individual meets the diagnostic criteria, typically on
the date of notification or visit. Although there arc limitations to this approach, the
time from symptom onset to notification and the time from symptom onset to visit by
a NCJDSU neurologist can be considered a measure of timeliness. In the analyses
that follow timeliness using these metrics was assessed for suspect cases that were, at
the time of data censoring, classified as definite or probable sCJD and vCJD cases
(denoted sCJD cases and vCJD cases). Data from selected years was examined. The
results from these analyses arc shown in Table 48.
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Table49imintervalsforvarioustepdiseasesur ei lanceCJDcas s(d finitp obable)ref r dthNCJDSU overselectedyears vCJDcases(definiteorprobable) StepinsurveillanceNumberMedianTime (IQR),daysPfortrend Onsettofir tseekingm dicalattention55109(56-8 )0.732 Medicalattentiontomissio54115(53-92)0.252 Medicalattentiontoreviewbyn urologist5987(42-173)0.839 AdmissiontoNCJDSUreferral5521(8-57)0.330 NeurologyreviewtoCJDSUferral6037(16-78)0.874 NCJDSUreferraltovisit6211(6- 8)0.143 Overallinterv ls OnsettoNCJDSUreferral63257(211-332)0.449 OnsettoNCJDSUvisi62274(233-352)0.439
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sCJD cases
For sCJD cases alive at the time of referral the overall median time from symptom
onset to NCJDSU referral was 97 (61 - 161) days (Table 48). Approximately a third
of this time was attributable to a delay in first seeking medical attention, a third from
first seeking medical attention to hospital admission/neurologist review (which ever
occurred first), and a third from hospital admission to NCJDSU referral. The median
number of days from NCJDSU referral to visit by a NCJDSU neurologist was 7 (5 —
14) days. This latter step accounted for approximately 6% of the reporting delay
(time from symptom onset to NCJDSU visit). The time taken for each of these steps
did not change over the study period.
When sCJD cases deceased at the time ofNCJDSU referral were considered the
overall median time from symptom onset to NCJDSU referral was 183 (83 - 317)
days. The time intervals from symptom onset to first seeking medical attention and
first seeking medical attention to hospital admission/neurology review were
comparable to those observed in sCJD cases alive at the time ofNCJDSU referral.
However the interval from hospital admission/neurology review to NCJDSU referral
was longer, by an average of 23/24 days respectively. The overall median time from
symptom onset to NCJDSU visit was 509 (425 — 720) days with the time from
NCJDSU referral to NCJDSU visit accounting for approximately 65% of the
reporting delay.
vCJD cases
vCJD analyses were not stratified according to vital status at referral. The number of
vCJD cases deceased at the time of referral was small and sensitivity analyses
revealed that including these cases with the overall cohort did not significantly
change the estimates produced. Overall the median time from symptom onset to
NCJDSU visit was 257 (211 - 332) days (Table 49). Approximately 40% of this time
was attributable to a delay in first seeking medical attention, 45% from first seeking
medical attention to hospital admission, approximately 10% from hospital
admission/neurology review to NCJDSU referral and less than 5% from NCJDSU
referral to visit by a NCJDSU neurologist. There was no significant change in the
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time taken for any of these steps over the study period. Of note the time intervals
were longer for vCJD, refleeting the longer illness duration and less specific clinical
picture at onset.
An alternate measure of timeliness can be considered as the time taken to identify a
change in disease occurrence. Within two years of symptom onset in the first vCJI)
case in the UK and within 10 years of peak exposure of the population to the BSE
agent, a further 9 cases of vCJD had been identified, without a prior case definition
of vCJD, in a population of 62 million people and these data published in the peer
reviewed medical press. The early detection and characterisation of vCJD and in turn
the identification through the TMER study of the secondary transmission of vC-TD
through the transfusion labile blood components, followed by the rapid dissemination
of these data to health care professionals, the public and politicians facilitated prompt
public health action both nationally and internationally. The 2001 Philips report, the
official enquiry into BSE and vCJD in the UK,
"commend[edj the sterling work of the CJDSU team, who so promptly
detected the emergence ofvariant CJD and so efficiently established the
clinical andpathological characteristics of the disease".(24)
Established pathways for data reporting, the content ofwhich is predefined, and most
ofwhich involve electronic data transfer or web publishing, ensures timely
dissemination of surveillance data. Senior members of the NCJDSU contribute to
key committees including SEAC, SaBTO and the ACDP which have national
scientific advisory and public health policy and practice remits in relation to prion
disease in humans. Involvement in such committees also facilitates rapid
dissemination of important or novel findings from surveillance data. Finally, the
NCJDSU enjoys an excellent working relationship with the DH (core funders) and
Health Protection Agencies, facilitating open lines of communication with senior
decision makers where issues of national public health importance arise.
Interpretation: Despite improving diagnostic technology and increased awareness
of human prion diseases among the public and health care professionals there is no
evidence of a temporal reduction in the time from symptom onset to the NCJDSU
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being notified of a sCJD or vCJD cases. Less than 5% of the reporting delay for
vCJD eases was attributable to the NCJDSU (time from NCJDSU referral to
NCJDSU visit). Corresponding figures for sCJD cases referred in life and following
death were approximately 6% and 65% respectively. The latter is likely to reflect a
desire for the NCJDSU to obtain other information, for example post mortem reports
or medical case notes to verify a clinical diagnosis before approaching grieving
relatives to request a visit to collect detailed epidemiological and clinical data. It
should also be considered that there are no significant public health implications of a
diagnosis of sCJD, therefore such a delay is of limited significance. In identifying the
primary and secondary vCJD epidemics the NCJDSU was found to have responded
in a timely fashion to facilitate public health action. Moreover routine and exception
reporting of data and communication with decision makers has been found to be
timely.
Stability
"Stability refers to the reliability (i.e., the ability to collect, manage, and
provide data properly withoutfailure) and availability (the ability to be
operational when it is needed) ofthe public health surveillance system. "
(222)
The stability of the system can be considered as the systems continued ability to
capture, analyse and disseminate surveillance data despite adverse events. The ability
to capture data is dependent upon willingness of patients, their families and health
care professionals to participate in surveillance and the ability of the surveillance
system to respond to referrals. The former was discussed under the sub-heading
'Acceptability', the latter under the sub-heading 'Flexibility'. There are multiple
methods by which a referral to the NCJDSU may be made, for example fax,
telephone, email and in person, therefore if one method is unavailable due to
unforeseen circumstances multiple other methods are accessible. The NCJDSU
endeavour to visit suspect sCJD and vCJD cases in life. In 1990 this was carried out
by a sole neurologist (ROW). By 2006 this was typically carried out by one of two
clinical research fellows accompanied by a research nurse. In the event that these
clinicians were unavailable, the senior neurologists (RK,RGW) fulfilled this role.
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Where the research nurse was unable, the research fellow and senior neurologists had
sufficient training to fulfil her role. Thus over time, through expansion, the stability
of the system in this respect has improved. Diagnostic services such as the CSF 14-3-
3 protein laboratory and the molecular genetics service have been established over
the period studies. For these services adequate staffing to ensure continuity of the
service, for example in the event of an extended absence from work, is available.
Surveillance data are collected in writing and held in paper based files in the
NCJDSU archives. Limited data, a minimum monitoring dataset and data relating to
the case-control study, are entered onto an electronic database for analysis. Over time
the volume of data held by the NCJDSU has increased, both numbers of cases and
the amount of information collected per case; the NCJDSU investigation protocol
ensures the collection of detailed clinical data extending far beyond the minimum
monitoring dataset. To date there have been no instances of data loss from paper
records, for example through flooding, however the potential exists for large volumes
of data to be lost if such an event occurs. In the absence of a computerised backup
there exists the potential for a catastrophic loss of data. In addition, the limited
amount of clinical data held electronically limits the NCJDSU's ability to interrogate
and analyse this rich data source beyond predetermined data reporting. The
establishment of reporting pathways, as previously outlined, many ofwhich utilize
electronic data transfer, and the publishing ofmonthly figures on the NCJDSU
website, ensures rapid dissemination of information to the public, media, health care
professionals and policy makers. The NCJDSU actively engage in international
surveillance and research networks, fostering opportunities to share expertise.
Interpretation: There is evidence of the stability of the NCJDSU increasing over
time despite increasing demands. A lack of computerized data archiving is a potential
threat to the stability of the system which should be addressed.
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Summary of key findings
• The PIIS system in the UK, though simple in design, is operationally complex.
• Overall the PHS system was found to be flexible in responding to a number of
changing demands and stable over time.
• Overall, the quality of the data collected by the NCJDSU was good, with
improvement in the validation of reported clinical, epidemiological and
diagnostic data over time, and low rates of loss to follow up.
• The activities and outputs from the system were found to be acceptable and
useful to patients, families, health care professionals and public health decision
makers, and timely.
• Whilst the system was found to have a high sensitivity, improving PPV and
collect representative data, this was undermined by evidence of sub-optimal, and
differential, use of diagnostic investigations.
• Coupled with an increasing reliance of clinical diagnostic criteria due to falling
autopsy rates this latter finding is of concern.
• An increasing PPV of the system in the face of falling referral rates of suspect
cases may also be of concern as this may compromise the NCJDSU's ability to
detect atypical disease phenotypes or novel prion diseases.
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Discussion
In this chapter I reported the findings from the first ever evaluation of the National
CJD Surveillance system in the UK. Ilere I discuss the key findings from this
evaluation.
The quality of a diagnosis of sCJD or vCJD
Overall the PHS system was found to have performed well, meeting many of its
stated objectives. However, the under-utilisation of diagnostic technology,
particularly CSF 14-3-3 protein and EEG which are integral to the clinical diagnostic
criteria in suspect sCJD, is cause for concern. The use of these investigations was
sub-optimal in the assessment of all suspect sCJD cases, but more so in non-sCJD
cases than cases. Resultantly, some non-sCJD cases will have failed to meet the
diagnostic criteria because they did not undergo appropriate investigation. Combined
with falling rates of post mortem examination, this may have resulted in under-
asccrtainment of sCJD cases.
An examination of the sensitivity of the surveillance system should provide some
insight into whether this was the case. Unfortunately a direct measure of the
sensitivity of the system was not available. Instead an indirect measure, sCJD
incidence rates reported in the UK compared to those reported internationally, was
selected. The incidence of sCJD has increased steadily over time in the UK and is in
keeping with internationally reported rates. As post mortem rates have fallen the
increasing sCJD incidence has been driven by a rising proportion of probable cases
that have met the diagnostic criteria based on CSF 14-3-3 protein examination. It
should however be considered that each ante-mortem diagnostic investigation has a
false positive rate. For CSF 14-3-3 protein this has been quoted as up to 16%.(231)
Reliance on clinical diagnostic criteria rather than case confirmation at autopsy will
lead to misclassification of a small number of cases. The overall effect on annual
sCJD incidence rates might be minimal, with the inclusion of non-cases
compensating for the exclusion of cases.
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In suspect vCJD there was evidence of under-utilisation ofMRI in non-cases which
may have a similar effect, although this was much less significant than for EEG and
CSF 14-3-3 protein in sCJD, and by the end of the study period virtually all suspect
vCJD cases underwent MRI scanning.
The proportion of suspect sCJD and vCJD cases undergoing PRNP Codon 129
genotyping and mutation testing was low with no evidence of improvement over
time and again with evidence of differential use of these investigations according to
case classification. This may have resulted in under-ascertainment of genetic prion
disease cases which can be phenotypically indistinguishable from other aetiological
prion diseases.
Falling post mortem rates also have implications for the PPV of the system. A low
PPV may suggest that the system is not performing adequately. This is not
necessarily the case. The WHO recommend that referrals to the system should
exceed confirmed cases by a factor of two, to facilitate the detection of cases with
unusual disease phenotypes that do not have sufficient clinical features to meet the
clinical diagnostic criteria. In the UK referral criteria arc broad to ensure this occurs.
The significant increase in the PPV observed, in the face of falling referral rates at
first glance may indicate increasing efficiency of the system at detecting cases.
However this may also be cause for concern, if in achieving a high PPV, the
sensitivity of the system has been compromised.
It has not been possible to formally assess the impact of increasing PPV on the
sensitivity of the surveillance system with a direct measure. The ratio of
neuropathologically confirmed to suspected CJD cases referred to the NCJDSU has
been maintained at or below the level recommended by the WIIO, despite falling
referral rates in the latter period of the study. This has occurred as a result of falling
post mortem rates leading to a reduction in the proportion of all referrals accounted
for by neuropathologically confirmed cases, whilst the PPV of the system has
increased as a result of the increasing ascertainment of probable sCJD cases based on
CSF 14-3-3 protein examination. As outlined in the preceding passages, careful
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consideration should be given as to whether this is appropriate, particularly in the
face of falling referral and case confirmation rates.
A tension exists between the desires of the surveillance system and the clinical
realities. Ideally all suspect CJD cases would undergo all investigations that might
support a diagnosis ofCJD, not solely to exclude other potentially treatable
conditions and obtain a definitive clinical diagnosis, but also to inform surveillance
practice. For example, to provide information about the validity of diagnostic tests
such as CSF 14-3-3 protein and the diagnostic criteria into which they are
incorporated. However, the NCJDSU does not directly manage patients with suspect
CJD. Clinical decision making and patient management is retained by the referring
clinical team. The decision to pursue a single or series of diagnostic investigations
will be made by the local clinical team in consultation with the patients' significant
others. Many factors will influence these decisions. For example a patient's clinical
condition may negate the use of certain investigations. It may not be possible to
obtain MRI images due to patient agitation. Invasive investigations such as lumbar
puncture to obtain CSF, tonsil or brain biopsy in life may be declined by the patient's
relatives on compassionate grounds, or these invasive investigations may prove
technically difficult. Locally, there may be limited access to certain diagnostic
technologies such as EEG or MRI. Accessing such investigations might require
patient transfer to another facility which may be deemed inappropriate in the
terminal phases of illness. CSF 14-3-3 protein, PRNP Codon 129 genotyping and
mutation testing are only available from the NCJDSU or the NPC; centralization of
these services ensures the validity of the investigations. These services are freely
available and accessible remotely from throughout the U1C therefore accessibility
should not be a major issue. However other issues may determine the use of these
services. For example a relative may refuse PRNP testing for mutations as a positive
result may have implications for that individual and their family. It should also be
considered that a clinician may decide not to pursue further investigations such as
CSF 14-3-3 protein in a patient with a classic clinical course and a typical EEG if
they feel that these features are sufficient to make a firm clinical diagnosis, or in a
moribund patient in whom consent for post mortem examination on expiration has
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been provided. Additional factors that may have contributed to falling post mortem
rates in the UK were reviewed in the discussion in the preceding chapter. Improving
the quality of diagnosis in suspect CJD therefore requires the engagement and
agreement ofpatients, their relatives and health care professionals. It should be
considered that aggressive pursuit of diagnostic investigations may have the
unintended consequence of compromising the acceptability of the NCJDSU to
referrers.
Other aspects of data quality
Several other aspects of data quality were assessed. Overall data quality was found to
be very good, with low levels of missing data, low rates of loss to follow up and
increasing levels of validation of clinical, diagnostic and epidemiological data.
However areas for improvement were identified. For example, EEGs were reviewed
in only two thirds of sCJD cases with evidence of review in a declining proportion of
sCJD cases since 2000. Whilst EEGs are requested on suspect cases referred to the
NCJDSU, rcferrers are under no obligation to provide these investigations. It is
possible that referrers may not fully understand the importance of central review of
EEGs for surveillance purposes and therefore be reluctant to send copies of EEGs
that do not contribute to the diagnostic classification of the patient. For example in
the case of an individual that has already met the diagnostic criteria based on clinical
features and CSF 14-3-3 protein. Further issues relating to evaluation of EEG in the
surveillance of sCJD will be discussed in greater detail in the Chapter that follows.
The proportion of sCJD cases for which medical case notes from primary care were
reviewed was also particularly low, although there was evidence of improvement
over time. Accessing medical records can be challenging without specific legal
authority to do so. Records may have been damaged or destroyed, or local health
authorities may be reluctant to release them, unaware of the importance of the
NCJDSU reviewing these. Further qualitative work may help elucidate the issues that
have contributed to the poor performance in these two areas.
Stability
The NCJDSU collects a wealth of clinical, diagnostic and epidemiological data on
CJD cases and suspect cases. However only a minority of these data arc
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electronically archived, the majority are paper based records. In many respects this is
inefficient as it limits the NCJDSU's ability to quickly interrogate the data. In
addition lack of computerized data archiving poses a potential threat to the stability
of the system which should be addressed.
Flexibility
Overall the system was found to be flexible to a number of changing demands,
including most significantly the emergence of vCJD. A fall in the proportion of sCJD
cases reviewed by a NCJDSU neurologist in 1997 and non-sCJD cases in 1997 and
2000 was observed. This may indicate that the system was struggling to respond to a
significant increase in demand. However reassuringly this did not impact on the
NCJDSU's ability to review suspect vCJD cases or compromise timeliness in this
respect. Given there are few public health implications of a diagnosis of sCJD, it
could be argued that the system responded appropriately. The system was further
able to respond to increasing demands for new diagnostic technologies through rapid
expansion, including the introduction of diagnostic laboratories such as the national
CSF 14-3-3 protein service, molecular genetics and protein biochemistry services.
These expansions have successfully occurred without compromising stability.
Timeliness
The relative importance of timeliness depends upon the condition under surveillance.
There arc few public health implications of a diagnosis of sCJD. There are a small
number of recognised routes of iatrogenic transmission of sCJD, most ofwhich arc
now of historical importance only. This is not the case for vCJD. Iatrogenic
transmission of vCJD via the transfusion of labile blood components has been
documented. Due to the pathogenesis of vCJD and the inherent difficulties in
decontaminating surgical instruments, instruments that have been used on vCJD
cases, in both the symptomatic and asymptomatic phases of illness, may present a
risk to others. In such cases prompt public health action is required to minimise the
number of individuals exposed to potentially contaminated labile blood components
or medical instruments and to inform those who have been exposed that they may be
'at risk' of vCJD such that they can, in turn, take appropriate precautions. An
assessment of the timeliness of the NCJDSU is challenging because many of the
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steps that occur prior to reporting are beyond the control of the NCJDSU; following
reporting many of the steps that lead to public health action are also beyond the
control of the NCJDSU. In this study a measure of the reporting delay was taken as
the time from symptom onset to NCJDSU referral. Despite improving diagnostic
technology and increased awareness of human prion diseases there was no temporal
reduction in the time from symptom onset to NCJDSU referral. Over a third of the
delay in reporting was due to delay in seeking medical attention with a similar period
due to a delay in moving from primary to secondary care. This reflects the fact that
symptom onset can be insidious and non-specific in nature. The remainder of the
delay occurred between neurology review or hospital admission and NCJDSU
referral, reflecting the time taken to reach a diagnosis. It is disappointing that this has
not improved over time. As therapeutic treatment options begin to emerge the early
identification of cases will become increasingly important.
Acceptability
The NCJDSU performed well on an overall assessment of acceptability. However it
should be noted that referrers engaged poorly with the National Reporting Form. In
theory, this form should stream-line the referral process, allowing referrers to inform
the Unit, local CCDC and NPC simultaneously. It may be that referring clinical
teams prefer to speak directly to a clinical colleague in the NCJDSU to discuss the
differential diagnosis in a complex neurological case, rather than completing a form
which has to be faxed to various external agencies. Having done so, they may feel
that completion of the form, whilst requested, is unnecessary duplication of effort
and does not appear directly relevant to the care of their patient. Others may find the
prospect of having to visit a website to download the form and in turn fax it to 3
different agencies a time-consuming and low priority task in a busy schedule. There
may be additional issues in accessing computing and facsimile facilities. Limited use
of the National Reporting Form has not had a significant impact on referrals to the
NCJDSU as a result of the continued willingness of the NCJDSU to accept referrals
in other formats. Indeed increasing use of the National Referral Form may have the
unintended consequence of reducing timeliness for the reasons highlighted above.
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An examination of sCJD eases deceased at the time of referral to the NCJDSU
revealed that the majority would have met the clinical diagnostic criteria as a
possible or probable case of sCJD in life. In over 95% of those who would have met
the clinical diagnostic criteria in life a diagnosis of sCJD had been considered in life;
in a further group, referral to the NCJDSU had been recommended but was not
followed through by the clinical team. There remain a small number of sCJD cases in
whom a diagnosis of sCJD is suspected in life that are not referred to the NCJDSU,
although this number is diminishing. Qualitative research may assist in determining
the barriers to referral to the NCJDSU in this group.
Usefulness
Perhaps one of the most important system attributes examined was usefulness. In its
activities and outputs the NCJDSU was found to have furthered scientific knowledge
through national surveillance, closely linked to research activity, and facilitated the
rapid transfer of knowledge to public health practice and policy, in addition to
making substantial contributions to international disease surveillance and research. In
many respects this is illustrated by central governments continued commitment to
providing core funding for the NCJDSU.
Evaluation design
In this chapter I applied a widely recognised framework for the evaluation of public
health surveillance systems.(222) PHS systems arc diverse in their methodologies
and objectives. The system attributes most relevant one system may not be relevant
to another. In this evaluation the attributes I considered highest priority were data
quality, sensitivity, flexibility, acceptability, timeliness and usefulness. It should be
noted that this approach requires a subjective assessment of system attributes. A
formal grading is not applied to the assessment of each system attribute to aid
interpretation of evaluation findings. Rather the evaluator makes a subjective overall
judgment as to whether the system is performing adequately and fit for purpose.
Many system attributes are interdependent. For example, if the quality of diagnosis is
poor (data quality) then this will affect the ability of the system to detect disease,
reducing sensitivity. If the system is unacceptable cases will not be referred which
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will have a negative impact on sensitivity, PPV and representativeness. Improvement
in one system attribute may compromise another. It is important to consider this in
interpreting evaluation findings and making recommendations. For example, in the
UK surveillance is both labour and time intensive. The lack of a single sensitive and
specific ante-mortem diagnostic test, the diverse disease phenotypc and specific
requirement to identify novel clinico-pathological expressions of prion disease,
necessitate broad referral criteria, the review of suspect cases in life and the
collection and validation of extensive clinical and epidemiological data in order to
maximise the sensitivity, PPV and representativeness of surveillance data. However
this has resulted in an intrinsically simple system becoming operationally complex.
Where possible this evaluation assessed multiple metrics for each system attribute in
an attempt to capture different facets of each attribute. For example, an assessment of
data quality included a measure ofmissing data which is a simple assessment of the
completeness of data recording that says little about the validity of the data collected.
To assess the latter, the review of clinical, epidemiological and diagnostic
information to validate data collected by the surveillance unit was also examined.
The quality of the diagnosis ofCJD is dependant, in part, upon the completeness of
diagnostic investigation. This is an indirect measure of data quality but is nonetheless
crucial to assess because it will influence the sensitivity and PPV of the system.
To evaluate some system attributes it was necessary to use indirect measures. For
example, assessment of sensitivity and representativeness requires knowledge of the
true number of prion disease cases occurring in the population. This is not known. In
the UK the surveillance system utilises a range of data sources to maximise case
ascertainment. Resultantly an external measure of the incidence of prion disease
against which the NCJDSU could be assessed was not readily available. A number of
retrospective studies have attempted to quantify whether there has been any
systematic undcr-asccrtainment ofCJD cases in the UK. For example Majecd et al
reviewed the medical case notes of patients identified from death certificates as
dying from selected neurological conditions in England and Wales between 1979 and
1996.(248) The authors determined that no additional cases of sCJD or vCJD were
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missed by the surveillance system in this sample. Hillier et al went further in re¬
examining neuropathological material, where available, from individuals aged 15 -
45 years old who had died in Wales between 1985 and 1995.(249) No cases of vCJD
prior to the first cases being ascertained by the NCJDSU were identified. From 1998
to 2007, Piccardo el al undertook a retrospective review of ncuropathological
material from sCJD cases and atypical dementias dating back to the 1970s to
determine whether vCJD cases had been missed.(250) This national study did not
identify missed cases of vCJD but did identify a number of sCJD cases that had been
misdiagnosed as atypical dementias. These studies are both labour and time intensive
and not without limitation. The limitations of death certificate data in the absence of
case confirmation will be discussed in detail in Chapter 5; retrospective examination
of neuropathological material determines the sensitivity of a neuropathological
diagnosis but does not determine the true incidence of disease, particularly in light of
falling autopsy rates. I used readily available surveillance data to assess sensitivity.
For example, a key objective of the surveillance system was the detection of vCJD.
The system has therefore demonstrated that it is sensitive, having identified and
characterised vCJD prior to a case definition being available. Two further measures
of sensitivity were considered: the comparability of incidence/mortality rates of
sCJD relative to internationally described rates and an assessment of the sensitivity
of the clinical surveillance system at detecting sCJD and vCJD cases in life. The
validity of these measures is not known.
Comparison with the literature
Two evaluations ofCJD surveillance systems have utilised the CDC evaluation
framework; both used indirect or proxy measures for the assessment of some system
attributes. Robotin assessed the sensitivity of the Australian surveillance system by
comparing rates of sCJD ascertained by the system to international rates, using a
similar approach to the present study to assessing scnsitivity.(233) In an examination
of the EUROCJD network Pedro-Cuesta, developed a number of proxy indicators
against which to assess sensitivity, including referral rates in those under 50 years of
age and the genotypic profile of sCJD cases under 50 years of age.(231) These
metrics reflected the overall aims of the surveillance network which were to identify
vCJD and any change in the phenotype of sCJD in the young. This evaluation was
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aided by an external data source, a central shared data repository to which
collaborators reported data, and against which the contribution of individual
countries could be assessed. In addition, in some analyses the UK was used as a
reference population for comparison. These approaches were not possible in the
present study and the metrics selected in the present study may not be valid in other
evaluations. For example, vCJD has not been described in Australia, therefore the
ability to detect an epidemic of vCJD could not be used as a measure of sensitivity,
or the ability of the system to respond to this epidemic as a measure of flexibility in
the study by Robotin.(233)
Strengths and limitations
There arc a number of other limitations to this evaluation that should be considered.
The main aim of this evaluation was to assess the performance of the system against
its stated objectives. Beyond NCJDSU staff, external stakeholders were not
identified and engaged in the process. The evaluation used quantitative data collected
by the system against which the performance of the system was evidenced. These
data were selected because they were readily available and accessible within the time
frame (and resource) of this research and it had been prospectively, systematically
collected by valid and reliable methods. For many analyses data from selected years,
at 3 yearly intervals, were examined rather than all 16 years over which systematic
prospective surveillance has been carried out. This approach was adopted for
pragmatic reasons owing to the volume of data collection required and the need for
manual data extraction from paper-based case records. The years selected were
strategically identified, for example 1991 was the first full year of systematic
prospective surveillance in the UK, 1994 the year before the first case of vCJD was
described, 1997 the year following characterisation of vCJD, 2000 the year that CSF
14-3-3 protein was incorporated into the WHO diagnostic criteria for sCJD and 2006
the year that 1 was employed as a Research Registrar in Neurology by the NCJDSU
and personally visited suspect cases to collect surveillance data. As previously noted,
for some attributes it would have been desirable to examine external data and it may
also have been useful to supplement these quantitative data with qualitative data to
provide greater insight into the quantitative findings. Only limited data were
available on iCJD and genetic prion disease cases against which to assess the
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performance of the system therefore minimal analyses were carried out using these
data. Finally, there is a genuine paucity ofpublished studies of this nature against
which to compare and contrast the validity of the evidence collected in this study to
examine key system attributes and the subjective interpretation of the study findings.
Recommendations
Based on the findings of this evaluation the following recommendations arc made:
• The differential use of investigations that support a diagnosis of sCJD or vCJD in
sCJD or vCJD cases and non-cases warrants further investigation to determine
whether specific groups, for example the elderly, arc being systematically under-
investigated and whether this may have contributed to the systematic under-
ascertainment of cases.
• Barriers to the use of investigation that support a diagnosis of sCJD or vCJD in
suspect sCJD or vCJD cases, particularly post mortem examination, should be
explored with key stakeholders including relatives, health care providers and
special interest groups to inform the development of strategies to facilitate the
use of such technologies.
• Consideration should be given to whether a rising PPV of the system is desirable
in the context of falling rates of referral of suspect sCJD and vCJD cases to the
NCJDSU and an increasing reliance on clinical diagnostic criteria.
• Similarly consideration should be given as to whether there is a need for further
contemporary studies, for example a capture-recapture study, to more directly
examine sensitivity in light of changing PPV and the falling data quality of
diagnosis reported.
• All surveillance data should be electronically archived to protect against data loss
and ensure the ability to rapidly interrogate and analyse the rich surveillance data
available to the NCJDSU
• Qualitative research should be considered to explore barriers to referral to the
NCJDSU in the minority of cases in whom CJD is considered in life but referral
to the NCJDSU is not made.
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Regular evaluation of the NCJDSU should follow to ensure that the system is
continues to meet it stated objectives and as part of an on-going process of quality
improvement. The engagement of key stakeholders in this process is crucial. The
dearth of published literature in this area is alarming given the rapid international
expansion ofCJD PHS system. The NCJDSU should endeavour to publish the output
of regular evaluations of the system to inform practice, and use its considerable
influence to encourage international collaborators to undertake regular evaluations of
the performance of their systems.
Conclusions
In this Chapter, I presented the findings of the first ever evaluation of the NCJDSU
in the UK. Over 16 years of prospective systematic surveillance the NCJDSU has
performed well in meeting many of it stated objectives. However, falling post
mortem rates and sub-optimal, and differential, use of investigations that support a
diagnosis of sCJD or vCJD in suspect sCJD and vCJD cases are cause for concern.
Falling rates of referral of suspect prion disease cases in the context of an increasing
PPV of the system may compromise the NCJDSU's ability to detect atypical or novel
prion diseases.
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Chapter 4. Prospective validation of NCJDSU
operational criteria for the assessment of
electroencephalography (EEG) in suspect sCJD
Introduction
Reliable diagnosis of suspect CJD in life is important. This allows clinicians to
exclude potentially treatable differential diagnoses, inform relatives of the likely
prognosis and facilitates prompt public health action where necessary. However
brain biopsy carries risk and rates ofpost mortem among suspect CJD cases in the
UK are falling. In the absence of neuropathological confirmation, presumptive
diagnosis of sCJD relies on a classical clinical history and characteristic findings on
EEG (PSWC) and/or the detection of CSF 14-3-3 protein.(98) Whilst the validity of
a CSF 14-3-3 protein test reported by a centralised national service can be assured,
the same cannot necessarily be said for EEGs which are carried out and reported in
medical centres across the UK. Given the importance of the EEG in diagnostic
classification of suspect sCJD central review of EEGs by the PHS system is
considered essential in the UK. Quantitative criteria for the assessment of EEG in
suspect sCJD have been adopted by the WHO for surveillance purposes (Table 6).
As previously noted there arc practical difficulties in obtaining and accessing
digitalised EEG recordings in the UK which have limited the use of these criteria in
disease surveillance. Operational criteria are used by the NCJDSU in the assessment
of EEG in case classification of suspect sCJD; these never been prospectively
validated.
Aim
The aim of this study was to prospectively validate the NCJDSU operational criteria




The surveillance protocol has been described in detail in the preceding chapters of
this thesis. Further details here are limited to those aspects directly relevant to the
evaluation ofEEGs. In the UK, representative samples from all EEGs carried out in
the investigation of suspect CJD cases referred to the NCJDSU are requested for
review. These are evaluated by one of two experienced clinicians (RGW, RK). In the
early phase of disease surveillance a system of EEG classification was developed
based on defined descriptive criteria which were employed by the same two
individuals who have reviewed the EEGs in this study. This classification comprises
of 5 broad categories (Table 50).
Table 50 Subjective criteria employed by the NCJDSU for EEG classification
Normal Normal EEG
Non-spccifically abnormal Deterioration of normal background rhythms
Within this scheme there is potential for overlap between categories, especially at the




but essentially non-specifically abnormal.
Deterioration of normal background rhythms
with the emergence ofbi- or tri-phasic
discharges, at times with some periodicity but
only for short periods and not truly generalised
Marked deterioration, or absence of, of normal
background rhythms. Periodic bi- or tri-phasic
discharges, for longish segments, but not
continuous throughout record and/or not always
truly generalised.
Absence of normal background rhythms.
Continuous, generalised, periodic bi- or tri¬
phasic discharges.
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suggcstivc/typical boundary. This classification of EEGs was carried on into the
more recent phase of surveillance but it did not necessarily map directly onto ease
classification as the case diagnostic criteria developed and changed. In general,
normal, non-specific and suggestive EEGs were not considered to support elevation
of a suspect sCJD case from possible to probable sCJD; typical EEGs were. The area
of uncertainty concerned highly suggestive EEGs. Some were so highly suggestive,
even if not absolutely typical, that they were used to support the diagnosis of
probable sCJD; others were felt not to be suggestive enough. Whilst this does
introduce a loosely defined and subjective element to the assessment of EEG in case
classification, it was based very firmly on the extensive experience ofROW and RK,
who had developed their judgments based on the outcome ofprevious case
assessments. In this study, the decisions concerning EEG classification were based
on the original 5 broad categories. Decisions concerning the use of the EEG in case
classification were based on the principles outlined in the paragraph above.
Evaluation of EEGs
This study included all consecutive suspect sCJD cases referred to the NCJDSU
between 1st January 2005 and 31st December 2006. All suspect sCJD cases were
followed for a minimum of 2 years. Data were censored at 31st December 2008. Final
case classifications at data censoring were used in these analyses. All sample EEGs
received by the NCJDSU were anonymised and blindly reviewed by two independent
clinicians (RGW, RK). The clinicians were not provided with any clinical data and
EEGs were reviewed in a random order. The aim of this study was to prospectively
validate the operational criteria used for the assessment ofEEG for case
classification in suspect sCJD. The clinicians were asked (Yes/No) whether would
they use the EEG in case classification, meaning would they use the EEG to change
case classification from possible to probable sCJD. In addition, the clinicians were
asked to classify the EEG using the categories described in Table 50. The purpose of
this was three fold (1) to assess the degree of inter-observer variation in the
classification of EEGs using these criteria (2) to explore how well the criteria used in
the EEG classification mapped to case classification in practice (3) to aid
interpretation of any disagreement between reviewers in case classification. One
clinician re-revicwed all EEGs to allow examination of intra-observer variance of
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assessment of EEG for case classification. This reviewer was blinded to his previous
grading and received the EEGs in a different order a minimum of one month after his
initial review. At the time of this second review the clinician was asked whether he
would use the EEG in case classification only.
Definitions
Studies of this nature typically consider the investigation as the unit of analysis,
rather than the individual. Suspect sCJD cases often undergo multiple EEG
examinations therefore disagreement between reviewers on the evaluation of one
EEG may not in practice have an impact on overall case classification. In this study
analyses were first carried out using EEGs as the unit of analysis. Multiple EEGs
were considered per suspect case. Each EEG was considered as an independent
observation. Analyses then considered the individual as the unit of analysis. If a
suspect case was considered by a reviewer to have had an EEG at any stage in their
clinical illness that could be used in case classification this individual was counted
once as having an EEG used in case classification. Conversely, if the individual,
despite serial investigations, did not have an EEG at any stage in their clinical illness
that could be used in case classification, this individual was counted once as not
having an EEG that could be used in case classification.
An assessment of the diagnostic value of a test (sensitivity, specificity, PPV and
NPV) requires comparison of the performance of the test against a gold standard.
Sensitivity was defined as the proportion of sCJD cases that had one or more EEG(s)
which could be used for case classification. Specificity was defined as the proportion
of non-cases that did not have any EEGs that could be used for case classification.
PPV was defined as the proportion of suspect cases that had one or more EEGs that
could be used for case classification who were sCJD cases and NPV the proportion
of individuals that did not have any EEGs that could be used in case classification
that were non-cases.
Definite diagnosis of sCJD requires neuropathological examination of tissue obtained
from brain biopsy in life, or more commonly post mortem following death. In
practice however a significant proportion of suspect sCJD cases do not undergo post
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mortem examination or brain biopsy and elinical diagnostic criteria, based on clinical
features and supportive investigations (EEG or CSF 14-3-3 protein), are applied that
allow classification of suspect sCJD cases with an extremely high degree of
diagnostic certainty. The use of elinical diagnostic criteria as a gold standard against
which to assess the diagnostic utility of EEG is flawed because EEG arc included in
the clinical diagnostic criteria. For the purposes of this study two definitions of sCJD
were considered. A narrow definition considered only individuals with a
neuropathologically confirmed diagnosis of sCJD and neuropathologically confirmed
non-cases (classifications 1.0 and 4.3 respectively). A broad clinical definition
considered sCJD cases as meeting the WHO diagnostic criteria as a definite or
probable case and non-cascs as individuals that did not meet the WHO diagnostic
criteria as a definite, probable or possible case (classifications 1.0, 2.0 or 3.0 and
classifications 4.1, 4.2 or 4.3 respectively).
Statistical analysis
The median age at symptom onset and sex distribution of all suspect sCJD cases
referred to the NCJDSU were described. The Wilcoxon Ranksum test was used to
examine differences in median age at symptom onset between suspect cases for
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which EEG examination(s) were, and were not, available for review; Chi test
(Fisher's exact where assumptions were violated) were used to compare the sex
distribution. Where a suspect sCJD case had undergone EEG examination and this
was available to the NCJDSU for review, age at symptoms onset, median illness
duration, the median number of EEGs per suspect case, the time to first EEG from
symptom onset and time from last EEG to death were described. The Wilcoxon
Ranksum test was used to compare these variables according to case classification
and among suspect sCJD cases according to whether EEG was used in case
classification at any stage in the clinical illness by cither reviewer; Chi' test (Fisher's
exact where assumptions were violated) were used to examine the sex distribution
according to case classification. Further univariate analyses using these parametric
and non-parametric tests as appropriate were carried out to determine whether the
baseline characteristics and clinical features of sCJD cases (both broadly and
narrowly defined) differed according to whether the EEG was or was not used in
case classification.
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Intra and inter-observer variance was assessed using the overall percentage
agreement. A Kappa statistic was used to determine the intra and inter-observer
agreement beyond that which would have arisen due to chance alone. A Kappa
statistic based on exact agreement only acknowledges agreement or disagreement,
without commenting on the extent of agreement or disagreement. Whilst this was
appropriate to examine intra and inter-observer agreement in case classification (a
dichotomous variable), it was not appropriate to examine intra and inter-observer
agreement in the descriptive EEG classification which used ordered categorical data.
If Reviewer 1 classified an EEG as typical whilst Reviewer 2 classified the same
EEG as normal the extent of disagreement would be greater than if Reviewer 1 had
classified the EEG as typical whilst Reviewer 2 classified the EEG as highly
suggestive according to this criteria. To take this into account the Kappa statistic was
weighted when analysing data on the classification of EEGs. Weights were pre-
specified based on the following calculation: 1- |i-j| / (k-1), where i and j index the
rows and columns of the ratings and k is the maximum number of ratings. Thus
where there was complete agreement in EEG classification a weight of 1.0000 was
applied and where there was complete disagreement (i.e. one Reviewer classified an
EEG as typical and another as normal) a weight of 0.0000 was applied. Where there
was disagreement between Reviewers in adjacent categories (i.e. typical and highly
suggestive) a weight of 0.7500 was applied, where there was disagreement between
Reviewers of two categories (i.e. typical and suggestive) a weight of 0.5000 and
where there was disagreement between Reviewers of three categories (i.e. typical and
non-specific) a weight of 0.2500 was applied. The Kappa statistic can take any value
between + 1.0 (indicating complete agreement) and -1 (indicating complete
disagreement). To aid interpretation I adopted the Landis and Koch classification
(251) as follows: A Kappa statistic of<0.00 indicates no agreement, 0.00 - 0.20
slight agreement, 0.21 - 0.40 fair agreement, 0.41 - 0.60 moderate agreement, 0.61 -
0.80, substantial agreement and > 0.81 almost perfect agreement. For each reviewer
corresponding values for sensitivity, specificity, PPV and NPV were calculated. All
statistical analyses were carried out using STATA (Version 11, Stata Corp.). A




From 1st January 2005 through 3lbt December 2006, 180 suspect sCJD were referred
to the NCJDSU; 141 (78.3%) were known to have undergone an EEG examination
during the course of their clinical illness. EEG was available for review at the
NCJDSU for 108 (76.6%) suspect cases. Suspect cases in which EEG was
unavailable for review comprised of 13 neuropathologically confirmed sCJD cases, 3
probable sCJD cases (based CSF 14-3-3 protein) and 17 non-cases (2
neuropathologically confirmed, the remainder had insufficient clinical features to
meet the diagnostic criteria). This group did not differ from those suspect cases for
whom an EEG was available for review with respect to age at onset (P=0.33) or sex
(P=0.09). The baseline characteristics of suspect sCJD cases for which an EEG was
available to the NCJDSU for review are outlined in Table 51.
In total, the two clinicians independently evaluated 166 EEGs from 108 suspect
sCJD cases. This final sample included 87 sCJD cases (52 definite and 35 probable),
3 possible sCJD cases and 18 non- cases (10 pathologically confirmed and 8 with an
alternate clinical diagnosis). In six probable sCJD cases, case classification was
based on EEG alone. Overall the median number ofEEGs per suspect sCJD case was
1 (range 1 - 4). Overall the time from symptom onset to first EEG was 96 days (57 -
172) and from last EEG to death was 31 days (17 - 50).
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Inter-observer variance in the classification of EEGs
Overall the percentage agreement between reviewers was 91.9%, with a weighted
Kappa statistics of 0.681, indicating substantial agreement between reviewers in
classifying EEGs using the descriptive criteria (Table 52).
Table 52 Agreement between reviewers examining all EEGs from all suspect
sCJD cases using descriptive criteria for EEG classification
Reviewer 2
Typical Highly Suggestive Non- Normal
suggestive specific
Typical 5 7 0 0 0
Highly 2 14 8 2 0
suggestive
Suggestive 0 10 31 8 0
Non¬ 0 0 7 63 7
specific
Normal 0 0 0 1 1
Inter-observer variance in the assessment of EEG for case
classification
The overall percentage agreement between clinicians in the evaluation of EEG for
case classification was 89.2% when EEGs were considered the unit of analysis
(Table 53). The Kappa statistic was 0.675, indicating substantial agreement. The
clinicians disagreed on whether the EEG should be used for case classification in 18
EEGs (18 individuals). This group was comprised of ten ncuropathologically
confirmed sCJI) cases, one neuropathologically confirmed non-case and seven
probable sCJD cases; in the latter case classification was based on EEG alone in
three cases. Limiting analyses to only EEGs from sCJD cases and non-cases
(narrowly and broadly defined) made little difference to the degree of inter-observer
variation or Kappa statistic.
When individuals rather than EEGs were considered the unit of analysis, the
percentage agreement between reviewers and the Kappa statistics were slightly
lower. This was of significance only when analyses were limited to individuals with
279
a ncuropathological diagnosis. For this group the percentage agreement fell from
88.7% (EEG) to 82.3% (individual) with a corresponding fall in the Kappa statistics
from 0.617 (EEG) indicating substantial agreement to 0.546 (individual) indicating
moderate agreement. The clinicians disagreed on whether the EEG could be used for
case classification in 16 individuals; ten neuropathologically confirmed sCJD cases,
one neuropathologically confirmed non-case and five probable sCJD cases. In the
latter, case classification was based on EEG alone in two cases.
Table 53 Inter-observer variance in the evaluation of EEG for case classification
Unit of analysis
EEG Individual
All suspect sCJD cases Agreement, n 148 92
Disagreement, n 18 16
Percentage agreement, % 89.2 86.7
Kappa Statistic 0.675 0.681
P Value <0.001 <0.001
Narrowly defined sCJD cases Agreement, n 86 51
and non-cases Disagreement, n 11 1 1
Percentage agreement, % 88.7 82.3
Kappa Statistic 0.617 0.546
P Value <0.001 <0.001
Broadly defined sCJI) cases Agreement, n 143 88
and non-cases Disagreement, n 18 16
Percentage agreement, % 88.8 84.6
Kappa Statistic 0.672 0.640
P Value <0.001 <0.001
Mapping of EEG classification to case classification
Table 54 maps EEG classification to case classification based on EEG for reviewers
1 and 2. For both reviewers EEGs categorised as normal, non-specific or suggestive
were not used in case classification. EEGs categorised as typical were always used in
case classification and there was some variability in the use of highly suggestive
EEGs in case classification.
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Tabic 54 Mapping of EEG classification to case classification
EEG classification Reviewer 1 Reviewer 2
Can the EEG be used in case classification
Yes No Yes No
Normal 0 2 0 8
Non-specific 0 77 0 74
Suggestive 0 49 0 46
Highly Suggestive 12 6 31 0
Typical 20 0 7 0
Using EEG classification to aid interpretation of episodes of inter-
observer variation in case classification
To aid interpretation of inter-observer disagreements (n=l 8), the EEG classification
was examined. In 17 instances one reviewer interpreted the EEG as 'highly
suggestive' whilst another 'suggestive'; in one instance the disagreement was 'highly
suggestive' to 'non-specifically abnormal'.
Intra-observer variance
The overall percentage agreement between reviews in the evaluation of EEG for case
classification was 92.8% when EEGs were considered the unit of analysis (Table 55).
The Kappa statistic was 0.750, indicating substantial agreement between reviews.
Altering the study population to examine EEGs from only sCJD cases and non-cases
(narrowly or broadly defined) made little difference to the degree of intra-observer
variation or Kappa statistic. When individuals rather than EEGs were considered the
unit of analysis the percentage agreement, irrespective of the population studied, was
100% with a Kappa statistic of 1.000 indicating complete agreement.
Between reviews there was disagreement in the use ofEEG for case classification in
12 EEGs (from 11 individuals). This group consisted of six neuropathologically
confirmed sCJD cases and five probable sCJD cases. Of the probable sCJD cases,
case classification based upon EEG findings alone in two cases.
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Table 55 Intra-observer variance in the evaluation of EEC for case classification
Unit of analysis
EEG Individual
All suspect sCJD Agreement, n 154 108
cases Disagreement, n 12 0
Percentage agreement, % 92.8 100
Kappa Statistic 0.750 1.000
P Value <0.001 <0.001
Narrowly defined Agreement, n 90 62
sCJI) cases and Disagreement, n 7 0
non-cases Percentage agreement, % 92.8 100
Kappa Statistic 0.732 1.000
P Value <0.001 <0.001
Broadly defined Agreement, n 149 104
sCJD cases and Disagreement, n 12 0
non-cases Percentage agreement, % 92.6 100
Kappa Statistic 0.748 1.000
P Value <0.001 <0.001
In five of the EEGs for which there was intra-observer disagreement, there was also
inter-observer disagreement. This latter group included one probable sCJD case
classified on EEG findings alone.
Sensitivity, specificity, positive and negative predictive values
The sensitivity, specificity, PPV and NPV ofEEGs for each reviewer are outlined in
Tables 56 (EEG unit of analysis) and 57 (individual unit of analysis) respectively.
The sensitivity of EEG was low however the specificity and PPV were extremely
high. For example when EEG was considered the unit of analysis estimates of
sensitivity ranged from 10.6% to 33.8%. Corresponding values for specificity and
positive predictive value were 77% to 100% and 72.7% to 100% respectively.
Sensitivity increased, although not significantly so, when individuals rather than
EEGs were considered the unit of analysis, at the expense of specificity and positive
predictive value. Estimates of sensitivity ranged from 14.0% to 51.3% whilst
estimates of specificity ranged from 55.5% to 100% and PPV from 71.3% to 100%.
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Table 56 Sensitivity, specificity, positive and negative predictive value of EEC
according to reviewer (unit of analysis EEG)
Estimate Reviewer 1 Reviewer 2 Reviewer 1
% (95%CI) (second review)
Narrow Prevalence 77.0% (68.0-85.2) 77.0% (68.0-85.2) 77.0% (68.0-85.2)
Definition Sensitivity 22.7% (13.8-33.8) 22.7% (13.8-33.8) 18.7% (10.6-29.3)
sCJD n~75 Specificity 100% (84.6- 100) 95.5% (77.2-99.9) 100% (84.6-100)
Non-cases PPV 100% (80.5- 100) 94.4% (72.7 - 99.9) 100% (76.8-100)
n-22 NPV 27.5% (18.1 -38.6) 26.6% (17.3 37.7) 26.5% (17.4-37.7)
Broad Prevalence 80.0% (73.0 - 86.0) 80.0% (73.0-86.0) 80.0% (73.0-86.0)
definition Sensitivity 24.8% (17.6-33.2) 28.7% (21.1 -37.3) 20.2% (13.6-28.1)
sCJD n=129 Specificity 100% (89.1 - 100) 96.9% (83.8-99.9) 100% (89.1 - 100)
Non-case PPV 100% (89.1-100) 97.4% (86.2 - 99.9) 100% (86.8- 100)
n-32 NPV 24.8(17.6-33.2) 25.2% (17.8-33.8) 23.7% (16.8-31.8)
Table 57 Sensitivity, specificity, positive and negative predictive value of EEG
according to reviewer (unit of analysis individual)
Estimate Reviewer 1 Reviewer 2 Reviewer 1
% (95%CI) (second review)
Narrow Prevalence 84.0% (72.0 - 92.0) 84.0% (72.0 - 92.0) 84.0% (72.0 - 92.0)
Definition Sensitivity 30.8% (18.7-45.1) 30.8% (18.7-45.1) 25.0% (14.0-38.9)
sCJD n=52 Specificity 100% (69.2-100) 90% (55.5-99.7) 100% (69.2-100)
Non-cases PPV 100% (79.4- 100) 94.1% (71.3-99.9) 100% (75.3-100)
n=10 NPV 21.7% (10.9-36.4) 20% (9.6-34.6) 20.4% (10.2-34.3)
Broad Prevalence 83.0% (74.0 - 89.5) 83.0% (74.0 - 89.5) 83% (74.0-89.5)
definition Sensitivity 34.5% (24.6-45.4) 40.2% (29.9-51.3) 27.6% (18.5-38.2)
sCJD n~87 Specificity 100% (81.5-100) 94.4% (72.7 - 99.9) 100% (81.5-100)
Non-cases PPV 100% (88.4- 100) 97.2% (85.5 - 99.9) 100% (85.8- 100)
n=18 NPV 24.0% (14.9-35.3) 24.5% (15.1 -36.5) 22.2% (13.7-32.8)
There was no statistically significant difference in these estimates according to the
definition of sCJD applied (narrow or broad). Nor was there a statistically significant
difference in sensitivity, specificity, PPV or NPV between reviewers or reviews.
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Sensitivity, specificity, positive and negative predictive values for
CSF 14-3-3 protein
For comparison the sensitivity, specificity, positive and negative predictive values
for CSF 14-3-3 protein in this population were calculated. Values for narrowly
defined sCJD were 82.5% (67.2 - 92.7), 75.0% (34.9 - 96.8), 94.3% (80.8 - 99.3)
and 46.2% (19.2 - 74.9) respectively; for broadly defined sCJD 87.3% (77.3 - 94.0),
42.9% (17.7-71.1), 88.6% (78.7 - 94.9) and 40.0% (16.3 - 67.7) respectively. At
the time ofwriting MR1 features were not included in the diagnostic criteria therefore
these data have not been presented.
Timing of EECs that were used in case classification
The first EEC that could be used for case classification was recorded a median of 65
days (41 - 97) after symptom onset and 22 days (15 - 34) before death. The timing
of the first and last EEG that could be used for case classification is shown in Figure
61. Of note following the recording of an EEG that could be used for case
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Figure 61 The timing of EEGs used for case classification
Characteristic EEG in a non-case
The EEG was considered characteristic of sCJD and would have been used in case
classification by one reviewer in a neuropathologically confirmed non-case.
Interestingly both reviewers considered the EEG in this individual to be highly
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suggestive. This individual was a 53 year old male, hetcrozygote (Codon 129 MV)
with an illness duration of 14 months, negative CSF 14-3-3 protein and MRI
examinations. Whilst a definitive diagnosis was not reached, there was no evidence
of abnormal prion protein on examination of tissue obtained from brain biopsy in this
case.
sCJD cases that did not have characteristic EEGs
In 26 neuropathologically confirmed sCJD cases and 12 probable sCJD cases neither
reviewer considered that features on EEG supported a diagnosis of sCJD. Table 58
compares the baseline characteristics of sCJD cases, narrowly and broadly defined,
according to whether EEG was, or was not, considered by either reviewer to support
a diagnosis of sCJD at any stage in the clinical illness.
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Summary of key findings
• There was substantial agreement between reviewers in the classification of EEG
using a 5 point descriptive scheme
• This scheme mapped well to case classification. Neither reviewer used normal,
non-specific or suggestive EEGs in case classification and both used all typical
EEGs. There was some variability in the use of highly suggestive EEGs in case
classification.
• There was substantial agreement between reviewers in assessment of EEG for
case classification.
• Reviewers disagreed on the classification of 10% of EEGs (accounting for 15%
of all suspect sCJD referrals), although in less than 2% of EEGs2% of suspect
sCJD cases) this disagreement was of clinical significance.
• Most cases of disagreement between reviewers arose as a result of close
disagreement between adjacent categories, one reviewer classifying the EEG as
highly suggestive whilst the other classified the EEG as suggestive.
• Intra-observcr variance in the assessment of EEG for case classification was
minimal.
• Disagreement between reviews was of clinical significance in just 2 EEGs from 2
individuals representing just 1.9% of the study population and 1.2% of all EEGs
reviewed; when individuals were considered rather than EEGs there was
complete agreement between reviews.
• The sensitivity of EEG was low however the specificity and PPV were high.
• Over the same period the sensitivity of CSF 14-3-3 protein was much higher than
that of EEG with a marginally lower sensitivity and PPV.
• In one pathologically confirmed non-case EEG was considered characteristic and
in the appropriate clinical context would have been used in case classification.
Both reviewers considered this EEG to be highly suggestive, although only one
indicated that they would use to EEG in case classification. A definitive
diagnosis was not reached in this case although there was no evidence of PrPSc on
tissue obtained from brain biopsy.
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Discussion
In this chapter the operational criteria for the evaluation of EEG in case classification
of suspect sCJD were prospectively validated. The main findings from this study will
be discussed in the section that follows.
Interpretation of EEG in suspect sCJD
The interpretation of the EEG in suspect sCJD is challenging for a number of
reasons.(103) Not all patients with sCJD develop PSWC on EEG. In the early, and
less commonly in the late, stages of illness the EEGs may show non-specific slow
wave abnormalities. Often the EEG progresses over the course of the clinical illness
necessitating serial examinations that may be increasingly suggestive and broadly
compatible with, but not entirely typical of, the PSWC classically associated with
sCJD.
Nevertheless the assessment of EEG is required in case classification of sCJD.
Whilst quantitative criteria for the assessment of digitalised EEG recordings have
been developed these have not been prospectively validated in a large scale study and
there arc practical difficulties in applying such criteria in the UK.(98) In the absence
of published criteria for the assessment EEG that can be practically applied in the
UK, the NCJDSU developed operational criteria, albeit loosely defined, that have
been employed by the same two clinicians since the inception of systematic
prospective disease surveillance in the UK but never prospectively validated.
In the present study two experienced CJD clinicians reviewed EEGs using an
internally developed descriptive scheme to classify EEGs and independently decided
whether the EEG should be used for case classification in sCJD. The overall
percentage agreement between reviewers was high with Kappa statistics indicating
moderate to substantial agreement in both EEG classification and the use of EEG in
case classification. The descriptive scheme mapped well to case classification.
Where there was disagreement between reviewers interpretation of this was aided by
an examination of the descriptive criteria. In most instances this was due to one
reviewer considering the EEG suggestive whilst another considered the EEG highly
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suggestive, in turn there was some variation between reviewers in the use of highly
suggestive EEGs for case classification; one reviewer indicated that he would use all
highly suggestive EEGs for ease classification whilst another indicated that he would
use just two thirds. These data highlight that interpretation of EEG, even in the hands
of experienced clinicians is challenging.
Disagreement between reviewers was of clinical significance, that is case
classification had been based on EEG alone, in just 3 cases. Nevertheless, given the
rarity of sCJD misclassification of even a single case may distort national trend data
with implications for national and indeed international public health policy. These
cases were reviewed in detail by both clinicians following this study; neither was
reclassified based on the findings from this study. This does however identify a need
for periodic quality assurance of EEG assessment by the NCJDSU. Independent
review of a random sample of EEGs from suspect sCJD cases by both clinicians
could be undertaken with case by case review of any instances in which
disagreement occurred to determine if case classification should be revised.
The remarkably consistent assessment of EEGs for case classification by one
reviewer suggests that a single individual should examine all EEG for disease
surveillance purposes. However such an approach would be neither stable nor
sustainable in the UK. There is a further issue regarding stability and sustainability in
the context of using un-validated criteria in the assessment ofEEG where this
assessment is in part subjective, based on the vast experience of the two clinicians
that participated in this study. This study has made some progress toward addressing
the issue of the validity of the NCJDSU operational criteria for the assessment of
EEG in disease surveillance. However further characterisation of the more subjective
elements relating to case classification are required. It would be important for the
NCJDSU to ensure succession planning such that any change in personnel will not
impact on this aspect of disease surveillance.
Central review of EEGs by the NCJDSU
The EEG was not available for review in almost a quarter (33) of suspect sCJD cases
that were known to have undergone EEG examination. While the NCJDSU
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endeavour to review all relevant investigation in suspeet sCJD cases there is no
statutory requirement for clinicians to provide these. The suspect cases for which
REG was unavailable did not differ in age or sex distribution from suspect sCJD
cases for which EEG was available and EEG classification was not integral to case
classification in any of these cases. However of these suspect cases the EEG was
reported by the local ncurophysiologist to have been consistent with a diagnosis of
sCJD in almost a fifth (6). The criteria applied by local neurophysiologists in the
assessment of EEGs in suspect sCJD are not known. It would be desirable to
examine the inter-observer variance in EEG reporting between the NCJDSU and
referring centres. Estimating this would go some way towards determining whether
the central review of EEG is necessary for surveillance purposes. However referrals
to the NCJDSU are made from hospitals across the UK. In this study the EEGs
reviewed were recorded and interpreted in 69 different centres. Logistically a
prospective study of this nature would be challenging. The reporting of EEGs in the
UK is not standardised in such a way as to facilitate a study of this nature
retrospectively.
It is unlikely that the assessment ofEEGs in different centres, nationally and
internationally is reproducible given the lack of practical objective criteria for this
purpose. The approach taken by international PHS systems to assessing EEGs in case
classification is unclear, although anecdotally there is said to be considerable
variation (personal communication R.Knight). Transparency in this area is required
to aid the interpretation of international surveillance data, particularly given the trend
toward the study of pooled data from multiple international collaborators, most
commonly in the EUROCJD group.
Comparison with the literature
Steinhoff et al in a small study of 29 suspect cases (15 sCJD and 14 non-cases based
on clinical criteria) reported a Kappa statistic of 0.95 for intra-observer reliability in
evaluation ofEEG applying objective quantitative criteria indicating almost perfect
agreement between reviewers.(105) The criteria used for assessment ofEEG in this
as previously noted, cannot be applied in the UK for practical reasons (Table 6).
Moreover this study included sCJD cases and non-cases based on clinical diagnostic
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criteria which include assessment of EEG. In the present study I was able to
overcome this by earrying out additional analyses which limited the study population
to only sCJD cases and non-cases with a neuropathologically confirmed diagnosis.
The present study is the only published study to examine intra-observer variation in
the assessment of EEG for case classification in the surveillance of sCJD.
Diagnostic value of the EEG in suspect sCJD
Until recently estimates of the sensitivity of EEG in sCJD have ranged from 58% -
66%.(96;97;104;105) In many countries including the UK, as illustrated in previous
chapters of this thesis, the importance of EEG in the diagnostic evaluation of suspect
sCJD cases has diminished since the incorporation of CSF 14-3-3 protein into the
WHO diagnostic criteria.(107) A reduction in the sensitivity of EEG post-1997, the
year that CSF 14-3-3 protein became widely available, has been reported by most
EUROCJD collaborators.(107) In Germany for example the sensitivity and
specificity of EEG in sCJD (definite or probable) was reported to be 32% and 94%
respectively between 2001 and 2003,(106) compared to 64% and 91% between 1996
and 2000.(104) This has been attributed to the introduction ofCSF 14-3-3 protein,
which the authors speculate has led to suspect sCJD cases being referred to the PHS
system at an earlier stage, prior to the onset of PSCW on EEG.(106) Using more
contemporary data collected by 12 international collaborators between 1998 and
2007, Zerr et al examined the diagnostic utility of EEG, CSF 14-3-3 protein and MRI
in 436 sCJD cases (definite or probable) and 141 non-cases (40% with a
neuropathological diagnosis).(99) The reported sensitivity of EEG in this study was
44%, with a specificity of 92%; corresponding values for CSF 14-3-3 protein 86%
and 68%; values not significantly different from those reported in the present study.
In the UK the sensitivity of EEG in the diagnosis of sCJD has been falling for some
time. In the second chapter of this thesis I reported a fall in the sensitivity of EEG in
sCJD cases, from 50.0% in 1990 to 33.0% in 2006 (P<0.001). In the third chapter of
this thesis I demonstrated that there was no evidence to suggest a temporal reduction
in time from symptom onset to suspect sCJD cases being referred to the NCJDSU
that could be attributed to the introduction ofCSF 14-3-3 protein. However the
median time from symptom onset to positive investigation is shorter for CSF 14-3-3
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protein (87 days (57 - 156)) than EEG (95 days (57 - 168)) and the sensitivity of
CSF 14-3-3 protein is significantly higher. If diagnosis of probable sCJD can be
reached using CSE 14-3-3 prior to EEG then an associated fall in the median number
of EEG undertaken would be expected. A non-significant fall in the median number
ofEEG undertaken over the course of the clinical illness in sCJD cases was noted in
the second chapter of this thesis. Combined these data suggest that CSF 14-3-3
protein has contributed to the fall in sensitivity of EEG through the earlier detection
of probable sCJD cases. This may not be apparent in an examination of temporal
trends in time to referral because the time between first positive CSF 14-3-3 protein
examination and first positive EEG is short.
A fall in sensitivity of EEG in sCJD in the UK was first noted in 1995 when CSF 14-
3-3 protein was an experimental assay and not widely used. The sensitivity of EEG
continued to fall until 2000 and has remained at approximately 25-30% since. A
number of factors may have contributed to this stabilisation. The use ofCSF 14-3-3
protein in the investigation of suspect sCJD in the UK is less common that in other
countries. EEG remains the most commonly used investigation to support a diagnosis
of sCJD in suspect sCJD cases in the UK. In addition, in certain molecular subtypes
of sCJD (MM 1 and MV1), EEG is an exceptionally useful investigation. Given these
sCJD cases often have a classical clinical illness, sCJD may be suspected in life and
sequential EEGs may be preferentially used to investigate suspect cases over the
more invasive investigations such as CSF 14-3-3 protein.
The specificity ofEEG was exceptionally high in this study and comparable to
published reports. In this study just one non-case was considered by a single
reviewer to have an EEG that could in the appropriate clinical context be used for
ease classification. A definitive diagnosis was not reached in this case despite the
individual undergoing brain biopsy in life. Heinemann et al reported that brain
biopsy was non-diagnostic in 42% of suspect CJD cases that underwent this
investigation in Germany between 1993 and 2005 (n=26). Only a quarter of suspect
cases without a definite diagnosis following brain biopsy underwent post mortem
examination therefore it is not known whether CJD cases were missed at brain
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biopsy.(135) Although post mortem examination was not earned out on the suspect
case identified in this study, ncuropathological tissue from brain biopsy was
evaluated by an experienced neuropathologist from the NCJDSU (JI) and in the
absence of histological changes or PrPSc sCJD was excluded as a differential
diagnosis.
For most diagnostic investigations the relationship between sensitivity and specificity
tends to be reciprocal such that as one increases the other is compromised. In many
respects for a condition such as sCJD it is preferable that a non-invasive investigation
such as EEG has a high specificity. Whilst the specificity indicates that EEG is
identifying individuals that do not have sCJD with a high degree of certainty, the low
sensitivity of this investigation means that up to 75% of sCJD eases will be missed.
In the investigation of suspect sCJD cases EEG should therefore be used conjunction
with other diagnostic tools such as CSF 14-3-3 protein and MRI.
Conclusions
This study has confirmed the validity of the NCJDSU operational criteria for the
assessment of EEG in case classification of suspect sCJD when applied by two
experienced CJD clinicians. It is not clear whether these results would be
reproducible in the hands of less experienced clinicians. Whilst the sensitivity of
EEG in sCJD is low, the specificity is high. As a non-invasive investigation EEG
remains a useful tool in the assessment of suspect sCJD cases if used in conjunction
with other diagnostic technology.
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Chapter 5. Death certificates in the surveillance of
prion disease in the UK
Introduction
In the USA the analysis of death certificates is considered to be the most"systematic
and cost effective method of[C.JD] surveillance.,\227) The examination of death
certificates is commonly used as an adjunct to other activities in the prion disease
surveillance (Table 18). There are however remarkably few contemporary studies
describing the diagnostic value of death certificate in prion disease surveillance, and
the approach taken to identifying prion disease on death certificates varies between
studies, some examining only the underlying cause of death as ICD coded,(51) others
examining multiple cause of death both ICD coded and recorded in the literal text of
the certificate.(50) Data describing the accuracy of ICD coding of prion diseases on
death certificates in the UK and elsewhere, arc lacking. A consensus as to the most
valid approach to adopt when using death certificates in surveillance has not been
reached. In this chapter I will address these critical gaps in the literature.
Aims and objectives
The overall aim of this chapter was to evaluate the use of death certificates in the
surveillance of prion disease in the UK from 1990 through 2006.
Specific objectives were as follows:
1. To describe the use of death certificates in the ascertainment of suspect prion
disease cases in the UK from 1990 through 2006.
2. To determine which approach to examining death certificates is optimal in
ascertaining suspect prion disease cases.
3. To examine the diagnostic value of death certificates (sensitivity, specificity,
PPV and NPV) in the surveillance of all human prion disease, sCJD cases and
vCJD cases in the UK from 1990 through 2006.
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4. To examine the aceuraey of ICD coding of prion diseases on death certificates in
the UK from 1990 through 2006
5. To compare age standardised mortality rates of human prion diseases produced
by the surveillance methods adopted by the NCJDSU to age standardised
mortality rates produced ascertaining prion disease cases using death certificates
alone
Methods
Death certification in the UK
In the UK death certificates are completed by a physician. The certificate consists of
two parts. In Part I, a sequence of up to three conditions that led to death are
recorded. The condition that led directly to death is recorded in the first position. The
underlying condition, to which all preceding conditions are attributable, is recorded
in the last position. In Part II co-morbid conditions that may have contributed to, but
did not directly cause death, are recorded. All death certificates arc returned to the
Office of National Statistics (ONS) (England and Wales) or General Register
Office's (GRO) (Scotland and Northern Ireland) where they are coded according to
the World Health Organisations International Classification of Diseases (ICD9 pre-
1996 and ICD 10 post-1996). The underlying cause of death is determined by the
ONS/GRO and ICD coded accordingly. The ONS/GRO may ICD code multiple
additional causes of death or co-morbid conditions at their own discretion. These
need not directly correspond to the sequence entered by the certifying physician.
The surveillance protocol
Quarterly the ONS/GRO send all death certificates from the UK coded under the
rubrics 046.1 'Jakob-Creutzfeldt Disease' (1CD9), 331.9 'Cerebral degeneration,
unspecified' (ICD9), A81.0 'Creutzfeldt-Jakob Disease' (ICD10) or F02.1 'Dementia
in Creutzfeldt-Jakob Disease' (ICD10) to the NCJDSU as part of routine surveillance
practice. On expiration, death certificates arc requested for all suspect prion disease
cases referred to the NCJDSU. Of note 331.9 is not a CJD specific code.
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Data collection
All suspect prion disease eases referred to the NCJDSU between 1st May 1990 and
31st December 2006 were followed for two years until 31st December 2008. A further
six months was given to ensure the death certificates of individuals deceased as of
31st December 2008 had been received by the NCJDSU. The following information
was extracted from death certificates and entered onto a password protected
database: name, date of birth, sex, date of death, place of death, occupation of
individual certifying death, causes of death as recorded at each position on the death
certificate (literal text), underlying cause of death (ICD coded), all other ICD coded
causes of death or co-morbidities contributing to death. These data were linked to the
following information extracted from the NCJDSU case record: case classification,
disease subtype (sporadic, variant, genetic or iatrogenic), date of referral to the
NCJDSU and referral source. Data were then anonymised.
Cleaning and coding of death certificate data
The following conditions recorded in the literal text of a death certificate were
considered to be indicative of a diagnosis ofCJD or genetic prion disease:
Creutzfeldt-Jakob Disease or Creutzfeldt-Jakob syndrome or Creutzfeldt-Jakob
dementia (various spellings), Jakob-Creutzfeldt Disease or Jakob-Creutzfeldt
syndrome or Jakob-Creutzfeldt dementia (various spellings), CJD, prion disease or
prion dementia, spongiform encephalopathy or Gerstman-Straussler-Schcinker
Syndrome (various spellings). The position in which this diagnosis was recorded on
the death certificate noted. This was categorised as follows:
• Recorded in the literal text as the immediate cause of death (Part la)
• Recorded in the literal text as the underlying cause of death (The last position on
Part I of the death certificate)
• Recorded in the literal text in any position (Part I or II)
Throughout this chapter 1 will refer to CJD recorded on the death certificate denoting
that either CJD or genetic prion disease were recorded in the literal text of the death
certificate.
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CJD or genetic prion disease was considered to have been ICD coded on a death
certificate if the following 1CD9 (ICD 10) codes were found: 046.1 (A81.0, F02.1).
The position of coding was considered in the following categories:
• ICD coded as the underlying cause of death as determined by the ONS/GRO
• ICD coded anywhere on the death certificate
Throughout this chapter I will refer to CJD having been ICD coded on the death
certificate if the aforementioned ICD codes appeared on the death certificate.
Age at death was treated as a continuous variable unless otherwise stated. The
following age categories were used to examine the diagnostic utility of death
certificates:
• vCJD: < 30 years, 31-49 years, >50 years
• sCJD: < 50 years, 50-59 years, 60-69 years, 70-79 years and >80 years
In the calculation of age-specific mortality rates, age was examined in 5 year bands
with a lower age limit of <20 years and an upper age limit of>85 years.
Year group was considered in the following categories:
• sCJD: 1990-1995, 1996-2000 and 2001-2006
• vCJD: 1996-2000 and 2000-2006
In general two approaches to examining death certificates in this field have been
adopted. One is to limit analyses to individuals for whom a neuropathologically
confirmed diagnosis is available (classifications 1.0 and 4.3). An alternative
approach, which more accurately reflects disease reporting practices, is to consider a
case as a definite or probable prion disease case (classification 1.0 or 2.0) and non-
case as a suspect case that failed to meet the diagnostic criteria (classification 4.1, 4.2
or 4.3). To reflect these differing approaches and ensure comparability with the
existing literature analyses examining the diagnostic utility of death certificates
applied two definitions as follows:
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• A narrow (neuropathological) definition considered only neuropathologically
confirmed cases (classification 1.0) and non-cases (classification 4.3).
• A broad (clinical) definition which considered cases as individuals meeting the
WHO criteria as a definite or probable case (classification 1.0 or 2.0) and non-
cases as individuals classified as 4.1, 4.2 or 4.3.
Statistical analyses
The baseline characteristics of all suspect prion disease cases referred to the
NCJDSU between 1st May 1990 and 31st December 2006 according to disease
subtype were described. The proportion of deceased cases for which a death
certificate was available to the NCJDSU was quantified according to disease subtype
and case classification. Non-parametric tests including the Wilcoxon-Ranksum test
and Fishers exact test were used to compare the baseline characteristics of those
suspect cases (deceased) for whom a death certificate was unavailable to the
NCJDSU to those for whom a death certificate was not available to the NCJDSU.
The annual number of suspect prion disease cases ascertained by the NCJDSU
through death certificate review alone was determined. Chi2 test for trend was used
to assess whether the proportion of all suspect prion disease cases ascertained by the
NCJDSU through this route had changed significantly over time.
The proportion of suspect prion disease cases that had CJD recorded in the literal text
and/or ICD coded on their death certificate, according to disease subtype and case
classification, were described. The position that CJD was recorded in the literal text
or ICD coded on the death certificate was considered.
To assess the diagnostic utility of death certificates the sensitivity, specificity, PPV
and NPV ofCJD ICD coded in any position on the death certificate was examined as
this reflects current surveillance practice. Sensitivity was defined as the proportion of
cases correctly identified by death certificates. Specificity defined as the proportion
of non-cases correctly identified by death certificates. PPV was defined as the
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proportion of those with prion disease on their death certificate that actually had
prion disease, and NPV the proportion of non- cases that did not have prion disease
on their death certificate. The latter measures, PPV and NPV, arc dependent on the
prevalence of disease in the population therefore disease prevalence estimates were
provided. All prion disease cases were considered first, then sCJD and vCJI). The
diagnostic utility according to age group and then year group was examined. Finally
a linear regression model was fitted to assess whether, following adjustment for age
group, the sensitivity of death certificates had increased over time. These analyses
were carried out for both narrowly defined (pathological) and broadly defined
(clinical) prion disease. These analyses were then repeated examining CJD recorded
in the literal text or ICD coded in any position on the death certificate as it was
determined in the course of this thesis that this approach to examining the fields on a
death certificate produced the greatest yield for disease surveillance purposes.
The accuracy of ICD coding of death certificates was assessed by examining the
number of suspect cases that had CJD recorded (literal text any position) but not ICD
coded (any position) on their death certificates. In turn the number of suspect cases
that had CJD ICD coded (any position) but not recorded (literal text any position).
The changing proportions of these groups over time was assessed using Chi2 tests
from trend to determine whether there was any temporal change in the accuracy of
ICD coding.
The number of deaths from prion disease annually (definite or probable) as
ascertained by the NCJDSU using all surveillance methodologies was quantified.
The number of deaths from prion disease annually as determined by review of death
certificates (CJD recorded in the literal text or ICD coded in any position) was
quantified. Age-specific mortality rates in men and women were calculated using
denominator data from mid-year population estimates in the UK for both. Directly
age standardised prion disease mortality rates were calculated for both using
denominator data from the 2001 Census. All analyses were carried out in STATA




In total 2,154 suspect prion disease cases were referred to the NCJDSU from 1st May
1990 through 31sl December 2006 (Table 59). Three referrals were subsequently
considered international cases due to their location at time of symptom onset. These
individuals died and were certified in the UK and were therefore retained in analyses.
As of 31st December 2008, 1894 (87.9%) suspect cases were deceased. Death
certificates were available for 1879 (99.5%); 1504 suspect sCJD cases, 221 suspect
vCJD cases, 53 suspect iCJD cases and 99 suspect genetic prion disease cases. A
death certificate was unavailable for 15 suspect cases, a third (5) of whom were
known to have died overseas. Suspect cases for whom a death certificate was not
available did not differ significantly from suspect cases for whom a death certificate
was available with respect to sex (P=0.507), case classification (P=0.229) or
aetiological subtype (P-0.109) but were approximately 11 years younger at death,
(55.2 (35.5 - 63.2) years vs. 66.4 (55.7 - 74.8) years, P=0.029).
Death certificates in the ascertainment of prion disease
Over the entire study period, 115 (5.3%) suspect prion disease cases were ascertained
by the NCJDSU through death certificate review alone; 108 (93.9%) were suspect
sCJD cases and 7 (6.1%) suspect genetic prion disease cases. Over time there was a
statistically significant reduction in the proportion of all suspect prion disease cases
ascertained by the NCJDSU through death certificate review alone, from 20.8% (II)
in 1990 to 0% (0) in 2006 (P<0.001) (Figure 62). Over the entire study period, 30
prion disease cases (definite or probable) were ascertained by review of death
certificates alone, representing 2.4% of all prion disease cases (definite or probable)
ascertained by the NCJDSU. This figure fell from 10.0% (2) in 1990 to 0.0% (0) in
2006.
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Figure 62 Number of suspect prion disease cases ascertained by the NCJDSU
through review of death certificate alone
CJD recorded on death certificates
Overall, 800 (42.6%) suspect cases referred to the NCJDSU had CJD recorded in the
literal text as the immediate cause of death (Part 1 a) on their death certificate (Table
60a). This rose to 1108 (59.3%), when CJD recorded in the literal text as the
underlying cause of death was considered. Rising further to 1191 (63.4%) when CJD
recorded in the literal text in any position (Part 1 or II) on the death certificate was
considered. Reassuringly, a high proportion of individuals that met the WHO
diagnostic criteria as a definite, probable or possible case had CJD recorded in the
literal text of their death certificate. This yield increased as multiple causes of death
were considered. Examining ICD codes rather than literal text produced similar
results although the yield was lower (Table 60b). For example, CJD was ICD coded
in any position on the death certificate in 1128 (60.0%) suspect cases, but recorded in
the literal text in any position on the death certificate in 1191 (63.4%) suspect cases.
An examination of ICD coding and literal text in any position on the death certificate
























□ Death certificate review alone
■ All other referral sources
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describing the underlying cause of death in prion disease cases (definite or probable)
according to disease subtype can be found in Appendix 5.
As noted in the methods section the NCJDSU routinely request death certificates
1CD 9 coded 046.1 or 331.9 and 1CD 10 coded A81.0 or F02.1. The 1CD 9 code
331.9, 'Cerebral degeneration, unspecified' is not specific to prion disease and was
therefore was not included in these analyses. This code was recorded (any position)
in just 12 death certificates received by the NCJDSU across the study period. None
of these suspect cases were ascertained by death certificate alone. In just one out of
these 12 suspect cases, CJD was recorded on the text of the death certificate. This
was a pathologically confirmed case of sCJD that had been referred to the NCJDSU
by a neuropathologist. Of note, no death certificates reviewed by the NCJDSU were
1CD coded (any position) under the rubrics F02.1 across the study period.
The degree ofmisclassification of death certificates in cases (narrowly and broadly
defined) varied according to disease subtype. For example, 16.6% of definite or
probable sCJD cases did not have CJD recorded or ICD coded in any position on
their death certificate compared to 17.9% of genetic prion disease cases, 6.3% of
vCJD cases and 3.4% of iCJD cases (P<0.001). Further analyses, where possible,
were therefore stratified according to disease subtype.
Supplemental analyses were carried out to determine whether any routinely available
information recorded on the death certificate could be used to distinguish cases from
non-cases in those certified as CJD, and whether cases that did and did not have CJD
recorded on their death certificate differed significantly. These analyses have been
presented in Appendix 6.
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The diagnostic utility of death certificates
The diagnostic utility of death certificates in the surveillance of prion disease in the
UK was assessed by examining the sensitivity, specificity, PPV and NPV of a death
certificate diagnosis ofCJD. These values were first assessed using CJD ICD coded
in any position on the death certificate as this reflects current practice.
The sensitivity, specificity, PPV and NPV ofCJD ICD coded on death certificates is
shown in Tables 61 and 62 (narrowly defined). Overall the sensitivity (all prion
disease) was 75.9% (75.0 - 78.6) with a specificity of 84.0% (78.9 — 88.3). PPV and
NPV were 94.6% (92.7 - 96.1) and 48.6 (43.8 - 53.4) respectively. Thus death
certificates correctly identified three out of every four prion disease cases and
correctly identified five out of every six non-cases. The PPV was extremely high
indicating that individuals with a death certificate diagnosis of prion disease had a
high (95%) probability of having prion disease. However the NPV was low, half of
those that did not have CJD ICD coded on their death certificate had prion disease.
The sensitivity was highest in the youngest age group, although there was no
discernable trend across age groups in these values. Data for sCJD very much
followed the overall trend for all prion disease. For vCJD the sensitivity and NPV
were higher than associated values for all prion disease and sCJD, with comparable
levels of specificity and PPV. There was no disccrnable pattern according to age
group. Across year groups there was an apparent increase in sensitivity between 1990
- 1995 and 2001 - 2006 for all prion disease and sCJD with no obvious improvement
in the sensitivity for vCJD. Similar trends were observed when a broad ease
definition was applied (Tables 63 and 64).
Following adjustment for age group there was a statistically significant increase in
sensitivity across year groups for all prion disease and sCJD (both narrowly and
broadly defined) but not vCJD (Tables 65). For example, for each increase in year
group these was a 7.5% (2.9 - 12.1) increase in the sensitivity of a death certificate
diagnosis of all prion disease (narrowly defined). The corresponding value for sCJD
was 8.4% (4.7-12.1).

















































































































































































































































































































































Further analyses assessed these values when CJD was recorded in the literal text or
ICD coded in any position on the death certificate as it had been demonstrated in
earlier analyses that this approach led to the greatest yield of suspect prion disease
cases. These results arc reported in Appendix 7. In brief, whilst the overall trends
were similar, identifying CJD on a death certificate using both literal text and 1CD
codes resulted in a higher sensitivity without compromising specificity significantly.
Accuracy of ICD coding of death certificates
There was evidence of ICD coding inaccuracies on 6.3% (135) of all death
certificates reviewed. Three quarters of inaccuracies occurred when CJD was
recorded in the literal text on the death certificate but was not ICD coded.
In 99 suspect cases, CJD was recorded in the literal text of the death certificate (any
position) but not ICD coded on the certificate (any position). The classification and
disease subtypes in this group are outlined in Table 66.
Table 66 Classification and disease subtype of suspect cases for whom CJD was
recorded in the literal text of their death certificate but not ICD coded
Case classification Disease subtype
sCJD vCJD iCJD Genetic prion disease
Definite or probable [1.0 or 2.0| 48 (34) 5 3 (3) 17 (16)
Possible [3.0] 3 0 0 0
Not CJD [4.1,4.2 or 4.3) 21(11) 1 0 0
Unclassifiable [0.0] 10 0 0
0 indicates ncuropathological diagnosis; [ ] indicates case classification
The causc(s) of death that were ICD coded on the death certificate of these suspect
cases arc described in Appendix 8. In one suspect prion disease cases, 'Other atypical
viruses of the central nervous system' was ICD coded (A81.8). In the 1CD coding
manual a footnote indicates that this refers to Kuru. In a further eight suspect cases
'Atypical virus infection of central nervous system, unspecified', with a footnote
indicating that this refers to 'Prion disease of central nervous system not otherwise
specified' was ICD coded (A81.9). This group included five genetic prion disease
cases, two sCJD and one iCJD case (all pathologically confirmed cases) and one
312
probable sCJD. Current algorithms for identifying prion disease on death certificates
in the UK do not consider these codes.
In a further 36 suspect cases CJD was ICD coded, when CJD had not been
mentioned in the literal text in any position on the death certificate. This group
comprised largely of neuropathologically confirmed cases (Table 67). The causes of
death as stated on the death certificate in these cases, according to position, are
shown in Appendix 8.
Table 67 Case classification and disease subtype of suspect cases for which CJD
was ICD coded but not recorded in the literal text of the death certificate
Case classification Disease subtype
sCJD vCJD iCJI) Genetic prion disease
Definite or probable [ 1.0 or 2.0| 26(26) 2(2) 1(1) 2(2)
Possible [3.0] 0 0 0 0
Not CJD [4.1,4.2 or 4.3[ 4 (2) I 0 0
Unclassiliable [0.0] 10 0 0
() indicates pathological diagnosis; [ ] indicates case classification
Over time there was a statistically significant reduction in the proportion of death
certificates on which CJD was ICD coded when CJD had not been recorded in the
literal text of the death certificate (P<0.001). As can be seen from Figure 63 this type
of error has not occurred since 2003 and peaked between 1996 and 1998, a period
over which ICD classification changed from the 9th to 10th revision. However there
was no change in proportion of death certificates on which CJD was not ICD coded
when CJD had been recorded in the literal text of the death certificate (P- 0.687).
This latter group accounted for the greatest number of ICD coding inaccuracies on
death certificates. The effect persisted when individuals that received an ICD code of
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Figure 63 Number of inaccuracies in coding of death certificates in suspect
prion disease cases according to year
Prion disease mortality rates
Figure 64 shows age-adjusted prion disease mortality rates according the method of
case ascertainment. There was no significant difference in the mortality rates
produced when all methods of case ascertainment employed by the NCJDSU were
compared (definite or probable cases) to those produced by an examination of death
certificates alone (all suspect cases identified from death certificate review).
1990 1992 1994 1996 1998 2000 2002 2004 2006
Year
Figure 64 Age standardised prion disease mortality rate (per million
population) according to method of case ascertainment
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Sex-specific and agc-spccific mortality rates produced by examination of death
certificates alone and all other surveillance methods are shown in Table 68. As can
be seen there is no significant difference in either sex-specific mortality rates or age-
specific mortality rates produced using these approaches to surveillance.
Table 68 Number and rate of deaths from prion disease according to sex and
age group as ascertained by all surveillance methods (definite or probable cases)
and death certificate review alone (all suspect cases identified on death
certificates)
All surveillance methods* Death certificates onlyf
Number of Number of
deaths Rate per million deaths Rate per million
Male 610 1.26(1.16- 1.36) 605 1.25 (1.15 - 1.34)
Sex
Female 619 1.21 (1.11 - 1.31) 622 1.22 (1.12 - 1.31)
<20 32 0.13(0.08-0.17) 30 0.12(0.08-0.16)
20-24 37 0.56 (0.38 - 0.74) 34 0.52 (0.34-0.69)
25-29 54 0.75 (0.55 - 0.95) 51 0.71 (0.52 - 0.90)
30-34 55 0.73 (0.54 - 0.92) 49 0.65 (0.47 - 0.83)
35-39 38 0.52 (0.35 - 0.68) 30 0.41 (0.26-0.56)
40-44 40 0.57 (0.40 - 0.75) 39 0.56 (0.38 -0.73)
45-49 45 0.69 (0.49 - 0.89) 42 0.64 (0.45 - 0.83)
Age group
50-54 77 1.27 (0.98- 1.55) 66 1.09 (0.82- 1.35)
(years)
55-59 119 2.13 (1.75 -2.52) 109 1.95 (1.59-2.32)
60-64 173 3.50 (2.98 - 4.02) 172 3.48 (2.96 - 4.00)
65-69 194 4.26 (3.66 - 4.86) 209 4.59 (3.97 - 5.22)
70-74 146 3.63 (3.04 - 4.22) 146 3.63 (3.04-4.22)
75-79 142 4.41 (3.69-5.14) 147 4.57 (3.83 -5.31)
80-84 59 2.62(1.96-3.29) 78 3.47(2.70-4.24)
>85 15 0.84 (0.42- 1.27) 24 1.35 (0.81 - 1.89)
"Definite and probable cases of CJD; ; CJD recorded in literal text or 1CD coded in any position
From these data the use of death certificates as the sole method of case ascertainment
in the surveillance ofprion diseases in the UK produces comparable mortality rates
to the current approach to disease surveillance. However this is as a result of the
inclusion of non-cases in the mortality figures (Figure 65). Relative to all other
surveillance approaches the use of death certificates alone undcr-ascertains prion
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disease eases in those under 60 years of age and over-estimates prion disease cases in
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Figure 65 Number of prion disease cases as ascertained by all surveillance
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Figure 66 Number of prion disease cases ascertained by all surveillance methods
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□ All suspect prion disease cases ascertained by death
Certftate review alone
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r1111111
** <&* <s& ^ ^
Age group (years)
Figure 67 Number of prion disease cases ascertained by all surveillance methods
and by death certificate review alone according to age group (women), 1990 -
2006
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Summary of key findings
• In the UK the reliance on death certificates alone as a method of case
ascertainment in the surveillance of prion disease has diminished with the
establishment of systematic prospective surveillance.
• The yield from reviewing death certificates is maximal when both the literal text
recorded on the death certificate and 1CD codes ascribed to this text arc
reviewed, and when multiple causes of death are considered.
• The sensitivity and specificity of a death certificate diagnosis of prion disease in
the UK are high. This is greatest in those aged under 50 years of age and for
vCJD.
• The sensitivity of a death certificate diagnosis of prion disease and sCJD has
increased over time following adjustment for age.
• Use of death certificates alone produces similar sex-specific, age-specific and
agc-adjustcd prion disease mortality rates to the combined surveillance
approaches currently adopted in the UK. However, this is as a result of the
inclusion of non-cases and the exclusion of cases.
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Discussion
In this chapter I examined the role of death certificates in the surveillance of prion
disease in the UK. This is the first longitudinal study to examine the diagnostic utility
of death certificates in the surveillance ofprion disease over time, adjusting for age
and disease subtype. Using data collected prospectively over 16 years from 2,154
suspect prion disease cases, including over 1200 pathologically confirmed cases, this
is the largest study of its kind. To the best ofmy knowledge this is the only
contemporary study that has explored the optimal approach to using death certificates
in the surveillance of prion disease. The key findings from this study will be
discussed here.
The use of death certificates in the ascertainment of suspect prion
disease
As systematic prospective surveillance has gained momentum in the UK the reliance
on death certificates in the ascertainment of suspect prion disease cases has fallen.
Will noted that 42% of definite or probable CJD cases in the UK were ascertained by
death certificate review alone in the 1970s, falling to 13% in the period 1980 — 1984
and falling further to 6% in 1990 - 1992 (the first years of prospective
surveillance).(72) In the present study just 30 definite or probable prion disease cases
were ascertained by death certificate review alone from 1990 through 2006,
representing 2.4% of all definite or probable cases ascertained by the NCJDSU over
this period; in 2006 no cases were ascertained by death certificate review alone.
Surprisingly few studies are available for comparison. Most studies reporting the
clinico-pathological epidemiology of prion disease as ascertained by surveillance
systems do not describe the source of referrals in sufficient detail to determine the
relative contribution that death certificates have made to case ascertainment. In
Australia, Collins et al report that a quarter of definite or probable prion disease
cases ascertained by the surveillance system from 1970 through 1999 were identified
by death certificate review alone. Prospective surveillance was not initiated in
Australia until 1993, prior to this surveillance was retrospective which might explain
the high proportion of cases ascertained by this route.(238) Perhaps the most widely
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cited study is by Davanipour et al who examined 69 pathologically confirmed sCJD
cases and 5 non-cases ascertained from 11 states in the USA between 1986 and
1988.(227) This study took place prior to systematic prospective disease surveillance
in the USA, at a time when there was limited understanding of the clinico-
pathological heterogeneity of sCJD and limited diagnostic technology. The authors
contacted neuropathologists and hospitals requesting information on sCJD and
reviewed routinely collated mortality data from death certificates. In the USA each
episode of care within a hospital stays is ICD coded with multiple diagnoses at the
time of discharge for billing purposes. The authors requested information on all
hospital stays ICD coded 046.1 (under the rubrics CJD). The same approach to
identifying sCJD on death certificates was adopted. It is unclear from the manuscript
whether multiple causes of death were considered. The response rate to the study was
extremely low. Just 29% of neuropathologists and 36% of hospitals contacted by the
authors responded to a request for information about suspect sCJD cases over the
study period. As noted in previous chapters of this thesis, given the nature of sCJD it
is likely that a clinical case would seek medical attention and be admitted to hospital
during the course of their clinical illness. Moreover in typical cases that death will
occur after a short illness, most likely in hospital. It is very likely then that the high
proportion of sCJD cases ascertained by death certificate review alone in this study
has arisen as a result of the poor response rate in other groups. For example, had the
response rate from hospitals been higher the authors may have found that a greater
proportion of cases were identified through review of hospital case records in
addition to death certificates rather than death certificates alone. Whilst a reported
42% of all pathologically confirmed sCJD cases were ascertained by review of death
certificates alone, just 27% of the suspect sCJD cases initially identified by the
authors were included in the study. Just one out of every six suspect sCJD case
identified by death certificates alone was included in the final sample as the authors
were unable to obtain clinical or neuropathological data to verify the diagnosis in
other suspect cases. These data should then be interpreted with caution as they are
likely to be subject to bias.
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More recently, Conti et al conducted a data linkage study in Italy, using routinely
collected mortality data from death certificates to determine the completeness of
active CJD surveillance from 1993 through 1999.(226) It is noteworthy that the
surveillance protocol in Italy does not include routine review of death certificates.
Overall 64 suspect CJD cases were identified by death certificate review that had not
been identified by the surveillance unit. Annually this figure fell from 12 suspect
cases in 1993, representing 22% of all suspect CJD deaths, to 5 suspect cases in
1999, representing 4% of all suspect CJD deaths. The major limitation of this study
is that the final diagnosis in death certificate only cases is unclear. The authors did
not attempted to validate the diagnosis through the review ofmedical case records
instead rather dubiously stating that it is
"reasonable to assume that more that 90% of the 64 deaths recorded only by
1STAT [death certificates] are really cases ofTSE who were not reported to
the CJD register
The optimal approach to using death certificates in the surveillance
of prion disease
A number of approaches to examining death certificates in the surveillance of prion
disease have been adopted, although few studies justify the approach taken. The vast
majority of studies examine only the underlying cause of death as ICD coded on the
death certificate. The ICD codes selected, and the periods of transition from ICD 9 to
ICD 10, vary internationally. For example in the study by Conti et al temporal trends
in CJD mortality from 1993 through 1999 were reported using the ICD codes 046.1
and 331.5 recorded as the underlying cause of death.(226) Information regarding the
completion of death certification in Italy and the process for ICD coding these data
was not provided. Doi et al reported temporal trends in CJD mortality in Japan from
1979 through 2004 using the underlying cause of death ICD coded as 046.1 (ICD 9
until 1994) and A81.0 (ICD 10 from 1994).(47) Whilst the authors report that a
clinician is responsible for completing the death certificate it is not clear who is
responsible for ICD coding these data. In Canada, ElSaadany et al produced a similar
study examining the underlying cause of death ICD coded under the rubrics 046.1
when describing mortality trends from 1979 through 1997.(51) The authors justified
the use of the underlying cause of death by stating that
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"as CJD is considered a disease that contributes to death directly, our study
used the underlying cause ofdeath code to identify all cases ofCJD
This assumes that those certifying CJD cases correctly complete death certificates
and in turn that those ICD coding death certificate data correctly identify the
underlying cause of death from the certificate. The examples provided above are
from three countries in different continents. Despite using death certificate data to
describe temporal trends in CJD mortality, none of the studies described the process
of completion of death certificates and coding of death certificate data in their
respective countries. Nor do they provide any information on the accuracy of ICD
coding.
The most comprehensive and contemporary study ofprion disease mortality using
death certificate data is from Holman and co-workers in the USA.(50) The authors
examine multiple causes of deaths ICD coded under the rubrics of 046.1 (ICD 9 1979
- 1998) and A81.0 (ICD 10 1999 - 2006). Following a change in ICD coding in
1999 (from ICD 9 to ICD 10), a coding related under-ascertainment of prion disease
cases was noted. At this time software was introduced to allow literal text search for
CJD and CJD related diagnoses on death certificates. The introduction of this
software was however staggered such that in 1993 less than half (18) of all States
were using this software. It was not until 2003 that all states were using the software.
This may have introduced information bias. Whilst the authors used additional
surveillance efforts to validate the diagnosis of CJD in selected groups, for example
in those under 55 years of age, not all diagnoses were validated by neuropathological
examination or review ofmedical records, again possibly introducing bias. The use
of software to search the literal text of death certificates allowed the authors to
exclude those death certificates on which CJD was ICD coded but not recorded and
conversely include those certificates on which CJD was recorded but not ICD coded.
However, the authors do not provide data to quantify the degree of coding
inaccuracies which is a major limitation of the study. To the best ofmy knowledge
there are no contemporary published studies reporting the coding accuracy of death
certificates in prion disease.
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In the UK death certificates are reviewed as a 'safety net' as part of routine
surveillance practice. Death certificates ICD coded under the rubrics of 046.1 or
331.9 (ICD 9) and A81.0 or F02.1 (ICD 10) are requested from the GROS / ONS.
The ICD 9 code 331.9 is not a CJD specific code but certificates coded under this
rubric were requested in an attempt to identify additional cases. The death certificates
of all suspect prion disease cases referred to the NJCDSU are also reviewed. In this
chapter I have shown that examining the literal text recorded on death certificates in
addition to ICD codes results in a higher yield of suspect cases. The greatest yield
comes from examining multiple causes of death rather than the underlying cause of
death. For example examining CJD ICD coded (046.1, A81.0 or F02.1) as the
underlying cause of death identified 78.3% of definite or probable prion disease
cases. Interestingly the figure for CJD recorded as the underlying cause of death was
virtually identical suggesting that in the UK coders are correctly identifying and
coding the underlying cause of death on death certificates. Examining the literal text
and aforementioned ICD codes in any position on the death certificate identified
85.3% of all definite or probable prion disease cases, equating to an additional 83
cases. This also resulted in the identification of an additional 25 non-cases (14 of
which had a neuropathologically confirmed diagnosis). The latter point highlights the
need for review ofmedical and neuropathological records in the verification of data
from death certificates. The 2010 study by Holman et al reported that CJD was
recorded as the underlying cause of death in 83% of deaths in individuals identified
from disease surveillance activities and death certificate review as having prion
disease, in the USA between 1979 and 2006.(50) However as previously noted the
authors did not verify the diagnosis in all suspect cases. Whilst the diagnosis was
verified in some groups, the proportion of those with a verified clinical or
pathological diagnosis ofprion disease, that had CJD recorded as the underlying
cause of death was not reported.
ICD coding inaccuracies
An additional advantage of examining the literal text on death certificates was that it
allowed an assessment of coding inaccuracies. Approximately 6% (135) of death
certificates reviewed in this study had evidence of inaccuracies in ICD coding. Three
quarters of these inaccuracies related to CJD not being ICD coded when it was
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recorded on the death certificate. There is no evidence of any improvement in this
area over time. It is possible that suspect prion disease cases in the UK have been
missed as a result of coding inaccuracies. However all of the 73 definite or probable
cases that had CJD recorded in the text of their death certificate but not ICD coded
had been ascertained by the NCJDSU prior to death certificate review, therefore it is
likely that the number of missed cases as a result of coding inaccuracies would be
small.
Over the entire study period 53 pathologically confirmed non-cases had CJD either
recorded in the literal text or ICD coded on their death certificate. In the UK death
certificates may be issued prior to the completion of neuropathological examination.
For example a death certificate in a suspect CJD case may be issued following
autopsy but prior to immunohistochemical results from brain tissue being available.
The latter process can take several weeks and given that a death certificate is
required prior to burial or cremation this would be an unacceptable delay in
proceedings for the patient's relatives. As further information becomes available the
death certificate should be updated to accurately reflect the final diagnosis. Updated
death certificates have not been received by the NCJDSU in these cases. It is unclear
whether this is due to updated certificates not being issued, or the GROS/ONS not
forwarding these certificates to the NCJDSU. However, this highlights the need to
verify the information obtained from death certificates. Through routine surveillance
activities the NCJDSU has obtained neuropathological reports and in almost half
(n=23) reviewed neuropathological material, from these cases to verified that final
diagnosis.
Practical issues in relation to reviewing death certificates
An examination of the literal text on death certificates is challenging. In the process
of this study I manually reviewed all death certificates received by the NCJDSU in
the 16 years since the inception of prospective surveillance. This was a labour and
time intensive task. Moreover this study was only feasible because the GROS/ ONS
historically sent a copy of the death certificate to the NCJDSU. A recent change in
the GROS/ ONS protocols for data sharing mean that they now no longer send death
certificates to the NCJDSU, instead providing ICD coded death certificate data only.
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This study has highlighted the importance of reviewing both ICD codes and literal
text on death certificates. Future research should focus on the development of
software, appropriate to the UK which could be applied to the literal text of death
certificate data collated nationally. In addition to increasing the yield of suspect cases
identified by death certificates this approach will allow a regular and systematic
assessment of coding inaccuracies and identification of the most useful ICD codes
for the purposes of surveillance. This would also allow an assessment ofwhether
prion disease cases, not referred to the NCJDSU by other sources and not identified
by an examination of ICD codes on review of death certificates, are being missed in
the UK. There would of course be cost implications to software development and
potential difficulties in obtaining agreement from the GROS / ONS in Scotland,
England, Northern Ireland and Wales to run such software. Nevertheless these issues
are likely to be surmountable as Holman and colleagues have demonstrated in the
USA.
Data from this study suggest that the ICD codes currently utilised by the NCJDSU in
the UK, whilst consistent with the approach adopted internationally, may not be
optimal. For example the ICD 10 code F02.1 was not recorded in any position on the
death certificate of any suspect prion disease case. However, nine prion disease cases
were coded under the rubrics A81.8 and A81.9, CJD specific codes and are not
currently examined by the NCJDSU. The latter cases would have been missed had
surveillance been reliant on death certificate review alone. The ICD codes that are
selected for use in the review of death certificates for disease surveillance should be
regularly reviewed to ensure that these are optimal.
The diagnostic value of death certificates in the surveillance
There is a paucity of studies examining the diagnostic value of death certificates in
the surveillance of prion disease. The most widely referenced study is by Davanipour
et al.(227) The limitations of this study have been outlined and should be considered
in interpreting the findings of this study. The sensitivity, specificity, PPV and NPV
of death certificates in this population was 79.9% (68.3 - 88.4), 0% (0 - 52.2%),
91.7% (81.6 - 97.2) and 0% (0 - 23.2). These data indicate that in this highly
selected population death certificates correctly identified four out of every five sCJD
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case. However, death certificates were very poor at excluding individuals without
sCJD. Despite the inherent limitations of this study, it is considered by some to have
demonstrated that death certificates are able to identify over 80% of sCJD cases in
the USA. Few citing authors acknowledge that Davanipour et al conclude their
manuscript by noting that whilst death certificates are a readily available and low
cost means of ascertaining CJD cases,
"review ofmedical records andpathology reports and verification of
diagnosis mustfollow the identification ofpotential cases by death
certificates. "(227)
In Italy, Conti et al linked death certificate data to the CJD surveillance register.(226)
Death certificates identified just 46.6% of all definite or probable CJD cases
ascertained by the surveillance system between 1993 and 1999. This fell from 47.2%
in 1993 to 42.0% in 1999. Under ascertainment of CJD cases based on death
certificate review was greatest in those aged 60 years and over. The reason for the
relatively low sensitivity of death certificates in this population is unclear. The
sensitivity of death certificates fell over the study period despite increasing case
ascertainment by the surveillance unit. The authors attribute this in part to poor
communication between the surveillance unit and certifying clinicians. In this study
20% of CJD cases that did not have CJD ICD coded on their death certificate as the
underlying cause of death, did not have a neurological disorder ICD coded as the
underlying cause of death either. In the present study just over half of all definite or
probable prion disease cases that did not have CJD recorded as their underlying
cause of death had a neurological diagnosis recorded as the underlying cause of
death. Following a careful examination ofunderlying causes of death I considered it
likely that the immediate cause of death was incorrectly recorded as the underlying
cause of death in 7.6% of definite or probable prion disease cases overall. In all other
cases was plausible that the underlying cause of death as recorded on the death
certificate was truly the underlying cause of death, even in the presence of a
clinically apparent neurological condition. Improvements in the quality of death
certification may be achieved through additional training of clinicians and a greater
appreciation within the clinical community of the value of routinely collected
mortality data in epidemiological research and disease surveillance. An examination
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ofmultiple causes of death would circumvent these issues in the UK. However, it is
unclear from the data presented in the study by Conti et al whether an examination of
multiple causes of death would have led to an increase the sensitivity of death
certificates in the Italian population.(226)
In the present study the overall sensitivity, specificity, PPV and NPV ofCJD ICD
coded in any position on death certificates was 75.9% (73.0 - 78.6), 84.0% (78.9 -
88.3), 94.6% (92.7 - 96.1) and 48.6% (43.8 - 53.4) when pathologically confirmed
cases were considered and 79.1% (76.7-81.4), 81.6% (78.3 - 84.7), 89.8% (87.8 -
91.6) and 65.7% (62.1 - 69.1) when definite or probable cases were considered. The
sensitivity of death certificates was highest in those under 50 years of age. There was
no discernable trend in sensitivity across age groups when those over 50 years of age
where examined. Values for sCJD were slightly lower that for all prion disease but
followed similar trends. The sensitivity, specificity, PPV and NPV for death
certificates in vCJD was exceptionally high at 88.4% (81.0 - 93.7), 88.2% (72.5 -
96.7), 96.1% (90.4 - 98.9) and 69.8 (53.9 - 82.8) respectively. This is perhaps
unsurprising given vCJD typically affects a younger age group, less than 50 years
old, and overall the sensitivity of death certificates is greatest in this age group.
Moreover in the UK vCJD has had an exceptionally high profile and there are
significant implications for patients, families and health care providers of a diagnosis
of vCJD, not least a complex compensation system that requires a diagnosis of vCJD
to be reached on the balance of probability. It should be noted however that,
particularly in the early years of the vCJD primary epidemic, there was considerable
stigma associated with a diagnosis of vCJD such that families may have requested
that vCJD was not recorded on a death certificate (personal communication R.
Knight).
Over time there was a statistically significant increase in the ability of death
certificates to identify all prion disease cases and sCJD cases (pathologically
confirmed and definite or probable cases). Will noted an increase in the sensitivity of
death certificates (definite or probable CJD cases) over time in the UK, from 39% in
the 1960s to 67% in the early 1990s.(72) The present study has shown that the
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sensitivity has continued to increase over time, from 71.8% (66.1 - 77.1) in the
period 1990 - 1995 to 85.3% (81.9 - 88.2) in the period 2001 - 2005. Following
adjustment for age this increase in sensitivity over time persisted. It is likely that this
increase sensitivity of death certificates has arisen as a result of systematic
prospective surveillance in the UK. Increasing awareness of all forms ofprion
disease as a result of the primary vCJD epidemic may also have contributed to this
trend. A trend toward an increase in the sensitivity of death certificates in vCJD was
observed however this was not statistically significant. It may be that analyses in this
group were underpowered due to the smaller sample size (146 cases with
pathologically confirmed diagnoses and 218 cases with a clinical or pathological
diagnosis).
In this study it was possible to compare the values of sensitivity, specificity, PPV and
NPV obtained from death certificates that identified CJD based on ICD coding, as is
the current approach in the surveillance ofCJD in the UK, to CJD identified by
examination of literal text and ICD codes from multiple causes of death.
Reassuringly, the sensitivity of death certificates increased when multiple causes of
death and both text and ICD coding were considered without a substantial fall in
specificity. This suggests that adopting the latter approach to surveillance in the UK
would increase the yield of prion disease cases identified without resulting in a
significant increase in the number of non-cases identified.
Prion disease mortality rates
There was no significant difference in sex-specific, age-specific or age-adjusted
prion disease mortality rates produced by examination of death certificates alone and
produced by data obtained from definite or probable prion disease cases ascertained
by combined surveillance activities. Reassuringly the mortality rates produced in this
study by both methods were consistent with international reports of prion disease
mortality and followed recognised age-specific trends. The age-specific mortality
rates produced by death certificates alone led to a slight under-estimation of
mortality rates in those under 50 years of age and a marginal over estimation in
mortality rates in those over 60 years of age. However the 95% confidence intervals
overlapped indicating that these differences were not statistically significant. This
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equilibrium has arisen because whilst death certificates identify over 80% of prion
disease cases, they also incorrectly identify approximately 20% of non-cases. In the
UK death certificate review alone would then produce a reasonable estimate of prion
disease mortality rates.
Strengths and limitations
This study examined death certificate data on all suspect prion disease cases referred
to the NCJDSU from 1990 through 2006. Death certificates were unavailable for a
small number of suspect cases. It is unlikely that the exclusion of these individuals
introduced significant bias to this study. A direct visual inspection of the death
certificate allowed examination ofmaterial that might otherwise have been available
had an automated computerised search retrieved records. This allowed subjective
assessment of the content of the certificate, particularly in relation to the literal text.
Whilst this approach was useful for the purposes of this research it is not a practical
approach that could be easily transferred to routine surveillance practice. Estimates
of the sensitivity and specificity of a death certificate diagnosis ofCJD produced in
this study are based on an examination of the death certificates from suspect prion
disease cases referred to the NCJDSU in life or following death, for whom it was
possible to obtain further information (clinical and pathological) to verify diagnoses.
This study does not however consider the hundreds of thousands of deaths in the UK
annually that are not referred to the NCJDSU in life and that do not have reference to
prion disease on their death certificate. Assuming that the NCJDSU achieves high
levels of case ascertainment, it is likely that the present study provides a reasonable
estimate of the sensitivity of a death certificate diagnosis of CJD but a biased
estimate (underestimating) of the true specificity of a death certificate diagnosis of
CJD.
Conclusions
In the UK the use of death certificates in the ascertainment of suspect prion disease
cases has diminished over time with the establishment of systematic prospective
surveillance. Death certificate review is a sensitive and specific way to identifying
prion disease. However this is likely to have arisen as a direct consequence of
systematic prospective surveillance. The yield from examining death certificates is
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maximal when both ICD codes and literal text in multiple causes of death are
considered. Death certificates in the UK produce a valid estimate ofprion disease
mortality for monitoring trends over time. However, this is as a result of the
inclusion of a small number of non-prion disease cases at the expense of the
exclusion of a small number ofprion disease cases. These findings highlight the
importance of the verification of data from death certificates through an examination
of clinical and pathological data.
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Chapter 6: General Discussion and Conclusions
The thesis evaluated various aspects of the surveillance ofCJD in the UK, from 1990
through 2006. In Chapter 2, the epidemiology and diagnostic features ofprion
disease in the UK were described using data collected by the NCJDSU over 16 years
of systematic prospective surveillance. In Chapter 3, using an established framework,
the performance ofNCJDSU was formally evaluated. In Chapter 4, a study to
validate the NCJDSU operational criteria for the assessment of EEG in case
classification of sCJD was carried out. Finally, in Chapter 5, the use of death
certificates in the surveillance ofprion disease in the UK was examined. The key
findings from this thesis are summarised below. A discussion of these findings,
placing them in context of the future challenges of prion disease PHS in the UK
follows.
Summary of key findings
• Systematic prospective surveillance ofCJD was initiated in the UK in 1990, the
aim ofwhich was to detect any change in the clinico-pathological phenotype of
CJD that could be attributable to BSE in cattle; in 1996 this was realised.
• The primary vCJD epidemic in the UK has been smaller than predicted and in
decline since 2000.
• Secondary transmission of vCJD via the transfusion of labile blood components
has been described. The risk of iatrogenic transmission of vCJD via other health
care associated procedures is unqualified.
• The pathogenesis of vCJD is poorly understood. The number of asymptomatic
but potentially infectious individuals in the population is unknown.
• Uncertainties remain around the susceptibility of non-methionine homozygote
genotypes to vCJD and the phenotypic expression of disease in such individuals;
long incubation periods are likely.
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The public health implications and the unanswered questions about the
epidemiology and pathogenesis of the vCJD, provide an imperative to continue
the PHS of all forms ofprion disease for the foreseeable future.
The NCJDSU performed well between 1990 and 2006 and would be in a strong
position to continue to undertake PHS ofprion disease in the UK.
However, falling post mortem rates have led to an increasing reliance on clinical
diagnostic criteria in the UK and there is credible evidence that the use of
investigations to support a diagnosis in suspect sCJD and suspect vCJD cases is
sub-optimal and differential.
In addition, the PPV of the system rose over the study period which in the face of
falling referral rates may compromise the ability of the NCJDSU to detect
atypical disease phenotypes or entirely novel prion diseases.
It was not possible to determine directly whether systematic under-ascertainment
ofprion disease have occurred as a result. There was however evidence to
suggest possible under-ascertainment of genetic prion disease, which may be
indistinguishable from sCJD, in the UK.
NCJDSU operational criteria for the assessment of EEG in case classification of
sCJD were validated; given the subjective elements to these criteria it is unclear
whether these findings would be reproducibility in the hands of less experienced
clinicians.
Clarification of the more subjective elements of the NCJDSU operational criteria
for the assessment ofEEG in case classification are required to ensure stability
and sustainability.
The sensitivity ofEEG in sCJD is low but specificity high; EEG remains a
useful, non-invasive test in the investigation of suspect sCJD cases, if used in
conjunction with other diagnostic tools.
The use of death certificates in the ascertainment of suspect prion disease cases
has diminished with the establishment of systematic prospective surveillance.
Death certificate review is a sensitive and specific way to monitor prion disease
mortality in the UK. However the high diagnostic value of death certificates in
the UK is likely to have arisen as a direct consequence of systematic prospective
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surveillance. The impact that a change in the surveillance protocol would have on
the value of death certificates in this context is unclear.
Future challenges in PHS of human prion diseases
A primary aim of systematic prospective PHS ofCJD in the UK was the
identification of a change in the clinico-pathological phenotype ofCJD that could be
attributable to BSE in humans. Following the identification of vCJD, a key driver for
on-going surveillance in the UK was to understand the public health implications of
this disease and thus facilitate prompt public health action where required. The large
epidemic of vCJD that was feared by some has not occurred and the primary
epidemic of vCJD has been in declined in the UK since 2000. Our knowledge of the
epidemiology of vCJD, and other human prion diseases, has been expanded
dramatically through systematic prospective surveillance in the UK. Although
uncertainties exist around the potential for a secondary epidemic of vCJD models
predict that this too will be small.(172) Currently the only recognised route of
secondary transmission of vCJD is via the transfusion of labile blood components.
Public health control measures have been put in place to minimise the risk of health
care associated iatrogenic transmission of vCJD. Progress is being made toward the
development of a blood test that could be used to screen blood and organ donations
for abnormal prion protein which would potentially further reduce the size of any
secondary epidemic. In this context and in the current financial climate systematic
prospective surveillance in the UK, in its current form, may no longer be considered
viable and alternate models of disease surveillance may be sought.
Referral to the NCJDSU
Unlike many other prion disease PHS systems, the UK system aims to identify and
review suspect cases in life. The enables the collection of detailed clinical, diagnostic
and epidemiological data, used to investigate putative risk factors for disease and
evaluated diagnostic technology, and also facilitate prompt public health action
where required. The ability of the NCJDSU to detect phenotypically diverse or novel
prion disease in life will be in part determined by the referral and review of atypical
cases. The willingness of individuals to refer suspect prion disease cases to the
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NCJDSU and ofpatients and their relatives to participate in surveillance was
demonstrated in Chapter 3. A high proportion of all suspect cases referred to the
NCJDSU were visited and assessed by a NCJDSU neurologist. However rates of
referral to the NCJDSU have fallen in recent years whilst the PPV of the system has
increased. This may compromise the NCJDSU's ability to detect atypical disease
phenotypes or entirely novel human prion diseases. The NCJDSU should consider
whether the current ratio of referrals to cases, definite or probable, not simply
definite, is appropriate. Any effort to increase referral rates through enhanced contact
should also consider the broadening range of health care professionals referring to
the NCJDSU.
Should prion disease be notifiable in the UK?
Should CJD become a notifiable disease in the UK to aid referral? Compulsory
notifiable disease reporting appears to have had mixed effects on referral rates
elsewhere. In Slovakia referrals to the surveillance system fell following the
introduction of compulsory notification as referrer's awaited case confirmation
before contacting the PHS system.(24) Other countries report no significant change
in referral rates.(230) A case definition is required for compulsory notification. In the
UK the identification of novel human prion diseases is a key objective of the
surveillance system. It is extremely unlikely that such cases would meet established
diagnostic criteria. Broad criteria for referral to the NCJDSU are therefore essential.
In addition, part of the success of the NCJDSU appears to be the value that referring
clinicians place on the ability to discuss a complex clinical case with a colleague who
may be able to offer advice and support in the investigation and management of that
case. Compulsory reporting may prohibit or inhibit such a dialogue. In this context I
would suggest that compulsory notification might act as a barrier rather than
facilitator, to the notification of atypical or unusual clinical or pathological cases.
Diagnostic technology
The diagnosis of CJD in life requires the application of diagnostic criteria based on
clinical features and supportive investigations. If the clinical phenotype of disease
changes these diagnostic criteria may be of limited value. This has occurred to some
extent in sCJD. An increasingly diverse clinical phenotype has been described in
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sCJD which varies according to PRNP Codon 129 genotype and prion protein type.
In turn, diagnostic investigations vary in sensitivity across the spectrum ofmolecular
subtypes. A recent manuscript by Zerr et al noted that the sensitivity of the
diagnostic criteria for sCJD could be improved by the addition ofMRT findings
which would be particularly useful in ascertaining rarer molecular subtypes of the
disease. The NCJDSU has been shown to be flexible to responding to changing
demand, such as changing diagnostic criteria, in the past. However it should be
considered that an unforeseen impact of increasingly sensitive and specific clinical
diagnostic criteria in life may be a further reduction in post mortem rates following
death.
Rather uniquely the NCJDSU identified vCJD prior to an established case definition
being available for the disease. The first few cases of vCJD were identified through
autopsy examination; young age at symptom onset may have increased the likelihood
of consent being granted for post mortem examination. Further cases were identified
by direct referral to the NCJDSU from families, in part as a result of the intense
media interest. It is worth reflecting on whether vCJD would have been so quickly
ascertained and characterised had it emerged in the elderly population; there is
already evidence to suggest under-ascertainment of sCJD in this population despite
surveillance efforts. The development of diagnostic criteria for vCJD was aided
considerably by the remarkably consistent clinico-pathological phenotype. Despite
this due to the small number of cases it was almost 15 years before the first study
validating the diagnostic criteria was published. The assessment ofmany
investigations including EEG and MRI is subjective. Validation of diagnostic criteria
for vCJD was only possible because cases and diagnostic investigations had been
reviewed centrally by individuals with considerable experience of human prion
diseases and a sizable number of cases and non-cases had undergone post mortem
examination to obtain a neuropathologically confirmed diagnosis. Falling post
mortem rates will not only limit our ability to detect novel or phenotypically diverse
form ofprion disease in humans, but also our ability to develop and validate
diagnostic criteria to facilitate the on-going identification of the cases in life and
death.
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Alternate models of PHS
The model of systematic prospective CJD surveillance in the UK is both labour and
time intensive, requiring considerable clinical expertise and associated with
significant financial cost. Whilst the NCJDSU has performed well, in the current
financial climate, as the primary BSE and vCJD epidemics wanes and novel threats
to human health emerge, the political will and public health imperative to continue to
fund systematic prospective CJD surveillance in its current model may diminish.
Alternate financially sustainable models of PHS surveillance may be sought. Much
of the cost associated with prospective systematic surveillance in the UK relates to
the cost of visits during which the NCJDSU has direct contact with cases and their
families. Many surveillance systems, for example France, Australia and USA do not
have direct contact with cases and yet are able to produce broadly comparable
surveillance data, including in the examples of France and USA ascertaining cases of
vCJD.
Ascertaining cases through laboratory results: CSF 14-3-3 protein
The PHS model in France relies primarily upon review of requests for CSF 14-3-3
protein. Adoption of this model in the UK would prove problematic for a number of
reasons. The UK CSF 14-3-3 protein laboratory received 330 requests in 2008 (the
end of follow up for this study), twice as many as formal referrals to the NCJDSU.
However, only 1 in every 5 samples was from an individual that met the diagnostic
criteria as a definite or probable prion disease case, indicating that the PPV of
referrals to this service low. Combined these data provide some evidence that CSF
14-3-3 protein is being used, inappropriately, as a screening test by some clinicians.
A negative investigation does not mean that a suspect case does not have prion
disease. This is an important point. CSF 14-3-3 protein is a test that has been
validated for sCJD in a specific reference population; outside this reference
population measures of sensitivity and specificity are invalid. CSF 14-3-3 protein is
not of value in vCJD for example and may not then be pursued. In sCJD, false
positive rates of up to 16% have been quoted for CSF 14-3-3 protein.(231) These
individuals would require careful review and follow up, as would individuals with
negative CSF 14-3-3 protein to capture false negatives and ensure that cases,
particularly those with atypical phenotypes in whom CSF 14-3-3 protein is of limited
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value, are not missed. Given the number of requests received by the CSF 14-3-3
protein service in the UK, follow up of all requests to the service would perhaps be
as time and labour intensive as the current arrangement.
There are further issues to be considered. The use of this service to identify suspect
cases is only of value if the investigation is widely pursued in all suspect cases.
There is clear evidence of sub-optimal use of this investigation in suspect sCJD in
the UK. It is entirely possible that the forthcoming addition ofMRI to the diagnostic
criteria for sCJD will result in preferentially used of this investigation rather than
CSF 14-3-3 protein. In individuals with a supportive MRI scan there would be no
additional clinical value in undertaking lumbar puncture examination for CSF 14-3-3
protein if a treatable differential diagnosis has been excluded. In this context, I would
predict that there will be a reduction in requests for CSF 14-3-3- protein over time in
the UK following this amendment to the diagnostic criteria.
Ascertaining cases through death certificate review
An alternative model that could be considered is that adopted in the USA. Routine
analysis ofmortality data obtained from death certificates are supplemented by the
review ofmedical records in all suspect vCJD cases notified to public health
authorities and the Centre for Disease Control (CDC), and all other prion disease
cases aged less than 55 years old that have been identified from death certificate
review. This system prioritises the collection and validation of detailed information
in suspect cases for which there are potential public health implications. Mortality
data are routinely collected, readily available and low cost. This may therefore be a
sustainable option for disease surveillance. There is an issue relating to timelineness,
particularly in suspect vCJD, where public health action may be required. This is
addressed by encouraging the referral in life of suspect vCJD cases, rather than all
suspect prion disease cases to the public health authorities or CDC. The ability of the
system to detect vCJD has not been significantly challenged however. Just three
cases of vCJD have been described in the USA; two cases were diagnosed in the UK
and the third was diagnosed clinically, undergoing both brain and tonsil biopsies in
life. It is not known therefore whether this system would be sensitive enough to
detect vCJD including novel clinical phenotypes if employed in the UK. The USA is
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the only country with a mature PHS system that has not reported an increasing in
sCJD mortality in recent years, and the only country to report racial differences in
sCJD mortality. These findings may be entirely novel, or may be as a result of
systematic under-ascertainment of sCJD cases. This should also be considered.
Data from this thesis confirmed that death certificates in the UK have a high
sensitivity for identifying prion disease, particularly vCJD. It is likely however that
the activities of the NCJDSU have made a significant contribution to this. It is not
known whether a change in surveillance activities in the UK would result in a fall in
the sensitivity of a death certificate diagnosis of prion disease. It should also be
considered that the interpretation of death certificate data requires the review of
medical records and neuropathological material. These steps are both labour and time
intensive. They require on-going cooperation of clinicians and local health
authorities in providing medical case records, an area that the NCJDSU is currently
under-performing in. There may also be issues relating to the reliability and
completeness of information relating to clinical history, clinical signs, date of onset
and so on, obtained from a retrospective review of medical case notes alone. Perhaps
more importantly, it is also unclear whether such a system would detect a further
change in clinical phenotype ofCJD or indeed a novel human prion disease given the
narrow referral criteria.
Optional appraisal
The current model of disease surveillance in the UK is expensive to deliver. In the
present financial climate the long term sustainability of this model is uncertain. Two
alternate models for delivering a sustainable prion disease PHS system in the UK
have been explored, each with inherent limitations. Any change to the model of
delivery of surveillance should first and foremost consider the objectives of the
surveillance system and the resource available to achieve these. Indeed in the context
of scarce resources it may be desirable and necessary to revise the objectives of the
system to focus more directly on vCJD given the limited public health implications
of other forms of human prion disease.
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Were I to speculate on which model the PHS system in the UK might adopt in the
future I would suggest a system in which the routine review ofmortality data are
supplemented by direct referral of suspect cases with the central review of medical
case records and diagnostic data to ensure diagnostic verification in all suspect cases
where possible, but without a neurologist visiting cases. Prioritisation would be given
to those cases in which there are public health implications of a diagnosis. This
system would be complemented by established surveillance activities such as the on¬
going TMER and PIND studies and enhanced surveillance in selected groups such as
the 'at risk' cohort. The NCJDSU has been found to be both stable and flexible over
time and will be well placed to adapt to any change in the model of surveillance.
However any change to the model ofPHS should be made following a full option
appraisal to identify the most sustainable and viable model for meeting the systems
objectives with the resources available.
Screening blood and organs for PrPSc
The discovery of a single, safe, sensitive and specific ante-mortem blood test for
prion disease will be the most significant forthcoming development to shape PHS.
The impact that such a test will have on PHS is unclear. This will in part be
determined by the properties of the test (the sensitivity and specificity) and the
prevalence of asymptomatic infection in the population. There are major ethical
considerations to introducing a blood test to screening blood and organ donations for
PrPSc, not least that the pathogenesis of vCJD is poorly understood therefore the
significance of a positive result would, based on current scientific knowledge, be
unknown. Nevertheless, any screening test, if introduced, is likely to result in the
identification of an increasing number of individuals that will be designated 'at risk'
for public health purposes in whom there will be a requirement for enhanced
surveillance. This group will consist of those genuinely 'at risk' and false positives
from the screening test; given that the prevalence of asymptomatic vCJD infection in
the population is currently thought to be low, the PPV of any screening test is likely
to be low, resulting in a large number of false positives who will undoubtedly be
subject to public health protection measures. There is also the requirement for a
confirmatory test for those individuals screening positive. Such a test does not
currently exist. Expertise and consistency in the interpretation of the results of both
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screening and diagnostic tests are crucial and pathways for patient care must be
developed to minimise the potential harm experienced by patients through screening.
Of course even with a screening program in place clinical prion disease cases will
continue to emerge that will require public health action. The NCJDSU are likely to
have a major role in these forthcoming developments.
Future research
There is a clear imperative for on-going prion disease PHS. Evaluation should be a
key component of the PHS, conducted regularly to ensure that the system continues
to meet its objectives. Comparative international data are crucial to interpret
surveillance data from the UK. It is therefore important that international PHS
systems also undertake regular evaluations. Given the increasing reliance on
diagnostic criteria transparency about the surveillance protocols used by international
collaborators, for example the approach to assessment ofEEGs orMRI scans, is
increasingly important. In addition, I would call for international collaborators to
publish details of rates of case confirmation to aid the interpretation of routinely
published incidence and mortality rates. Multi-site international studies examining
the reproducibility and validity of the approaches taken to assess ofEEG and MRI in
disease surveillance would be welcomed. The NCJDSU may wish to further explore
the key areas of concern that were identified in the evaluation in Chapter 3. In
addition, acknowledging that the current model of disease surveillance in the UK
may not be sustainable in the long-term, an option appraisal exploring other possible
models of delivering PHS surveillance should be considered.
Conclusions
Prospective systematic CJD surveillance in the UK has successfully identified and
characterised a novel prion disease, vCJD, in humans. Secondary transmission of
vCJD via a previously unrecognised route has provided the public health imperative
to continue disease surveillance for the foreseeable future. The NCJDSU in the UK is
well placed to achieve this.
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Appendix 1
Additional web-based resources accessed in search of grey literature
UK Government Departments or Affiliated Agencies
Department ofHealth
Department of Environment, Food and Rural Affairs
Food Standards Agency
The National Archives (access to BSE Inquiry)
Spongiform Encephalopathy Advisory Committee (SEAC)
CJD Incident Panel
Health Protection Agency
NIBSC CJD Resource Centre
Advisory Committee on Dangerous Pathogens
vCJD Trust






Medical Research Council: TSE Research List




European Food Safety Authority (EFSA)
European Centre for Disease Prevention and Control
Worldwide resources
Centre for Disease Control and Prevention
World Health Organization
National Prion Disease Pathology Surveillance Center (USA)
Alberta Prion Research Institute (Canada)
Patient Groups
CJD Support Network (UK)




Brain and Spine Foundation
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Appendix 2
WHO Diagnostic criteria for human prion diseases (98)
SPORADIC CJD
Definite
Neuropathological/immunocytochemical confirmation is required for a diagnosis of definite sCJD
Probable
Rapidly progressive dementia, and at least two of the following four symptoms:
a. myoclonus
b. visual or cerebellar problems
c. pyramidal or extra-pyramidal features
d. akinetic mutism
plus typical electroencephalogram (EEG) with generalised triphasic periodic complexes at
approximately 1 per second
or
clinical criteria forpossible sCJD and a positive assay for CSF 14-3-3 protein
Possible
Rapidly progressive dementia, two of the symptoms listed in above (a-d) and an illness duration of
less than 2 years.
VARIANT CJD
Definite
A progressive neuropsychiatric disorder and neuropathological confirmation of the disease, showing
spongiform change and extensive PrPSc deposition with florid plaques throughout the cerebrum and
cellebellum.
Probable
A progressive neuropsychiatric disorder of a duration greater than 6 months, where routine
investigations do not suggest an alternative diagnosis and at least four of the following five
symptoms:
a. early psychiatric symptoms (depression, anxiety, apathy withdrawal, delusions)
b. persistent painful sensory symptoms (including both frank pain and/or unpleasant dysaesthesia)
c. ataxia
d. myoclonus or chorea or dystonia
e. dementia
An EEG will not show the typical appearances of sporadic CJD, or no EEG has been performed and
there is a symmetrical high signal in the posterior thalamus on a MRI brain scan. The patient would
have had no history of potential iatrogenic exposure and no evidence of a familial form of TSE.
or
A progressive neuropsychiatric disorder for a period of longer than six months, where routine
investigations do not support an alternative diagnosis, and where there is no history of potential of
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iatrogenic exposure or evidence of a genetic form ofprion disease, plus a tonsil biopsy which is
positive for PrPSc.
Possible
A progressive neuropsychiatric disorder of a duration greater than 6 months, where routine
investigations do not suggest an alternative diagnosis, and there is no history of potential iatrogenic
exposure or evidence of a genetic prion disease, and at least four out of five of the symptoms listed




A neuropathological diagnosis of CJD in a patient with a recognised risk factor for iatrogenic CJD
Probable
A progressive predominantly cerebellar syndrome in a human pituitary growth hormone recipient, or a
clinical diagnosis of probable sCJD (see above) in a patient with a recognised risk factor for iatrogenic
CJD
Relevant exposure risks for iatrogenic CJD
The relevance of any exposure to disease causation must take into account the timing of the exposure
in relation to disease onset
• Treatment with human pituitary growth hormone, human pituitary gonadotrophin or human dura
mater graft
• Corneal graft in which the corneal donor has been classified as definite or probable human prion
disease
• Exposure to neurosurgical instruments previously used in a case of definite or probable human
prion disease
• Transfusion of blood from a donor subsequently diagnosed with vCJD*
This list is provisional as previously unrecognised mechanisms ofhuman prion disease may occur
*note cases of acquired vCJD as a result for transfusion of blood from a donor subsequently
diagnosed with vCJD are designated vCJD cases for disease surveillance purposes
GENETIC PRION DISEASE
Definite
A neuropathological confirmation of prion disease, plus either definite genetic prion disease in a first
degree relative (i.e. a parent, child or sibling), or a pathogenic PRNP mutation
Probable
A progressive neuropsychiatric disorder plus either definite orprobable genetic prion disease in a first
degree relative, or a pathogenic PRNP mutation
Pathogenic PRNP Mutations
• PRNP Mutations associated with GSS neuropathological phenotype
P102L, P105L, A117V, G131V, F198S, D202N, Q212P, Q217R, M232T, 192 bpi
• PRNP Mutations associated with CJD neuropathological phenotype
D178N-129V, VI801, V180I+M232R, T183A, T188A, E196K, E200K, V203I, R208H, V210I,
E211Q, M232R, 96 bpi, 120 bpi, 144 bpi, 168 bpi, 48 bpdel
• PRNP Mutations associated with FFI neuropathological phenotype
D178N-129M
• PRNP Mutation associated with vascular PrP amyloid
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Y145s
PRNP Mutations associated with proven but unclassified prion disease
H187R, 216 bpi
PRNP Mutations associated with neuro-psychiatric disorder, but not proven prion disease
I138M, G142S, Q160S, T188K, M232R, 24 bpi, 48 bpi, 48 bpi + nucleotide substitution in
octapeptides
PRNP Mutations without clinical and neuropathological data:
T188R, P238S
PRNP Polymorphisms with established influence on phenotype:
Ml 29V
PRNP polymorphisms with suggested influence on phenotype:
N171S,E219K, 24 bp deletion
PRNP polymorphisms without established influence on phenotype:
P68P, A117A, G124G, V161V, N173N, H177H, T188T, D202D, Q212Q, R228R, S230S
Appendix 3
Clinical presentation sCJD (230)
It may not be possible to classify a particular case. If the case has good data but does not clearly fit
into one of the specified categories then the code 'other' should be used. If there are insufficient data
to categorise the cases then 'not specified' should be used.
Rapidly progressive dementia (RPD)
The majority of cases will probably be in this category. Precise presenting symptoms will vary from
case to case. The picture is one of an encephalopathic illness with dementia and diverse other
neurological features, progressing rapidly over weeks to a few months with no individual cognitive or
physical deficit being present alone for more than two weeks
Heidenhain Variant
These cases present with impairment of visual acuity and/or field, progressing on to clinical blindness
without other significant clinical deficit for the first two weeks of illness. Visual symptoms might
include visual loss, visual inattention, visual illusions and hallucinations. It is essential that the
symptoms progress to cortical blindness. Cases with other onsets that progress to include cortical
blindness are not included in this category.
Pure psychiatric onset
These cases present with psychiatric symptoms such as depression, anxiety, paranoia and delusions,
without the presence of other features for a period of at least four weeks. Non-specific malaise or
apathy do not count unless accompanied by some of the above symptoms. Visual or auditory
hallucinations alone do not count but may accompany the above fates. It may be difficult to
distinguish between the early features of dementia and a more specifically psychiatric onset.
Behavioural change straightforwardly due to a developing dementia is not included in this category.
The essential characteristics of this presentation is that the patients present with a disturbance that
suggests a psychiatric disturbance rather than an obvious dementia and specifically neurological
features are absent.
Slowly progressive dementia
These cases present with a slowly progressive dementia, developing over months to years without any
other significant neurological features for the first six months.
Pure cerebellar onset
Presentation is with a progressive cerebellar syndrome without other significant features.
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Extra-pyramidal onset
Presentation is with an extra-pyramidal syndrome involving Parkinsonian features with or without
chorea, athetosis or dystonia but without other significant features for at least two weeks.
Stroke-like onset
Presentation is abrupt enough for a diagnosis of stroke to be entertained in the initial stages.
Sensory symptoms at onset
Presentation with somato-sensory symptoms alone for at least two weeks. Such symptoms might
include parasthesia, dysaesthesis, numbness, specifically neurogenic pain etc but would not include
vague, non-specific aches and pains. This category does not include presentation with special sensory
symptoms (i.e. visual, auditory, olfactory, gustatory). Sensory symptoms may be present along with
other symptoms (for example as part of a RPD) but this category is for essentially 'pure' sensory
presentation.
Other
None of the presentations describe above is applicable
Not specified
There is no clear clinical information available or the information does not allow a definite
classification according to the above criteria.
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Appendix 4
Clinical presentation vCJD (185)
Psychiatric features Neurological features
Anxiety Gait disturbance
Irritability Impairment of language
Insomnia Pyramidal features
Social withdrawal Impaired coordination










Hypersomnia Other involuntary movements
Hallucinations Pain
Paranoid delusions Visual symptoms
Inappropriate affect Primitive reflexes
Obsessive features Swallowing impairment
Suicidal ideation Incontinence
Panic attacks Headache
Diurnal mood variation Dizziness
Loss of confidence Dysdiadochokinesia
Bizarre behaviour Extra-pyramidal features
Paranoid ideation Seizures
Lack of emotion Facial weakness




Supplemental analyses describing the underlying cause of death recorded in the literal text of death
certificates in prion disease cases (definite or probable) are reported here, according to disease subtype
(Table 69).
CJD was recorded as the underlying cause of death in 676 (76.1%) sCJD cases. In 264 (39.1%) sCJD
was identified as the underlying cause of death; in two vCJD. Of the sCJD cases (n=208) that did not
have CJD recorded as the underlying cause of death, a neurological disorder was recorded as the
underlying cause of death in 118 (56.7%). In 67 (32.2%), representing 7.6% of all sCJD cases, the
diagnosis recorded as underlying cause of death was most likely the immediate cause of death, for
example, cardiac arrest or pneumonia.
The underlying cause of death was recorded as CJD in 142 (89.9%) vCJD cases, of which the
majority, 110 (77.5%) were identified as vCJD cases on their death certificate; two were identified as
iCJD cases. Of the vCJD cases (n=17) that did not have CJD recorded as the underlying cause of
death, 8 (47.1%) had a neurological diagnosis recorded as the underlying cause of death. The
remaining 9 (52.9%) vCJD cases, representing 5.4% of all vCJD cases, the immediate cause of death
was most likely recorded as the underlying cause of death, for example pneumonia.
The underlying cause of death was recorded as CJD in 46 (88.5%) iCJD cases. Of these 21 were
identified as being aetiologically iCJD with cadaveric-derived hGH being identified as the route of
exposure in ten and cadaveric-derived dura mater grafting in one. Of the remaining iCJD cases, four
had a neurological diagnosis recorded as the underlying cause of death. For two, representing 3.7% of
all iCJD cases, the immediate cause of death was most likely recorded as the underlying cause of
death (both pneumonia).
Finally, the underlying cause of death was recorded as CJD in 72.6% (68) of definite or probable
genetic prion disease cases; 32 (47.1%) of these were identified as being of a genetic aetiology and 6
(8.9%), sporadic. Of the remaining 26 cases, half (13) had a neurological diagnosis recorded as the
underlying cause of death and the other halfmost likely had their immediate cause of death incorrectly
recorded as the underlying cause of death.
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Table 69 Underlying cause of death as recorded in the literal text of death
certificate in definite and probable prion disease case according to disease
subtype
Underlying cause of death Number (%)
sCJD 887 (100)
CJD 676 (76.2)
Neurological Disease 118 (13.3)
Cardiovascular Disease 14(1.6)
Gastrointestinal Disease 4 (<0.1)
Malignancy 3 (<0.1)
Other 2 (<0.1)
Most likely immediate cause of death (pneumonia, pulmonary embolism,
sepsis, cardiac arrest) 67 (7.6)
vCJD 159 (100)
CJD 142 (89.3)
Neurological Disease 8 (5.0)
Most likely immediate cause of death (pneumonia, immobility, hypostasis) 9 (5.7)
Genetic Prion Disease 52 (100)
CJD 46 (88.5)
Neurological Disease 4 (7.7)




Most likely immediate cause of death (pneumonia, sepsis) 13 (13.8)
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Appendix 6
These analyses consider two issues. Firstly, whether any routinely available information recorded on
the death certificate could be used to distinguish CJD cases from non-cases in those certified as having
CJD. Secondly, whether there was any significant difference between cases of CJD that did and did
not have CJD recorded on their death certificate. In the analyses that follow only CJD stated or coded
in any diagnostic position was considered as assessment of death certificates using this criteria had
produced the greatest yield. Analyses were first carried out on the entire cohort and then stratified
according to disease subtype given that the degree ofmisclassification of death certificates was shown
to vary according to subtype. There were insufficient non-cases to analyse data from iCJD or genetic
prion disease cases. Stratified analyses were therefore limited to sCJD and vCJD
Further methodological issues and definitions
In addition to cause of death, the date and place of death and name of the individual certifying death is
recorded on a death certificate. Where a physician is unable to certify a death for medico-legal
reasons, the case is referred to the coroner (in Scotland, the Procurator Fiscal). This individual
determines whether a death requires further investigation. He/she may be satisfied that the death can
be certified, or may request a post mortem examination to determine the cause of death. Where the
cause of death cannot be determined following post mortem examination or death is deemed to have
occurred due to violent or unnatural causes an inquest will be held. This is a publically held, legal
investigation into the circumstances of a death. Following an inquest the coroner may issue a death
certificate. Where an inquest into a death has been held the verdict of this inquest is recorded. The
place of death was determined from each death certificate and categorised as follows: Hospital,
hospice, an individuals own home or home of next ofkin, nursing or residential home and other. The
individual certifying death was categorised as follows based upon information available on each death
certificate:
• Hospital doctor: Cases where death occurred in hospital and death was not certified by a
neuropathologist or coroner/procurator fiscal
• Hospice doctor: Cases where death occurred in a hospice and death was not certified by a
neuropathologist or coroner/procurator fiscal
• General practitioner: Cases where death occurred at home or in nursing or residential care and
death was not certified by a neuropathologist or coroner/procurator fiscal
• Deaths certified by a coroner or procurator fiscal
• Deaths certified by a neuropathologist or pathologist
Univariate analyses using the Chi2 test (and non-parametric equivalents where assumptions violated)
and Wilcoxon Ranksum test were carried out.
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Results
There was no difference in the sex distribution of cases and non-cases certified as CJD (Table 70).
Cases were younger than non-cases and more likely to die in a hospice or at home than non-cases,
although the greatest proportion of both cases and non-cases died in hospital. Reflecting this cases and
non-cases were most frequently certified by a hospital physician although the distribution of
certification between cases and non-cases was significantly different, such that cases were more likely
to be certified by a coroner than non-cases.
When analyses were stratified by disease subtype age at death remained significantly lower in sCJD
cases compared to non-cases but few other associations remained statistically significant (Table 71).
For vCJD there was no significant difference between cases and non-cases on statistical testing
although the statistical power to detect an effect was limited by the small number of non-cases (Table
72).
372























































































Pvalue 0.708 <0.001 0.007 <0.001
*CJDcaselassifi d1.0andnon-case4 3;fCJDc elas if dr2non-cas.1,2
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Placeof DeathTotalnumber(%) Male,n(%) Medianagetd a h,Y rs(IQR) Hospital Hospice Usualhome Nursingorresidentialhome Other Unknown Hospitald ctor Hospiced ctor GeneralPractitioner Coroner Neuropathologist UnknownCertifier
544
269(49.5)
67.3(60.8-74.8) 398(73.2) 58(10.7) 46(8.5) 42(7.7) 0 312(57.4) 45(8.3) 61(1 .2) 120(22.1) 1(0.2) 5(0.9)
46
25(54.4)
73.8(67.6-80.7) 40(87.0) 3(6.5) 2(4.4) 1(2.2) 0 35(76.1) 2(4.4) 4(8.7) 5(10.9) 0 0
0.314 <0.001 0.290 0.322
740
360(48.7)
67.6(61.2-74.7) 528(71.4) 93(12.6) 67(9.1) 52(7.0) 0 438(59.2) 80(10.8) 91(12.3) 120(16.2) 1(0.1) 10(1.4)
123
59(48.0)
71.6(65.2-79.8) 91(74.0) 10(8.1) 7(5.7) 15(12.2) 82(66.7) 9(7.3) 26(21.1) 6(4.9) 0 0
0.889 <0.001 0.086 0.002
*CJDcaseclassifi da1.0ndnon-case4 3;tCJclassifiedr2non-cas1,.2
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*CJDcaselassifi da1.0ndnon-case4 3;tCJcl ir2n -1,2
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Comparison was next drawn between cases (narrowly and broadly defined) that did, and did not, have
CJD recorded in the literal text or ICD coded in any position on their death certificate. Table 73
includes all disease subtypes, whilst Table 73 and Table 75 examine only sCJD and vCJD cases
respectively. Overall there was no difference in the sex distribution of cases according to whether CJD
was on the death certificate or not. Cases that had CJD on their death certificate were younger
(narrowly defined CJD: median of 62.8 years old (45.3 - 71.0) vs. 66.4 years old (58.2 - 74.6),
P<0.001). There was no difference in median duration of illness between groups. A greater than
expected proportion of cases that had CJD recorded or coded on their death certificate died in a
hospice or at home, and accordingly a greater proportion were certified by a general physician or
hospice doctor when compared to those who did not have CJD on their death certificate. In the latter
group a greater than expected proportion of cases died in hospital or in nursing home care and more
than expected were certified by a coroner.
When sCJD cases only were examined there was no longer a significant difference in age between
groups, however the median illness duration in the group that had CJD on their death certificate was
shorter than for the group that did not. The trends in place of death and the individual responsible for
certifying death for sCJD cases were no different from the overall cohort.
Analyses of vCJD cases should be interpreted with caution due to a lack of statistical power as a result
of the small sample size. There was no significant difference between either group with respect to sex,
age, median illness duration or certifier. However vCJD cases that had CJD on their death certificate
were more likely to die at home than those who did not, the latter comparison group being more likely
to die in hospital. This finding, also observed for all subtypes and in the analysis of sCJD cases only,
may reflect diagnostic certainty in that patients in whom a clinical or pathological diagnosis has been
reached may be more likely to be discharged home to receive end of life care. This is less likely to
occur if the diagnosis remains unclear, for example if a reversible cause for the illness has not yet
been excluded.
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The sensitivity, specificity, PPV and NPV of a death certificate diagnosis of CJD (recorded in the
literal text or ICD coded in any position) are outlined in Tables 76-79. The overall sensitivity for all
prion disease was higher using this approach than simply examining ICD coding alone, with no
significant difference in other measures. For narrowly defined prion disease the overall sensitivity was
82.2% (79.5 - 84.6), with a specificity of 80.0% (74.5 - 84.8), PPV of 93.8 (91.9 - 95.4) and NPV of
54.9 (49.7 - 60.1). The sensitivity was highest in the youngest age group but there was no discernable
pattern across age groups. Again values for sCJD followed the overall trend for all prion disease
whilst values for vCJD were significantly higher. The overall trends were the same irrespective of
whether a narrow or broad definition of prion disease was applied, although as for previous analyses
values were slightly higher when a broad definition of prion disease was applied. Once again
following adjustment for age there was a statistically significant increase in sensitivity over time when
all prion disease and sCJD were examined but not vCJD (Table 80).


































































































































































































































































































































































































The underlying causes of death as ICD coded on death certificates of suspect cases that had CJD
recorded in the literal text of their death certificate but not ICD coded are shown in Table 81. In Table
82 the causes of death as recorded in the literal text of death certificates of suspect cases that had CJD
ICD coded without mention of CJD in the literal text are shown.
Table 81 Causes of death as ICD coded in suspect prion disease cases with CJD
recorded in the literal text of the death certificate (any position) but not ICD
coded (any position)
ICD 9 Diagnosis corresponding to ICD code ICD 10 Diagnosis corresponding to ICD code
1629 Malignant neoplasm of bronchus/ lung A818 * Other atypical virus infections of CNS
2041 * Chronic lymphoid leukaemia A819 (8)* Atypical virus infection of CNS
2533* Pituitary dwarfism A872* Lymphocytic choriomeningitis
2901 (20)* Presenile dementia C541 Malignant neoplasm of endometruim
2950* Schizophrenic Disorders E852 (2)* Heredofamilial amyloidosis
2989* Unspecified psychosis F812* Specific disorders of arithmetical skills
3239* Unspecified cause of encephalitis, G122 Motor Neuron Disease
myelitis, and encephalomyelitis
3319* Cerebral degeneration, unspecified G319 (2)* Degenerative disease of CNS
3498 (2)* Other specified disorders of CNS G98* Other disorders of CNS
410 Acute myocardial infarction 1219* Acute myocardial infarction
4151 Pulmonary embolism and infarction 1259 Chronic ischaemic heart disease
436 (2)* Stroke, subtype not specified 1269* Pulmonary embolism without cor
pulmonale
4660 Acute bronchitis 164 Stroke, subtype not specified
485 (15)* Bronchopneumonia, organism unspecified J181* Lobar pneumonia, unspecified
5789 Haemorrhage of gastrointestinal tract J411 * Mucopurulent chronic bronchitis
8769* Open wounds ofback W061 * Fall involving bed
887 Traumatic amputation of arm and hand
indicate definite or probable cases, 14 pre-senile dementia, 10 bronchopneumonia
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Table 82 Causes of death according to position for individuals that had a CJD
related ICD code on their death certificate without mention of CJD in the literal
text of their death certificate
Position Cause of death Number
Part la Acute confusional state 1
Aspiration pneumonia 1
Bronchopneumonia 15 (3)









Rapidly progressive dementia 1
Septicaemia secondary to aspiration 1
Part lb Cerebral Arterial Atherosclerosis 1
Deep Vein Thrombosis 2
Dementia 1
Encephalitis 1
Encephalopathy (unknown cause) 4
Nevin Jones Syndrome 1
Presenile dementia 1
Progressive neurodegenerative Disease 3
Spongiform myelin encephalopathy 1 (1)
Part lc Alzheimer's Disease 1
Encephalopathy 1
Immobilisation due to Parkinsonism 1
Part II Dementia 4 (3)




() indicate definite or probable prion disease case
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